Title Page

Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Sponsor: TESARO, Inc. TESARO UK, Limited 1000 Winter Street 21 Holborn Viaduct Suite 3300 London EC1A2DY Waltham, MA 02451 United Kingdom +1 339 970 0900 +44 29 3300 0105

Medical Monitor: Senior Medical Director

Clinical Research Organization:

Sponsor Protocol No.: 3000-PN162-01-001
IND No(s).: 100,996 and 117,580
EudraCT No.: 2015-003398-14
Study Drug Names: Niraparib capsules/pembrolizumab for injection
Development Phase: 1/2
Date of Original Protocol: 19 October 2015
Version of Protocol: 1.0

The study will be conducted according to the protocol and in compliance with Good Clinical Practice (GCP), with the Declaration of Helsinki, and with other applicable regulatory requirements.

Confidentiality Statement

All information contained in this document is privileged and confidential to TESARO. Any distribution, copying, or disclosure is strictly prohibited without prior written approval by TESARO.
SPONSOR SIGNATURE PAGE

Declaration of Sponsor or Responsible Medical Officer

Title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

This study protocol was subjected to critical review and has been approved by the Sponsor. The information it contains is consistent with the current risk/benefit evaluation of the investigational products as well as with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice.

[Signature]

Senior Medical Director, TESARO, Inc.

Date

10/21/2015
Declaration of the Principal Investigator

Title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

I have read this study protocol, including all appendices. By signing this protocol, I agree to conduct the clinical study, following approval by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), in accordance with the study protocol, the current International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), and applicable regulatory requirements. I will ensure that all personnel involved in the study under my direction will be informed about the contents of this study protocol and will receive all necessary instructions for performing the study according to the study protocol.

Principal Investigator

_____________________________________ _____________________  ______________________________________________ ________________
Name:  Date
Title:  Institution:
SYNOPSIS

**Name of Sponsor/Company:** TESARO, Inc.

**Name of Investigational Product:** niraparib and pembrolizumab

**Name of Active Ingredient:** niraparib and pembrolizumab

**Title of Study:** Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

**Study Center(s):** Phase 1: approximately 6 centers in the United States; Phase 2: approximately 40 centers worldwide

**Studied Period (years):**
- Estimated date first patient enrolled: December 2015
- Estimated date last patient completed: May 2017

**Phase of Development:** 1/2

**Objectives:**

*Primary objectives:*
- Phase 1: To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment, and to establish a recommended Phase 2 dose (RP2D) and schedule
- Phase 2: To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separately for the triple-negative breast cancer (TNBC) and ovarian cancer (OC) cohorts.

*Secondary objectives:*
- Phase 1 and Phase 2: To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST (irRECIST)
  - Duration of response (DOR) by RECIST v1.1 and irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
  - Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
  - Overall survival (OS).
- Phase 1 and 2: To evaluate the pharmacokinetics (PK) of niraparib during combination treatment.

*Exploratory objectives (both phases):*
- To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of tumor-
**Name of Sponsor/Company:** TESARO, Inc.

**Name of Investigational Product:** niraparib and pembrolizumab

**Name of Active Ingredient:** niraparib and pembrolizumab

**Title of Study:** Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

infiltrating lymphocytes (TILs), and circulating biomarkers.

- To correlate homologous recombination deficiency (HRD) score with other immune-related biomarkers and with efficacy outcomes.

**Methodology:**

**Overall**

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) previously treated with chemotherapy for advanced/metastatic disease and in patients with advanced, recurrent, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (OC) previously treated with chemotherapy who are currently platinum-resistant but previously experienced a response lasting for at least 6 months to first-line platinum-based therapy. Eligible TNBC patients in Phase 1 have received up to 3 lines of prior chemotherapy and in Phase 2, up to 2 lines; eligible OC patients in Phase 1 have received up to 4 lines of prior chemotherapy and in Phase 2, up to 3 lines. Study treatment should be considered an appropriate option by the Investigator.

The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the RP2D and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab, and the Phase 2 portion will further evaluate the RP2D and schedule in 2 cohorts of 48 patients each with TNBC or OC as described above.

The study will be conducted in conformance with Good Clinical Practice (GCP). The study schema is provided in Figure 1.

**Figure 1: Study Schema**

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>OC and TNBC: up to 36 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>DL2</td>
<td>6 patients</td>
</tr>
<tr>
<td>N: 300mg d1-21; q21d</td>
<td>P: 200mg d1; q21d</td>
</tr>
<tr>
<td>&lt;1/3 DLT</td>
<td></td>
</tr>
<tr>
<td>DL1</td>
<td>6 patients</td>
</tr>
<tr>
<td>N: 200mg d1-21; q21d</td>
<td>P: 200mg d1; q21d</td>
</tr>
<tr>
<td>≥1/3 DLT</td>
<td></td>
</tr>
<tr>
<td>DL(-1)</td>
<td>6 patients</td>
</tr>
<tr>
<td>N: 200mg or 300mg; d1-14; q21d</td>
<td>P: 200mg d1; q21d</td>
</tr>
<tr>
<td>≥1/3 DLT</td>
<td></td>
</tr>
<tr>
<td>DL(-2)</td>
<td>6 patients</td>
</tr>
<tr>
<td>N: 200mg or 300mg; d1-7; q21d</td>
<td>P: 200mg d1; q21d</td>
</tr>
<tr>
<td>≥1/3 DLT</td>
<td></td>
</tr>
</tbody>
</table>

**Phase 2**

OC: n=48

TNBC: n=48

Abbreviations: AE = adverse event; d = day(s); DL = dose level; DLT = dose-limiting toxicity; OC = ovarian cancer; PK = pharmacokinetics; N = niraparib; P = pembrolizumab; RP2D = recommended Phase 2 dose; q21d = every 21 days; TNBC = triple-negative breast cancer.
### Phase 1: Dose Escalation Phase

At Dose Level 1, a cohort of 6 patients with either TNBC or OC will be enrolled. After all patients in Dose Level 1 who are evaluable for safety have completed Cycle 1 of combination treatment, the next higher dose level (Dose Level 2) will be open for enrollment if less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) in Dose Level 1 experience a DLT during Cycle 1 (see DLT definition below).

Based on current single-agent niraparib experience (see niraparib Investigator’s Brochure), hematological laboratory abnormalities are expected in a significant proportion of patients. If 2 of 6 initially enrolled patients in a cohort experience hematologic DLTs, a lower dose level will be evaluated. If, however, the 2 observed DLTs include 1 hematologic DLT and 1 non-hematologic DLT or 2 non-hematologic DLTs, a cohort may be expanded up to approximately 12 patients to better characterize the safety of the combination treatment.

Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either TNBC or OC will be enrolled in Dose Level 2. No further dose escalation will be considered if Dose Level 2 is reached.

The maximum tolerated dose (MTD) will be defined as the highest dose with DLTs observed in less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be opened for enrollment if not yet evaluated. Alternative dosing schedules may be explored.

Additional cohorts of 6 patients may be opened to evaluate Dose Level (-1) or Dose Level (-2), which will explore lower niraparib dose intensity, for example, by introducing an alternative dosing schedule following agreement by the Investigators and Sponsor.

The RP2D will be determined following discussion and agreement between Investigators and the Sponsor (see Section 9.12) based on an evaluation of multiple endpoints, which may include the DLT rate in first and subsequent cycles of combination treatment, the rate of dose modifications for non-DLT adverse events (AEs), the ability to manage toxicities, PK, niraparib dose intensity, and signs of clinical efficacy. The goal will be to identify the dose/regimen of niraparib with the greatest dose intensity that can be safely combined with the recommended dose/regimen of pembrolizumab.

**DLT criteria (as assessed during Cycle 1, ie, during the first 21 days of treatment - Day 1 through Day 21):**

- Any treatment-related Grade ≥ 3 non-hematologic clinical (non-laboratory) AE
- Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory abnormality if:
  - Medical intervention is required to treat the patient, or
  - The abnormality leads to hospitalization, or
  - The abnormality persists for ≥ 7 days.
Any treatment-related hematologic toxicity specifically defined as:

- Thrombocytopenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion;
- Neutropenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia;
- Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion

Any treatment-related AE leading to niraparib dose interruption per the following criteria:

- A dose interruption per dose modification rules (see Section 5.4.1, Table 2) for a non-DLT laboratory abnormality (eg, for Grade 2 or 3 thrombocytopenia or for Grade 3 anemia or neutropenia) lasting ≥ 14 days
- A dose interruption per dose modification rules (see Section 5.4.1, Table 1) for non-hematologic AE leading to < 80% of an intended dose being administered (eg, niraparib dose interruption for > 4 days within Cycle 1).

Note that niraparib dosing has been safely managed with dose interruptions and/or adjustments for AEs, including laboratory abnormalities, while maintaining activity in the single-agent setting (see Section 5.4.1, Table 2 and niraparib Investigator’s Brochure). Therefore, niraparib dose interruption and/or reduction for an AE that does not meet a DLT definition as described above will be considered a non-DLT modification. The non-DLT dose modifications will not be considered in determining the MTD but will be considered in determining the niraparib dose intensity and RP2D.

**Phase 2: Efficacy Phase**

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion. Two cohorts of 48 patients each with advanced or metastatic TNBC or recurrent OC as outlined above will be enrolled.

Patients in this phase of the study will receive the RP2D of niraparib in combination with pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Pembrolizumab/niraparib combination treatment may continue for up to 2 years or until disease progression, unacceptable toxicity, patient withdrawal, Investigator’s decision, or death. Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

**General Study Conduct: Phase 1 and 2**

All patients will begin treatment with niraparib and pembrolizumab on Cycle 1/Day 1; additional on-treatment assessments will be conducted on Days 8 and 15 of Cycle 1 and on Day 1 of all subsequent cycles. Safety assessments conducted throughout the treatment period include symptom-directed physical examination, vital signs, electrocardiograms (ECGs), Eastern Cooperative Oncology Group (ECOG) performance status, and clinical laboratory assessments (complete blood count [CBC], coagulation [Phase 1 only], chemistry, thyroid stimulating hormone [TSH], triiodothyronine [T3] or free T3 [FT3], free thyroxine [FT4], urinalysis, cancer antigen-125 [CA-125] [OC patients only], and
Radiographic evaluations (CT/MRI of chest [all TNBC patients and OC patients with abnormal screening scan or with clinical indication], abdomen, and pelvis) to assess extent of disease will be conducted every 9 weeks (63 days ± 7 days) while on study treatment independent of cycle delays and/or dose interruptions, and/or at any time when progression of disease is suspected. Brain scan will be conducted if clinically indicated; bone scans will be conducted per standard of care. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ± 7 days). If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals (ie, every 9 weeks for the first year and every 12 weeks thereafter). All radiographic images/scans will be sent to a central imaging vendor upon acquisition and archived for potential future evaluation. Per RECIST v1.1, complete response (CR) or partial response (PR) should be confirmed; tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated. Blood sampling for PK evaluations will be conducted for patients in both Phase 1 and Phase 2.

In patients who consent to fresh biopsies, serial fresh biopsies will be obtained for exploratory biomarker analysis at 3 time points: during the screening period, 8 to approximately 12 weeks after initiating study treatment and, whenever possible, at the time of disease progression (note: while the biopsy is voluntary, it is highly encouraged). A core biopsy is recommended (details are provided in the Study Manual); if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy.

All patients will undergo an End-of-Treatment (EOT) visit within 7 days of the last dose of study treatment and a safety follow-up visit conducted 30 days (+7 days) post-treatment. Thereafter, all patients will enter the post-treatment period for telephone assessment of survival status and the occurrence of any new malignancies every 90 days (± 7 days).

All AEs will be collected and recorded for each patient from the day of signing the informed consent form until 30 days after last study drug administration; serious adverse events (SAEs) and Events of Clinical Interest (ECI) (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured. All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.
Name of Sponsor/Company: TESARO, Inc.

Name of Investigational Product: niraparib and pembrolizumab

Name of Active Ingredient: niraparib and pembrolizumab

Title of Study: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Criteria for Inclusion:
To be considered eligible to participate in this study, all of the following requirements must be met:

1. Patient is male or female at least 18 years of age.

2. Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below.
   a. Patients with breast cancer that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (triple-negative breast cancer, TNBC) who have been treated with at least 1 prior regimen for advanced/metastatic disease or who relapsed/progressed while on or within 1 month from completion of adjuvant chemotherapy. Note: if progression occurred on or within 1 month of adjuvant platinum-containing treatment, the patient will not be eligible.
      i. Up to 3 lines of prior chemotherapy are allowed for patients in Phase 1 and up to 2 lines for patients in Phase 2.
   b. Patients with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who have recurrent disease and have been previously treated with chemotherapy for advanced/metastatic disease and who experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered platinum-resistant.
      i. Up to 4 lines of prior chemotherapy are allowed for patients in Phase 1 and up to 3 lines for patients in Phase 2.

3. Patient has archival tumor tissue available that is formalin-fixed and paraffin-embedded.
   a. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation.
   b. Serial fresh tumor tissue samples will be collected in patients with lesions amenable for a biopsy who consent to such a procedure.

4. Patient has measurable lesions by RECIST v1.1.

5. Patient has an ECOG performance status of 0 to 1.

6. Patient has adequate organ function, defined as:
   a. Absolute neutrophil count (ANC) ≥ 2,000/µL
   b. Platelets ≥ 175,000/µL
   c. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
   d. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
**Name of Sponsor/Company:** TESARO, Inc.

**Name of Investigational Product:** niraparib and pembrolizumab

**Name of Active Ingredient:** niraparib and pembrolizumab

**Title of Study:** Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>e.</td>
<td>Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN</td>
</tr>
<tr>
<td>f.</td>
<td>Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN</td>
</tr>
<tr>
<td>g.</td>
<td>International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants</td>
</tr>
<tr>
<td>h.</td>
<td>Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants</td>
</tr>
</tbody>
</table>

7. Patient is able to take oral medications.

8. Female patient has a negative serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):

   a. ≥ 45 years of age and has not had menses for >1 year
   
   b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation
   
   c. Post hysterectomy, bilateral oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study therapy. Please see Section 5.7.2 for a list of acceptable birth control methods. Information must be captured appropriately within the site's source documents.
   
   d. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

9. Male patient agrees to use an adequate method of contraception (please see Section 5.7.2 for a list of acceptable birth control methods) starting with the first dose of study therapy through 120 days after the last dose of study therapy.

   Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

10. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.
<table>
<thead>
<tr>
<th><strong>Name of Sponsor/Company:</strong></th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name of Investigational Product:</strong></td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td><strong>Name of Active Ingredient:</strong></td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td><strong>Title of Study:</strong></td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
</tbody>
</table>

**Criteria for Exclusion:**

Patients will not be eligible for study entry if any of the following criteria are met:

1. Patient has progressed while on platinum treatment or within 1 month from completion of platinum-containing regimen in any line of therapy.

2. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

   Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.

3. Patient has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

4. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).

5. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality (including active or uncontrolled myelosuppression [ie, anemia, leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the study, interfere with the patient’s participation for the full duration of the study treatment, or suggests it is not in the best interest of the patient to participate.

6. Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.

7. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

8. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

9. Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or
10. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

11. Patient has a history of interstitial lung disease.

12. Patient has not recovered (ie, to ≤Grade 1 or to baseline) from chemotherapy induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 4 weeks prior to the first dose of study treatment.

Note: Patients with ≤ Grade 1 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.

13. Patient has a known history of platelet transfusion for chemotherapy-induced thrombocytopenia or persistent (> 4 weeks) ≥ Grade 3 hematological toxicity or fatigue from prior cancer therapy.

14. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

15. Patient has had a prior anticancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1; prior chemotherapy or targeted small molecule therapy within 4 weeks prior to study Day 1; or radiation therapy encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

16. Patient has not recovered adequately from AEs and/or complications from any major surgery prior to starting therapy.

17. Patient has received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent or the patient has previously participated in Merck MK-3475 (pembrolizumab) clinical studies.

18. Patient has received a live vaccine within 30 days of planned start of study therapy.

19. Patient has undergone prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor.

20. Patient has a heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening.

21. Patient has a known hypersensitivity to niraparib or pembrolizumab components or excipients.

22. Patient has any known history of myelodysplastic syndrome (MDS) or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS/acute myeloid leukemia (AML)

23. Patient is receiving concomitant medications that prolong QTc and is unable to discontinue use
**Name of Sponsor/Company:** TESARO, Inc.

**Name of Investigational Product:** niraparib and pembrolizumab

**Name of Active Ingredient:** niraparib and pembrolizumab

**Title of Study:** Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer for the duration of the study (Appendix B).

**Investigational Product, Dosage, and Mode of Administration:**

**Niraparib**

Niraparib will be administered orally throughout the 21-day cycle at the assigned dose and schedule. On Day 1 of each cycle, a niraparib dose will be administered upon completion of pembrolizumab infusion. Depending on dose schedule, 1, 2, or 3 capsules of 100 mg strength niraparib will be taken at each dose administration (total dose 100 mg, 200 mg, or 300 mg per dose schedule, respectively). Patients will be instructed to take their niraparib dose at the same time each day, preferably in the morning. Patients must swallow and not chew all capsules. The consumption of water and food is permissible.

Niraparib will be dispensed to patients on Day 1 of every cycle (every 21 days) thereafter until the patient discontinues study treatment. The Pharmacy Manual contains descriptions of the packaging of niraparib and instructions for the preparation and administration of niraparib.

**Pembrolizumab**

Pembrolizumab will be administered on Day 1 of each 21-day treatment cycle after all procedures and assessments have been completed as detailed in Table 5.

Pembrolizumab will be administered at a dose of 200 mg IV using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Given the variability of infusion pumps from site to site, however, a window between -5 minutes and +10 minutes is permitted.

The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion and administration of the infusion solution.

**Duration of Treatment and Study Conduct:**

Treatment duration for individual patient: Patients may continue the pembrolizumab/niraparib combination treatment for up to 2 years or until disease progression, unacceptable toxicity, patient withdrawal, Investigator’s decision, or death. Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

Long-term follow-up: Every 3 months (90 days), via telephone.

Planned study conduct duration: the first data cutoff will occur at approximately 18 months (time from first patient enrolled [when responder or discontinuation status for all patients is known] (ie, approximately 6 months after last patient is enrolled). The final analysis, including updated time-to-event data will be conducted at approximately 24 months after the first patient is enrolled (ie, approximately 12 months after the last patient is enrolled).

**Criteria for Evaluation:**

**Safety**

- Dose-limiting toxicities during the first cycle (ie, during the first 21 days of treatment, *ie,*...
<table>
<thead>
<tr>
<th>Name of Sponsor/Company:</th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Investigational Product:</td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td>Name of Active Ingredient:</td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td>Title of Study:</td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
</tbody>
</table>

**Cycle 1/Day 1 through Cycle 1/Day 21** (Phase 1 only)

- Incidence of treatment-emergent AEs (TEAEs) during the first cycle compared to the second and subsequent cycles
- Incidence of TEAEs occurring while patients are on treatment or up to 30 days after the last dose of study drug
- Incidence of SAEs and ECI occurring while patients are on treatment or up to 90 days after the last dose of study drug
- Changes in clinical laboratory parameters (hematology, chemistry, coagulation, thyroid function, urinalysis), vital signs, ECOG performance status, ECG parameters, physical examinations, and usage of concomitant medications
- Whole blood samples will be collected prior to the start of the study drug and at treatment discontinuation for cytogenetic analysis

**Efficacy**

- Primary endpoint: ORR, defined as the proportion of patients who have achieved CR or PR, evaluated using RECIST v1.1 based on Investigator assessment
- The following secondary endpoints will also be evaluated based on Investigator assessment:
  - ORR by irRECIST
  - Duration of response, defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST v1.1 and by irRECIST
  - Disease control rate defined as the percentage of patients who have achieved CR, PR, or stable disease (SD) per RECIST v1.1 and irRECIST
  - Progression-free survival, defined as the time from first dose to the earlier date of assessment of progression, or death by any cause in the absence of progression, by RECIST v1.1 and by irRECIST
  - Overall survival as measured from the date of first dose to the date of death by any cause

**Pharmacokinetics**

Samples for PK determination will be collected from patients in both Phase 1 (plasma and serum) and Phase 2 (plasma only) and the plasma will be analyzed using liquid chromatography with mass spectrometric detection (LC-MS-MS) for niraparib. The serum may be analyzed for pembrolizumab using enzyme-linked immunosorbent assay (ELISA). Model predicted area under the concentration × time curves (AUCs) will be derived. Parameters of interest are AUC, minimum concentration ($C_{min}$), maximum concentration ($C_{max}$), clearance after oral administration (CL/F) and volume of distribution.
### Name of Sponsor/Company: TESARO, Inc.

### Name of Investigational Product: niraparib and pembrolizumab

### Name of Active Ingredient: niraparib and pembrolizumab

### Title of Study: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

After oral administration (Vz/F), AUC at steady state (AUC<sub>ss</sub>), C<sub>min</sub> at steady state (C<sub>min,ss</sub>), C<sub>max</sub> at steady state (C<sub>max,ss</sub>).

### Biomarkers

Biomarker classifiers will be evaluated in archival and fresh tumor samples obtained during screening; in addition, in the subset of patients who undergo serial biopsies, biomarkers will be evaluated in fresh tumor samples obtained at 8 to approximately 12 weeks after initiating study treatment and, whenever possible, at the time of disease progression. Blood samples for biomarker analysis will be obtained predose on Day 1 of Cycles 1 and 2 for analysis of circulating biomarkers.

Tumor markers, including mutations in homologous recombination genes, such as breast cancer gene 1 and 2 (BRCA1 and 2) mutations, may be explored. The magnitude of HRD positivity and tumor immune microenvironment may be evaluated. PD-L1 expression and other related markers in tumor and tumor-infiltrating immune cells may be explored.

HRD score and other biomarkers may be correlated with efficacy outcomes.

### Statistical Methods:

#### Sample Size Considerations

**Phase 1:** A total sample size of approximately 18 patients is estimated for the Phase 1 portion of the study to provide initial comparison of incidence of DLTs and safety profiles of the combination treatment between dose schedules in each patient population. More patients could be enrolled (e.g., if the Dose Level -2 is explored or if expansion at any dose level is required to better understand safety and tolerability); up to a total of 36 patients may be enrolled.

**Phase 2:** A total of approximately 96 evaluable patients (48 patients in each tumor type) will be enrolled to ensure understanding of the activity of the combination treatment and to obtain adequate representation of different molecular cancer subtypes and biomarkers.

### Analysis Populations

Three analysis populations will be defined as follows:

- **Safety Population:** All patients who receive any amount of study drug. The assessment of DLTs in Phase 1 will include only those patients completing the first cycle of therapy, unless the patient discontinued study drug due to a DLT.

- **Full Analysis Set (FAS):** All patients who receive any amount of study drug. The primary analysis of efficacy endpoints will be performed on the FAS population.

- **Per-Protocol Population:** All patients who receive at least two cycles of study drug, have protocol-required post-baseline disease assessments and have no major protocol violations that would impact efficacy evaluations. Supportive analyses of efficacy endpoints will be performed on the per-protocol population.
Name of Sponsor/Company: TESARO, Inc.

Name of Investigational Product: niraparib and pembrolizumab

Name of Active Ingredient: niraparib and pembrolizumab

Title of Study: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

General Methods
All analyses will include summary statistics, including number and percentage for categorical variables and number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables. Two-sided 90% confidence intervals (CIs) will be provided where appropriate. Time-to-event analyses will be performed using Kaplan-Meier methods. Comparisons in the Phase 1 portion of the study will be made using descriptive statistics. As the Phase 2 portion of the study is single-arm, any statistical analysis to be performed among subgroups is for descriptive and future study purposes. Further detail will be provided in the study statistical analysis plan.

Safety
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) for purposes of summarization. All AEs occurring during the study will be included in by-patient data listings and tabulated by MedDRA system organ class and preferred term. Safety endpoints for AEs include the following: incidence of DLTs, TEAEs, ECI, TEAEs leading to death, SAEs and AEs leading to discontinuation; tabulations will be produced by MedDRA system organ class and preferred term. Tabulations of TEAEs will also be produced by severity and by relationship to study drug.

Additional safety summaries will be provided for clinical laboratory tests, vital signs, ECOG performance status, and ECGs.

Results of cytogenetic analysis, including incidence of cytogenetic abnormalities at end of study treatment, will be summarized.

Efficacy
Tumor response will be summarized using descriptive statistics and a 1-sided 95% CI, corresponding to the specifications of the sample size calculation. Best overall response will be summarized by number and percentage.

Duration of response, PFS, and OS will be summarized using Kaplan-Meier analysis, including number and percentage of events, number and percentage of censored patients, and 25th, 50th, and 75th percentiles of times to event with 95% CIs.

Pharmacokinetics
Pharmacokinetic parameters will be summarized by study phase and dose schedule using descriptive statistics.

Biomarkers
The incidence of biomarkers will be summarized using descriptive statistics. Comparisons of efficacy endpoints between biomarker subpopulations may be performed.

Interim Analysis
In order to minimize the risk of exposing patients to an ineffective treatment, a series of futility assessments will be performed when 6, 12, 18, and 24 of 48 Phase 2 patients from each cancer type have at least 2 post-baseline tumor assessments. A formal decision regarding futility, which could result in
stopping the study early, will be made separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier assessments, however, will inform the conduct of the formal interim analysis as follows: If all 3 futility assessments from 6, 12, and 18 patients cross the futility boundary, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If any single futility assessment from 6, 12, or 18 patients fails to cross the futility boundary, then enrollment will not be curtailed.
TABLE OF CONTENTS

TITLE PAGE ...................................................................................................................................1
SPONSOR SIGNATURE PAGE ....................................................................................................2
INVESTIGATOR SIGNATURE PAGE .........................................................................................3
SYNOPSIS .......................................................................................................................................4
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ...................................................24
1. INTRODUCTION ..................................................................................................................28
   1.1. Background ..................................................................................................................28
   1.1.1. PARP and Homologous Recombination Deficiency ...........................................28
   1.1.2. Immune Surveillance and PD-1 Inhibitors .........................................................29
   1.2. Study Treatments .......................................................................................................30
   1.2.1. Niraparib ..............................................................................................................30
   1.2.2. Pembrolizumab ....................................................................................................31
   1.3. Rationale for Current Study .......................................................................................32
2. STUDY OBJECTIVES .........................................................................................................34
   2.1. Primary Objective ........................................................................................................34
   2.2. Secondary Objectives .................................................................................................34
   2.3. Exploratory Objectives ...............................................................................................34
3. INVESTIGATIONAL PLAN ...............................................................................................35
   3.1. Overall Study Design and Plan ....................................................................................35
   3.1.1. Overview ..................................................................................................................35
   3.1.2. Phase 1 Dose Escalation .....................................................................................36
   3.1.3. Phase 2 Expansion ...............................................................................................37
   3.1.4. General Study Conduct: Phase 1 and 2 ..............................................................37
4. STUDY POPULATION .......................................................................................................40
   4.1. Inclusion Criteria .........................................................................................................40
   4.2. Exclusion Criteria ........................................................................................................41
   4.3. Patient Withdrawal and Replacement .......................................................................44
   4.3.1. Discontinuation from Treatment ............................................................................44
   4.3.2. Discontinuation from the Study .............................................................................44
   4.3.3. Replacement of Patients .......................................................................................45
   4.4. Patient Identification and Randomization ...................................................................45
<table>
<thead>
<tr>
<th>Section</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4.1</td>
<td>Patient Identification</td>
<td>45</td>
</tr>
<tr>
<td>4.4.2</td>
<td>Randomization Scheme</td>
<td>45</td>
</tr>
<tr>
<td>5.</td>
<td>STUDY MEDICATION</td>
<td>46</td>
</tr>
<tr>
<td>5.1</td>
<td>Identity</td>
<td>46</td>
</tr>
<tr>
<td>5.1.1</td>
<td>Niraparib</td>
<td>46</td>
</tr>
<tr>
<td>5.1.2</td>
<td>Pembrolizumab</td>
<td>46</td>
</tr>
<tr>
<td>5.2</td>
<td>Administration</td>
<td>46</td>
</tr>
<tr>
<td>5.2.1</td>
<td>Niraparib</td>
<td>46</td>
</tr>
<tr>
<td>5.2.2</td>
<td>Pembrolizumab</td>
<td>46</td>
</tr>
<tr>
<td>5.3</td>
<td>Dose-Limiting Toxicity</td>
<td>47</td>
</tr>
<tr>
<td>5.4</td>
<td>Dose Modification</td>
<td>47</td>
</tr>
<tr>
<td>5.4.1</td>
<td>Niraparib</td>
<td>48</td>
</tr>
<tr>
<td>5.4.2</td>
<td>Pembrolizumab</td>
<td>50</td>
</tr>
<tr>
<td>5.5</td>
<td>Packaging, Labeling, and Storage</td>
<td>54</td>
</tr>
<tr>
<td>5.6</td>
<td>Drug Accountability</td>
<td>54</td>
</tr>
<tr>
<td>5.7</td>
<td>Previous and Concomitant Medications</td>
<td>54</td>
</tr>
<tr>
<td>5.7.1</td>
<td>Prohibited Medications</td>
<td>54</td>
</tr>
<tr>
<td>5.7.2</td>
<td>Contraception</td>
<td>56</td>
</tr>
<tr>
<td>5.7.3</td>
<td>Rescue Medications and Supportive Care Guidelines During Treatment</td>
<td>56</td>
</tr>
<tr>
<td>5.7.4</td>
<td>Other Study Restrictions</td>
<td>60</td>
</tr>
<tr>
<td>6.</td>
<td>ENDPOINTS AND METHODS OF ASSESSMENT</td>
<td>61</td>
</tr>
<tr>
<td>6.1</td>
<td>Safety Endpoints</td>
<td>61</td>
</tr>
<tr>
<td>6.1.1</td>
<td>Definitions</td>
<td>61</td>
</tr>
<tr>
<td>6.1.2</td>
<td>Assessment of Adverse Events</td>
<td>62</td>
</tr>
<tr>
<td>6.1.2.1</td>
<td>Intensity</td>
<td>62</td>
</tr>
<tr>
<td>6.1.2.2</td>
<td>Causality</td>
<td>62</td>
</tr>
<tr>
<td>6.1.3</td>
<td>Collecting and Recording Adverse Events</td>
<td>63</td>
</tr>
<tr>
<td>6.1.4</td>
<td>Reporting Disease Progression</td>
<td>64</td>
</tr>
<tr>
<td>6.1.5</td>
<td>Serious Adverse Events</td>
<td>64</td>
</tr>
<tr>
<td>6.1.5.1</td>
<td>Reporting of Serious Adverse Events</td>
<td>64</td>
</tr>
<tr>
<td>6.1.5.2</td>
<td>Submission and Distribution of Adverse Events/Serious Adverse Events</td>
<td>65</td>
</tr>
<tr>
<td>6.1.6</td>
<td>Events of Clinical Interest</td>
<td>65</td>
</tr>
</tbody>
</table>
6.1.6.1. Pembrolizumab ................................................................. 65
6.1.6.2. Niraparib ................................................................. 65
6.1.7. Pregnancy Reporting and Follow-up .......................... 65
6.1.8. Clinical Laboratory Assessments ................................ 66
6.1.9. Physical Examination and Vital Signs ....................... 68
6.1.10. Eastern Cooperative Oncology Group Performance Status .......................... 68
6.1.11. Additional Safety Assessments .................................. 68
6.2. Demographics and Baseline Characteristics .............. 68
6.2.1. Patient Eligibility .......................................................... 68
6.2.2. Patient Demography ..................................................... 68
6.2.3. Disease History ............................................................ 68
6.2.4. Medical and Surgical History ..................................... 69
6.2.5. Previous and Concomitant Medications ..................... 69
6.3. Efficacy Endpoint(s) ......................................................... 69
6.3.1. Evaluation of Tumor Response ................................. 69
6.3.1.1. Overview ................................................................. 69
6.3.1.2. Timing of Radiographic Evaluations ....................... 70
6.3.1.3. Assessment of Response by RECIST ..................... 71
6.3.1.4. Assessment of Response by Immune-Related RECIST .......... 71
6.3.2. Efficacy Endpoints .......................................................... 72
6.3.2.1. Objective Response Rate ......................................... 72
6.3.2.2. Duration of Response .............................................. 72
6.3.2.3. Disease Control Rate .............................................. 73
6.3.2.4. Progression-Free Survival ....................................... 73
6.3.2.5. Overall Survival ....................................................... 73
6.4. Pharmacokinetics .............................................................. 73
6.4.1. Phase 1 ........................................................................ 73
6.4.2. Phase 2 ........................................................................ 73
6.4.3. Determination of Pharmacokinetic Parameters ........... 74
6.5. Biomarkers ........................................................................ 74
7. STUDY CONDUCT .............................................................. 76
7.1. Schedule of Procedures .................................................... 76
7.2. Procedures by Visit ............................................................ 83
7.2.1. Screening (Day -21 to Day -1) ................................................................. 83
7.2.2. Cycle 1/Day 1 ...................................................................................... 84
7.2.3. Cycle 1/Day 2 (Phase 1 Patients Only) .................................................. 85
7.2.4. Cycle 1/Day 8 ...................................................................................... 85
7.2.5. Cycle 1/Day 15 .................................................................................... 85
7.2.6. Day 1, Subsequent Cycles ................................................................. 86
7.2.7. Cycle 2, Day 2 (Phase 1 Patients Only) ................................................ 88
7.2.8. End of Treatment (within 7 days of last dose) ...................................... 88
7.2.9. Safety Follow-up (30 days [+ 7 days] Post-treatment) ......................... 88
7.2.10. Follow-up Assessments .................................................................... 89
7.2.11. Unscheduled Assessments ................................................................. 90
8. STUDENT METHODS .................................................................................. 91
8.1. Study Populations ................................................................................... 91
8.2. Demographics, Medical History, Baseline Characteristics, and Concomitant Medications .................................................................................................................. 91
8.3. Safety Analyses ...................................................................................... 91
8.4. Pharmacokinetic Analyses ..................................................................... 92
8.5. Post-Treatment Analyses ....................................................................... 92
8.6. Efficacy Analyses .................................................................................. 92
8.6.1. Primary Efficacy Parameter ............................................................... 93
8.6.2. Secondary Efficacy Parameter(s) ....................................................... 93
8.7. Biomarker Analyses ............................................................................... 93
8.8. Probability of Dose Escalation ............................................................... 93
8.9. Interim Analyses ................................................................................... 96
8.10. Determination of Sample Size ............................................................. 97
9. ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS ......................... 98
9.1. Data Quality Assurance ...................................................................... 98
9.2. Access to Source Data/Documents ....................................................... 98
9.3. Archiving Study Documents .............................................................. 99
9.4. Good Clinical Practice ......................................................................... 99
9.5. Informed Consent ................................................................................. 99
9.6. Protocol Approval and Amendment .................................................... 99
9.7. Patient Confidentiality and Data Protection ......................................... 100
9.8. Study Monitoring .......................................................................................................100
9.9. Audits and Inspections ...............................................................................................100
9.10. Ethical Considerations ...............................................................................................100
9.11. Publication Policy ......................................................................................................101
9.12. Study Committee .......................................................................................................101
10. REFERENCE LIST ...................................................................................................102

APPENDIX A. DRUGS KNOWN TO INHIBIT OR INDUCE CYP1A2 OR ARE SUBSTRATES OF CYP1A2 ............................................................................108

APPENDIX B. DRUGS ASSOCIATED WITH QT PROLONGATION AND TORSADES DE POINTES (TDP) .....................................................................109

APPENDIX C. DRUGS THAT ARE SUBSTRATES OR INHIBITORS OF P-GLYCOPROTEIN ............................................................................................110

APPENDIX D. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST), V1.1 .................................................................................................111

APPENDIX E. IMMUNE-RELATED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS ..............................................................................................113

APPENDIX F. ASSESSMENT OF RESPONSE IN OVARIAN CANCER BY GYNECOLOGIC CANCER INTERGROUP (GCIG) CRITERIA ........................................114

APPENDIX G. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS .................................................................................................115
LIST OF TABLES
Table 1  Niraparib Dose Reductions for Non-Hematologic Toxicity ........................................48
Table 2  Management of Hematologic Toxicities* ................................................................50
Table 3  Pembrolizumab Dose Modifications for Non-hematologic Toxicities ....................52
Table 4  Pembrolizumab Infusion Reaction Treatment Guidelines ......................................59
Table 5: Schedule of Events ..................................................................................................77
Table 6: Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 1 ...............81
Table 7: Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 2 ...............82
Table 8: Niraparib Administration – Phase 1 ......................................................................82
Table 9: Dose Escalation Decision Rules ............................................................................94
Table 10: Drugs Associated with QT prolongation and Torsades de Pointes .....................109
Table 11: RECIST Response for Patients with Measurable Disease (ie, Target Disease) ....112
Table 12: RECIST Response For Patients with Non-Measurable Disease (ie, Non- Target Disease) .....................................................................................................................112
Table 13 Imaging and Treatment after First Radiologic Evidence of Progressive Disease .................................................................................................................................113

LIST OF FIGURES
Figure 1: Study Schema .......................................................................................................5
Figure 2: Study Schema .......................................................................................................35
Figure 3: Probability of Dose Escalation in a 6 + 6 Design ..................................................95
Figure 4: Probability of Dose Escalation in a 6 + 6 Design versus 3 + 3 Design at a Fixed Rate of 0.05 for Non-hematologic DLTs .................................................................96
### LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADL</td>
<td>activities of daily living</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>alt-NHEJ</td>
<td>alternative nonhomologous end-joining</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukemia</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>aPTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>ATM</td>
<td>ataxia telangiectasia mutated</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration × time curve</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;ss&lt;/sub&gt;</td>
<td>area under the concentration × time curve at steady state</td>
</tr>
<tr>
<td>BCG</td>
<td>bacille Calmette-Guerin</td>
</tr>
<tr>
<td>BER</td>
<td>base excision repair</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BRCA</td>
<td>breast cancer (gene)</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>clearance after oral administration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max,ss&lt;/sub&gt;</td>
<td>maximum concentration at steady state</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>minimum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min,ss&lt;/sub&gt;</td>
<td>minimum concentration at steady state</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DCR</td>
<td>disease control rate</td>
</tr>
<tr>
<td>DKA</td>
<td>diabetic ketoacidosis</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECI</td>
<td>events of clinical interest</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EOT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>ER-</td>
<td>estrogen receptor</td>
</tr>
<tr>
<td>FT3</td>
<td>free triiodothyronine</td>
</tr>
<tr>
<td>FT4</td>
<td>free thyroxine</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>gBRCA&lt;sup&gt;mut&lt;/sup&gt;</td>
<td>germline breast cancer gene mutation</td>
</tr>
<tr>
<td>GCIG</td>
<td>Gynecologic Cancer Intergroup</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCV RNA</td>
<td>hepatitis C virus ribonucleic acid</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>homologous recombination</td>
</tr>
<tr>
<td>HRD</td>
<td>homologous recombination deficiency</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IgG</td>
<td>immunoglobulin G</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>irRECIST</td>
<td>immune-related Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ITIM</td>
<td>immunoreceptor tyrosine-based inhibition motif</td>
</tr>
<tr>
<td>ITSM</td>
<td>immunoreceptor tyrosine-based switch motif</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan-Meier</td>
</tr>
<tr>
<td>LC-MS-MS</td>
<td>liquid chromatography with mass spectroscopic detection</td>
</tr>
<tr>
<td>mAb</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplastic syndrome</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>NHEJ</td>
<td>nonhomologous end-joining</td>
</tr>
<tr>
<td>OC</td>
<td>primary peritoneal ovarian cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PARP</td>
<td>poly(ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death-1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed death ligand-1</td>
</tr>
<tr>
<td>PD-L2</td>
<td>programmed death ligand-2</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PO</td>
<td>oral(ly)</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PR-</td>
<td>progesterone receptor</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>QD</td>
<td>once daily</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>RP2D</td>
<td>recommended Phase 2 dose</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>T3</td>
<td>triiodothyronine</td>
</tr>
<tr>
<td>TEAE</td>
<td>treatment-emergent adverse event</td>
</tr>
<tr>
<td>TIL</td>
<td>tumor-infiltrating lymphocytes</td>
</tr>
<tr>
<td>TNBC</td>
<td>triple-negative breast cancer</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid-stimulating hormone</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>V-type</td>
<td>variable-type</td>
</tr>
<tr>
<td>V$_d$/F</td>
<td>volume of distribution after oral administration</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

1.1. Background

1.1.1. PARP and Homologous Recombination Deficiency

Poly(ADP-ribose) polymerases (PARP)1 and PARP2 are zinc-finger deoxyribonucleic acid (DNA)-binding enzymes that play a crucial role in DNA repair. Upon formation of DNA breaks, PARP binds at the end of broken DNA strands, a process that activates its enzymatic activity. Activated PARP catalyzes the addition of long polymers of ADP-ribose onto PARP and several other proteins associated with chromatin, including histones and various DNA repair proteins. This results in chromatin relaxation, fast recruitment of DNA repair proteins, and efficient repair of DNA breaks. In this manner, PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single-strand break repair pathways.

Normal cells repair up to 10,000 DNA defects daily, and single-strand breaks are the most common form of DNA damage. Cells that are unable to repair this burden of DNA damage, such as those with defects in the homologous recombination (HR) or BER pathways, are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. They enter the S phase (DNA replication) of the cell cycle with unrepaired single- and double-strand breaks. Pre-existing single-strand breaks are converted to double-strand breaks as the replication machinery passes. Accumulated double-strand breaks present during S phase are repaired by HR. Homologous recombination is the preferred repair pathway because it is associated with a much lower error rate than other forms of repair. Cells unable to perform DNA repair via HR (eg, due to inactivation of genes required for HR, such as breast cancer gene [BRCA]1- or BRCA2-mutated cells) are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. These cells accumulate stalled replication forks during S phase and are more likely to use the error-prone nonhomologous end-joining (NHEJ) or alternative (alt)-NHEJ pathways to repair double-strand breaks in DNA. Accumulation of errors in DNA by NHEJ contributes to mutation burden that promotes the development of cancer. Over time, the buildup of excessive DNA errors in combination with the inability to complete S phase (because of stalled replication forks) contributes to cell death.

Treatment with PARP inhibitors could represent a novel opportunity to selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. For example, a tumor arising in a patient with a germline BRCA mutation (gBRCA mut) has a defective HR DNA repair pathway and would be increasingly dependent on NHEJ, alt-NHEJ, and BER for maintenance of genomic integrity. PARP inhibitors block alt-NHEJ and BER, forcing tumors with BRCA deficiencies to use the error-prone NHEJ to fix double-strand breaks. Non-BRCA deficiencies in HR DNA repair genes could also enhance tumor cell sensitivity to PARP inhibitors. The rationale for anticancer activity in a subset of non-gBRCA mut tumors is that they share distinctive DNA repair defects with gBRCA mut carriers, a phenomenon broadly described as “BRCAness.” DNA repair defects can be caused by germline or somatic alterations to the HR DNA repair pathway. In a recent analysis of approximately 500 high-grade serous ovarian adenocarcinoma tumors, approximately 50% contained HR defects. A subset of these tumors had biologically plausible...
molecular alterations that may make them sensitive to PARP inhibition by niraparib. A similar analysis of triple-negative breast cancer (TNBC) indicates up to 40% of these patients have tumors with HR defects.\(^{(6)}\)

Homologous recombination is a complex pathway, and several genes other than BRCA1 and BRCA2 are required either to sense or repair DNA double-strand breaks via the HR pathway. Therefore, PARP inhibitors are also selectively cytotoxic for cancer cells with deficiencies in DNA repair proteins other than BRCA1 and BRCA2, including RecA homologs (RAD51 and RAD54), X-ray repair complementing defective repair in Chinese hamster cells (XRCC2 and XRCC3), DSS1, replication protein A1 (RPA1), ataxia telangiectasia mutated (ATM), ATM and Rad3-related (ATR), check point kinases (CHK1, CHK2), Nijmegen breakage syndrome 1 (NBS1), and the components of the Fanconi anemia repair pathway.\(^{(1, 4, 7)}\)

Clinical studies have shown that PARP inhibitors are active for recurrent ovarian cancer (OC).\(^{(1-3, 8-11)}\) Clinical anticancer activity has been observed in patients with and without gBRCA\(^{\text{mut}}\) and in patients who are platinum-sensitive and platinum-resistant. PARP inhibition appears to be most active in patients with gBRCA\(^{\text{mut}}\) platinum-sensitive disease.\(^{(3, 9)}\) Additionally, maintenance therapy in patients with relapsed, platinum-sensitive OC appears promising.\(^{(10)}\) Of patients with a BRCA mutation, median progression-free survival (PFS) was significantly longer in the PARP inhibitor group than in the placebo group (11.2 months vs. 4.3 months; hazard ratio: 0.18; p< 0.0001). Similar findings were noted for patients with wild-type BRCA, although the difference between groups was smaller (7.4 months vs. 5.5 months; hazard ratio: 0.54; p = 0.007).

Recent clinical studies also have shown PARP inhibitors to be active in breast and ovarian cancer. Clinical anticancer activity with PARP inhibitors has been seen in both patients with gBRCA\(^{\text{mut}}\) and without gBRCA\(^{\text{mut}}\); however, activity is more robust in patients with the germline mutation.\(^{(1, 3, 8, 10-12)}\)

In summary, treatment with PARP1/2 inhibitors represents a novel opportunity to selectively kill a subset of cancer cell types by exploiting their deficiencies in DNA repair. Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair. These deficiencies render cancer cells more dependent on the remaining DNA repair pathways, and targeting these pathways is expected to have a much greater impact on the survival of the tumor cells than on normal cells.

**1.1.2. Immune Surveillance and PD-1 Inhibitors**

The importance of intact immune surveillance in controlling outgrowth of neoplastic transformation has been known for decades.\(^{(13)}\) Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes (TILs) in cancer tissue and prognosis in various malignancies.\(^{(14-26)}\) In particular, the presence of CD8+ T cells and the ratio of CD8+ effector T cells/FoxP3+ regulatory T cells seem to correlate with improved prognosis and long-term survival in many solid tumors.\(^{(22, 27-33)}\)

The programmed death-1 (PD-1) receptor-ligand interaction is a major pathway hijacked by tumors to suppress immune control.\(^{(34)}\) The normal function of PD-1, expressed on the cell surface of activated T cells under healthy conditions, is to down-modulate unwanted or excessive immune responses, including autoimmune reactions. PD-1 (encoded by the gene Pdcd1) is an immunoglobulin (Ig) superfamily member related to CD28 and CTLA-4, which has been shown
to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2). The structures of murine PD-1 alone (35) and in complex with its ligands were first resolved (36, 37), and more recently the nuclear magnetic resonance-based structure of the human PD-1 extracellular region and analyses of its interactions with its ligands were also reported. (38) PD-1 and family members are type I transmembrane glycoproteins containing an Ig variable-type (V-type) domain responsible for ligand binding and a cytoplasmic tail, which is responsible for the binding of signaling molecules. The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). Following T cell stimulation, PD-1 recruits the tyrosine phosphatases SHP-1 and SHP-2 to the ITSM motif within its cytoplasmic tail, leading to the dephosphorylation of effector molecules, such as CD3ζ, PKCθ and ZAP70, which are involved in the CD3 T cell signaling cascade. (39) The mechanism by which PD-1 down-modulates T cell responses is similar to, but distinct from, that of CTLA-4. (40) PD-1 was shown to be expressed on activated lymphocytes, including peripheral CD4+ and CD8+ T cells, B cells, T regs, and natural killer cells. (41) Expression has also been shown during thymic development on CD4-/CD8- (double-negative) T cells, (42) as well as subsets of macrophages (43) and dendritic cells. (44) The ligands for PD-1 (PD-L1 and PD-L2) are constitutively expressed or can be induced in a variety of cell types. (45) PD-L1 is expressed at low levels on various non-hematopoietic tissues, most notably on vascular endothelium, whereas PD-L2 protein is predominantly expressed on antigen-presenting cells found in lymphoid tissue or chronic inflammatory environments. (45) Both ligands are type I transmembrane receptors containing both IgV- and IgC-like domains in the extracellular region and short cytoplasmic regions with no known signaling motifs. Binding of either PD-1 ligand to PD-1 inhibits T cell activation triggered through the T cell receptor. PD-L2 is thought to control immune T cell activation in lymphoid organs, whereas PD-L1 serves to dampen unwarranted T cell function in peripheral tissues. Although healthy organs express little (if any) PD-L1, a variety of cancers were demonstrated to express abundant levels of this T cell inhibitor, (46, 47) which, via its interaction with the PD-1 receptor on tumor-specific T cells, plays a critical role in immune evasion by tumors. (48) As a consequence, the PD-1/PD-L1 pathway is an attractive target for therapeutic intervention in cancer. (49)

1.2. Study Treatments

1.2.1. Niraparib

Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the HR DNA repair pathway or that are driven by PARP-mediated transcription factors.

Nonclinical data on niraparib are discussed in detail in the Investigator’s Brochure. Briefly, in nonclinical models, niraparib has been observed to inhibit normal DNA repair mechanisms and induce synthetic lethality when administered to cells with HR defects. In a BRCA1-mutant xenograft study, niraparib dosed orally caused tumor regression, which was mirrored by > 90% reduction in tumor weight compared with control. In a BRCA2-mutant xenograft study, niraparib-dosed mice showed 55% to 60% growth inhibition, both by tumor volume and weight.

Niraparib displayed strong antitumor activity in in vivo studies with BRCA1-mutant breast cancer (MDA-MB-436), BRCA2-mutant pancreatic cancer (CAPAN-1), ATM-mutant mantle
cell lymphoma (GRANTA-519), serous OC (OVCAR3), and colorectal cancer (HT29 and DLD-1) xenograft models and with patient-derived Ewing sarcoma mice models. Utilizing patient-derived ovarian and breast cancer xenograft models, niraparib demonstrated response in both BRCA mutation and BRCA wild-type tumors.

Niraparib clinical data are discussed in detail in the niraparib Investigator’s Brochure. In the Phase 1 clinical program, niraparib, as a monotherapy or in combination with chemotherapy, has been administered to 144 patients. As of 02 February 2015, 427 patients have received niraparib or placebo in the ongoing Phase 3 clinical studies, for which preliminary data are available. Treatment with niraparib has been generally well tolerated in these studies.

In the Phase 1 program (n=144), the most common (> 20.0% of patients) adverse events (AEs), were fatigue (58.3%), nausea (54.9%), anemia (50.7%), constipation (39.6%), thrombocytopenia (37.5%), vomiting (36.8%), decreased appetite (31.9%), neutropenia (28.5%), headache (26.4%), diarrhea (21.5%), dyspnea (21.5%), cough (20.8%), and leukopenia (20.8%).

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed in patients receiving treatment with olaparib, a PARP inhibitor; given the common mechanism of action, MDS and AML therefore represent a potential risk to patients receiving niraparib. Guidance on monitoring patients for new events of MDS/AML and the follow-up of patients with suspected MDS/AML is provided in Section 6.1.8 and Section 7.

Clinical activity data for niraparib administered as monotherapy in patients with OC are available from 1 early-phase clinical study. In the Phase 1/2 study PN001, 104 patients with advanced solid tumors who had received a median of 5 prior therapies were enrolled; 49 had OC (13 platinum-sensitive, 35 platinum-resistant, and 1 platinum-refractory). Of the 49 patients, 22 had confirmed BRCA1 or BRCA2 mutation, of whom 20 were radiologically assessable. Eight (40%) of these 20 patients achieved a confirmed partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 Gynecologic Cancer Intergroup (GCIG) criteria at doses ranging from 80 to 400 mg per day. Median response duration was 387 days (range: 159 to 518 days). Three (33%) of 9 patients with platinum-resistant BRCA-mutant OC had PR by RECIST and CA-125 criteria. Additionally, a 50% response rate (5 of 10 evaluable patients) was observed at daily doses ranging from 290 to 300 mg among patients with BRCA-mutant OC who had received more than 3 lines of prior chemotherapy (data on file).

1.2.2. Pembrolizumab

Pembrolizumab [Keytruda® (US); previously known as MK-3475 and SCH 9000475] is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Pembrolizumab was recently approved in the US for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. It is the first anti-PD-1 therapy to receive regulatory approval in the US, while in the European Union it is approved for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Refer to the Investigator’s Brochure and the approved labeling for detailed information on pembrolizumab.
Pembrolizumab has demonstrated initial clinical efficacy in single-arm monotherapy clinical studies in patients with non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, gastric cancer, TNBC, and Hodgkin lymphoma as determined by response rate. Ongoing clinical studies are being conducted in these tumor types as well as a number of other advanced solid tumor indications and hematologic malignancies.

### 1.3. Rationale for Current Study

Current treatment options for patients with advanced or metastatic TNBC and patients with recurrent OC are limited, with no approved standard of care.

Triple-negative breast cancer is an aggressive histologic subtype of breast cancer, clinically defined by lack of expression of the estrogen receptor (ER-) and progesterone receptor (PR-) and lack of overexpression or amplification of HER2-receptor. The malignancy constitutes an aggressive form of the disease regardless of stage at diagnosis, and in patients with metastatic TNBC, there are currently no approved therapies or standard of care.

Similarly for recurrent OC, there are no approved treatments or standard of care. Although the National Comprehensive Cancer Network guidelines recommend treatment with single-agent topotecan, doxorubicin, or gemcitabine, the optimal combination and sequence of these agents is unclear, and the exact population who would derive the most benefit is not well defined.

Over recent years, research has revealed the importance of TILs in controlling the clinical progression of various cancers and their presence in a tumor is associated with response to immune checkpoint inhibitors. Accumulating evidence suggests that basal-type TNBC may be the ER(-) breast cancer most regulated by intratumoral T cells and thus the most potentially responsive to immunotherapies. In addition, the frequency of BRCA1/2 deficiency, both BRCA mutations and silencing of BRCA expression, in TNBC is between 45% and 70%. Similarly in OC, intraepithelial CD8+ T-cells correlated with the presence of mutation or loss of expression of BRCA1 through promoter methylation. Collectively, metastatic TNBC and OC patient populations that were sensitive to agents targeting defects in DNA repair are likely to overlap with those tumors with an active yet checkpoint-blocked immune response.

Despite promising activity of PD-1 inhibitors observed in some types of cancer, including melanoma and NSCLC, activity in TNBC (objective response rate [ORR] of 18.5% with pembrolizumab) and ovarian cancer (ORR of 11%-12% on pembrolizumab or avelumab) observed thus far have been modest. Although promising in selected patients with BRCA mutations or potentially with HR deficiency, modest activity of PARP inhibitors in unselected ovarian cancer patients with resistant disease has been observed (ORR of 16% with niraparib and 0% with olaparib). Synergistic interactions have been observed, however, between immune checkpoint inhibitors and PARP inhibitors; nonclinical experiments in syngeneic mouse models have shown an increased response rate to the combination of anti-PD-1 and niraparib over either agent alone, providing additional support to investigate this combination in patients. Exposure of a tumor in vivo to PARP inhibitor results in increased cancer cell death by 2 independent mechanisms. First, through the mechanism of synthetic lethality, the PARP inhibitor can kill HR-deficient tumors through apoptosis. Second, the PARP inhibitor can increase the number of CD8+ T cells and natural killer (NK) cells, as well as their production of IFN-γ and TNF-α, resulting in an improved response to checkpoint blockade. Accordingly, the
biomarkers for this combination clinical study will include a wide range of assays, including the measurement of tumor cell death, genomic changes, apoptosis, and immune response.

Given the unmet medical need of patients with advanced or metastatic TNBC and patients with platinum-resistant recurrent OC, the non-overlapping safety and metabolic profile (please see the current versions of the niraparib Investigator’s Brochure and the pembrolizumab Investigator’s Brochure for details), and preclinical data suggesting possible synergistic interaction between immune checkpoint inhibitors and PARP inhibitors along with a potential overlap for PD-l- and PARP-sensitive patient populations, this study is designed to evaluate the combination of niraparib and pembrolizumab in these populations.
2. STUDY OBJECTIVES

2.1. Primary Objective
The primary objectives of this study, by phase, are as follows:

- Phase 1: To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment and to establish a recommended Phase 2 dose (RP2D) and schedule.
- Phase 2: To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of ORR as assessed by the Investigators using RECIST v1.1 separately for the TNBC and OC cohorts.

2.2. Secondary Objectives
The secondary objectives of the study are as follows:

- Phase 1 and Phase 2: To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03).
- Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST (irRECIST)
  - Duration of response (DOR) by RECIST v1.1 and by irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
  - Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
  - Overall survival (OS).
- Phase 1 and Phase 2: To evaluate the pharmacokinetics (PK) of niraparib during combination treatment.

2.3. Exploratory Objectives
The exploratory objectives of the study for both phases are as follows:

- To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of TILs, and circulating biomarkers.
- To correlate homologous recombination deficiency (HRD) score with other immune-related biomarkers and with efficacy outcomes.
3. INVESTIGATIONAL PLAN

3.1. Overall Study Design and Plan

3.1.1. Overview

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with previously treated TNBC or OC. Specifically, patients eligible for this study are those with:

- Advanced or metastatic TNBC (in Phase 1 patients may have received up to 3 lines of chemotherapy for advanced/metastatic disease or in Phase 2, up to 2 lines of chemotherapy for advanced/metastatic disease); or

- Advanced, recurrent, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who are currently platinum-resistant but experienced a response lasting for at least 6 months to first-line platinum-based therapy (in Phase 1 patients may have received up to 4 lines of chemotherapy or in Phase 2, up to 3 lines of chemotherapy).

Study treatment should be considered an appropriate option by the Investigator.

The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the RP2D and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab, and the Phase 2 portion will further evaluate the RP2D and schedule in 2 cohorts of 48 patients each with TNBC or OC as described above. Figure 2 presents an overview of the planned study schema. The schedule of events for the study is provided in Table 5.

Figure 2: Study Schema

Abbreviations: AE = adverse event; d= day(s); DL = dose level; DLT = dose-limiting toxicity; OC = ovarian cancer; PK = pharmacokinetics; q21d = every 21 days; N = niraparib; P = pembrolizumab; RP2D = recommended Phase 2 dose; TNBC = triple-negative breast cancer.
The study will be conducted in conformance with Good Clinical Practice (GCP).

3.1.2. **Phase 1 Dose Escalation**

The following are the planned dose levels and treatment schedule for the Phase 1 portion of the study. Initially, 6 patients will be enrolled within a cohort. Based on current single-agent niraparib experience (see niraparib Investigator’s Brochure), hematological laboratory abnormalities are expected in a significant proportion of patients; therefore, cohorts may be expanded up to approximately 12 patients if needed to better characterize the safety of the combination treatment.

- **Dose Level 1**: niraparib 200 mg/day orally (PO) on Days 1-21 and pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.
- **Dose Level 2**: niraparib 300 mg/day PO on Days 1-21 and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- **Dose Level (-1)**: niraparib 200 or 300 mg/day PO on Days 1-14 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).
- **Dose Level (-2)**: niraparib 200 or 300 mg/day PO on Days 1 – 7 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).

Dosing will initiate at Dose Level 1 with a cohort of 6 patients with either TNBC or OC enrolled and treated with a combination of niraparib 200 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. After all patients in Dose Level 1 who are evaluable for safety have completed Cycle 1 of combination treatment, a review of the safety of treatment will be conducted by the Investigators and Sponsor (see Section 9.12). A patient will be considered non-evaluable if, for any reason other than safety, the patient is unable to complete the 21-day combination treatment DLT observation period or is unable to take > 80% of the intended dose of either agent. Patients in Phase 1 considered unevaluable may be replaced after consultation between the Sponsor and Principal Investigator. If 2 of 6 initially enrolled patients in a cohort experience hematologic DLTs, a lower dose level will be opened. If, however, the 2 observed DLTs include 1 hematologic DLT and 1 non-hematologic DLT or 2 non-hematologic DLTs, a cohort may be expanded up to approximately 12 patients to better characterize the safety of the combination treatment. Following the safety review, the next higher dose level (Dose Level 2) will be open for enrollment if less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) in Dose Level 1 experience a DLT during Cycle 1 (see Section 5.3 for the definition of DLT).

Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either TNBC or OC will be enrolled in Dose Level 2 and treated with a combination of niraparib 300 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. No further dose escalation will be considered if Dose Level 2 is reached.
The maximum tolerated dose (MTD) will be defined as the highest dose with DLTs observed in less than one-third of patients (i.e., < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be opened for enrollment if not yet evaluated. Alternative dosing schedules may be explored.

Additional cohorts of 6 patients may be opened to evaluate Dose Level (-1) or Dose Level (-2), which will explore lower niraparib dose intensity by, for example, introducing an alternative dosing schedule, following agreement by the Investigators and Sponsor (see Section 9.12).

Patients in Phase 1 who complete the 21-day DLT evaluation period may continue the pembrolizumab/niraparib combination treatment for up to 2 years unless specific withdrawal criteria are met (Section 4.3). Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator. Appropriate niraparib dose modification can be made according to Section 5.4.1.

The RP2D will be determined following discussion and agreement between Investigators and the Sponsor based on evaluation of multiple endpoints, which may include the DLT rate in first and subsequent cycles of combination treatment, the rate of dose modifications for non-DLT AEs, the ability to manage toxicities, PK, niraparib dose intensity, and signs of clinical efficacy. The goal will be to identify the dose/regimen of niraparib with the greatest dose intensity that can be safely combined with the recommended dose/regimen of pembrolizumab.

### 3.1.3. Phase 2 Expansion

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion. Two cohorts of 48 patients each with advanced TNBC or OC as outlined above will be evaluated.

Patients in this phase of the study will receive the RP2D of niraparib in combination with pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Combination pembrolizumab/niraparib treatment may continue for up to 2 years unless specific withdrawal criteria are met (Section 4.3). Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

### 3.1.4. General Study Conduct: Phase 1 and 2

Following informed consent, all patients in both Phase 1 and Phase 2 will undergo screening procedures within 21 days prior to the first dose of study treatment to determine eligibility for study entry. Screening procedures include medical, surgical, cancer, and medication history; complete physical examination, including vital signs, height, and weight; Eastern Cooperative Oncology Group (ECOG) performance status; clinical laboratory tests (complete blood count [CBC], coagulation, chemistry, thyroid-stimulating hormone [TSH], triiodothyronine [T3] or free T3 [FT3], free thyroxine [FT4], urinalysis, pregnancy test for women of childbearing potential, serum CA-125 [OC patients only]); electrocardiogram (ECG); and whole blood sample for fluorescence in situ hybridization (FISH)/MDS test and other cytogenetic analysis. Tumor samples must be available from all patients (fresh samples or archived paraffin blocks; see Study Manual for details on sample collection and preparation) and will be sent to a centralized laboratory for biomarker testing. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy.
Radiographic evaluations (computed tomography [CT, preferred method] or magnetic resonance imaging [MRI, if clinically indicated]) of the chest, abdomen, and pelvis must be conducted at screening to determine extent of disease and confirm presence of measurable disease. Brain scan will be conducted if clinically indicated; bone scans will be conducted per standard of care. Scans performed prior to the signing of the informed consent form (ICF) as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and are performed within 21 days prior to first dose date.

All patients will begin treatment with niraparib and pembrolizumab on Cycle 1/Day 1; additional on-treatment assessments will be conducted on Days 8 and 15 of Cycle 1 and on Day 1 of all subsequent cycles. Safety assessments conducted throughout the treatment period include symptom-directed physical examination, vital signs, ECGs, ECOG performance status, and clinical laboratory assessments (CBC, coagulation [Phase 1 only], chemistry, TSH, T3 or FT3, FT4, urinalysis, CA-125 [OC patients only], and pregnancy testing). Radiographic evaluations (CT/MRI of chest [all TNBC patients and OC patients with abnormal screening scan or with clinical indication], abdomen, and pelvis) to assess extent of disease will be conducted every 9 weeks (63 days ±7 days) after Cycle 1/Day 1 while on study treatment independent of cycle delays and/or dose interruptions and/or at any time when progression of disease is suspected. The same modality (CT or MRI) should be used throughout the study for a given patient. Brain scans will be conducted if clinically indicated; bone scans will be conducted per standard of care. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days) until disease progression. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals (ie, every 9 weeks for the first year and every 12 weeks thereafter). All radiographic images/scans will be sent to a central imaging vendor upon acquisition and archived for future evaluation if needed. Per RECIST v1.1, patients who achieved complete response (CR) or partial response (PR) should have the response confirmed; tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated. Blood sampling for PK evaluations will be conducted for patients in both Phase 1 and Phase 2 (see Section 6.4).

In patients who consent to fresh biopsies, serial fresh biopsies will be obtained for exploratory biomarker analysis at 3 time points: during the screening period, 8 to approximately 12 weeks after initiating study treatment and, whenever possible, at the time of disease progression (note: while the biopsy is voluntary, it is highly encouraged). A core biopsy is recommended (details are provided in the Study Manual); if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy. Blood samples will also be obtained for biomarker analysis predose on Day 1 of Cycles 1 and 2.

All patients will undergo an End-of-Treatment (EOT) visit within 7 days of the last dose of study treatment and a safety follow-up visit conducted 30 days (+7 days) post-treatment. Thereafter, all patients will enter the post-treatment period for telephone assessment of survival status and the occurrence of any new malignancies every 90 days (±14 days).

All AEs will be collected and recorded for each patient from the day of signing the ICF until 30 days after last study drug administration; serious adverse events (SAEs) and Events of
Clinical Interest (ECIs) (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies are to be captured through 120 days post-treatment. All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.
4. **STUDY POPULATION**

4.1. **Inclusion Criteria**

To be considered eligible to participate in this study, all of the following requirements must be met:

1. Patient is male or female at least 18 years of age.

2. Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below,
   a. Patients with breast cancer that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (triple-negative breast cancer, TNBC) who have been treated with at least 1 prior regimen for advanced/metastatic disease or who relapsed/progressed while on or within 1 month from completion of adjuvant chemotherapy. Note: if progression occurred on or within 1 month of adjuvant platinum-containing treatment, the patient will not be eligible.  
   - Up to 3 lines of prior chemotherapy are allowed for patients in Phase 1 and up to 2 lines for patients in Phase 2.
   b. Patients with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who have recurrent disease and have been previously treated with chemotherapy for advanced/metastatic disease and who experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered platinum-resistant.
   - Up to 4 lines of prior chemotherapy are allowed for patients in Phase 1 and up to 3 lines for patients in Phase 2.

3. Patient has archival tumor tissue available that is formalin-fixed and paraffin-embedded.
   a. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation.
   b. Serial fresh tumor tissue samples will be collected in patients with lesions amenable for a biopsy who consent to such a procedure.

4. Patient has measurable lesions by RECIST v1.1.

5. Patient has an ECOG performance status of 0 to 1.

6. Patient has adequate organ function, defined as:
   a. Absolute neutrophil count (ANC) ≥ 2,000/µL
   b. Platelets ≥ 175,000/µL
   c. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
   d. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
   e. Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN
f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN.

g. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.

h. Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.

7. Patient is able to take oral medications.

8. Female patient has a negative serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):

   a. ≥ 45 years of age and has not had menses for > 1 year
   b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation
   c. Post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study therapy. Please see Section 5.7.2 for a list of acceptable birth control methods. Information must be captured appropriately within the site's source documents.
   d. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

9. Male patient agrees to use an adequate method of contraception (please see Section 5.7.2 for a list of acceptable birth control methods) starting with the first dose of study therapy through 120 days after the last dose of study therapy.

   Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

10. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.

### 4.2. Exclusion Criteria

Patients will not be eligible for study entry if any of the following criteria are met:

1. Patient has progressed while on platinum treatment or within 1 month from completion of platinum-containing regimen in any line of therapy.
2. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.

3. Patient has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

4. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).

5. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality (including active or uncontrolled myelosuppression [ie, anemia, leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the study, interfere with the patient’s participation for the full duration of the study treatment, or suggests it is not in the best interest of the patient to participate.

6. Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.

7. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

8. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

9. Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected).

10. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
11. Patient has a history of interstitial lung disease.

12. Patient has not recovered (i.e., to ≤Grade 1 or to baseline) from chemotherapy-induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 4 weeks prior to the first dose of study treatment.

Note: Patients with ≤ Grade 1 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.

13. Patient has a known history of platelet transfusion for chemotherapy-induced thrombocytopenia or persistent (> 4 weeks) ≥ Grade 3 hematological toxicity or fatigue from prior cancer therapy.

14. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

15. Patient has had a prior anticancer mAb within 4 weeks prior to study Day 1; prior chemotherapy or targeted small molecule therapy within 4 weeks prior to study Day 1; or radiation therapy encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

16. Patient has not recovered adequately from AEs and/or complications from any major surgery prior to starting therapy.

17. Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or the patient has previously participated in Merck MK-3475 (pembrolizumab) clinical studies.

18. Patient has received a live vaccine within 30 days of planned start of study therapy.

19. Patient has undergone prior treatment with a known PARP inhibitor.

20. Patient has a heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening.

21. Patient has a known hypersensitivity to niraparib or pembrolizumab components or excipients.

22. Patient has any known history of MDS or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS/AML.

23. Patient is receiving concomitant medications that prolong QTc and is unable to discontinue use for the duration of the study (Appendix B).
4.3.  Patient Withdrawal and Replacement

4.3.1. Discontinuation from Treatment

Patients may be discontinued from study treatment at any time. Specific examples of reasons for discontinuing all study treatments are given below.

- Adverse event
- Disease progression as outlined in Section 6.3 or based on clinical criteria by Investigator
- Risk to patient as judged by the Investigator and/or Sponsor
- Severe noncompliance with the protocol as judged by the Investigator and/or Sponsor
- Patient request
- Patient becomes pregnant
- Sponsor decision to terminate study

Details of required niraparib dose modifications, including interruptions, dose reductions, and permanent discontinuations, related to toxicity are provided in Section 5.4.1.

Details of required pembrolizumab dose interruptions and permanent discontinuation related to toxicity are provided in Section 5.4.2.

Note: If a patient is required to be discontinued from one of the study medications in the combination, treatment with the other study medication may be continued per decision of the Investigator in consultation with Sponsor.

Discontinuation of treatment may be considered for patients who have attained a confirmed CR, have been treated for at least 24 weeks with study treatments, and had at least 2 cycles of treatment beyond the date when the initial CR was declared.

Patients who discontinue from all study treatments will continue to receive follow-up assessments (see Table 5) as part of the study unless they are discontinued from the study (Section 4.3.2).

4.3.2. Discontinuation from the Study

Patients may be discontinued from the study for any of the following reasons:

- Withdrawal of consent by the patient, who is at any time free to discontinue their participation in the study, without prejudice to further treatment
- Death from any cause
- Loss to follow-up

If a patient is lost to follow-up or withdraws from study treatment, attempts should be made to contact the patient to determine the reason for discontinuation. For patients who are lost to follow-up, at least 3 documented attempts, including one via certified mail, should be made to contact the patient before considering the patient lost to follow-up.
4.3.3. **Replacement of Patients**

After consultation between the Sponsor and the Principal Investigator, enrollment may be extended to replace patient(s) that become non-evaluable for safety during Phase 1.

In Phase 2, if a patient discontinues study treatment prior to the first assessment of disease (either scheduled radiological assessment at 9 weeks post treatment initiation or clinically indicated disease assessment prior to 9 weeks), the patient should be replaced for the purposes of efficacy analysis after consultation between the Sponsor and Principal Investigator.

4.4. **Patient Identification and Randomization**

4.4.1. **Patient Identification**

All patients who enter into the screening period of the study (defined as the point at which the patient signs the ICF) will receive a unique patient identification number. This number will be used to identify the patient throughout the study and must be used on all study documentation related to that patient. A patient will be considered enrolled when the patient has been consented, screened, and all eligibility criteria have been confirmed in the eCRF. The patient identification number must remain constant throughout the entire study; it must not be changed at the time of enrollment.

4.4.2. **Randomization Scheme**

Not applicable, as this is a single-arm study.
5. STUDY MEDICATION

5.1. Identity

5.1.1. Niraparib
Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl] piperidine [tosylate monohydrate salt]) is an orally available, potent, highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied as 100-mg capsules.

5.1.2. Pembrolizumab
Pembrolizumab is a potent and highly selective humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pembrolizumab Powder for Solution for Infusion is a sterile, non-pyrogenic lyophilized powder for IV infusion supplied in single-use Type I glass vial containing 50 mg of pembrolizumab. The product is preservative-free, white to off-white powder and free from visible foreign matter.

5.2. Administration

5.2.1. Niraparib
Niraparib will be supplied as 100-mg capsules and will be administered orally once daily (QD) continuously starting on Cycle 1/Day 1. The daily dose to be administered each day (ie, 300 mg as 3 × 100-mg capsules, 200 mg as 2 × 100-mg capsules, or 100 mg as 1 × 100-mg capsules) will depend on the phase of the study, and in Phase 1, the cohort assignment. Patients will be instructed to take their dose at the same time each day, preferably in the morning. Patients must swallow and not chew all capsules. The consumption of water and food is permissible.

Niraparib capsules will be dispensed to patients on Cycle 1/Day 1 and on Day 1 of every cycle (21-day cycles) thereafter until the patient discontinues study treatment. On Day 1 of each cycle, a niraparib dose will be administered at the clinic upon completion of the pembrolizumab infusion.

Details on the administration of niraparib can be found in the Pharmacy Manual.

5.2.2. Pembrolizumab
Pembrolizumab will be administered at the study site on Day 1 of each 21-day treatment cycle after all procedures and assessments have been completed as detailed in Table 5. Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

Pembrolizumab will be administered at a dose of 200 mg IV using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Given the variability of infusion pumps from site to site, however, a window between -5 minutes and +10 minutes is permitted.
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion and administration of the infusion solution.

5.3. Dose-Limiting Toxicity

The following are to be considered DLTs for this study (as assessed during Cycle 1, ie, during the first 21 days of treatment - Day 1 through Day 21 during Phase 1):

- Any treatment-related Grade ≥ 3 non-hematologic clinical (non-laboratory) AE
- Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory abnormality if:
  - Medical intervention is required to treat the patient, or
  - The abnormality leads to hospitalization, or
  - The abnormality persists for ≥ 7 days.
- Any treatment-related hematologic toxicity specifically defined as:
  - Thrombocytopenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion;
  - Neutropenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia;
  - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion.
- Any treatment-related AE leading to niraparib dose interruption per the following criteria:
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 2) for a non-DLT laboratory abnormality (eg, for Grade 2 or 3 thrombocytopenia or for Grade 3 anemia or neutropenia) lasting ≥ 14 days.
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 1) for non-hematologic AE leading to < 80% of an intended dose being administered (eg, niraparib dose interruption for > 4 days within Cycle 1).

Note that niraparib dosing has been safely managed with dose interruptions and/or adjustments for AEs, including laboratory abnormalities, while maintaining activity in the single-agent setting (see Section 5.4.1, Table 1 and Table 2 and niraparib Investigator’s Brochure). Therefore, niraparib dose interruption and/or reduction for an AE that does not meet a DLT definition as described above will be considered a non-DLT modification. The non-DLT dose modifications will not be considered in determining the MTD but will be considered in determining the niraparib dose intensity and RP2D.

5.4. Dose Modification

Study treatment dosing interruptions are permitted in the case of medical / surgical events or logistical reasons not related to study therapy (eg, surgery, unrelated medical events, patient vacation, and/or holidays). Patients should be placed back on study therapy within 28 days of the scheduled interruption, unless otherwise discussed with the Sponsor.
All treatment interruptions and dose reductions (including any missed doses), and the reasons for the reductions/interruptions, are to be recorded in the electronic case report form (eCRF).

5.4.1. Niraparib

Dose interruption of niraparib may be implemented per the Investigator’s judgement after Cycle 1 in patients enrolled in Phase 1 and at any time in patients enrolled in Phase 2. See the following sections for permitted duration of interruption prior to required discontinuation from treatment.

Intra-patient Dose Escalation

For patients in the Phase 1 part of the study, the dose of niraparib may be increased after Cycle 1 to a higher dose level that has been found to be safe during the dose escalation phase following discussion with the Sponsor.

Niraparib Dose Modifications for Non-Hematologic Toxicity

Treatment with niraparib must be interrupted for any treatment-related non-hematologic CTCAE Grade 3 or 4 event. Once resolved to Grade ≤ 1, the patient may restart treatment with niraparib with a dose level reduction (see Table 1) unless prophylaxis is considered feasible. If the event recurs at a similar or worse grade, treatment should be interrupted again and, upon resolution, a further dose reduction must be made to a lower dose level, if available, or niraparib dosing should be discontinued. If the toxicity requiring dose interruption has not resolved to CTCAE Grade ≤ 1 during a maximum 4-week (28-day) dose interruption period, and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), the patient must permanently discontinue treatment with niraparib. Once the dose of niraparib has been reduced, any re-escalation must be discussed with the Sponsor. Note that treatment with pembrolizumab may continue if discontinuation criteria as outlined in Section 5.4.2 have not been met.

Table 1 Niraparib Dose Reductions for Non-Hematologic Toxicity

<table>
<thead>
<tr>
<th>Event</th>
<th>Dose&lt;sup&gt;a,b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial dose</td>
<td>300 mg QD</td>
</tr>
<tr>
<td>1st dose reduction for treatment-related CTCAE Grade 3 or 4 AE or SAE where prophylaxis is not considered feasible</td>
<td>200 mg QD</td>
</tr>
<tr>
<td>2nd dose reduction for treatment-related CTCAE Grade 3 or 4 AE or SAE where prophylaxis is not considered feasible</td>
<td>100 mg QD</td>
</tr>
<tr>
<td>Continued treatment-related CTCAE Grade 3 or 4 AE or SAE ≥ 28 days</td>
<td>Discontinue niraparib</td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; CTCAE = Common Terminology for Adverse Events; QD = once daily; SAE = serious adverse event.

<sup>a</sup> Dose not to be decreased below 100 mg daily.

<sup>b</sup> If initial dose is below 300 mg, the same dose reduction principles will apply with fewer dose modification steps available.
Niraparib Dose Modifications for Hematologic Toxicity

The dose interruption/modification criteria for niraparib for hematologic toxicities will be based on blood counts and are outlined in Table 2.

For thrombocytopenia, patients with a platelet count ≥ 25,000 to < 75,000/µL must have niraparib interrupted and have blood counts monitored twice weekly until recovery to ≥ 100,000/µL; upon recovery, niraparib can be resumed at the same dose for the first occurrence with once weekly monitoring for 3 weeks to confirm no recurrence of thrombocytopenia. For a further recurrence of platelet count at this level or any occurrence of platelet count < 25,000/µL, dose interruption followed by dose reduction upon recovery to ≥ 100,000/µL with subsequent monitoring once weekly for 3 weeks to ensure the safety of the new dose level is required (see Table 1).

For Grade 3 or 4 neutropenia or anemia, treatment with niraparib must be interrupted with blood counts monitored twice weekly for neutropenia and once or twice weekly for anemia until recovery to ≤ Grade 1. Niraparib dosing should be resumed with a dose level reduction (see Table 1) at that time and the patient monitored once weekly for 3 weeks to ensure the safety of the new dose level. If clinically indicated, use of G-CSF is allowed according to current American Society of Clinical Oncology (ASCO) guidelines.(60)

If the hematologic toxicity does not recover to the specified level within 4 weeks (28 days) of dose interruption and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), then niraparib should be discontinued.

Any patient requiring transfusion of platelets or red blood cells (1 or more units) or hematopoietic growth factor support must undergo a niraparib dose reduction upon recovery if study treatment is resumed.

It is strongly recommended that the patient be referred to a hematologist for further evaluation (1) if transfusions are required on more than 1 occasion or (2) if the treatment-related hematologic toxicities have not recovered to CTCAE ≤ Grade 1 within 4 weeks. If a diagnosis of MDS/AML is confirmed by a hematologist, the patient must permanently discontinue niraparib. Note that treatment with pembrolizumab may continue following discussion with the Sponsor if discontinuation criteria as outlined in Section 5.4.2 have not been met.

The reason for interruption, reduction, or discontinuation of niraparib should be recorded in the eCRF.
### Table 2  Management of Hematologic Toxicities*

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet count 25,000 to &lt; 75,000/μL</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly complete blood counts (CBC) monitored until recovery. Niraparib may then be resumed at same dose. After recovery, blood counts once weekly for 3 weeks.</td>
</tr>
<tr>
<td>Further occurrence of platelet count 25,000 to &lt; 75,000/μL</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 1); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level. A further dose reduction should be made if an additional treatment interruption is needed in less than 3 weeks after resuming treatment.</td>
</tr>
<tr>
<td>Platelet count &lt; 25,000/μL</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 1); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
<tr>
<td>Neutrophil &lt; 1,000/μL</td>
<td>Niraparib must be interrupted until neutrophil counts are ≥ 1,500/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 1); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
<tr>
<td>Hemoglobin ≤ 8 g/dL</td>
<td>Niraparib must be interrupted until hemoglobin is ≥ 9 g/dL with once- or twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 1); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
</tbody>
</table>

Abbreviations: CBC = complete blood count.
* If blood counts do not recover within 28 days to normal values (ie, platelets ≥ 100,000/μL, hemoglobin ≥ 9 g/dL, neutrophils ≥ 1,500/μL) niraparib should be discontinued.

5.4.2.  **Pembrolizumab**

Adverse events (both non-serious and serious) associated with pembrolizumab exposure may represent an immunologic etiology. These AEs may occur shortly after the first dose or several months after the last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or life-threatening AEs per Table 3. See also Section 6.1.6, Events of Clinical Interest.

Table 3 provides detailed information for dose interruptions and discontinuations related to toxicity for pembrolizumab. No dose reductions of pembrolizumab are permitted. Note that
treatment with niraparib may continue following discussion with the Sponsor if discontinuation criteria as outlined in Section 5.4.1 have not been met.

The reason for interruption or discontinuation of pembrolizumab should be recorded in the eCRF.
Table 3  Pembrolizumab Dose Modifications for Non-hematologic Toxicities

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Hold Treatment For Grade</th>
<th>Timing for Restarting Treatment</th>
<th>Treatment Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea/colitis</td>
<td>2-3</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>AST, ALT, or increased bilirubin</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose.</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>Permanently discontinue (see exception below).a</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Type 1 diabetes mellitus (if new onset) or hyperglycemia</td>
<td>T1DM or 3-4</td>
<td>Hold pembrolizumab for new onset Type 1 diabetes mellitus or Grade 3-4 hyperglycemia associated with evidence of beta cell failure.</td>
<td>Resume pembrolizumab when patients are clinically and metabolically stable.</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>2-4</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>3</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td></td>
<td>Therapy with pembrolizumab can be continued while thyroid replacement therapy is instituted.</td>
<td>Therapy with pembrolizumab can be continued while thyroid replacement therapy is instituted.</td>
</tr>
<tr>
<td>Infusion reaction</td>
<td>2b</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Permanently discontinue if toxicity develops despite adequate premedication.</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
</tbody>
</table>
### Table 3 Pembrolizumab Dose Modifications for Non-hematologic Toxicities (Continued)

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Hold Treatment For Grade</th>
<th>Timing for Restarting Treatment</th>
<th>Treatment Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonitis</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3-4 Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Renal failure or nephritis</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3-4 Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
</tbody>
</table>
| All other drug-related toxicity
c | 3 or severe              | Toxicity resolves to Grade 0-1. | Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks. |
|                                 |                          | 4 Permanently discontinue.      | Permanently discontinue.   |

Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; T1DM = type 1 diabetes mellitus.

Note: Permanently discontinue for any severe or Grade 3 (Grade 2 for pneumonitis) drug-related AE that recurs or any life-threatening event.

a For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by greater than or equal to 50% relative to baseline and lasts for at least 1 week, then patients should be discontinued.

b If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (e.g., from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the patient should be premedicated for the next scheduled dose; Refer to Section 5.7.3, Infusion Reaction Treatment Guidelines, for further management details.

c Patients with intolerable or persistent Grade 2 drug-related AE may hold study medication at physician discretion. Permanently discontinue study drug for persistent Grade 2 adverse reactions for which treatment with study drug has been held, that do not recover to Grade 0-1 within 12 weeks of the last dose.
5.5. Packaging, Labeling, and Storage

Niraparib 100-mg capsules will be packed in high-density polyethylene bottles with child-resistant closures.

Pembrolizumab for injection is supplied as 50-mg lyophilized powder single-use vials.

The label text of the study treatments will comply with Good Manufacturing Practice and national legislation to meet the requirements of the participating countries. The study treatment will be open-label and non-patient-specific.

All study treatment supplies must be stored in accordance with the Pharmacy Manual instructions and package labeling. Until dispensed or administered to the patients, the study treatment will be stored in a securely locked area, accessible to authorized personnel only.

5.6. Drug Accountability

The Investigator or designee is responsible for maintaining accurate dispensing records of the study treatments throughout the clinical study.

Details of maintaining drug accountability, including information on the accountability log, will be provided in the Pharmacy Manual.

All dispensation and accountability records will be available for Sponsor review. The study monitor will assume the responsibility to reconcile the study treatment accountability log. The pharmacist will dispense study treatment for each patient according to the protocol and Pharmacy Manual, if applicable.

5.7. Previous and Concomitant Medications

Any medication the patient takes during the study other than the study treatments, including herbal and other nontraditional remedies, is considered a concomitant medication. All concomitant medications must be recorded in the eCRF. The following information must be recorded in the eCRF for each concomitant medication: generic name, route of administration, start date, stop date, dosage, and indication. Any changes in the dosage or regimen of a concomitant medication must be recorded in the eCRF.

At screening, patients will be asked what medications they have taken during the last 30 days. At each subsequent study visit, patients will be asked what concomitant medications they are currently taking or have taken since the previous visit.

5.7.1. Prohibited Medications

Known prior medications that exclude a patient from participating in the study are described in the exclusion criteria (Section 4.2).

Patients are prohibited from receiving the following therapies during the screening and treatment phase of this study:

- Antineoplastic systemic chemotherapy or biological therapy
- Immunotherapy not specified in this protocol
Chemotherapy not specified in this protocol

Investigational agents other than niraparib and pembrolizumab

Radiation therapy is prohibited if encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

Note: The following may be considered exceptions on a case-by-case basis after consultation with the Sponsor: Radiation therapy to pre-existing small areas of painful metastases that cannot be managed with local or systemic analgesics (excluding palliative radiotherapy encompassing > 20% of the bone marrow) as long as no evidence of disease progression is present. The patient must have clear measurable disease outside the radiated field. Administration of palliative radiation therapy may be considered clinical progression for the purposes of determining PFS.

Systemic glucocorticoids for any purpose other than to modulate symptoms from an ECI of suspected immunologic etiology. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.

Note: Inhaled steroids are allowed for the management of asthma.

Live vaccines within 30 days prior to the first dose of study treatment and while participating in the study. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacille Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. Intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines and are not allowed.

Niraparib has potential to induce cytochrome P450 (CYP)1A2 and is a substrate for P-glycoprotein (P-gp); therefore, patients should be advised to use caution with drugs metabolized by CYP1A2 (see Appendix A) as well as drugs that are inhibitors or substrates of P-gp (Appendix C).

The niraparib safety profile includes risk for thrombocytopenia; therefore, patients should be advised to use caution with anticoagulation and antiplatelet drugs.

Prophylactic cytokines (G-CSF) should not be administered in the first cycle of the study but may be administered in subsequent cycles according to current ASCO guidelines. (60)

Patients are not to take medications known to prolong QTc (Appendix B) while participating in the study.

If there is a clinical indication for any medication or vaccination specifically prohibited during the study, discontinuation from study therapy may be required. The Investigator should discuss any questions regarding this with the Sponsor. The final decision on any supportive therapy or vaccination rests with the Investigator and/or the patient’s primary physician. The decision to continue the patient on study therapy, however, requires the mutual agreement of the Investigator, the Sponsor, and the patient.
5.7.2. **Contraception**

Pembrolizumab and niraparib are known to have properties that require the patient to use contraception. For details on niraparib, please refer to the Investigator’s Brochure.

Pembrolizumab may have adverse effects on a fetus in utero. Furthermore, it is not known if pembrolizumab has transient adverse effects on the composition of sperm. Therefore, non-pregnant, non-breastfeeding women may only be enrolled if they are willing to use 2 methods of birth control or are considered highly unlikely to conceive. Highly unlikely to conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥ 45 years of age and has not had menses for > 1 year will be considered postmenopausal), or 3) not heterosexually active for the duration of the study. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Patients should start using birth control from screening throughout the study period up to 120 days after the last dose of pembrolizumab.

The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents). Abstinence is acceptable if this is the established and preferred contraception for the patient.

Patients should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in the study they must adhere to the contraception requirement (described above) for the duration of the study and through 120 days after the last study treatment. If there is any question that a patient will not reliably comply with the requirements for contraception, that patient should not be entered into the study.

5.7.3. **Rescue Medications and Supportive Care Guidelines During Treatment with Pembrolizumab**

Patients should receive appropriate supportive care measures as deemed necessary by the treating Investigator. Suggested supportive care measures for the management of AEs with potential immunologic etiology are outlined below. Note that several courses of steroid tapering may be necessary, as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the Investigator determines the events to be related to pembrolizumab.

Note: it may be necessary to perform additional procedures such as bronchoscopy, endoscopy, or skin photography as part of evaluation of the event.

The following text details specific guidance by type of AE.

- **Pneumonitis:**
  - For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.
- For Grade 3-4 events, immediately treat with IV steroids. Administer additional anti-inflammatory measures, as needed.
- Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration.

**Diarrhea/Colitis:**

Patients should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus).

- All patients who experience diarrhea/colitis should be advised to drink liberal quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion. For Grade 2 or higher diarrhea, consider gastrointestinal consultation and endoscopy to confirm or rule out colitis.
- For Grade 2 diarrhea/colitis that persists greater than 3 days, administer oral corticosteroids.
- For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with IV steroids followed by high-dose oral steroids.
- When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.

**Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis (DKA):**

- For Type 1 diabetes mellitus or Grade 3-4 hyperglycemia
  - Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
  - Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide.

**Hypophysitis:**

- For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.
- For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.

**Hyperthyroidism or Hypothyroidism:**

Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment,
and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.

− Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):
  • In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are suggested as initial therapy.
  • In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyronine, is indicated per standard of care.

− Grade 3-4 hyperthyroidism
  • Treat with an initial dose of IV corticosteroids followed by oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.

• **Hepatic:**
  − For Grade 2 events, monitor liver function tests more frequently until returned to baseline values (consider weekly).
    − Treat with IV or oral corticosteroids.
  − For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours.
  − When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over no less than 4 weeks.

• **Renal Failure or Nephritis:**
  − For Grade 2 events, treat with corticosteroids.
  − For Grade 3-4 events, treat with systemic corticosteroids.
  − When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.

• **Management of Infusion Reactions:** Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of infusion.

  Table 4 shows treatment guidelines for patients who experience an infusion reaction associated with administration of pembrolizumab.
### Table 4 Pembrolizumab Infusion Reaction Treatment Guidelines

<table>
<thead>
<tr>
<th>NCI CTCAE Grade</th>
<th>Treatment</th>
<th>Premedication at Subsequent Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild reaction;</td>
<td>Increase</td>
<td>None</td>
</tr>
<tr>
<td>infusion</td>
<td>monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.</td>
<td></td>
</tr>
<tr>
<td>interruption not indicated; intervention not indicated</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grade 2</strong></td>
<td>Stop infusion and monitor symptoms.</td>
<td>Patient may be premedicated 1.5 hour (± 30 minutes) prior to infusion of pembrolizumab with:</td>
</tr>
<tr>
<td>Requires infusion interruption but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 hrs</td>
<td>Additional appropriate medical therapy may include but is not limited to:</td>
<td>Diphenhydramine 50 mg PO (or equivalent dose of antihistamine).</td>
</tr>
<tr>
<td></td>
<td>IV fluids</td>
<td>Acetaminophen 500-1000 mg PO (or equivalent dose of antipyretic).</td>
</tr>
<tr>
<td></td>
<td>Antihistamines</td>
<td>Cocorticosteroids</td>
</tr>
<tr>
<td></td>
<td>NSAIDS</td>
<td>Epinephrine</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen</td>
<td>Oxygen</td>
</tr>
<tr>
<td></td>
<td>Narcotics</td>
<td>Pressors</td>
</tr>
<tr>
<td></td>
<td>Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.</td>
<td>Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.</td>
</tr>
<tr>
<td></td>
<td>If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (eg, from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the patient should be premedicated for the next scheduled dose.</td>
<td>Hospitalization may be indicated.</td>
</tr>
<tr>
<td></td>
<td><strong>Patients who develop Grade 2 toxicity despite adequate premedication should be permanently discontinued from further study treatment administration.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Grades 3 or 4</strong></td>
<td>Stop Infusion.</td>
<td>No subsequent dosing</td>
</tr>
<tr>
<td>Grade 3:</td>
<td>Additional appropriate medical therapy may include but is not limited to:</td>
<td></td>
</tr>
<tr>
<td>Prolonged (ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae (eg, renal impairment, pulmonary infiltrates)</td>
<td>IV fluids</td>
<td></td>
</tr>
<tr>
<td>Grade 4:</td>
<td>Antihistamines</td>
<td></td>
</tr>
<tr>
<td>Life-threatening; pressor or ventilatory support indicated</td>
<td>NSAIDS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acetaminophen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Narcotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxygen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pressors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epinephrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospitalization may be indicated.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Patient is permanently discontinued from further study treatment administration.</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** IV=intravenous; NSAID=nonsteroidal anti-inflammatory; PO=oral.

**Note:** Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of drug administration.
5.7.4. Other Study Restrictions

Patients who are blood donors should not donate blood during the study and for 90 days after the last dose of study treatment.

Patients should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea, or vomiting.
6. ENDPOINTS AND METHODS OF ASSESSMENT

6.1. Safety Endpoints

Safety parameters evaluated during the conduct of the study include: treatment-emergent AEs (TEAEs), clinical laboratory values (hematology, chemistry, coagulation, thyroid function, urinalysis), vital signs, ECGs, physical examination findings, and use of concomitant medications. Additionally, the relationship between cytogenetic abnormalities and safety parameters may be explored.

6.1.1. Definitions

**Adverse event:** An *adverse event* is any untoward medical occurrence that occurs in a patient or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product.

Adverse events may include the onset of new illness and the exacerbation of pre-existing medical conditions. An AE can include an undesirable medical condition occurring at any time, including baseline or washout periods, even if no study treatment has been administered.

A *treatment-emergent adverse event* will be defined as any new AE that begins, or any preexisting condition that worsens in severity, after at least 1 dose of study treatment has been administered.

**Serious adverse event:** A *serious adverse event* is defined as any untoward medical occurrence that, at any dose:

- Results in death
- Is life-threatening
  - Note: This means that the patient is at immediate risk of death at the time of the event; it does not mean that the event hypothetically might have caused death if it were more severe
- Requires inpatient hospitalization or prolongation of existing hospitalization
  - Any AE that prolongs hospitalization will be considered an SAE.
  - Exception: Planned hospitalization (eg, for observation, protocol compliance, elective procedures, social reasons, etc.) will not be considered an SAE; however, the reason for the planned hospitalization should be captured in medical history.
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly or birth defect
6.1.2. Assessment of Adverse Events
Each AE will be assessed by the Investigator with regard to intensity and causality with regard to study treatment as outlined in the following sections.

6.1.2.1. Intensity
Investigators should assess the severity of AEs according to CTCAE. In general, CTCAE (v4.03) severity grades are:

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). (Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.)

Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. (Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.)

Grade 4: Life-threatening consequences; urgent intervention indicated

Grade 5: Death related to AE

A distinction should be made between **serious** and **severe** AEs. Severity is a measure of intensity whereas seriousness is defined by the criteria above in Section 6.1.1. For example, a mild degree of gastrointestinal bleeding requiring an overnight hospitalization for monitoring purposes may be considered an SAE but is not necessarily severe. Similarly, an AE that is severe in intensity is not necessarily an SAE. For example, alopecia may be assessed as severe in intensity but may not be considered an SAE.

6.1.2.2. Causality
The Investigator will assess the causality/relationship between the study drug and the AE. One of the following categories should be selected based on medical judgment, considering the definitions and all contributing factors:

- Related: A clinical event, including laboratory test abnormality, occurs in a plausible time relationship to treatment administration, and which concurrent disease or other drugs or chemicals cannot explain. The response to withdrawal of the treatment should be clinically plausible.
• **Possibly related**: A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the treatment, unlikely to be attributed to concurrent disease or other drugs or chemicals.

• **Unlikely related**: A clinical event, including laboratory test abnormality, with a temporal relationship to treatment administration which makes a causal relationship improbable, or in which other drugs, chemicals or underlying disease provide likely explanations.

• **Unrelated**: A clinical event, including laboratory test abnormality, with little or no temporal relationship with treatment administration. Typically explained by extraneous factors (eg, concomitant disease, environmental factors, or other drugs or chemicals).

### 6.1.3. Collecting and Recording Adverse Events

All AEs, regardless of the source of identification (eg, physical examination, laboratory assessment, ECG, reported by patient), must be documented in the eCRF.

All AEs will be collected and recorded in the eCRF for each patient from the day of signed informed consent until 30 days after the last dose of study treatment; SAEs will be monitored through 90 days after the last dose of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy). All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, any abnormal laboratory values have returned to baseline or normal levels, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.

If an Investigator becomes aware of an SAE after the specified follow-up period post treatment discontinuation and considers the SAE related to investigational product, the Investigator should report the SAE to the Sponsor according to timelines for reporting SAEs described in this section.

Adverse events may be volunteered spontaneously by the study patient, or discovered by the study staff during physical examinations or by asking an open, non-leading question such as: “How have you been feeling since you were last asked?” The Investigator will document the nature of AE, date of onset of the AE (and time, if known), date of outcome of the AE (and time, if known), severity of the AE, action taken with study drug as a result of the AE, assessment of the seriousness of the AE, and assessment of the causal relationship of the AE to study drug and/or study procedure.

All AEs should be recorded individually in the patient’s own words (verbatim) unless, in the opinion of the Investigator, the AEs constitute components of a recognized condition, disease, or syndrome. In the latter case, the condition, disease, or syndrome should be named rather than each individual symptom.

Concomitant illnesses that existed before entry into the study will not be considered an AE unless the illness worsens during the treatment period. Pre-existing conditions will be recorded in the eCRF as well as on the SAE Report Form medical history section.
6.1.4. Reporting Disease Progression

The event of disease progression is an efficacy criterion and is therefore not considered an AE. Disease progression should be reported within the eCRF. If AEs/SAEs occur in relation to disease progression, the AEs/SAEs must be reported per AE/SAE reporting requirements described in Section 6.1.3 and Section 6.1.5.

6.1.5. Serious Adverse Events

6.1.5.1. Reporting of Serious Adverse Events

The Investigator must report all SAEs within 24 hours of becoming aware of the initial SAE or any follow-up information regarding the SAE using the SAE reporting contact information as printed on the SAE forms and in the SAE Completion guidelines.

For all SAEs, an SAE report form must be completed by the Investigator for all initial and follow-up SAEs. A follow-up SAE report must be completed each time an Investigator becomes aware of any additional information regarding the SAE. For the follow-up SAE Report Form, the following fields must be completed on each form: follow-up number, site number, patient/subject number, protocol number, and the SAE term(s) and date of awareness. Only the appropriate field(s) on the SAE Report Form where the Investigator received additional or updated information should be completed. Previously provided information does not have to be entered on the follow-up SAE Report Form.

Initial and follow-up SAE reports and any additional supporting documentation (eg, hospital reports, consultant reports, death certificates, autopsy reports, etc.) included with the SAE report should be sent to the Sponsor (or designee) within 24 hours of the Investigator/site awareness or receipt. If supporting documentation is provided, the Investigator should highlight all relevant and pertinent information. Also, any additional SAE documentation must be a clear photocopy with the patient’s personal identifiers removed. The Investigator must sign and date all SAE forms.

The minimum information required for an initial SAE report is:

- Name of person sending the report (ie, name, address of Investigator)
- Patient identification (screening/randomization number, initials [if permitted by local data privacy regulations], NOT patient name)
  - Protocol number
  - Description of SAE
  - Causality assessment

In case the Investigator has no ability to either fax or email an SAE (eg, due to technical issues), pharmacovigilance can be contacted by phone. If an SAE is reported via phone and during usual business hours, the Sponsor pharmacovigilance (or designee) will capture the information on a telephone contact form or similar method. Outside usual business hours, the message will be recorded and the required follow-up actions initiated during the next business day. Once technical issues are resolved, the Investigator should fax or email the completed SAE form to the Sponsor (or designee).
After receipt of the initial report, the Sponsor (or designee) will review the information and, if necessary, contact the Investigator to obtain further information.

6.1.5.2. Submission and Distribution of Adverse Events/Serious Adverse Events

Per regulatory requirements, if an SAE is required to be submitted to a Regulatory Authority a copy of this report (CIOMS or MedWatch 3500A) will be distributed to the Investigators/site. The Investigator/site will submit a copy the report to their respective IRB or EC.

6.1.6. Events of Clinical Interest

6.1.6.1. Pembrolizumab

Selected non-serious AEs and SAEs are also known as Events of Clinical Interest (ECI) and must be recorded as such on the eCRF and reported within 24 hours to the Sponsor as noted for SAEs in Section 6.1.5.1. Patients are to be monitored through 90 days after the last dose of study treatment for the following ECI:

1. An overdose of pembrolizumab that is not associated with clinical symptoms or abnormal laboratory results. For this study, an overdose is defined as a dose ≥ 1000 mg (5 times the dose) of pembrolizumab. No specific information is available on the treatment of overdose of pembrolizumab. In the event of overdose, the patient should be observed closely for signs of toxicity. Appropriate supportive treatment should be provided if clinically indicated.

2. An elevated AST or ALT value that is ≥ 3× ULN concurrent with an elevated total bilirubin value that is ≥ 2× ULN and, at the same time, an alkaline phosphatase value that is < 2× ULN, as determined by protocol-specified laboratory testing or unscheduled laboratory testing.

Note: These criteria are based upon available regulatory guidance documents. The purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology. The study site guidance for assessment and follow up of these criteria can be found in the Investigator Trial File Binder (or equivalent).

6.1.6.2. Niraparib

In conjunction with the survival assessment, new malignancy information will collected for all patients via telephone every 90 (±14) days (Section 7.2.10). Additionally, the relationship between cytogenetic abnormalities and safety parameters may be explored.

6.1.7. Pregnancy Reporting and Follow-up

Pregnancies occurring in patients enrolled in a study or in a female partner of a male patient must be reported and followed to outcome. If a female patient inadvertently becomes pregnant while on study treatment, the patient will immediately be removed from the study. Any pregnancies that occur within 120 days following the last dose of study treatment must be captured in the eCRF.
The Investigator should complete the Initial Pregnancy Notification report form and forward it to the Sponsor (or designee) within 24 hours of knowledge of the pregnancy. If there is an associated serious outcome, then both the Initial Pregnancy Notification report form and SAE report form should be completed.

The site will follow-up with the patient at least monthly and document the patient’s status until the pregnancy has been completed or terminated. The Investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male patient impregnates his female partner, the study personnel at the site must be informed immediately and the pregnancy reported to the Sponsor and followed as described above. The Pregnancy Outcome report form should be completed and submitted to the Sponsor within 24 hours after the Investigator becomes aware of the pregnancy outcome.

In the event the pregnancy outcome occurs following the end of the study and database lock, the Investigator will report the pregnancy outcome to the Sponsor (or designee) within 24 hours after the outcome of the pregnancy is known to the Investigator in accordance with the procedure for reporting SAEs (see Section 6.1.5).

Pregnancy alone is not regarded as an AE unless there is a possibility that the study drug may have interfered with the effectiveness of a contraceptive medication. Elective abortions without complications should not be considered AEs unless they were therapeutic abortions. Hospitalization for normal delivery of a healthy newborn should not be considered an SAE. Pregnancy is not considered an SAE unless there is an associated serious outcome. Spontaneous abortions should always be reported as SAEs.

Any SAE that occurs during pregnancy must be recorded on the SAE Report Form (eg, maternal serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, birth defect) and reported within 24 hours in accordance with the procedure for reporting SAEs.

6.1.8. Clinical Laboratory Assessments

The following laboratory variables will be determined in accordance with the schedule of events (Table 5). These tests will be performed by the local laboratory at the clinical site.

- **Complete blood count:**
  - Hemoglobin
  - Platelets
  - Mean corpuscular volume
  - Mean platelet volume (optional)*
  - White blood cell count
  - Differential white cell count

* Note: Although mean platelet volume collection is optional, it is highly encouraged, especially for patients with high-grade thrombocytopenia.

- **Coagulation factors:**
  - International normalized ratio
  - Activated partial thromboplastin time
• **Serum chemistry:**
  - Sodium
  - Potassium
  - Calcium
  - Magnesium
  - Chloride
  - Glucose
  - Creatinine
  - Urea or blood urea nitrogen
  - Amylase
  - Total bilirubin
  - Alkaline phosphatase
  - Aspartate aminotransferase
  - Alanine aminotransferase
  - Total protein
  - Albumin
  - Lactate dehydrogenase

• **Urinalysis:**
  - Specific gravity
  - Leukocyte esterase
  - Nitrite
  - Blood
  - Bilirubin
  - Protein
  - Glucose
  - Ketones
  - Urobilinogen

• **Thyroid-stimulating hormone (TSH), Triiodothyronine [T3] or Free T3 [FT3], and Free Thyroxine [FT4]**

• **Serum CA-125 (OC patients only)**

• **Serum pregnancy testing / urine pregnancy testing**

Any laboratory values assessed as clinically significant should be recorded as an AE. If SAE criteria are met or the laboratory abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).

Hematological testing may occur more frequently than is specified in Table 5 when additional testing is medically indicated per Investigator judgment or if the event meets the criteria for niraparib dose modification (see Section 5.4.1). Additional tests may be performed at a laboratory facility other than the study site, but test results must be reported to the study site, the study site must keep a copy of test results with the patient’s study file, and the results must be entered into the eCRF.

It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings, which must include a classification according to World Health Organization (WHO),\(^{(64)}\) and other sample testing reports related to MDS/AML.
Report data will be entered in the appropriate eCRF pages and the site must keep a copy of all reports with the patient’s study file.

Whole blood samples will be collected prior to the start of the study drug and at treatment discontinuation for cytogenetic analysis. Further details on sample collection and analysis can be found in the Study Manual.

### 6.1.9. Physical Examination and Vital Signs

Physical examinations, including height (screening only), weight, and vital signs (blood pressure [BP], pulse, and temperature), will be performed in accordance with the schedule of events (Table 5).

Any physical examination or vital signs assessed as clinically significant should be recorded as an AE or SAE. If SAE criteria are met or the abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).

### 6.1.10. Eastern Cooperative Oncology Group Performance Status

Performance status will be assessed using the ECOG scale (see Appendix G) in accordance with the schedule of events (Table 5). The same observer should assess performance status each time.

### 6.1.11. Additional Safety Assessments

All patients will undergo ECGs in accordance with the schedule of events (Table 5). Electrocardiograms should be performed prior to blood draws for PK. Patients will be supine and rested for approximately 2 minutes before ECGs are recorded.

Any ECG findings assessed as clinically significant should be recorded as an AE. If SAE criteria are met or the abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).

### 6.2. Demographics and Baseline Characteristics

Demographics and baseline characteristics consist of those variables that are assessed at screening/baseline.

#### 6.2.1. Patient Eligibility

Compliance with inclusion and exclusion criteria will be assessed as outlined in Section 4.1 and Section 4.2.

#### 6.2.2. Patient Demography

Patient demography consists of age at screening, race, ethnicity, and sex.

#### 6.2.3. Disease History

For disease history the following will be documented:

- Date of first diagnosis
- Tumor type
• Stage at time of initial diagnosis
• Histology and grade of disease at diagnosis and most recent biopsy if additional biopsy performed
• Information on first anticancer treatment:
  – Intent (adjuvant, neoadjuvant, curative, palliative) (TNBC patients)
  – Date of start of first treatment
  – Agents used in first treatment
  – Date of last dose of first treatment
• Information on second and subsequent anticancer treatments:
  – Intent (adjuvant, neoadjuvant, curative, palliative) (TNBC patients)
  – Dates of start of all subsequent treatments
  – Agents in all subsequent treatments
  – Dates of last dose of all subsequent treatments
• Best response and toxicities (including hematologic events) for each prior anticancer treatment
• Date of recurrence for each prior anticancer treatment

6.2.4. Medical and Surgical History

Major medical and surgical history (including medication history), including history of thrombocytopenia, neutropenia, leukopenia, or anemia, will be collected. Details of any prior invasive malignancy will be collected. Medical and surgical history will be obtained by interviewing the patient or by reviewing the patient’s medical records.

6.2.5. Previous and Concomitant Medications

Previous and concomitant medication will be documented as described in Section 5.7. Medications will be coded using World Health Organization Anatomical Therapeutic Chemical classification.

6.3. Efficacy Endpoint(s)

6.3.1. Evaluation of Tumor Response

6.3.1.1. Overview

The efficacy of combination treatment with niraparib and pembrolizumab will be evaluated by assessment of tumor response to treatment according to RECIST v1.1 (65) and irRECIST (see Section 6.3.1.3 and Section 6.3.1.4, respectively). Tumor marker data (CA-125) will not be used for defining objective responses or disease progression; however CA-125 can be used for clinical decisions. Clinical criteria such as the GCIG criteria (66) (see Appendix F) will also be considered for management of OC patients with clinical events (eg, bowel obstruction) without radiographic
evidence of disease progression. The Study Committee will adjudicate such cases (see Section 9.12).

Response to treatment will primarily be based on Investigator evaluation of radiographic images. All radiographic images/scans at the time points specified in Table 5, as well as any unscheduled images/scans, will be sent by the study sites to the central imaging vendor upon acquisition and archived for potential future evaluation.

The process for image collection and transmission to the central imaging vendor can be found in the Site Imaging Manual.

Tumor imaging (chest, abdomen, and pelvis [plus brain if clinically indicated]) should be performed by CT (preferred). Magnetic resonance imaging should only be used when CT is contraindicated or for imaging of the brain, but the same imaging technique should be used in a patient throughout the study. CT scan is the more commonly used modality and is preferred for the majority of patients. An MRI can be utilized if clinically appropriate. Positron emission tomography/CT may be used according to RECIST guidelines.

If the chest (OC patients only) and/or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up.

Bone scans should be conducted per standard of care.

6.3.1.2. Timing of Radiographic Evaluations

All patients will undergo serial radiographic assessments to assess tumor response. Initial tumor imaging at screening must be performed within 21 days prior to the date of the first dose of study treatment. Scans performed prior to the signing of the ICF as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and performed within 21 days prior to first dose date.

The first on-study imaging assessment should be performed at 9 weeks (63 ± 7 days) from the date of first dose of study treatment; in the case of progressive disease (PD), a confirmatory image will be required 4 weeks later (eg, 13 weeks [91 ±7 days]) (see Section 6.3.1.4). Subsequent tumor imaging should be performed every 9 weeks (63 ± 7 days) or more frequently if clinically indicated and at the time of suspected disease progression. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days). Imaging should not be delayed for delays in cycle starts or extension of combination treatment cycle intervals.

Per RECIST v1.1 (see Appendix D), CR or PR should be confirmed by a repeat tumor imaging assessment. The tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated.

Continue to perform imaging until whichever of the following occurs:

- The start of new anticancer treatment
- Withdrawal of consent
- Death
• End of the study (when responder or discontinuation status for all patients is known)

Patients who discontinue study treatment for reasons other than PD will continue post-treatment imaging studies for disease status follow-up at the same frequency as already followed, eg, every 9 or 12 weeks (± 7 days) depending on the length of treatment with the study combination drugs, until disease progression, start of a non–study anticancer treatment, withdrawal of consent to study participation, becoming lost to follow-up, death, or end of the study.

6.3.1.3. Assessment of Response by RECIST

RECIST v1.1 will be used by the Investigator as the primary measure for assessment of tumor response, date of disease progression, and as a basis for all protocol guidelines related to disease status. Note that irRECIST will be followed in cases of disease progression to assess continuation of treatment in clinically stable patients until progression is confirmed (see Section 6.3.1.4).

Details on RECIST v1.1, including evaluation of target and non-target lesions and definitions of response are provided in Appendix D.

6.3.1.4. Assessment of Response by Immune-Related RECIST

RECIST v1.1 will be adapted to account for the unique tumor response characteristics seen during treatment with pembrolizumab. Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by potentiating endogenous cancer-specific immune responses. The response patterns seen with such an approach may extend beyond the typical time course of responses seen with cytotoxic agents and can manifest a clinical response after an initial increase in tumor burden or even the appearance of new lesions. Standard RECIST v1.1 may, thus, not provide an accurate response assessment of immunotherapeutic agents such as pembrolizumab. irRECIST will be used by local site Investigators to assess tumor response and progression and make treatment decisions.

Therefore, RECIST v1.1 will be used with the following adaptations (ie, irRECIST) (see also Appendix E).

• If repeat imaging shows < 20% increase in tumor burden compared with nadir, stable or improved previous new lesion (if identified as cause for initial PD), and stable/improved non-target disease (if identified as cause for initial PD), treatment may be continued / resumed, and the next tumor imaging should be conducted according to the protocol schedule of every 9 weeks (63 ± 7 days) (or every 12 weeks [84 ± 7 days] if after 1 year).

• If repeat imaging confirms PD due to any of the scenarios listed below, patients will be discontinued from study therapy.

In determining whether or not the tumor burden has increased or decreased per irRECIST, the local site Investigator should consider all target and non-target lesions, as well as any incremental new lesion(s).

If ANY of the following occur by irRECIST on repeat imaging, PD is confirmed:

− Tumor burden remains ≥ 20% and at least 5-mm absolute increase compared with nadir
− Non-target disease resulting in initial PD is worse (qualitative)
− New lesion resulting in initial PD is worse (qualitative)
− Additional new lesion(s) since last evaluation
− Additional new non-target progression since last evaluation

In patients who have initial evidence of radiological PD, it is at the discretion of the treating physician whether to continue a patient on study treatment until repeat imaging is obtained. This clinical judgment decision should be based on the patient’s overall clinical condition, including performance status, clinical symptoms, and laboratory data. Patients may receive pembrolizumab treatment while waiting for confirmation of PD if they are clinically stable as defined by the following criteria:

- Absence of signs and symptoms indicating clinically significant progression of disease, including worsening of laboratory values
- No decline in ECOG performance status
- Absence of rapid progression of disease
- Absence of progressive tumor at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention

When feasible, patients should not be discontinued until progression is confirmed. This allowance to continue treatment despite initial radiologic progression takes into account the observation that some patients can have a transient tumor flare in the first few months after the start of immunotherapy but with subsequent disease response. Patients who are deemed clinically unstable are not required to have repeat imaging for confirmation of progressive disease.

6.3.2. Efficacy Endpoints

6.3.2.1. Objective Response Rate

The primary efficacy endpoint is ORR, defined as the proportion of patients achieving CR or PR as assessed by the Investigator per RECIST (v1.1) (Appendix D). Tumor assessments after the initiation of further anticancer therapy are excluded for the assessment of best overall response. ORR by irRECIST (Section 6.3.1.4) will also be evaluated as a secondary endpoint.

6.3.2.2. Duration of Response

Duration of response will be evaluated as a secondary endpoint and is defined as the time from first documentation of CR or PR by RECIST v1.1 until: (1) the time of first documentation of disease progression per RECIST v1.1 (Appendix D); and (2) the time of first documentation of disease progression per irRECIST (Section 6.3.1.4). Note that date of progression based on either RECIST v1.1 or irRECIST may be overwritten in patients with OC if clinical criteria (Appendix F) indicate earlier progression as adjudicated by the Study Committee (Section 9.12).
6.3.2.3. Disease Control Rate

Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST v1.1 (Appendix D) and irRECIST (Section 6.3.1.4).

6.3.2.4. Progression-Free Survival

Progression-free survival will be assessed as a secondary endpoint and is defined as the time from enrollment to the earlier date of assessment of progression or death by any cause in the absence of progression based on: (1) the time of first documentation of disease progression per RECIST v1.1 (Appendix D); and (2) the time of first documentation of disease progression per irRECIST (Section 6.3.1.4). Note that date of progression based on either RECIST v1.1 or irRECIST may be overwritten in patients with OC if clinical criteria (Appendix F) indicate earlier progression as adjudicated by the Study Committee (Section 9.12).

6.3.2.5. Overall Survival

Overall survival will be assessed as a secondary endpoint and is defined as the time from date of first dose of study treatment to the date of death by any cause. New malignancy information will also be collected as part of this assessment (Section 7.2.10).

6.4. Pharmacokinetics

Pharmacokinetic samples will be collected from patients in both Phase 1 and Phase 2. An overview of sampling times for blood for PK analysis and concurrent ECG assessments, see Table 6 (Phase 1) and Table 7 (Phase 2).

For niraparib, the plasma samples from both Phase 1 and Phase 2 patients will be analyzed using liquid chromatography with mass spectroscopic detection (LC-MS-MS). For pembrolizumab in Phase 1, serum PK samples will be collected according to the schedule defined in Section 6.4.1, and the samples in an individual patient may be analyzed using enzyme-linked immunosorbent assay (ELISA) if required for understanding of AEs.

The timing of the last dose of niraparib and of the start and end of the infusion of pembrolizumab relative to PK blood draws will be recorded.

Complete instructions for collection, processing, shipping, and handling of samples are detailed in the Study Manual.

6.4.1. Phase 1

For all patients in Phase 1, blood samples for measurements of plasma levels of niraparib will be obtained on Day 1 of Cycles 1 and 2 at the following time points: 0 (predose within 30 minutes) and 1 hour (±5 minutes), 2 hours (±5 minutes), 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours (±10 minutes), and 24 hours (±30 minutes) postdose.

In addition, blood samples for measurements of drug levels of niraparib will be obtained on Day 1 of Cycles 4 and 8 at the following time points: 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.
For all patients in Phase 1, blood samples for pembrolizumab will only be analyzed to understand an AE in an individual patient. The samples will be collected according to the following schedule, stored, and analyzed as needed. Predose blood samples for trough measurement of serum levels of pembrolizumab will be obtained at Cycles 1, 2, 4, and 8. All predose trough samples should be drawn within 30 minutes (±5 minutes) before infusion of pembrolizumab. Additional postdose peak PK serum samples will be drawn within 30 minutes after the end of the pembrolizumab infusion at Cycles 1 and 8. An additional single PK serum sample should be drawn at 24 hours (±30 minutes) (Day 2), 168 hours (±2 hours) (Day 8), and 336 hours (±4 hours) (Day 15) after Cycle 1 dosing.

6.4.2. Phase 2
For patients in Phase 2, blood samples for measurements of plasma levels of niraparib will be obtained on Day 1 of Cycles 1, 2, 4, and 8 at the following time points: 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.

6.4.3. Determination of Pharmacokinetic Parameters
Model predicted area under the concentration × time curves (AUCs) will be derived. Parameters of interest are AUC, minimum concentration (Cmin), maximum concentration (Cmax), clearance after oral administration (CL/F), volume of distribution after oral administration (Vz/F), AUC at steady state (AUCss), Cmin at steady state (Cmin,ss), and Cmax at steady state (Cmax,ss).

6.5. Biomarkers
Biomarker classifiers will be evaluated in archival and fresh OC and TNBC tumor samples obtained during screening. In addition, in the subset of patients who undergo serial biopsies, biomarkers will be evaluated in fresh tumor samples obtained at 8 to approximately 12 weeks after initiating study treatment and, whenever possible, at the time of disease progression. Core biopsies (3 to 6) are preferred, but fine-needle aspirate may be performed if clinically indicated at the discretion of the interventional radiologist performing the procedure.

Blood samples for biomarker analysis will be obtained predose on Day 1 of Cycles 1 and 2 for analysis of tumor-related circulating biomarkers, such as circulating tumor cells and circulating tumor DNA. Biopsy samples will be collected and managed centrally, and tumor sections will be distributed to the designated translational research laboratories. DNA/RNA will be extracted from samples at a central location and analyzed for exploratory biomarkers including HRD, gene sequencing and RNA expression (ie, NanoString). Immunohistochemistry for additional immune checkpoint proteins as well as PD-L1 and immune microenvironment evaluation will also be performed. Other exploratory analyses may be performed with the remaining samples.

Homologous recombination deficiency score and other biomarkers will be correlated with efficacy outcomes. Also, the magnitude of the PD-L1 score, the HRD positivity, and the other biomarkers will be correlated with efficacy outcomes. Special attention will be devoted to subsets of OC and TNBC which may have distinct underlying DNA repair pathway deficiency (HR, NER, and MMR deficiency) and distinct drug responses.

Details on blood and tissue sample collection and analysis can be found in the Study Manual.
Samples from blood and tumor will be stored and may be used at a later time for biomarker testing, including potential to bridging to candidate companion diagnostic assays.
7. STUDY CONDUCT

7.1. Schedule of Procedures

A schedule of study procedures is provided in Table 5.
### Table 5: Schedule of Events

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cycle/Visit:</th>
<th>Screen</th>
<th>Cycle 1</th>
<th>Subsequent Cycles&lt;sup&gt;a&lt;/sup&gt;</th>
<th>EOT&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>8&lt;sup&gt;d&lt;/sup&gt;</td>
<td>15</td>
<td>Cycle n, Day 1</td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor biopsy&lt;sup&gt;e&lt;/sup&gt;&lt;sup&gt;f&lt;/sup&gt;</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>X&lt;sup&gt;f&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for PK&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Tumor assessment (RECIST and irRECIST)</td>
<td>X&lt;sup&gt;j&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>X&lt;sup&gt;j&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC&lt;sup&gt;k&lt;/sup&gt;</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X&lt;sup&gt;d&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Serum chemistry</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Coagulation</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;o&lt;/sup&gt;</td>
<td>X&lt;sup&gt;α&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;β&lt;/sup&gt;</td>
<td>X&lt;sup&gt;β&lt;/sup&gt;</td>
<td>X&lt;sup&gt;β&lt;/sup&gt;</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;q&lt;/sup&gt;</td>
<td>X&lt;sup&gt;α&lt;/sup&gt;</td>
<td>X&lt;sup&gt;α&lt;/sup&gt;</td>
<td>X&lt;sup&gt;α&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X&lt;sup&gt;r&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;q&lt;/sup&gt;</td>
<td>X&lt;sup&gt;q&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom-directed physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure:</td>
<td>Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>8&lt;sup&gt;d&lt;/sup&gt;</td>
<td>15</td>
<td>Cycle n, Day 1</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>-----------</td>
<td>---</td>
<td>--------</td>
<td>------</td>
<td>------</td>
<td>----------------</td>
</tr>
<tr>
<td>Vital signs, height, and weight&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X&lt;sup&gt;g&lt;/sup&gt;</td>
<td>X</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;e&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collected&lt;sup&gt;v&lt;/sup&gt;</td>
<td>X&lt;sup&gt;w&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;w&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for FISH/MDS</td>
<td>X&lt;sup&gt;y&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X&lt;sup&gt;y&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECI = event of clinical interest; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; FISH = fluorescence in situ hybridization; irRECIST = immune-related RECIST; IV = intravenous; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; OC = ovarian cancer; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; RP2D = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.

<sup>a</sup> Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.

<sup>b</sup> EOT visit should be completed within 7 days of the last dose of study drug.

<sup>c</sup> Required for Phase 1 patients only.

<sup>d</sup> Patients in Phase 1 are required to have an in-clinic visit on Day 8 with CBC done at the study center’s laboratory. For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an
adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

c For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy.

d In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 8 to approximately 12 weeks after initiating study treatment, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. A core biopsy is recommended; if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion.

e Standard of care tests/procedures, including biopsy, radiographic scans, laboratory assessments, ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first dose for these procedures with the exception of the biopsy, which may have been conducted within 12 weeks of first dose, and pregnancy test, which must be conducted within 72 hours of first dose) and any relevant guidelines (eg, diagnostic quality for scans).

f Required on Day 1 of Cycle 2 only.

g Blood samples are to be obtained for niraparib and pembrolizumab PK assessments; see Table 6 and Table 7 for the detailed schedule.

h Tumor assessment per RECIST and irRECIST via CT or MRI (chest, abdomen, and pelvis [brain, only if clinically indicated]) required at screening, every 9 weeks (63 ±7 days) from Cycle 1/Day 1 for the first year, and then every 12 weeks (84 ±7 days) until progression; at the time of progression, a final follow up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.

i If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly (thrombocytopenia or neutropenia) or once weekly (anemia) blood draws (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.

j If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.

k Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples.

l Required on Day 1 of Cycle 2 and Cycle 3 only.

m Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.

n If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.

o Blood samples for TSH, T3 or FT3, and FT4 are to be collected at screening, every 6 weeks thereafter, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 30-day post-treatment safety follow-up only if assessment is clinically indicated.

p Patients will undergo ECG monitoring as per Table 6 and Table 7.
Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only. AEs are required to be captured through 30 days after cessation of study treatment, SAEs and ECIs (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

Administer pembrolizumab once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

See Table 8 for details of niraparib administration in Phase 1. The RP2D of the combination will be based on the results of Phase 1.

Niraparib dose administered upon completion of pembrolizumab infusion.

FISH/MDS: test result must be negative for cytogenetic abnormalities commonly observed in myeloid malignancies. The FISH/MDS result must be received prior to first dose.

Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor’s medical monitor finds evaluation necessary for assessing niraparib-related risk for MDS/AML (eg, the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s medical monitor. The study site must receive a copy of the hematologist’s report of aspirate/biopsy findings, which must include a classification according to WHO criteria, and other sample testing results related to MDS/AML.
Table 6: Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 1

<table>
<thead>
<tr>
<th>Visit/Cycle:</th>
<th>Screen</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 4</th>
<th>Cycle 8</th>
<th>EOT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>2</td>
<td>8</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td>Pre Niraparib dose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Niraparib dose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1 hr (±5 min)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Pembrolizumab infusion&lt;sup&gt;d&lt;/sup&gt;</td>
<td>30 min (±5 minutes)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Pembrolizumab infusion&lt;sup&gt;d&lt;/sup&gt;</td>
<td>24 hrs (±30 minutes)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Pembrolizumab infusion&lt;sup&gt;d&lt;/sup&gt;</td>
<td>168 hrs (±2 hours)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Pembrolizumab infusion&lt;sup&gt;d&lt;/sup&gt;</td>
<td>336 hour (±4 hours)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Abbreviations: ECG = electrocardiogram; EOT = end of treatment; hr = hour; min = minute

<sup>a</sup> To be obtained within 30 minutes of niraparib dose; ECG should be conducted prior to blood draws.

<sup>b</sup> Sample to be obtained 2 hours ±15 minutes post niraparib dose.

<sup>c</sup> To be obtained within 30 minutes before the start of infusion of pembrolizumab; samples will only be analyzed to understand any AE in an individual patient.

<sup>d</sup> Samples will only be analyzed to understand an AE in an individual patient. Times are relative to the end of the infusion.
### Table 7: Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 2

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Point:</strong></td>
<td><strong>Assessment:</strong></td>
<td>ECG</td>
<td>ECG</td>
<td>Blood</td>
<td>ECG</td>
<td>Blood</td>
</tr>
<tr>
<td>Anytime</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Niraparib dose</td>
<td>X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post Niraparib dose</td>
<td>X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 hr (+15 min)</td>
<td>X X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ECG = electrocardiogram; EOT = end of treatment; hr = hour; min = minute

*a To be obtained within 30 minutes of niraparib dose; ECG should be conducted prior to blood draws.

### Table 8: Niraparib Administration – Phase 1

<table>
<thead>
<tr>
<th>Cycle</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day</strong></td>
<td>1</td>
</tr>
<tr>
<td>Niraparib 200 mg QD PO (Dose Level 1)*</td>
<td>X-----------------------------</td>
</tr>
<tr>
<td>Niraparib 300 mg QD PO (Dose Level 2)*</td>
<td>X-----------------------------</td>
</tr>
<tr>
<td>Niraparib 200 or 300 mg QD PO (Dose Level -1)*b</td>
<td>X-----------------------------</td>
</tr>
<tr>
<td>Niraparib 200 or 300 mg QD PO (Dose Level -2)*b</td>
<td>X-----------------------------</td>
</tr>
</tbody>
</table>

Abbreviations: PO = oral; QD = once daily

*a For all dose levels, niraparib will be administered during Cycle 1 in combination with pembrolizumab (200 mg IV on Day 1 of the 21-day cycle).

*b Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).
7.2. Procedures by Visit

7.2.1. Screening (Day -21 to Day -1)

Standard of care tests/procedures, including laboratory assessments, ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first with the exception of the pregnancy test which must be conducted within 72 hours of first dose). Note that source documents must clearly identify the standard of care tests/procedures that are used for screening and the results of these tests/procedures must be entered in the eCRF.

At screening, the following procedures/tests will be performed:

- Obtain written informed consent
  - A single study ICF will be signed before any study procedures
- Inclusion/exclusion criteria review
- Demographics
- Medical/surgical/cancer/medication history
- Tumor sample for biomarker testing
  - For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy.
- Sample collection (whole blood) for FISH, MDS, and other cytogenetic analysis.
- Tumor assessment (CT/MRI) for determination of measurable disease (RECIST v1.1)
  - Chest, abdomen, and pelvis (brain, if clinically indicated) CT (preferred method) or MRI (if clinically indicated). If the chest (applies to OC patients only) and/or brain (applies to OC and TNBC patients) CT/MRI is clear at screening, repeat imaging is not required in the absence of clinical indication requiring follow-up. Positron emission tomography (PET)/CT may be used according to RECIST v1.1 guidelines.
  - Scans performed prior to informed consent as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and are performed within 21 days prior to first dose date.
- Bone scans performed per standard of care.
- Laboratory assessments:
  - Serum pregnancy test for women of childbearing potential within 72 hours of first dose of study treatment
- CBC
- Serum chemistry
- TSH, T3 or FT3, and FT4
- Coagulation
- Serum CA-125 (OC patients only)
- Urinalysis

- ECG
- Physical examination
- Vital signs (BP, pulse, and temperature) and weight
- Height
- ECOG performance status
- Concomitant medications
- AE monitoring

7.2.2. Cycle 1/Day 1

- Inclusion/exclusion criteria review
- Laboratory assessments (if screening assessments were performed within 72 hours of Day 1, repeat testing is not required):
  - CBC
  - Serum chemistry
  - Serum CA-125 (OC patients only)
  - Urinalysis
- Symptom-directed physical examination
- Vital signs (BP, pulse, and temperature) and weight
- Concomitant medications
- AE monitoring
- Blood sample to be obtained predose for exploratory biomarkers
- Pembrolizumab study treatment administered after other visit procedures are completed
- Blood samples for pembrolizumab PK assessment
  - Phase 1 patients only: Blood samples will be obtained predose (within 30 minutes) and within 30 minutes (±5 minutes) after the end of the pembrolizumab infusion.
• Niraparib first dose administered in clinic after completion of pembrolizumab infusion
• ECG
  – ECG monitoring to be conducted prior to the niraparib dose and 2 hours postdose. ECGs should be performed prior to PK blood draws.
• Blood samples for niraparib PK assessment
  – Phase 1 patients only: Patients at each dose level will undergo intensive niraparib PK evaluation with blood samples obtained at 0 (predose within 30 minutes) and at 1, 2, 4, and 6 hours (±5 minutes), and 8 hours (±10 minutes) postdose.
  – Phase 2 patients: Blood samples for niraparib PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.

7.2.3. Cycle 1/Day 2 (Phase 1 Patients Only)
• Blood samples for pembrolizumab PK assessment
  – Phase 1 patients only: Obtain blood sample 24 hours (±30 minutes) after the end of the pembrolizumab infusion.
• Blood sample for niraparib PK assessment
  – Phase 1 patients only: Obtain blood sample 24 hours (±30 minutes) postdose following the Cycle 1, Day 1 dose.

7.2.4. Cycle 1/Day 8
For Phase 1 patients, visit to be conducted at the study site to include:
• Vital signs (BP, pulse, and temperature) and weight
• Blood samples for pembrolizumab PK assessment obtained 168 hours (±2 hours) Day 8) after the end of the pembrolizumab infusion.
• CBC
• Concomitant medications
• AE monitoring

For Phase 2 patients:
• CBC: may be done at the study center’s local laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

7.2.5. Cycle 1/Day 15
• Laboratory assessments:
  – CBC
− Serum chemistry
− Coagulation (Phase 1 patients only)

Symptom-directed physical examination

Vital signs (BP, pulse, and temperature) and weight

Phase 1 patients only: Blood samples for pembrolizumab PK will be obtained 336 hours (±4 hours) (Day 15) after the end of the pembrolizumab infusion.

Concomitant medications

AE monitoring

7.2.6. Day 1, Subsequent Cycles

Tumor assessment (RECIST v1.1 and irRECIST)

− Conduct radiographic evaluations of chest (all TNBC patients and OC patients with abnormal screening assessment or clinical indication), abdomen, pelvis, and brain (if abnormal at screening or clinical indication). The first on-study imaging assessment should be performed at 9 weeks (63 ±7 days) from the date of first dose of study treatment; in the case of PD, a confirmatory image will be required 4 weeks later (eg, 13 weeks [91 ±7 days]) (see Section 6.3.1.4). Subsequent tumor imaging should be performed every 9 weeks (63 ±7 days) or more frequently if clinically indicated and at the time of suspected disease progression. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days). Imaging should not be delayed for delays in cycle starts or extension of combination treatment cycle intervals. The same modality (ie, CT or MRI) should be used for a given patient throughout the study. PET/CT may be used according to RECIST v1.1 guidelines.

− Patients with CR or PR should have the response confirmed by a repeat tumor imaging assessment performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated.

Bone scans performed per standard of care.

Laboratory assessments:
− CBC
− Serum chemistry
− Coagulation (Phase 1 patients only; Day 1 of Cycles 2 and 3 only)
− TSH, T3 or FT3, and FT4 (every 6 weeks)
− Serum CA-125 (OC patients only)
− Urinalysis
- Urine pregnancy test for females of childbearing potential conducted every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc.).

- Symptom-directed physical examination
- Vital signs (BP, pulse, and temperature) and weight
- ECOG performance status
- Blood sample to be obtained prior to study treatment for exploratory biomarkers on Day 1 of Cycle 2 only
- Pembrolizumab study treatment administered after other visit procedures are completed
- Blood samples for pembrolizumab PK assessment
  - Phase 1 patients (Cycles 2, 4, and 8 only): Blood samples will be obtained predose (within 30 minutes). An additional sample will be obtained within 30 minutes after the end of the pembrolizumab infusion in Cycle 8.
- Niraparib dose administered in clinic after completion of pembrolizumab infusion
- ECG
  - Patients will undergo ECG monitoring on Cycle 2/Day 1 prior to the niraparib dose and 2 hours postdose and on Cycle 4/Day 1 and Cycle 8/Day 1 predose. ECGs should be performed prior to PK blood draws.
- Blood samples for niraparib PK assessment
  - Phase 1 patients (Cycle 2 only): Patients at each dose level will undergo intensive niraparib PK evaluation with blood samples obtained at 0 (predose within 30 minutes) and at 1, 2, 4, and 6 hours (±5 minutes), and 8 hours (±10 minutes postdose).
  - Phase 1 patients (Cycles 4 and 8 only): Blood samples for niraparib PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.
  - Phase 2 patients (Cycles 2, 4, and 8 only): Blood samples for niraparib PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.
- Optional fresh tumor sample
  - Sample to be obtained on or after Cycle 3/Day 1 but prior to Cycle 4/Day 1 (ie, 8 to approximately 12 weeks after first dose). See the Study Manual for details on sample collection and processing.
- Concomitant medications
- AE monitoring
- Niraparib study treatment dispensed/colleced
7.2.7. **Cycle 2, Day 2 (Phase 1 Patients Only)**
- Blood sample for niraparib PK assessment
  - Phase 1 patients only: Obtain blood sample 24 hours (±30 minutes) postdose following the Cycle 2, Day 1 dose.

7.2.8. **End of Treatment (within 7 days of last dose)**
- Optional fresh tumor sample
  - If possible, sample to be obtained at the time of disease progression. See the Study Manual for details on sample collection and processing.
- Sample collection (whole blood) for cytogenetic analysis.
- Tumor assessment (RECIST and irRECIST)
  - A final set of radiographic images is required at the time of disease progression, if not done within the last 4 weeks.
  - If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, radiographic scans/images and CA-125 testing (OC patients only) should continue every 9 weeks (63 ±7 days) through 1 year and every 12 weeks (84 ±7 days) thereafter.
- ECG
- Laboratory assessments:
  - CBC
  - Serum chemistry
  - TSH, T3 of FT3, and FT4
  - Serum CA-125 (OC patients only)
  - Urinalysis
- Physical examination
- Vital signs (BP, pulse, and temperature) and weight
- ECOG performance status
- Concomitant medications
- AE monitoring
- Niraparib study treatment collected

7.2.9. **Safety Follow-up (30 days [+ 7 days] Post-treatment)**
- Tumor assessment (RECIST and irRECIST) and serum CA-125 (OC patients only)
  - Patients who discontinue treatment for reasons other than disease progression, death, withdrawal of consent, or loss to follow-up will be followed for disease
assessments, including radiographic scans and CA-125 testing (OC patients only), per the specified schedule.

- Symptom-directed physical examination
- Laboratory assessments:
  - CBC
  - Serum chemistry
  - TSH, T3 or FT3, and FT4 (only if clinically indicated)
  - Serum CA-125 (OC patients only)
  - Urine pregnancy test
  - Urinalysis
- Vital signs (BP, pulse, and temperature) and weight
- Concomitant medications
- AE monitoring – AEs are required to be captured through 30 days after cessation of study treatment, SAEs, and ECI (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

7.2.10. **Follow-up Assessments**

- Tumor assessment (RECIST and irRECIST) and serum CA-125 (OC patients only)
  - Patients who discontinue treatment for reasons other than disease progression, death, withdrawal of consent, or loss to follow-up will be followed for disease assessments, including radiographic scans and CA-125 testing (OC patients only), per the specified schedule.

- Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples (see Section 7.2.4).

- AE monitoring – SAEs and ECI (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy)

- Pregnancy status assessed (through Day 120 post-treatment)

- Survival/new malignancy assessment
  - Patients will be followed by telephone every 90 days for survival status and the occurrence of any new malignancies
7.2.11. Unscheduled Assessments

- For any patient diagnosed with MDS/AML while on study, a bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis. See Section 6.1.8 for details.
8. **STATISTICAL METHODS**

Details of the statistical analyses presented below will be provided in the study’s statistical analysis plan (SAP). A change to the data analysis methods described in the protocol will require a protocol amendment only if it alters a principal feature of the protocol. The SAP will be finalized prior to database lock. Any changes to the methods described in the plan will be described and justified in the final clinical study report.

8.1. **Study Populations**

Three analysis populations will be defined as follows:

- **Safety Population:** All patients who receive any amount of study drug. The assessment of DLTs in Phase 1 will include only those patients completing the first cycle of therapy, unless the patient discontinued study drug due to a DLT.
- **Full Analysis Set (FAS):** All patients who receive any amount of study drug. The primary analysis of efficacy endpoints will be performed on the FAS population.
- **Per-Protocol Population:** All patients who receive at least two cycles of study drug, have protocol-required post-baseline disease assessments and have no major protocol violations that would impact efficacy evaluations. Supportive analyses of efficacy endpoints will be performed on the per-protocol population.

8.2. **Demographics, Medical History, Baseline Characteristics, and Concomitant Medications**

Demographics, baseline characteristics, and medical history information will be summarized by dose level for Phase 1, and by indication for Phase 2, for the Safety population using descriptive statistics. No formal statistical comparisons will be performed.

Demographic, baseline characteristics, and medical history data for each patient will be provided in data listings.

8.3. **Safety Analyses**

The following key safety parameters will be evaluated by study phase, pooled dose schedule across phases, by disease type, and overall, unless noted otherwise:

- Dose-limiting toxicities during the first cycle (ie, during the first 21 days of treatment, ie, Cycle 1/Day 1 through Cycle 1/Day 21) for Phase 1
- Incidence of TEAEs during the first cycle compared to the second and subsequent cycles
- Incidence of TEAEs occurring while patients are on treatment or up to 30 days after the last dose of study drug
- Incidence of SAEs and ECI occurring while patients are on treatment or up to 90 days after the last dose of study drug
- Incidence of any new malignancies
Changes in clinical laboratory parameters (hematology, chemistry, thyroid function, coagulation, urinalysis), vital signs, ECOG performance status, ECG parameters, physical examinations, and usage of concomitant medications

All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system and displayed in tables and data listings using system organ class and preferred term. Analyses of AEs will be performed for those events that are considered treatment-emergent, where treatment-emergent is defined per protocol as any AE with onset beginning at the day of first administration of study drug, throughout the treatment period until 30 days after the last dose of study drug, any SAE or ECI that occurs through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), or any event that was present at baseline but worsened in intensity or was subsequently considered drug-related by the Investigator through the end of the study. DLTs will be tabulated by dose level in Phase 1.

The number and percentage of patients with any TEAE, with any TEAE assessed by the Investigator as related to treatment (definite, probable, or possible relationship), and with any SAE will be summarized by treatment group and overall. In these tabulations, each patient will contribute only once (ie, the most related occurrence or the most intense occurrence) to each of the incidence rates in the descriptive analysis, regardless of the number of episodes. No formal hypothesis-testing analysis of AE incidence rates will be performed.

The occurrence of and reasons for any requirement for dose interruption or modification will be tabulated, and distinguished as to presumptive causality from niraparib or pembrolizumab, if known.

All AEs occurring on-study will be listed in patient data listings. By-patient listings also will be provided for the following: patient deaths, SAEs, and AEs leading to withdrawal.

8.4. Pharmacokinetic Analyses

All patients who receive at least 1 dose of study drug and have measureable drug concentrations will be included in PK analyses.

Non-compartmental methods will be used to evaluate the PK characteristics of niraparib and pembrolizumab as appropriate. Pharmacokinetic parameters to be determined will include AUC, AUC$_{ss}$, C$_{min}$, C$_{max}$, CL/F, V$_z$/F, C$_{min,ss}$, and C$_{max,ss}$. Plasma concentrations and PK parameter estimates will be presented using descriptive statistics by dose level.

8.5. Post-Treatment Analyses

Descriptive summary statistics will be used to summarize post-treatment data (ie, any new occurrence of MDS/AML).

8.6. Efficacy Analyses

All efficacy endpoints will be summarized on the Phase 2 population by disease type; in addition, data may be pooled for patients in Phase 1 and Phase 2, by disease type. All analyses will include summary statistics, including number and percentage for categorical variables and number of patients, mean, standard deviation, median, minimum, and maximum for continuous
variables. Two-sided exact 90% confidence intervals (CIs) based on the Clopper-Pearson method (67) will be provided where appropriate. Time-to-event analyses will be performed using Kaplan-Meier (KM) methods. Comparisons in the Phase 1 portion of the study will be made using descriptive statistics. As the Phase 2 portion of the study is single-arm, any statistical analysis to be performed among subgroups is for descriptive and future study purposes.

8.6.1. Primary Efficacy Parameter
The primary efficacy endpoint will be ORR, defined as the achievement of CR or PR using RECIST (v1.1), as assessed by the Investigator. Point estimates and 1-sided 95% CI, corresponding to the specifications of the sample size calculation will be provided. The primary analysis will be performed for each patient cohort and no multiplicity adjustment will be made since separate inferences will be drawn for each cohort.

8.6.2. Secondary Efficacy Parameter(s)
Objective response rate as assessed by the Investigator using irRECIST will be assessed as a secondary endpoint.

Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving CR, PR, or SD as assessed by the Investigator per RECIST v1.1 and irRECIST, with point estimates and 2-sided 90% CIs.

Duration of response, PFS and OS will be presented through use of summary statistics using KM methods, to include 25th, 50th (median), and 75th percentiles and associated 2-sided 95% CIs, number of events and number of censored observations. DOR and PFS will be defined by both RECIST v1.1 and irRECIST criteria, based on the date of PD that will be used to determine duration, and will be analyzed separately by both criteria.

8.7. Biomarker Analyses
For each patient in the study, blood and tumor samples will be prospectively collected, evaluated and archived to support exploratory biomarker analysis. PD-L1 expression (retrospective analysis), HRD score, immune cell infiltrates, and other exploratory biomarkers will be correlated with response.

8.8. Probability of Dose Escalation
Based on the dose escalation schema planned for the Phase 1 portion of the study as outlined in Section 3.1.2, the following decision rules will be used to determine if a dose is or is not increased:
Table 9: Dose Escalation Decision Rules

<table>
<thead>
<tr>
<th>First 6 Patients</th>
<th>Second 6 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Hematologic DLTs</td>
<td>Number of Non-hematologic DLTs</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Any</td>
</tr>
</tbody>
</table>

Abbreviations: DLT = dos-limiting toxicity; NA = not applicable; second 6 patients are not required to be enrolled.

To model the probabilities of dose escalation given various rates of true hematological and non-hematological DLTs, let X = number of hematological DLTs observed and Y = number of non-hematological DLTs observed. Then the joint distribution of (X,Y) is multinomial (trinomial) with parameters: N = number of patients evaluated, PH = true probability of a hematological DLT, and PN = true probability of a non-hematological DLT. There are 2 probabilities to calculate. First, the probability of escalation based on the first 6 patients enrolled. Second is the conditional probability of escalation based on the second 6 patients enrolled, given (X,Y) = (1,1) or (0,2) in the first 6 patients. The probability of dose escalation is the sum of these 2 probabilities. It is assumed that a given patient cannot have more than 1 DLT, and that hematologic DLTs take precedence over non-hematologic DLTs. The following graph presents the probabilities of dose escalation for ranges of true rates of DLTs, where it is assumed the true rates will be approximately 18% (range 12-24%) for hematologic DLTs and 5% (range 3-7%) for non-hematologic DLTs.

As shown in Figure 3, the probability of dose escalation decreases as the DLT rate increases, as expected. Over the restricted range of DLT rates, the probabilities are close to a linear relationship as the true DLT rates increase.
Figure 3: Probability of Dose Escalation in a 6 + 6 Design

Figure 4 shows the probability of dose escalation for a standard 3+3 escalation design, contrasted with the 6 + 6 design, at the fixed rate of 0.05 for non-hematologic DLTs (the anticipated rate). As can be seen, the protocol-specified 6 + 6 design has a similar probability of escalation as the 3+3 design, and is, in fact, somewhat more conservative for hematologic DLT rates >0.15.
8.9. Interim Analyses

To minimize the risk of exposing patients to an ineffective treatment, a series of futility assessments will be performed when 6, 12, 18, and 24 of 48 Phase 2 patients from each cancer type have at least 2 post-baseline tumor assessments. A formal decision regarding futility, which could result in stopping the study early, will be conducted separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier assessments, however, will inform the conduct of the formal interim analysis as follows: If all three futility assessments from 6, 12, and 18 patients cross the futility boundary, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If any single futility assessment from 6, 12, or 18 patients fails to cross the futility boundary, then enrollment will not be curtailed. The futility boundaries in terms of the numbers of responders (that is, patients with a confirmed PR or CR) are summarized in the table below.

<table>
<thead>
<tr>
<th>Interim Look #</th>
<th>Number of Patients</th>
<th>Number of Responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>&lt; 3</td>
</tr>
<tr>
<td>5(^a)</td>
<td>48</td>
<td>&lt; 12</td>
</tr>
</tbody>
</table>

\(^a\) This represents the final analysis for response rate.
Thus, the decision rule regarding the formal interim analysis at N=24 is as follows: If there are no responders at interim looks 1, 2, and 3, then enrollment will be suspended at 24 patients until after interim look #4. If, however, there is at least 1 responder at any of the first 3 looks, then enrollment will not be curtailed. Note that the number of responders is cumulative in the sense that a response at an early look will be included in the counts of responders at all subsequent looks. Note also that the decision rule implies that a response at look #1 or look #2 would eliminate the need for another look until look #4.

If, at the 4th look, there are fewer than 3 responders out of 24, enrollment may be closed and the study may be stopped for futility. Otherwise, the study will continue to the planned enrollment of 48 patients. If, at the 5th and final look, there are at least 12 responders out of 48, then the Phase 2 primary objective will have been met.

8.10. Determination of Sample Size

Phase 1: A total sample size of approximately 18 patients is estimated for the Phase 1 portion of the study to provide initial comparison of incidence of DLTs and safety profiles of the combination treatment between dose schedules in each patient population. More patients could be enrolled (eg, if the Dose Level -2 is explored or if expansion at any dose level is required to better understand safety and tolerability); up to a total of 36 patients may be enrolled.

Phase 2: A total of approximately 96 evaluable patients (48 patients in each tumor type) will be enrolled to ensure understanding of the activity of the combination treatment and to obtain adequate representation of different molecular cancer subtypes and biomarkers.

The following table shows the two-sided 90% CI for ORR based on 48 subjects for different observed response rates.

<table>
<thead>
<tr>
<th>Number of Observed Responses</th>
<th>ORR Estimate</th>
<th>90% CI for ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>16.7%</td>
<td>(8.6%, 28.1%)</td>
</tr>
<tr>
<td>10</td>
<td>20.8%</td>
<td>(11.8%, 32.8%)</td>
</tr>
<tr>
<td>12</td>
<td>25.0%</td>
<td>(15.1%, 37.3%)</td>
</tr>
<tr>
<td>14</td>
<td>29.2%</td>
<td>(18.6%, 41.8%)</td>
</tr>
<tr>
<td>16</td>
<td>33.3%</td>
<td>(22.2%, 46.1%)</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; ORR = objective response rate
9. ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS

9.1. Data Quality Assurance

The Sponsor (or designee) will conduct a study initiation visit to verify the qualifications of the Investigator, inspect the facilities, and inform the Investigator of responsibilities and procedures for ensuring adequate and correct documentation.

The Investigator must prepare and maintain adequate and accurate records of all observations and other data pertinent to the clinical study for each study participant. Frequent communication between the clinical site and the Sponsor is essential to ensure that the safety of the study is monitored adequately. The Investigator will make all appropriate safety assessments on an ongoing basis. The Sponsor’s Medical Monitor may review safety information as it becomes available throughout the study.

All aspects of the study will be carefully monitored with respect to GCP and standard operating procedures for compliance with applicable government regulations. The Study Monitor will be an authorized individual designated by the Sponsor. The Study Monitor will have access to all records necessary to ensure integrity of the data and will periodically review the progress of the study with the Principal Investigator.

9.2. Access to Source Data/Documents

An electronic data capture system to manage data collection will be utilized during this study. The electronic data capture system is a software tool designed to ensure quality assurance and facilitate data capture during clinical studies. The system is fully compliant with Code of Federal Regulations 21 Part 11.

The Investigator will ensure the accuracy, completeness, and timeliness of the data reported to the Sponsor. Data collection processes and procedures will be reviewed and validated to ensure completeness, accuracy, reliability, and consistency. A complete audit trail will be maintained of all data changes. The Investigator or designee will cooperate with the Sponsor’s representative(s) for the periodic review of study documents to ensure the accuracy and completeness of the data capture system at each scheduled monitoring visit.

Electronic consistency checks and manual review will be used to identify any errors or inconsistencies in the data. This information will be provided to the respective study sites by means of electronic or manual queries.

The Investigator or designee will prepare and maintain adequate and accurate study documents (medical records, ECGs, AE, and concomitant medication reporting, raw data collection forms, etc.) designed to record all observations and other pertinent data for each patient receiving study treatment.

The Investigator will allow Sponsor representatives, contract designees, authorized regulatory authority inspectors, and the institutional review board (IRB)/independent ethics committee (IEC) to have direct access to all documents pertaining to the study.
9.3. Archiving Study Documents

Essential clinical documents will be maintained to demonstrate the validity of the study and the integrity of the data collected. Master files should be established at the beginning of the study, maintained for the duration of the study, and retained according to the appropriate regulations. According to International Conference on Harmonisation (ICH) guidelines, essential documents should be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the study treatment.

9.4. Good Clinical Practice

This study will be conducted in accordance with the ICH for GCP and the Declaration of Helsinki (Version 2008). The clinical study will also be carried out in accordance with national and local regulatory requirement(s).

9.5. Informed Consent

Before each patient is enrolled in the clinical study, written informed consent will be obtained from the patient according to the regulatory and legal requirements of the participating country. As part of this procedure, the Investigator must explain orally and in writing the nature, duration, and purpose of the study, and the action of the study treatment in such a manner that the patient is aware of the potential risks, inconveniences, or AEs that may occur. The patient should be informed that he or she is free to withdraw from the study at any time. The patient will receive all information that is required by regulatory authorities and ICH guidelines. The Investigator or designee will provide the Sponsor with a copy of the IRB/IEC-approved ICF prior to the start of the study.

The ICF must be signed and dated; one copy will be given to the patient and the Investigator will retain a copy as part of the clinical study records. The Investigator will not undertake any investigation specifically required for the clinical study until written consent has been obtained. The terms of the consent and when it was obtained must also be documented.

If a protocol amendment is required, then the ICF may need to be revised to reflect the changes to the protocol. If the ICF is revised, it must be reviewed and approved by the responsible IRB/IEC and signed by all patients subsequently enrolled in the clinical study as well as those currently enrolled in the clinical study.

9.6. Protocol Approval and Amendment

Before the start of the study, the study protocol and/or other relevant documents will be approved by the IEC/IRB/Competent Authorities, in accordance with local legal requirements. The Sponsor must ensure that all ethical and legal requirements have been met before the first patient is enrolled in the study.

This protocol is to be followed exactly. To alter the protocol, amendments must be written, receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority approval prior to implementation (if appropriate). In the United States, following approval, the protocol amendment(s) will be submitted to the IND under which the study is being conducted.
Administrative changes (not affecting the patient benefit/risk ratio) may be made without the need for a formal amendment. All amendments will be distributed to all protocol recipients, with appropriate instructions.

9.7. **Patient Confidentiality and Data Protection**

All clinical study findings and documents will be regarded as confidential. Study documents (protocols, IBs, and other material) will be stored appropriately to ensure their confidentiality. The Investigator and members of his/her research team (including the IRB/IEC) must not disclose such information without prior written approval from the Sponsor, except to the extent necessary to obtain informed consent from patients who wish to participate in the study or to comply with regulatory requirements.

The anonymity of participating patients must be maintained. Patients will be specified on study documents by their enrollment number or birth date, not by name. Documents that identify the patient (e.g., the signed informed consent document) must be maintained in confidence by the Investigator.

9.8. **Study Monitoring**

Monitoring and auditing procedures approved by the Sponsor will be followed in order to comply with GCP guidelines. On-site checking of the eCRFs for completeness and clarity, cross-checking with source documents, and clarification of administrative matters will be performed.

The study will be monitored by the Sponsor or its designee. Monitoring will be done by personal visits from a representative of the Sponsor (site monitor) who will review the eCRFs and source documents. The site monitor will ensure that the investigation is conducted according to protocol design and regulatory requirements by frequent site visits and by communications (letter, telephone, and fax).

All unused study treatment and other study materials will be returned to the Sponsor after the clinical phase of the study has been completed.

9.9. **Audits and Inspections**

Regulatory authorities, the IRB/IEC, and/or the Sponsor’s clinical quality assurance group, or its designee, may request access to all source documents, eCRFs, and other study documentation for on-site audit or inspection. Direct access to these documents must be guaranteed by the Investigator, who must provide support at all times for these activities.

9.10. **Ethical Considerations**

The study will be conducted in accordance with ethical principles founded in the Declaration of Helsinki. The IRB/IEC will review all appropriate study documentation in order to safeguard the rights, safety, and well-being of the patients. The study will only be conducted at sites where IRB/IEC approval has been obtained. The protocol, Investigator Brochure, informed consent, advertisements (if applicable), written information given to the patients, safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB/IEC by the Investigator.
9.11. Publication Policy

Information regarding publication of study results is contained in the Clinical Trial Agreement for this study.

9.12. Study Committee

A Study Committee comprising Investigators and Sponsor representatives will be established to provide review and assessment of the study data on an ongoing basis and to safeguard the interest and safety of the participating patients in the study. The details on membership, key responsibilities, and corresponding procedures are provided in the Study Committee charter.
10. **REFERENCE LIST**


57. Data on file at Tesaro.


APPENDIX A. DRUGS KNOWN TO INHIBIT OR INDUCE CYP1A2 OR ARE SUBSTRATES OF CYP1A2

<table>
<thead>
<tr>
<th>Inhibitors of CYP1A2</th>
<th>Strong</th>
<th>Moderate</th>
<th>Weak</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≥ 5-fold increase in AUC or &gt; 80% decrease in CL</td>
<td>≥ 2 but &lt; 5-fold increase in AUC or 50%-80% decrease in CL</td>
<td>≥ 1.25 but &lt; 2-fold increase in AUC or 20%-50% decrease in CL</td>
</tr>
<tr>
<td>Ciprofloxacin, enoxacin, fluvoxamine</td>
<td>Methoxsalen, mexiletine, oral contraceptives, phenylpropanolamine, thia bendazole, vemurafenib, zileuton</td>
<td>Acyclovir, allopurinol, caffeine, cimetidine, Daidzein, disulfiram, Echinacea, famotidine, norfloxacin, propafenone, propranolol, terbinafine, ticlopidine, verapamil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inducers of CY1A2</th>
<th>Strong</th>
<th>Moderate</th>
<th>Weak</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>80% decrease in AUC</td>
<td>50%-80% decrease in AUC</td>
<td>20%-50% decrease in AUC</td>
</tr>
<tr>
<td>Montelukast, phenytoin, smokers versus non-smokers</td>
<td>Moricizine, omeprazole, phenobarbital</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Substrates of CYP1A2</th>
<th>Sensitive substrates(^a)</th>
<th>Substrates with narrow therapeutic range(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alosetron, caffeine, duloxetine, melatonin, ramelteon, tacrine, tizanidine</td>
<td>Theophylline, tizanidine, warfarin</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AUC = area under the curve; CL = clearance.
Source: (68)
\(^a\) Sensitive CYP substrates refers to drugs whose plasma AUC values have been shown to increase 5-fold or higher when coadministered with a known CYP inhibitor or AUC ratio in poor metabolizers vs. extensive metabolizers is greater than 5-fold.
\(^b\) CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety concerns (eg, Torsades de Pointes).
APPENDIX B. DRUGS ASSOCIATED WITH QT PROLONGATION AND TORSADES DE POINTE (TDP)

Table 10: Drugs Associated with QT prolongation and Torsades de Pointes

<table>
<thead>
<tr>
<th>Antiarrhythmics</th>
<th>Antimicrobials</th>
<th>Antidepressants</th>
<th>Antipsychotics</th>
<th>Others (including Selected Antiemetics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>Levofloxacin</td>
<td>Amitriptyline</td>
<td>Haloperidol</td>
<td>Cisapride</td>
</tr>
<tr>
<td>Sotalol</td>
<td>Ciprofloxacin</td>
<td>Doxepin</td>
<td>Droperidol</td>
<td>Sumatriptan</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Gatifloxacin</td>
<td></td>
<td>Quetiapine</td>
<td>Zolmitriptan</td>
</tr>
<tr>
<td>Procainamide</td>
<td>Moxifloxacin</td>
<td></td>
<td>Thioridazine</td>
<td>Arsenic</td>
</tr>
<tr>
<td>Dofetilide</td>
<td>Clarithromycin</td>
<td></td>
<td>Ziprasidone</td>
<td>Dolasetron</td>
</tr>
<tr>
<td>Ibutilide</td>
<td>Erythromycin</td>
<td></td>
<td></td>
<td>Methadone</td>
</tr>
<tr>
<td>Ketoconazole*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Topical use allowed for ketoconazole

Sources:
CredibleMeds. Available at: https://www.crediblemeds.org
US Pharmacist. Drug-induced QT prolongation page. Available at:
## APPENDIX C. DRUGS THAT ARE SUBSTRATES OR INHIBITORS OF P-GLYCOPROTEIN

<table>
<thead>
<tr>
<th>Substrates</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aliskiren</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Ambrisentan</td>
<td>Azithromycin</td>
</tr>
<tr>
<td>Colchicine</td>
<td>Captopril</td>
</tr>
<tr>
<td>Dabigatran etexilate</td>
<td>Carvedilol</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Clarithromycin</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Conivaptan</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td>Imatinib</td>
<td>Diltiazem</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Dronedarone</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>Erythromycin</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>Felodipine</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Itraconazole</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>Ketoconazole</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>Lopinavir and Ritonavir</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Quercetin</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Talinolol</td>
<td>Ranolazine</td>
</tr>
<tr>
<td>Tolvaptan</td>
<td>Ticagrelor</td>
</tr>
<tr>
<td>Topotecan</td>
<td>Verapamil</td>
</tr>
</tbody>
</table>

Source: [68]
APPENDIX D. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST), V1.1

Response Criteria by RECIST v1.1

Evaluation of Target Lesions

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Note: If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).

Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
Table 11: RECIST Response for Patients with Measurable Disease (ie, Target Disease)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
<th>Best Overall Response when Confirmation is Required*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR CR</td>
<td>No</td>
<td>CR</td>
<td>&gt; 4 wks. Confirmation**</td>
<td></td>
</tr>
<tr>
<td>CR Non-CR/Non-PD</td>
<td>No</td>
<td>PR</td>
<td>&gt; 4 wks. Confirmation**</td>
<td></td>
</tr>
<tr>
<td>CR Non-CR/Non-PD</td>
<td>Not evaluated</td>
<td>PR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SD Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>SD</td>
<td>documented at least once &gt; 4 wks. from baseline**</td>
<td></td>
</tr>
<tr>
<td>PD Any</td>
<td>Yes or No</td>
<td>PD</td>
<td>no prior SD, PR or CR</td>
<td></td>
</tr>
<tr>
<td>Any PD***</td>
<td>Yes or No</td>
<td>PD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Any</td>
<td>Yes</td>
<td>PD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease
* See RECIST v1.1 publication (65) for further details on what is evidence of a new lesion.
** Only for non-randomized trials with response as primary endpoint.
*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document the objective progression even after discontinuation of treatment.

Table 12: RECIST Response For Patients with Non-Measurable Disease (ie, Non-Target Disease)

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD*</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>not evaluated</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; PD = progressive disease
* ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised
APPENDIX E. IMMUNE-RELATED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS

Immune-related RECIST will be used by local site Investigators to assess tumor response and progression and make treatment decisions.

Table 13 provides a high-level summary of the imaging procedures and treatment decisions to be made based on evidence of progression of disease per RECIST v1.1. See also details provided in Section 6.3.1.4.

Table 13 Imaging and Treatment after First Radiologic Evidence of Progressive Disease

<table>
<thead>
<tr>
<th>Timing of Imaging</th>
<th>Clinically Stable</th>
<th>Clinically Unstable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tumor Imaging</td>
<td>Treatment</td>
</tr>
<tr>
<td>1st radiologic evidence of PD</td>
<td>Repeat imaging at ≥ 4 weeks at site to confirm PD</td>
<td>May continue study treatment at the local site Investigator’s discretion while awaiting confirmatory tumor imaging</td>
</tr>
<tr>
<td>Repeat tumor imaging confirms PD</td>
<td>No additional imaging required</td>
<td>Discontinue treatment</td>
</tr>
<tr>
<td>Repeat tumor imaging shows SD, PR or CR</td>
<td>Continue regularly scheduled imaging assessments</td>
<td>Continue study treatment at the local site Investigator’s discretion</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; irRECIST = immune-related Response Criteria in Solid Tumors; N/A = not applicable; PD = progressive disease; PR = partial response; RECIST = Response Criteria in Solid Tumors; SD = stable disease
APPENDIX F. ASSESSMENT OF RESPONSE IN OVARIAN CANCER BY GYNECOLOGIC CANCER INTERGROUP (GCIG) CRITERIA

Because of the pelvic location of the primary tumor in patients with OC and the frequent occurrence of peritoneal disease, imaging may not always be reliable for documentation of PD in patients with OC. Criteria other than RECIST may be applicable to define PD in these patients. For this protocol, the GCIG criteria for disease progression will also be considered for patients with OC. Based on these criteria, PD may also be determined if at least 1 of the following criteria is met:

1. Additional diagnostic tests (eg, histology/cytology, ultrasound techniques, endoscopy, positron emission tomography) identify new lesions or determine existing lesions qualify for unequivocal PD AND CA-125 progression according to GCIG criteria.

2. Definitive clinical signs and symptoms of PD unrelated to nonmalignant or iatrogenic causes ([a] intractable cancer-related pain; [b] malignant bowel obstruction/worsening dysfunction; or [c] unequivocal symptomatic worsening of ascites or pleural effusion) AND CA-125 progression according to GCIG criteria.

Abnormal CA-125 levels on-study do not represent disease progression; however, they may prompt imaging if clinically indicated. Progressive disease will not be diagnosed in case of CA-125 progression in the absence of at least 1 of the criteria defined above.

The Investigator will describe how PD was diagnosed in the eCRF.

The date of PD is defined as the earliest time point when one of the PD criteria is met. If CT/MRI shows existing (baseline) lesions that only equivocally suggest PD and additional diagnostic tests are required to determine unequivocal PD, the official date of PD will be the date PD was unequivocally determined. Alternatively, with new lesions (except ascites and effusions) that are initially equivocal that are later unequivocally determined, the date of progression will be the date the lesion was initially identified.
APPENDIX G. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS

<table>
<thead>
<tr>
<th>Description</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully active, able to carry on all pre-disease performance without restriction.</td>
<td>0</td>
</tr>
<tr>
<td>Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, ie, light house work, office work.</td>
<td>1</td>
</tr>
<tr>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.</td>
<td>2</td>
</tr>
<tr>
<td>Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.</td>
<td>3</td>
</tr>
<tr>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.</td>
<td>4</td>
</tr>
</tbody>
</table>

Source: [69]
Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Sponsor: TESARO, Inc.
1000 Winter Street
Suite 3300
Waltham, MA 02451
+1 339 970 0900

TESARO UK, Limited
55 Baker Street.
London W1U7EU,
United Kingdom
+44 1753 910398

Medical Monitor: Senior Medical Director

Clinical Research Organization:

Sponsor Protocol No.: 3000-PN162-01-001
IND No(s.): 100,996 and 117,580
EudraCT No.: 2015-003398-14
Study Drug Names: Niraparib capsules/pembrolizumab for injection
Development Phase: 1/2
Date of Original Protocol: 19 October 2015
Date of Protocol Amendment 1: 28 July 2016
Date of Protocol Amendment 2: 01 March 2017
Version of Protocol: 3.0

The study will be conducted according to the protocol and in compliance with Good Clinical Practice (GCP), with the Declaration of Helsinki, and with other applicable regulatory requirements.
SPONSOR SIGNATURE PAGE

Declaration of Sponsor or Responsible Medical Officer

Title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

This study protocol was subjected to critical review and has been approved by the Sponsor. The information it contains is consistent with the current risk/benefit evaluation of the investigational products as well as with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice.

_____________________________________ _____________________
Senior Medical Director
TESARO, Inc.

Date
Declaration of the Principal Investigator

Title: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

I have read this study protocol, including all appendices. By signing this protocol, I agree to conduct the clinical study, following approval by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), in accordance with the study protocol, the current International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), and applicable regulatory requirements. I will ensure that all personnel involved in the study under my direction will be informed about the contents of this study protocol and will receive all necessary instructions for performing the study according to the study protocol.

Principal Investigator

______________________________  ______________________
Name:  Date
Title:  
Institution:
SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor/Company:</th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Investigational Product:</td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td>Name of Active Ingredient:</td>
<td>niraparib and pembrolizumab</td>
</tr>
<tr>
<td>Title of Study:</td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
<tr>
<td>Study Center(s):</td>
<td>Phase 1: approximately 6 centers in the United States; Phase 2: approximately 40 centers in the United States</td>
</tr>
<tr>
<td>Study Period (years):</td>
<td>Estimated date first patient enrolled: April 2016</td>
</tr>
<tr>
<td></td>
<td>Estimated date last patient completed: November 2019</td>
</tr>
<tr>
<td>Phase of Development:</td>
<td>1/2</td>
</tr>
</tbody>
</table>

Objectives:

*Primary objectives:*
- Phase 1: To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment, and to establish a recommended Phase 2 dose (RP2D) and schedule
- Phase 2: To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separately for the triple-negative breast cancer (TNBC) and ovarian cancer (OC) cohorts.

*Secondary objectives:*
- Phase 1 and Phase 2: To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST (irRECIST)
  - Duration of response (DOR) by RECIST v1.1 and irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
– Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
– Overall survival (OS).

• Phase 1 and 2: To evaluate the pharmacokinetics (PK) of niraparib and associated major metabolite M1 during combination treatment.

Exploratory objectives (both phases):

• To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of tumor-infiltrating lymphocytes (TILs), and circulating biomarkers.
• To correlate homologous recombination deficiency (HRD) status with other immune-related biomarkers and with efficacy outcomes.

Methodology:

Overall

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with previously treated TNBC or OC. Specifically, patients eligible for this study are those with:

• Advanced or metastatic TNBC (in Phase 1 patients may have received up to 4 lines of cytotoxic therapy for advanced/metastatic disease or in Phase 2, up to 2 lines of cytotoxic therapy for advanced/metastatic disease); or
• Advanced, recurrent epithelial (for Phase 1: any serous, endometroid, mucinous, clear cell; for Phase 2: high-grade serous or endometroid) ovarian, fallopian tube, or primary peritoneal cancer who are currently platinum-resistant but previously experienced a response lasting for at least 6 months to first-line platinum-based therapy (in Phase 1 patients may have received up to 5 lines of cytotoxic therapy or in Phase 2, up to 4 lines of cytotoxic therapy). Study treatment should be considered an appropriate option by the Investigator.

The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the RP2D and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab, and the Phase 2 portion will further evaluate the RP2D and schedule in 2 cohorts of approximately 48 patients each with TNBC or OC as described above.

The study will be conducted in conformance with Good Clinical Practice (GCP). The study schema is provided below.
Phase 1 Dose Escalation

At Dose Level 1, a cohort of 6 patients with either TNBC or OC will be enrolled. After all patients in Dose Level 1 who are evaluable for safety have completed Cycle 1 of combination treatment, the next higher dose level (Dose Level 2) will be open for enrollment if less than one-third of patients (i.e., < 2 of 6 patients or < 4 of 12 patients) in Dose Level 1 experience a DLT during Cycle 1 (see DLT definition below).

Based on current single-agent niraparib experience (see niraparib Investigator’s Brochure), hematological laboratory abnormalities are expected in a significant proportion of patients. If 2 of 6 initially enrolled patients in a cohort experience hematologic DLTs, a lower dose level will be evaluated. If, however, the 2 observed DLTs include 1 hematologic DLT and 1 non-hematologic DLT or 2 non-hematologic DLTs, a cohort may be expanded up to approximately 12 patients to better characterize the safety of the combination treatment.

Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either TNBC or OC will be enrolled in Dose Level 2. No further dose escalation will be considered if Dose Level 2 is reached.

The maximum tolerated dose (MTD) will be defined as the highest dose with DLTs observed in less than one-third of patients (i.e., < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be opened for enrollment if not yet evaluated. Alternative dosing schedules may be explored.

Additional cohorts of 6 patients may be opened to evaluate Dose Level (-1) or Dose Level (-2), which will explore lower niraparib dose intensity, for example, by introducing an alternative dosing schedule following agreement by the Investigators and Sponsor.

The RP2D will be determined following discussion and agreement between Investigators and the Sponsor (see Section 9.12) based on an evaluation of multiple endpoints, which may include the DLT rate in first and subsequent cycles of combination treatment, the rate of dose modifications for non-DLT adverse events (AEs), the ability to manage toxicities, PK, niraparib...
dose intensity, and signs of clinical efficacy. The goal will be to identify the dose/regimen of niraparib with the greatest dose intensity that can be safely combined with the recommended dose/regimen of pembrolizumab.

In the Phase 1 portion of this study, 14 patients with advanced TNBC or OC were enrolled in Dose Level 1 or Dose Level 2. Twelve patients were eligible for DLT evaluation. In Dose Level 1, 1 of 6 DLT-eligible patients experienced multiple DLTs including Grade 3 anemia, Grade 4 neutropenia, and Grade 4 thrombocytopenia. In Dose Level 2, 1 of 6 DLT-eligible patients experienced 1 DLT, Grade 4 thrombocytopenia; an additional patient experienced an adverse event that was deemed to be a DLT-equivalent; the patient had epistaxis on C1D17 and Grade 4 thrombocytopenia on C2D1.

**DLT criteria (as assessed during Cycle 1, ie, during the first 21 days of treatment - Day 1 through Day 21):**

- Any treatment-related Grade ≥ 3 non-hematologic clinical (non-laboratory) AE
- Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory abnormality if:
  - Medical intervention is required to treat the patient, or
  - The abnormality leads to hospitalization, or
  - The abnormality persists for ≥ 7 days.
- Any treatment-related hematologic toxicity specifically defined as:
  - Thrombocytopenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion;
  - Neutropenia Grade 4 for ≥ 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia;
  - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion
- Any treatment-related AE leading to niraparib dose interruption per the following criteria:
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 3) for a non-DLT laboratory abnormality (eg, for Grade 2 or 3 thrombocytopenia or for Grade 3 anemia or neutropenia) lasting ≥ 14 days
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 2) for non-hematologic AE leading to < 80% of an intended dose being administered (eg, niraparib dose interruption for > 4 days within Cycle 1).

Note that niraparib dosing has been safely managed with dose interruptions and/or adjustments for AEs, including laboratory abnormalities, while maintaining activity in the single-agent setting (see Section 5.4.1, Table 3 and niraparib Investigator’s Brochure). Therefore, niraparib dose interruption and/or reduction for an AE that does not meet a DLT definition as described above will be considered a non-DLT modification. The non-DLT dose modifications will not be considered in determining the MTD but will be considered in determining the niraparib dose
intensity and RP2D.

**Phase 2: Efficacy Phase**

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion. Two cohorts of approximately 48 patients each with advanced or metastatic TNBC or recurrent OC as outlined above will be enrolled.

Patients in this phase of the study will receive the RP2D dose: niraparib 200 mg/day PO on days 1-21 and pembrolizumab 200 mg IV on day 1 of each 21-day cycle; niraparib dose may be escalated on or after C3D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL and neutrophils ≥ 1500/µL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

Pembrolizumab/niraparib combination treatment may continue for up to 2 years or until disease progression, unacceptable toxicity, patient withdrawal, Investigator’s decision, or death. Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

**General Study Conduct: Phase 1 and 2**

All patients will begin treatment with niraparib and pembrolizumab on Cycle 1/Day 1; additional on-treatment assessments will be conducted on Days 8 and 15 of Cycle 1 and on Day 1 of all subsequent cycles. Safety assessments conducted throughout the treatment period include symptom-directed physical examination, vital signs, ECGs, ECOG performance status, and clinical laboratory assessments (complete blood count [CBC], coagulation [Phase 1 only], chemistry, thyroid stimulating hormone [TSH], triiodothyronine [T3] or free T3 [FT3], free thyroxine [FT4], urinalysis, cancer antigen-125 [CA-125] [OC patients only], and pregnancy testing). Radiographic evaluations (computed tomography/magnetic resonance imaging [CT/MRI] of chest [all TNBC patients and OC patients with abnormal screening scan or with clinical indication], abdomen, and pelvis) to assess extent of disease will be conducted every 9 weeks (63 days ±7 days) while on study treatment independent of cycle delays and/or dose interruptions, and/or at any time when progression of disease is suspected. Brain scan will be conducted if clinically indicated; bone scans will be conducted per standard of care. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days). If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals (ie, every 9 weeks for the first year and every 12 weeks thereafter). All radiographic images/scans will be sent to a central imaging vendor upon acquisition and archived for potential future evaluation. Per RECIST v1.1, complete response (CR) or partial response (PR) should be confirmed; tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated. Blood sampling for PK and biomarker evaluations will be conducted for patients in both Phase 1 and Phase 2.

In patients who consent to fresh biopsies, serial fresh biopsies will be obtained for exploratory biomarker analysis at 3 time points: during the screening period, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion and, whenever possible, at the time of disease progression (note: although the biopsy is voluntary, it is highly encouraged). The serial biopsies at different
time points should preferably be on the same lesion. A core biopsy is recommended (details are provided in the Study Manual); if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted in lieu of the screening biopsy. Blood samples will also be obtained for biomarker analysis predose on Day 1 of Cycle 1 and Cycle 2, as well as at the end of treatment (EOT).

All patients will undergo an EOT visit within 7 days of the last dose of study treatment and a safety follow-up visit conducted 30 days (+7 days) post-treatment. Thereafter, all patients will enter the post-treatment period for telephone assessment of survival status and the occurrence of any new malignancies every 90 days (±14 days).

All AEs will be collected and recorded for each patient from the day of signing the informed consent form until 30 days after last study drug administration; serious adverse events (SAEs) and Events of Clinical Interest (ECI) (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured. All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.

**Number of Patients (Planned):**

Phase 1: A total of approximately 18 patients (up to 36 patients may be included)

Phase 2: A total of approximately 96 patients (ie, approximately 48 patients enrolled into each cohort of TNBC and OC patients)

**Criteria for Inclusion:**

To be considered eligible to participate in this study, all of the following requirements must be met:

1. Patient is male or female, at least 18 years of age. Male patients are only for TNBC and not OC.

2. Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below according to study phase and disease type:
   a. Phase 1 patients (breast or ovarian cancer)
      - Patients with advanced or metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (ie, TNBC). Patients with disease recurrence or progression following neoadjuvant or adjuvant therapy are eligible. Patients with advanced or metastatic disease may have up to 4 lines of cytotoxic therapy. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal
antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.

- Patients must have any epithelial (ie, serous, endometroid, mucinous, clear cell) ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator’s assessment (e.g., patient is not eligible for further platinum containing treatment). Patients may have received up to 5 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Treatment with small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.

b. Phase 2 patients (breast or ovarian cancer)

- Patients with advanced or metastatic breast cancer must have TNBC. Patients with disease recurrence or progression following neoadjuvant or adjuvant therapy are eligible. Patients with advanced or metastatic disease may have received up to 2 lines of cytotoxic therapy. Adjuvant and/or neoadjuvant therapies are not counted in the number of lines of therapy. Targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted. TNBC patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within 8 weeks from the day of the last platinum administration.

- Patients must have with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator’s assessment (e.g., patient is not eligible for further platinum containing treatment). Patients may have had up to 4 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as one line of therapy. Treatment with small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.

3. Patient has archival tumor tissue available that is formalin-fixed and paraffin-embedded.

a. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation.

b. Serial fresh tumor tissue samples will be collected in patients with lesions amenable for a biopsy who consent to such a procedure.

4. Patient has measurable lesions by RECIST v1.1.
5. Patient has an ECOG performance status of 0 to 1.

6. Patient has adequate organ function, defined as (Note: complete blood count [CBC] test should be obtained without transfusion or receipt of colony stimulating factors before 2 weeks of obtaining sample):
   a. Absolute neutrophil count (ANC) ≥ 1500/µL
   b. Platelets ≥ 100,000/µL
   c. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
   d. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
   e. Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN
   f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN
   g. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
   h. Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

7. Patient is able to take oral medications.

8. Female patient has a negative serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):
   a. ≥ 45 years of age and has not had menses for >1 year
   b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation
   c. Post hysterectomy, bilateral oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study therapy. See Section 5.7.2 for a list of acceptable birth control methods. Information must be captured appropriately within the site’s source documents.

   Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

9. Male patient agrees to use an adequate method of contraception (please see Section 5.7.2 for a list of acceptable birth control methods) starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

10. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.

**Criteria for Exclusion:**

Patients will not be eligible for study entry if any of the following criteria are met:

1. Patients with primary platinum refractory ovarian cancer (ie, progressive disease on or within 6 months of first-line platinum therapy) are not eligible in Phase 1 or Phase 2 of this study.

2. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

   Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.

3. Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

4. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, history of (non-infectious) pneumonitis that required steroids or current pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).

5. Patient has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient’s participation for the full duration of the study treatment. Patients who received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment are not eligible.

6. Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.

7. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or...
any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

8. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

9. Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected).

10. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

11. Patient has not recovered (ie, to ≤Grade 1 or to baseline) from cytotoxic therapy-induced AEs. Note: Patient with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia is an exception to this criterion and may qualify for the study.

12. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

13. Patient has had a prior cytotoxic therapy, anticancer targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents within 5 half-lives, or monoclonal antibodies (mAb) within 5 half-lives or 4 weeks (whichever is shorter) of that treatment prior to study Day 1 or radiation therapy encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

14. Patient has not recovered adequately from AEs and/or complications from any major surgery prior to starting therapy.

15. Patient has received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent or the patient has previously participated in Merck MK-3475 (pembrolizumab) clinical studies.

16. Patient has received a live vaccine within 30 days of planned start of study therapy.

17. Patient has undergone prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor.

18. Patient has a heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening.

Note: If a patient has a prolonged QT interval and the prolongation is deemed to be due to a pacemaker upon Investigator evaluation (ie, the patient otherwise has no cardiac abnormalities), the patient may be eligible to participate in the study following discussion with the Medical Monitor.

19. Patient has a known hypersensitivity to niraparib or pembrolizumab components or excipients.
20. Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Investigational Product, Dosage, and Mode of Administration:

Niraparib

Niraparib will be administered orally (PO) throughout the 21-day cycle at the assigned dose and schedule. On Day 1 of each cycle, a niraparib dose will be administered upon completion of pembrolizumab infusion. Depending on dose schedule, 1, 2, or 3 capsules of 100 mg strength niraparib will be taken at each dose administration (total dose 100 mg, 200 mg, or 300 mg per dose schedule, respectively). Patients will be instructed to take their niraparib dose at the same time each day, preferably in the morning. Patients must swallow and not chew all capsules. The consumption of water and food is permissible.

Niraparib will be dispensed to patients on Day 1 of every cycle (every 21 days) thereafter until the patient discontinues study treatment. The Pharmacy Manual contains descriptions of the packaging of niraparib and instructions for the preparation and administration of niraparib.

Pembrolizumab

Pembrolizumab will be administered at a dose of 200 mg intravenously (IV) using a 30-minute IV infusion on Day 1 of each 21-day treatment cycle after all procedures and assessments have been completed as detailed in Table 6. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Given the variability of infusion pumps from site to site, however, a window between -5 minutes and +10 minutes is permitted.

The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion and administration of the infusion solution.

Duration of Treatment and Study Conduct:

Treatment duration for individual patient: Patients may continue the pembrolizumab/niraparib combination treatment for up to 2 years or until disease progression, unacceptable toxicity, patient withdrawal, Investigator’s decision, or death. Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

Long-term follow-up: Every 3 months (90 days), via telephone.

Planned study conduct duration: the first data cutoff will occur at approximately 18 months (ie, time from first patient enrolled/when responder or discontinuation status for all patients is known/approximately 6 months after last patient is enrolled). The final analysis of primary and secondary endpoints will be conducted at approximately 12 months after the last patient is enrolled.

Criteria for Evaluation:

Safety

- Dose-limiting toxicities during the first cycle (ie, during the first 21 days of treatment/ Cycle 1/Day 1 through Cycle 1/Day 21) (Phase 1 only)
• Incidence of treatment-emergent AEs (TEAEs) during the first cycle compared to the second and subsequent cycles
• Incidence of TEAEs occurring while patients are on treatment or up to 30 days after the last dose of study drug
• Incidence of serious adverse events (SAEs) and events of clinical interest (ECI) occurring while patients are on treatment or up to 90 days after the last dose of study drug
• Changes in clinical laboratory parameters (hematology, chemistry, coagulation, thyroid function, urinalysis), vital signs, ECOG performance status, ECG parameters, physical examinations, and usage of concomitant medications
• Whole blood samples will be collected prior to the start of the study drug and at treatment discontinuation for cytogenetic analysis

Efficacy
• Primary endpoint: ORR, defined as the proportion of patients who have achieved CR or PR, evaluated using RECIST v1.1 based on Investigator assessment
• The following secondary endpoints will also be evaluated based on Investigator assessment:
  – ORR by irRECIST
  – Duration of response, defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression by RECIST v1.1 and by irRECIST
  – Disease control rate defined as the percentage of patients who have achieved CR, PR, or stable disease (SD) per RECIST v1.1 and irRECIST
  – Progression-free survival, defined as the time from first dose to the earlier date of assessment of progression, or death by any cause in the absence of progression, by RECIST v1.1 and by irRECIST
  – Overall survival as measured from the date of first dose to the date of death by any cause

Pharmacokinetics
Samples for PK determination will be collected from patients in both Phase 1 (plasma and serum) and Phase 2 (plasma only) and the plasma will be analyzed using liquid chromatography with mass spectroscopic detection (LC-MS-MS) for niraparib and major metabolite M1. The serum may be analyzed for pembrolizumab using enzyme-linked immunosorbent assay (ELISA). Model predicted area under the concentration × time curves (AUCs) will be derived. Parameters of interest are AUC, minimum concentration (Cmin), maximum concentration (Cmax), clearance after oral administration (CL/F) and volume of distribution after oral administration (Vz/F), AUC at steady state (AUCss), Cmin at steady state (Cmin,ss), Cmax at steady state (Cmax,ss).

Biomarkers
Biomarker classifiers will be evaluated in archival and fresh tumor samples obtained during screening; in addition, in the subset of patients who undergo serial biopsies, biomarkers will be evaluated in fresh tumor samples obtained 1 to 3 days before or on C3D1 prior to pembrolizumab infusion and, whenever possible, at the time of disease progression. Blood samples for biomarker analysis will be obtained predose on Day 1 of Cycle 1 and Cycle 2, as well as at the EOT visit. Tumor and blood markers, including mutations in homologous recombination genes, such as breast cancer gene 1 and 2 (BRCA1 and 2) mutations, may be explored. The magnitude of homologous recombination deficiency (HRD) positivity and tumor immune microenvironment may be evaluated. Programmed death ligand-1 (PD-L1) expression and other related markers in tumor and tumor-infiltrating immune cells may be explored.

HRD status and other biomarkers may be correlated with efficacy outcomes.

Statistical Methods:

Sample Size Considerations

Phase 1: A total sample size of approximately 18 patients is estimated for the Phase 1 portion of the study to provide initial comparison of incidence of DLTs and safety profiles of the combination treatment between dose schedules in each patient population. More patients could be enrolled (eg, if the Dose Level -2 is explored or if expansion at any dose level is required to better understand safety and tolerability); up to a total of 36 patients may be enrolled.

Phase 2: A total of approximately 96 evaluable patients (approximately 48 patients in each tumor type) will be enrolled to ensure understanding of the activity of the combination treatment and to obtain adequate representation of different molecular cancer subtypes and biomarkers.

Analysis Populations

Three analysis populations will be defined as follows:

- Safety Population: All patients who receive any amount of study drug. The assessment of DLTs in Phase 1 will include only those patients completing the first cycle of therapy, unless the patient discontinued study drug due to a DLT.

- Full Analysis Set (FAS): All patients who receive any amount of study drug. The primary analysis of efficacy endpoints will be performed on the FAS population.

- Per-Protocol Population: All patients who receive at least two cycles of study drug and have at least one protocol-required post-baseline disease assessments and have no major protocol violations that would impact efficacy evaluations. Supportive analyses of efficacy endpoints will be performed on the per-protocol population.

General Methods

All analyses will include summary statistics, including number and percentage for categorical variables and number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables. Time-to-event analyses will be performed using Kaplan-Meier methods. As the Phase 2 portion of the study is single-arm, any statistical analysis to be performed among subgroups is for descriptive and future study purposes. Further detail will be
provided in the study statistical analysis plan.

Safety

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) for purposes of summarization. All AEs occurring during the study will be included in by-patient data listings and tabulated by MedDRA system organ class and preferred term. Safety endpoints for AEs include the following: incidence of DLTs, TEAEs, ECI, TEAEs leading to death, SAEs and AEs leading to discontinuation; tabulations will be produced by MedDRA system organ class and preferred term. Tabulations of TEAEs will also be produced by severity and by relationship to study drug.

Additional safety summaries will be provided for clinical laboratory tests, vital signs, ECOG performance status, and ECGs.

Results of cytogenetic analysis, including incidence of cytogenetic abnormalities at end of study treatment, will be summarized.

Efficacy

ORR and DCR will be summarized using descriptive statistics including number, percentage and 1-sided 90% CI.

Duration of response, PFS, and OS will be summarized using Kaplan-Meier analysis, including number and percentage of events, number and percentage of censored patients, and 25th, 50th, and 75th percentiles of times to event with 95% CIs.

Pharmacokinetics

Pharmacokinetic parameters will be summarized by study phase and dose schedule using descriptive statistics.

Biomarkers

The incidence of biomarkers will be summarized using descriptive statistics. Comparisons of efficacy endpoints between biomarker subpopulations may be performed.

Interim Analysis

To minimize the risk of exposing patients to an ineffective treatment, a series of response assessments will be performed when 6, 12, and 18 of 48 Phase 2 patients from each cancer type have at least 2 post-baseline tumor assessments. A formal decision regarding futility, which could result in stopping the study early, will be conducted separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier response assessments, however, will inform the conduct of the formal interim analysis as follows: If no responder is observed in all three response assessments from 6, 12, and 18 patients, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If \( \geq 1 \) responder is observed in any single response assessment from 6, 12, or 18 patients, then enrollment will not be curtailed. The decision rule regarding the formal interim analysis at N=24 is as follows: If there are fewer than 3 responders out of 24, enrollment may be closed and the corresponding cohort may be stopped for futility. Otherwise, the study will continue to
the planned enrollment of approximately 48 patients.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>INTRODUCTION</td>
<td>29</td>
</tr>
<tr>
<td>1.1.</td>
<td>Background</td>
<td>29</td>
</tr>
<tr>
<td>1.1.1.</td>
<td>PARP and Homologous Recombination Deficiency</td>
<td>29</td>
</tr>
<tr>
<td>1.1.2.</td>
<td>Immune Surveillance and PD-1 Inhibitors</td>
<td>30</td>
</tr>
<tr>
<td>1.2.</td>
<td>Study Treatments</td>
<td>31</td>
</tr>
<tr>
<td>1.2.1.</td>
<td>Niraparib</td>
<td>31</td>
</tr>
<tr>
<td>1.2.2.</td>
<td>Pembrolizumab</td>
<td>34</td>
</tr>
<tr>
<td>1.3.</td>
<td>Rationale for Current Study</td>
<td>34</td>
</tr>
<tr>
<td>2.</td>
<td>STUDY OBJECTIVES</td>
<td>36</td>
</tr>
<tr>
<td>2.1.</td>
<td>Primary Objective</td>
<td>36</td>
</tr>
<tr>
<td>2.2.</td>
<td>Secondary Objectives</td>
<td>36</td>
</tr>
<tr>
<td>2.3.</td>
<td>Exploratory Objectives</td>
<td>36</td>
</tr>
<tr>
<td>3.</td>
<td>INVESTIGATIONAL PLAN</td>
<td>37</td>
</tr>
<tr>
<td>3.1.</td>
<td>Overall Study Design and Plan</td>
<td>37</td>
</tr>
<tr>
<td>3.1.1.</td>
<td>Overview</td>
<td>37</td>
</tr>
<tr>
<td>3.1.2.</td>
<td>Phase 1 Dose Escalation</td>
<td>38</td>
</tr>
<tr>
<td>3.1.2.1.</td>
<td>Recommended Phase 2 Dose</td>
<td>39</td>
</tr>
<tr>
<td>3.1.3.</td>
<td>Phase 2 Expansion</td>
<td>40</td>
</tr>
<tr>
<td>3.1.4.</td>
<td>General Study Conduct: Phase 1 and 2</td>
<td>40</td>
</tr>
<tr>
<td>4.</td>
<td>STUDY POPULATION</td>
<td>42</td>
</tr>
<tr>
<td>4.1.</td>
<td>Inclusion Criteria</td>
<td>42</td>
</tr>
<tr>
<td>4.2.</td>
<td>Exclusion Criteria</td>
<td>44</td>
</tr>
<tr>
<td>4.3.</td>
<td>Patient Withdrawal and Replacement</td>
<td>46</td>
</tr>
<tr>
<td>4.3.1.</td>
<td>Discontinuation from Treatment</td>
<td>46</td>
</tr>
<tr>
<td>4.3.2.</td>
<td>Discontinuation from the Study</td>
<td>47</td>
</tr>
<tr>
<td>4.3.3.</td>
<td>Replacement of Patients</td>
<td>47</td>
</tr>
</tbody>
</table>
6.1.5.2. Submission and Distribution of Adverse Events/Serious Adverse Events ..........67
6.1.6. Events of Clinical Interest ...........................................................................67
6.1.6.1. Pembrolizumab .........................................................................................67
6.1.6.2. Niraparib ...................................................................................................67
6.1.7. Pregnancy Reporting and Follow-up ............................................................68
6.1.8. Clinical Laboratory Assessments .................................................................69
6.1.9. Physical Examination and Vital Signs .........................................................70
6.1.10. Eastern Cooperative Oncology Group Performance Status .....................70
6.1.11. Additional Safety Assessments .................................................................70
6.2. Demographics and Baseline Characteristics ..................................................71
6.2.1. Patient Eligibility .........................................................................................71
6.2.2. Patient Demography ....................................................................................71
6.2.3. Disease History ...........................................................................................71
6.2.4. Medical and Surgical History .....................................................................71
6.2.5. Previous and Concomitant Medications .....................................................72
6.3. Efficacy Endpoint(s) ......................................................................................72
6.3.1. Evaluation of Tumor Response ....................................................................72
6.3.1.1. Overview ..................................................................................................72
6.3.1.2. Timing of Radiographic Evaluations .......................................................72
6.3.1.3. Assessment of Response by RECIST .......................................................73
6.3.1.4. Assessment of Response by Immune-Related RECIST .........................73
6.3.2. Efficacy Endpoints ......................................................................................75
6.3.2.1. Objective Response Rate .........................................................................75
6.3.2.2. Duration of Response ...............................................................................75
6.3.2.3. Disease Control Rate ...............................................................................75
6.3.2.4. Progression-Free Survival .......................................................................75
6.3.2.5. Overall Survival .......................................................................................75
6.4. Pharmacokinetics .........................................................................................75
6.4.1. Phase 1 ........................................................................................................76
6.4.2. Phase 2 ........................................................................................................76
6.4.3. Determination of Pharmacokinetic Parameters ........................................76
6.5. Biomarkers .....................................................................................................76
7. STUDY CONDUCT

7.1. Schedule of Procedures

7.2. Procedures by Visit

7.2.1. Screening (Day -21 to Day -1)

7.2.2. Cycle 1/Day 1

7.2.3. Cycle 1/Day 2 (Phase 1 Patients Only)

7.2.4. Cycle 1/Day 8

7.2.5. Cycle 1/Day 15

7.2.6. Day 1, Subsequent Cycles

7.2.7. Cycle 2, Day 2 (Phase 1 Patients Only)

7.2.8. End of Treatment (within 7 days of last dose)

7.2.9. Safety Follow-up (30 days [+ 7 days] Post-treatment)

7.2.10. Follow-up Assessments

7.2.11. Unscheduled Assessments

8. STATISTICAL METHODS

8.1. Study Populations

8.2. Demographics, Medical History, Baseline Characteristics, and Concomitant Medications

8.3. Safety Analyses

8.4. Pharmacokinetic Analyses

8.5. Post-Treatment Analyses

8.6. Efficacy Analyses

8.6.1. Primary Efficacy Parameter

8.6.2. Secondary Efficacy Parameter(s)

8.7. Biomarker Analyses

8.8. Probability of Dose Escalation

8.9. Interim Analyses

8.10. Determination of Sample Size

9. ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS

9.1. Data Quality Assurance

9.2. Access to Source Data/Documents

9.3. Archiving Study Documents
9.4. Good Clinical Practice ........................................................................................................... 106
9.5. Informed Consent .................................................................................................................... 106
9.6. Protocol Approval and Amendment ....................................................................................... 106
9.7. Patient Confidentiality and Data Protection ......................................................................... 107
9.8. Study Monitoring .................................................................................................................. 107
9.9. Audits and Inspections ......................................................................................................... 107
9.10. Ethical Considerations ........................................................................................................ 107
9.11. Publication Policy .............................................................................................................. 108
9.12. Study Committee ................................................................................................................ 108
10. REFERENCE LIST .................................................................................................................. 109
APPENDIX A. ASCO TNBC GUIDANCE 2010(70) ............................................................................. 115
APPENDIX B. DRUGS KNOWN TO INHIBIT OR INDUCE CYP1A2 OR ARE SUBSTRATES OF CYP1A2 .................................................................................................................. 116
APPENDIX C. DRUGS THAT ARE SUBSTRATES OR INHIBITORS OF P-GLYCOPROTEIN .............................................................................................................................. 117
APPENDIX D. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST), V1.1 ........................................................................................................................................ 118
APPENDIX E. IMMUNE-RELATED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (IRRECIST) .................................................................................................................. 120
APPENDIX F. ASSESSMENT OF RESPONSE IN OVARIAN CANCER BY GYNECOLOGIC CANCER INTERGROUP (GCIG) CRITERIA ..................................................................................... 121
APPENDIX G. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS................................................................................................................................. 122
LIST OF TABLES

Table 1  Progression-Free Survival in Ovarian Cancer Patients in NOVA........................................32
Table 2  Niraparib Dose Reductions for Non-Hematologic Toxicity..............................................50
Table 3  Management of Hematologic Toxicities* ........................................................................52
Table 4  Pembrolizumab Dose Modifications for Non-hematologic Toxicities..............................54
Table 5  Pembrolizumab Infusion Reaction Treatment Guidelines.............................................61
Table 6  Schedule of Events ..........................................................................................................79
Table 7  Schedule of Events - Phase 2 Only ................................................................................83
Table 8  Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 1 .........................87
Table 9  Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 2 .........................88
Table 10 Niraparib Administration – Phase 1 ................................................................................88
Table 11 Niraparib Administration – Phase 2 ................................................................................89
Table 12 Dose Escalation Decision Rules .....................................................................................101
Table 13 RECIST Response for Patients with Measurable Disease (ie, Target Disease) .......119
Table 14 RECIST Response for Patients with Non-Measurable Disease (ie, Non-Target Disease) .........................................................................................................................119
Table 15 Imaging and Treatment after First Radiologic Evidence of Progressive Disease ....120

LIST OF FIGURES

Figure 1  Study Schema .............................................................................................................38
Figure 2  Probability of Dose Escalation in a 6 + 6 Design..........................................................102
Figure 3  Probability of Dose Escalation in a 6 + 6 Design versus 3 + 3 Design at a Fixed Rate of 0.05 for Non-hematologic DLTs.........................................................................................103
### LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADL</td>
<td>activities of daily living</td>
</tr>
<tr>
<td>ADP</td>
<td>adenosine diphosphate</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>alt-NHEJ</td>
<td>alternative nonhomologous end-joining</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukemia</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>aPTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>ATM</td>
<td>ataxia telangiectasia mutated</td>
</tr>
<tr>
<td>ATR</td>
<td>ATM and Rad3-related</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration × time curve</td>
</tr>
<tr>
<td>$\text{AUC}_{ss}$</td>
<td>area under the concentration × time curve at steady state</td>
</tr>
<tr>
<td>BCG</td>
<td>bacille Calmette-Guerin</td>
</tr>
<tr>
<td>BER</td>
<td>base excision repair</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BRCA</td>
<td>breast cancer (gene)</td>
</tr>
<tr>
<td>CA-125</td>
<td>cancer antigen 125</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CHK</td>
<td>check point kinases</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>clearance after oral administration</td>
</tr>
<tr>
<td>$C_{\text{max}}$</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>$C_{\text{max,ss}}$</td>
<td>maximum concentration at steady state</td>
</tr>
<tr>
<td>$C_{\text{min}}$</td>
<td>minimum concentration</td>
</tr>
<tr>
<td>$C_{\text{min,ss}}$</td>
<td>minimum concentration at steady state</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>DCR</td>
<td>disease control rate</td>
</tr>
<tr>
<td>DKA</td>
<td>diabetic ketoacidosis</td>
</tr>
<tr>
<td>DL</td>
<td>dose level</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECI</td>
<td>events of clinical interest</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EOT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>ER</td>
<td>estrogen receptor</td>
</tr>
<tr>
<td>FT3</td>
<td>free triiodothyronine</td>
</tr>
<tr>
<td>FT4</td>
<td>free thyroxine</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>gBRCA&lt;sup&gt;mut&lt;/sup&gt;</td>
<td>germline breast cancer gene mutation</td>
</tr>
<tr>
<td>GCIG</td>
<td>Gynecologic Cancer Intergroup</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCV RNA</td>
<td>hepatitis C virus ribonucleic acid</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HRD</td>
<td>homologous recombination deficiency</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IgG</td>
<td>immunoglobulin G</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>irRECIST</td>
<td>immune-related Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>ITIM</td>
<td>immunoreceptor tyrosine-based inhibition motif</td>
</tr>
<tr>
<td>ITSM</td>
<td>immunoreceptor tyrosine-based switch motif</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan-Meier</td>
</tr>
<tr>
<td>LC-MS-MS</td>
<td>liquid chromatography with mass spectroscopic detection</td>
</tr>
<tr>
<td>mAb</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplastic syndrome</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>MMR</td>
<td>mismatch repair deficiency</td>
</tr>
<tr>
<td>NBS1</td>
<td>Nijmegen breakage syndrome 1</td>
</tr>
<tr>
<td>NER</td>
<td>nucleotide excision repair</td>
</tr>
<tr>
<td>NHEJ</td>
<td>nonhomologous end-joining</td>
</tr>
<tr>
<td>OC</td>
<td>primary peritoneal ovarian cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PARP</td>
<td>poly(ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death-1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed death ligand-1</td>
</tr>
<tr>
<td>PD-L2</td>
<td>programmed death ligand-2</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PO</td>
<td>oral(ly)</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PR</td>
<td>progesterone receptor</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>QD</td>
<td>once daily</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>RP2D</td>
<td>recommended Phase 2 dose</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>T3</td>
<td>triiodothyronine</td>
</tr>
<tr>
<td>TEAE</td>
<td>treatment-emergent adverse event</td>
</tr>
<tr>
<td>TIL</td>
<td>tumor-infiltrating lymphocytes</td>
</tr>
<tr>
<td>TNBC</td>
<td>triple-negative breast cancer</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid-stimulating hormone</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>V-type</td>
<td>variable-type</td>
</tr>
<tr>
<td>$V_{z/F}$</td>
<td>volume of distribution after oral administration</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

1.1. Background

1.1.1. PARP and Homologous Recombination Deficiency

Poly(ADP-ribose) polymerases (PARP)1 and PARP2 are zinc-finger deoxyribonucleic acid (DNA)-binding enzymes that play a crucial role in DNA repair. Upon formation of DNA breaks, PARP binds at the end of broken DNA strands, a process that activates its enzymatic activity. Activated PARP catalyzes the addition of long polymers of adenosine diphosphate (ADP)-ribose onto PARP and several other proteins associated with chromatin, including histones and various DNA repair proteins. This results in chromatin relaxation, fast recruitment of DNA repair proteins, and efficient repair of DNA breaks. In this manner, PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single-strand break repair pathways. 

Normal cells repair up to 10,000 DNA defects daily, and single-strand breaks are the most common form of DNA damage. Cells that are unable to repair this burden of DNA damage, such as those with defects in the homologous recombination or BER pathways, are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. They enter the S phase (DNA replication) of the cell cycle with unrepaired single- and double-strand breaks. Pre-existing single-strand breaks are converted to double-strand breaks as the replication machinery passes. Accumulated double-strand breaks present during S phase are repaired by homologous recombination. Homologous recombination is the preferred repair pathway because it is associated with a much lower error rate than other forms of repair. Cells unable to perform DNA repair via homologous recombination (e.g., due to inactivation of genes required for homologous recombination, such as breast cancer gene [BRCA]1- or BRCA2-mutated cells) are at risk for accumulating multiple lesions that will ultimately trigger apoptosis. These cells accumulate stalled replication forks during S phase and are more likely to use the error-prone nonhomologous end-joining (NHEJ) or alternative (alt)-NHEJ pathways to repair double-strand breaks in DNA. Accumulation of errors in DNA by NHEJ contributes to mutation burden that promotes the development of cancer. Over time, the buildup of excessive DNA errors in combination with the inability to complete S phase (because of stalled replication forks) contributes to cell death.

Treatment with PARP inhibitors could represent a novel opportunity to selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. For example, a tumor arising in a patient with a germline BRCA mutation (gBRCAmut) has a defective homologous recombination DNA repair pathway and would be increasingly dependent on NHEJ, alt-NHEJ, and BER for maintenance of genomic integrity. PARP inhibitors block alt-NHEJ and BER, forcing tumors with BRCA deficiencies to use the error-prone NHEJ to fix double-strand breaks. Non-BRCA deficiencies in homologous recombination DNA repair genes could also enhance tumor cell sensitivity to PARP inhibitors. The rationale for anticancer activity in a subset of non-gBRCAmut tumors is that they share distinctive DNA repair defects with gBRCAmut carriers, a phenomenon broadly described as “BRCAness.” DNA repair defects can be caused by germline or somatic alterations to the homologous recombination DNA repair pathway. In a recent analysis of
approximately 500 high-grade serous ovarian adenocarcinoma tumors, approximately 50% contained homologous recombination defects.\(^5\) A subset of these tumors had biologically plausible molecular alterations that may make them sensitive to PARP inhibition by niraparib. A similar analysis of triple-negative breast cancer (TNBC) indicates up to 40% of these patients have tumors with homologous recombination defects.\(^6\)

Homologous recombination is a complex pathway, and several genes other than BRCA1 and BRCA2 are required either to sense or repair DNA double-strand breaks via the homologous recombination pathway. Therefore, PARP inhibitors are also selectively cytotoxic for cancer cells with deficiencies in DNA repair proteins other than BRCA1 and BRCA2, including RecA homologs (RAD51 and RAD54), X-ray repair complementing defective repair in Chinese hamster cells (XRCC2 and XRCC3), DSS1, replication protein A1 (RPA1), ataxia telangiectasia mutated (ATM), ATM and Rad3-related (ATR), check point kinases (CHK1, CHK2), Nijmegen breakage syndrome 1 (NBS1), and the components of the Fanconi anemia repair pathway.\(^1,4,7\)

Clinical studies have shown that PARP inhibitors are active for recurrent ovarian cancer (OC).\(^1-3,8-11\) Clinical anticancer activity has been observed in patients with and without gBRCA\(^{\text{mut}}\) and in patients who are platinum-sensitive and platinum-resistant. PARP inhibition appears to be most active in patients with gBRCA\(^{\text{mut}}\) platinum-sensitive disease.\(^3,9\) Additionally, maintenance therapy in patients with relapsed, platinum-sensitive OC appears promising.\(^10\) Of patients with a BRCA mutation, median progression-free survival (PFS) was significantly longer in the PARP inhibitor group than in the placebo group (11.2 months vs. 4.3 months; hazard ratio: 0.18; \(p<0.0001\)). Similar findings were noted for patients with wild-type BRCA, although the difference between groups was smaller (7.4 months vs. 5.5 months; hazard ratio: 0.54; \(p = 0.007\)).

Recent clinical studies also have shown PARP inhibitors to be active in breast and ovarian cancer. Clinical anticancer activity with PARP inhibitors has been seen in both patients with gBRCA\(^{\text{mut}}\) and without gBRCA\(^{\text{mut}}\); however, activity is more robust in patients with the germline mutation.\(^1,3,8,10-12\)

In summary, treatment with PARP1/2 inhibitors represents a novel opportunity to selectively kill a subset of cancer cell types by exploiting their deficiencies in DNA repair. Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair. These deficiencies render cancer cells more dependent on the remaining DNA repair pathways, and targeting these pathways is expected to have a much greater impact on the survival of the tumor cells than on normal cells.

### 1.1.2. Immune Surveillance and PD-1 Inhibitors

The importance of intact immune surveillance in controlling outgrowth of neoplastic transformation has been known for decades.\(^13\) Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes (TILs) in cancer tissue and prognosis in various malignancies.\(^14-26\) In particular, the presence of CD8+ T cells and the ratio of CD8+ effector T cells/FoxP3+ regulatory T cells seem to correlate with improved prognosis and long-term survival in many solid tumors.\(^22,27-33\)

The programmed death-1 (PD-1) receptor-ligand interaction is a major pathway hijacked by tumors to suppress immune control.\(^34\) The normal function of PD-1, expressed on the cell surface of activated T cells under healthy conditions, is to down-modulate unwanted or excessive immune
responses, including autoimmune reactions. PD-1 (encoded by the gene Pdcd1) is an immunoglobulin (Ig) superfamily member related to CD28 and CTLA-4, which has been shown to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2). The structures of murine PD-1 alone and in complex with its ligands were first resolved, and more recently the nuclear magnetic resonance-based structure of the human PD-1 extracellular region and analyses of its interactions with its ligands were also reported. PD-1 and family members are type I transmembrane glycoproteins containing an Ig variable-type (V-type) domain responsible for ligand binding and a cytoplasmic tail, which is responsible for the binding of signaling molecules. The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). Following T cell stimulation, PD-1 recruits the tyrosine phosphatases SHP-1 and SHP-2 to the ITSM motif within its cytoplasmic tail, leading to the dephosphorylation of effector molecules, such as CD3ζ, PKCθ and ZAP70, which are involved in the CD3 T cell signaling cascade. The mechanism by which PD-1 down-modulates T cell responses is similar to, but distinct from, that of CTLA-4. PD-1 was shown to be expressed on activated lymphocytes, including peripheral CD4+ and CD8+ T cells, B cells, T regs, and natural killer cells. Expression has also been shown during thymic development on CD4-/CD8- (double-negative) T cells, as well as subsets of macrophages and dendritic cells. The ligands for PD-1 (PD-L1 and PD-L2) are constitutively expressed or can be induced in a variety of cell types.

PD-L1 is expressed at low levels on various non-hematopoietic tissues, most notably on vascular endothelium, whereas PD-L2 protein is predominantly expressed on antigen-presenting cells found in lymphoid tissue or chronic inflammatory environments. Both ligands are type I transmembrane receptors containing both IgV- and IgC-like domains in the extracellular region and short cytoplasmic regions with no known signaling motifs. Binding of either PD-1 ligand to PD-1 inhibits T cell activation triggered through the T cell receptor. PD-L2 is thought to control immune T cell activation in lymphoid organs, whereas PD-L1 serves to dampen unwarranted T cell function in peripheral tissues. Although healthy organs express little (if any) PD-L1, a variety of cancers were demonstrated to express abundant levels of this T cell inhibitor, which, via its interaction with the PD-1 receptor on tumor-specific T cells, plays a critical role in immune evasion by tumors. As a consequence, the PD-1/PD-L1 pathway is an attractive target for therapeutic intervention in cancer.

1.2. Study Treatments

1.2.1. Niraparib

Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

Nonclinical data on niraparib are discussed in detail in the Investigator’s Brochure. Briefly, in nonclinical models, niraparib has been observed to inhibit normal DNA repair mechanisms and induce synthetic lethality when administered to cells with homologous recombination defects. In a BRCA1-mutant xenograft study, niraparib dosed orally caused tumor regression, which was mirrored by > 90% reduction in tumor weight compared with control. In a BRCA2-mutant xenograft study, niraparib-dosed mice showed 55% to 60% growth inhibition, both by tumor volume and weight.
Niraparib displayed strong antitumor activity in in vivo studies with BRCA1-mutant breast cancer (MDA-MB-436), BRCA2-mutant pancreatic cancer (CAPAN-1), ATM-mutant mantle cell lymphoma (GRANTA-519), serous OC (OVCAR3), and colorectal cancer (HT29 and DLD-1) xenograft models and with patient-derived Ewing sarcoma mice models. Utilizing patient-derived ovarian and breast cancer xenograft models, niraparib demonstrated response in both BRCA mutation and BRCA wild-type tumors.

Niraparib clinical data are discussed in detail in the niraparib Investigator’s Brochure. In the Phase 1 clinical program, niraparib, as a monotherapy or in combination with chemotherapy, has been administered to 144 patients.

In the Phase 1 program (n=144), the most common (> 20.0% of patients) adverse events (AEs), were fatigue (58.3%), nausea (54.9%), anemia (50.7%), constipation (39.6%), thrombocytopenia (37.5%), vomiting (36.8%), decreased appetite (31.9%), neutropenia (28.5%), headache (26.4%), diarrhea (21.5%), dyspnea (21.5%), cough (20.8%), and leukopenia (20.8%).

In the randomized, double-blind, Phase 3 NOVA trial (Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer), a total of 553 patients were randomized at 107 centers worldwide. Patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. The study enrolled 203 patients in the gBRCAmut cohort and 350 patients in the non-gBRCAmut cohort. Among the 350 patients in the non-gBRCAmut cohort, 162 had tumors that were defined as HRDpos and 134 had tumors that were HRD negative (HRDneg). HRD status was not determined (HRDnd) for 54 patients.

Demographic and baseline characteristics were well balanced. Table 1 shows the results for the PFS primary endpoint for each of the 3 primary efficacy populations (ie, gBRCAmut cohort, HRDpos cohort, and overall non-gBRCAmut cohort). In addition, median PFS in patients with HRD negative (HRDneg) tumors was 6.9 months (95% CI: 5.6, 9.6) in the niraparib arm, versus 3.8 months (95% CI: 3.7, 5.6) in the placebo arm, with a hazard ratio (HR) of 0.58 (95% CI: 0.361, 0.922) (p=0.0226).

### Table 1  Progression-Free Survival in Ovarian Cancer Patients in NOVA

<table>
<thead>
<tr>
<th></th>
<th>gBRCAmut Cohort</th>
<th>non-gBRCAmut Cohort (regardless of HRD status)</th>
<th>HRDpos (within non-gBRCAmut cohort)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Niraparib (N=138)</td>
<td>Placebo (N=65)</td>
<td>Niraparib (N=234)</td>
</tr>
<tr>
<td>PFS Median (95% CI)*</td>
<td>21.0 (12.9, NR)</td>
<td>5.5 (3.8, 7.2)</td>
<td>9.3 (7.2, 11.2)</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
The primary data to support the safety of treatment with niraparib are derived from the NOVA main study in which a total of 546 patients received study treatment.

All 367 patients who received niraparib and 171 (96%) of 179 patients who received placebo experienced at least 1 treatment-emergent adverse event (TEAE). The high rate of TEAEs in the placebo group indicates the burden of prior chemotherapy and the patient’s underlying ovarian cancer. Review of the data across study cohorts for TEAE incidence showed that, in general, the results were similar in the gBRCAmut and non-gBRCAmut cohorts. In the overall safety population, for the niraparib versus placebo treatment arms, the incidences of Grade 3/4 TEAEs (74% vs. 23%), serious adverse events (SAEs) (30% vs. 15%), TEAEs leading to treatment interruption (69% vs. 5%), TEAEs leading to dose reduction (67% vs. 15%), and TEAEs leading to treatment discontinuation (15% vs 2%) were higher for niraparib. There were no on-treatment deaths reported.

The most commonly observed non-hematologic TEAEs (all grades) observed in niraparib-compared to placebo-treated patients were nausea (74% vs. 35%), fatigue (46% vs. 32%), constipation (40% vs. 20%), and vomiting (34% vs. 16%). The majority of the non-hematological TEAEs were mild to moderate in severity. The most commonly observed hematologic TEAEs (all grades) of niraparib were anemia (49%), thrombocytopenia (46%), and neutropenia (18%). Although Grade 3/4 hematologic laboratory events were common at the initiation of treatment, no severe clinical sequelae were observed, and relatively few patients discontinued due to these AEs.

Dose adjustment based on individual tolerability during the first 3 cycles substantially reduced the incidence of these events beyond Cycle 3, indicating the overall effectiveness of the approach to dose modification. These TEAEs can be monitored routinely using standard assessments of hematological laboratory parameters, as is routine for patients with ovarian cancer receiving anticancer therapies. In the NOVA study, niraparib dose adjustment tended to occur early with most patients reaching their individual adjusted dose level at the end of Month 3 (ie Cycle 3) of treatment. ~36% pts were kept on 300mg and ~64% pts had dose adjustment after 3 cycles in NOVA. However, in the Phase 1 portion of this study (3000-PN162-01-001) no patients were able to tolerate the 300 mg dose of niraparib.

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed in patients receiving treatment with olaparib, a PARP inhibitor; given the common mechanism of action, MDS and AML therefore represent a potential risk to patients receiving niraparib. In the Phase 3 NOVA study, the incidence of MDS/AML in patients who received niraparib (5 of 367;
1.4%) was similar to its incidence in patients who received placebo (2 of 179; 1.1%). Guidance on monitoring patients for new events of MDS/AML and the follow-up of patients with suspected MDS/AML is provided in Section 6.1.8 and Section 7.

Study PR-30-5011-C1 (NOVA QTc substudy n=26) is an open-label evaluation of the effects of niraparib on QTc measurements in patients with histologically diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. There were no reports of clinically significant abnormal electrocardiogram (ECG) changes, including QTc interval prolongation, attributed to niraparib. Administration of niraparib at the therapeutic dose did not prolong the QT interval. There was no correlation between the exposure level (ie, plasma concentration) of niraparib and QTc changes (ie, ΔQTcF).

Clinical activity data for niraparib administered as monotherapy in patients with OC are available from 1 early-phase clinical study. In the Phase 1/2 study PN001, 104 patients with advanced solid tumors who had received a median of 5 prior therapies were enrolled; 49 had OC (13 platinum-sensitive, 35 platinum-resistant, and 1 platinum-refractory). Of the 49 patients, 22 had confirmed BRCA1 or BRCA2 mutation, of whom 20 were radiologically assessable. Eight (40%) of these 20 patients achieved a confirmed partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) and cancer antigen (CA)-125 Gynecologic Cancer Intergroup (GCIG) criteria at doses ranging from 80 to 400 mg per day. Median response duration was 387 days (range: 159 to 518 days). Three (33%) of 9 patients with platinum-resistant BRCA-mutant OC had PR by RECIST and CA-125 criteria. Additionally, a 50% response rate (5 of 10 evaluable patients) was observed at daily doses ranging from 290 to 300 mg among patients with BRCA-mutant OC who had received more than 3 lines of prior chemotherapy (data on file).

1.2.2. Pembrolizumab

Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda™ (pembrolizumab) is indicated for the treatment of patients across a number of indications. For more details on specific indications refer to the Investigator brochure.

1.3. Rationale for Current Study

Current treatment options for patients with advanced or metastatic TNBC and patients with recurrent OC are limited, with no approved standard of care.

Triple-negative breast cancer is an aggressive histologic subtype of breast cancer, clinically defined by lack of expression of the estrogen receptor (ER-) and progesterone receptor (PR-) and lack of overexpression or amplification of HER2-receptor. The malignancy constitutes an aggressive form of the disease regardless of stage at diagnosis, and in patients with metastatic TNBC, there are currently no approved therapies or standard of care.

Similarly for recurrent OC, there are no approved treatments or standard of care. Although the National Comprehensive Cancer Network guidelines recommend treatment with single-agent
topotecan, doxorubicin, or gemcitabine, the optimal combination and sequence of these agents is unclear, and the exact population who would derive the most benefit is not well defined.

Over recent years, research has revealed the importance of TILs in controlling the clinical progression of various cancers and their presence in a tumor is associated with response to immune checkpoint inhibitors.\textsuperscript{(50)} Accumulating evidence suggests that basal-type TNBC may be the ER(-) breast cancer most regulated by intratumoral T cells and thus the most potentially responsive to immunotherapies.\textsuperscript{(51)} In addition, the frequency of BRCA1/2 deficiency, both BRCA mutations and silencing of BRCA expression, in TNBC is between 45\% and 70\%.\textsuperscript{(6)} Similarly in OC, intraepithelial CD8+ T-cells correlated with the presence of mutation or loss of expression of BRCA1 through promoter methylation.\textsuperscript{(52)} Collectively, metastatic TNBC and OC patient populations that were sensitive to agents targeting defects in DNA repair are likely to overlap with those tumors with an active yet checkpoint-blocked immune response.

Despite promising activity of PD-1 inhibitors observed in some types of cancer, including melanoma and NSCLC,\textsuperscript{(53)} activity in TNBC (objective response rate [ORR] of 18.5\% with pembrolizumab) and ovarian cancer (ORR of 11\%-12\% on pembrolizumab or avelumab) observed thus far have been modest.\textsuperscript{(54-56)} Although promising in selected patients with BRCA mutations or potentially with homologous recombination deficiency, modest activity of PARP inhibitors in unselected ovarian cancer patients with resistant disease has been observed (ORR of 16\% with niraparib and 0\% with olaparib).\textsuperscript{(3,11)} Synergistic interactions have been observed, however, between immune checkpoint inhibitors and PARP inhibitors; nonclinical experiments in syngeneic mouse models have shown an increased response rate to the combination of anti-PD-1 and niraparib over either agent alone, providing additional support to investigate this combination in patients.\textsuperscript{(57-59)} Exposure of a tumor in vivo to PARP inhibitor results in increased cancer cell death by 2 independent mechanisms. First, through the mechanism of synthetic lethality, the PARP inhibitor can kill HRD tumors through apoptosis. Second, the PARP inhibitor can increase the number of CD8+ T cells and natural killer (NK) cells, as well as their production of IFN-\gamma and TNF-\alpha, resulting in an improved response to checkpoint blockade.\textsuperscript{(59)} Accordingly, the biomarkers for this combination clinical study will include a wide range of assays, including the measurement of tumor cell death, genomic changes, apoptosis, and immune response.

Given the unmet medical need of patients with advanced or metastatic TNBC and patients with platinum-resistant recurrent OC, the non-overlapping safety and metabolic profile (see the current versions of the niraparib Investigator’s Brochure and the pembrolizumab Investigator’s Brochure for details), and preclinical data suggesting possible synergistic interaction between immune checkpoint inhibitors and PARP inhibitors along with a potential overlap for PD-1- and PARP-sensitive patient populations, this study is designed to evaluate the combination of niraparib and pembrolizumab in these populations.
2. STUDY OBJECTIVES

2.1. Primary Objective

The primary objectives of this study, by phase, are as follows:

- **Phase 1**: To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment, and to establish a recommended Phase 2 dose (RP2D) and schedule.

- **Phase 2**: To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of ORR as assessed by the Investigators using RECIST v1.1 separately for the TNBC and OC cohorts.

2.2. Secondary Objectives

The secondary objectives of the study are as follows:

- **Phase 1 and Phase 2**: To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03).

- **Phase 2**: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST (irRECIST)
  - Duration of response (DOR) by RECIST v1.1 and by irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
  - Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
  - Overall survival (OS).

- **Phase 1 and Phase 2**: To evaluate the pharmacokinetics (PK) of niraparib and associated major metabolite M1 during combination treatment.

2.3. Exploratory Objectives

The exploratory objectives of the study for both phases are as follows:

- To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of TILs, and circulating biomarkers.

- To correlate homologous recombination deficiency (HRD) status with other immune-related biomarkers and with efficacy outcomes.
3. INVESTIGATIONAL PLAN

3.1. Overall Study Design and Plan

3.1.1. Overview

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with previously treated TNBC or OC. Specifically, patients eligible for this study are those with:

- Advanced or metastatic TNBC (in Phase 1 patients may have received up to 4 lines of cytotoxic therapy for advanced/metastatic disease or in Phase 2, up to 2 lines of cytotoxic therapy for advanced/metastatic disease); or

- Advanced, recurrent epithelial (for Phase 1: any serous, endometroid, mucinous, clear cell; for Phase 2: high-grade serous or endometroid) ovarian, fallopian tube, or primary peritoneal cancer who are currently platinum-resistant but previously experienced a response lasting for at least 6 months to first-line platinum-based therapy (in Phase 1 patients may have received up to 5 lines of cytotoxic therapy or in Phase 2, up to 4 lines of cytotoxic therapy).

Study treatment should be considered an appropriate option by the Investigator. The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the RP2D and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab, and the Phase 2 portion will further evaluate the RP2D and schedule in 2 cohorts of approximately 48 patients each with TNBC or OC as described above. See Section 3.1.2.1 for the RP2D.

Figure 1 presents an overview of the planned study schema. The schedule of events for the study is provided in Table 6.
The study will be conducted in conformance with Good Clinical Practice (GCP).

3.1.2. **Phase 1 Dose Escalation**

The following are the planned dose levels and treatment schedule for the Phase 1 portion of the study. Initially, 6 patients will be enrolled within a cohort. Based on current single-agent niraparib experience (see niraparib Investigator’s Brochure), hematological laboratory abnormalities are expected in a significant proportion of patients; therefore, cohorts may be expanded up to approximately 12 patients if needed to better characterize the safety of the combination treatment.

- **Dose Level 1:** niraparib 200 mg/day orally (PO) on Days 1-21 and pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.

- **Dose Level 2:** niraparib 300 mg/day PO on Days 1-21 and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.

- **Dose Level (-1):** niraparib 200 or 300 mg/day PO on Days 1-14 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).

- **Dose Level (-2):** niraparib 200 or 300 mg/day PO on Days 1 – 7 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).

Dosing will initiate at Dose Level 1 with a cohort of 6 patients with either TNBC or OC enrolled and treated with a combination of niraparib 200 mg PO daily for Days 1-21 and pembrolizumab...
200 mg IV on Day 1 every 21 days. After all patients in Dose Level 1 who are evaluable for safety have completed Cycle 1 of combination treatment, a review of the safety of treatment will be conducted by the Investigators and Sponsor (see Section 9.12). A patient will be considered non-evaluable if, for any reason other than safety, the patient is unable to complete the 21-day combination treatment DLT observation period or is unable to take > 80% of the intended dose of either agent. Patients in Phase 1 considered unevaluable may be replaced after consultation between the Sponsor and Principal Investigator. If 2 of 6 initially enrolled patients in a cohort experience hematologic DLTs, a lower dose level will be opened. If, however, the 2 observed DLTs include 1 hematologic DLT and 1 non-hematologic DLT or 2 non-hematologic DLTs, a cohort may be expanded up to approximately 12 patients to better characterize the safety of the combination treatment. Following the safety review, the next higher dose level (Dose Level 2) will be open for enrollment if less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) in Dose Level 1 experience a DLT during Cycle 1 (see Section 5.3 for the definition of DLT).

Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either TNBC or OC will be enrolled in Dose Level 2 and treated with a combination of niraparib 300 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. No further dose escalation will be considered if Dose Level 2 is reached.

The maximum tolerated dose (MTD) will be defined as the highest dose with DLTs observed in less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be opened for enrollment if not yet evaluated. Alternative dosing schedules may be explored.

Additional cohorts of 6 patients may be opened to evaluate Dose Level (-1) or Dose Level (-2), which will explore lower niraparib dose intensity by, for example, introducing an alternative dosing schedule, following agreement by the Investigators and Sponsor (see Section 9.12).

Patients in Phase 1 who complete the 21-day DLT evaluation period may continue the pembrolizumab/niraparib combination treatment for up to 2 years unless specific withdrawal criteria are met (Section 4.3). Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator. Appropriate niraparib dose modification can be made according to Section 5.4.1.

3.1.2.1. Recommended Phase 2 Dose

The RP2D was determined following discussion and agreement between Investigators and the Sponsor based on evaluation of multiple endpoints, which may include the DLT rate in first and subsequent cycles of combination treatment, the rate of dose modifications for non-DLT AEs, the ability to manage toxicities, PK, niraparib dose intensity, and signs of clinical efficacy. The goal will be to identify the dose/regimen of niraparib with the greatest dose intensity that can be safely combined with the recommended dose/regimen of pembrolizumab.

In the Phase 1 portion of this study, 14 patients with advanced TNBC or OC were enrolled in Dose Level 1 or Dose Level 2. Twelve patients were eligible for DLT evaluation. In Dose Level (DL) 1, 1 of 6 DLT-eligible patients experienced multiple DLTs including Grade 3 anemia, Grade 4 neutropenia, and Grade 4 thrombocytopenia. In Dose Level 2, 1 of 6 DLT-eligible patients experienced 1 DLT, Grade 4 thrombocytopenia; an additional patient experienced an adverse event
that was deemed to be a DLT-equivalent; she had epistaxis on C1D17 and Grade 4 thrombocytopenia on C2D1. Based on the observed DLTs in DL1 and DL2, the RP2D to be implemented in the Phase 2 portion of this study is niraparib 200 mg/day PO on days 1-21 and pembrolizumab 200 mg IV on day 1 of each 21-day cycle; niraparib dose may be escalated on or after C3D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL and neutrophils ≥ 1500/µL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

3.1.3.  Phase 2 Expansion

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion. Two cohorts of approximately 48 patients each with advanced TNBC or OC as outlined above will be evaluated.

Patients in this phase of the study will receive the RP2D as described in Section 3.1.2.1. Combination pembrolizumab/niraparib treatment may continue for up to 2 years unless specific withdrawal criteria are met (Section 4.3). Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator.

3.1.4.  General Study Conduct: Phase 1 and 2

Following informed consent, all patients in both Phase 1 and Phase 2 will undergo screening procedures within 21 days prior to the first dose of study treatment to determine eligibility for study entry. Screening procedures include medical, surgical, cancer, and medication history; complete physical examination, including vital signs, height, and weight; Eastern Cooperative Oncology Group (ECOG) performance status; clinical laboratory tests (complete blood count [CBC], coagulation, chemistry, thyroid-stimulating hormone [TSH], triiodothyronine [T3] or free T3 [FT3], free thyroxine [FT4], urinalysis, pregnancy test for women of childbearing potential, serum CA-125 [OC patients only]) and electrocardiogram (ECG). Tumor samples must be available from all patients (fresh samples or archived paraffin blocks; see Study Manual for details on sample collection and preparation) and will be sent to a centralized laboratory for biomarker testing. Radiographic evaluations (computed tomography [CT, preferred method] or magnetic resonance imaging [MRI, if clinically indicated]) of the chest, abdomen, and pelvis must be conducted at screening to determine extent of disease and confirm presence of measurable disease. Brain scan will be conducted if clinically indicated; bone scans will be conducted per standard of care. Scans performed prior to the signing of the informed consent form (ICF) as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and are performed within 21 days prior to first dose date.

All patients will begin treatment with niraparib and pembrolizumab on Cycle 1/Day 1; additional on-treatment assessments will be conducted on Days 8 and 15 of Cycle 1 and on Day 1 of all subsequent cycles. Safety assessments conducted throughout the treatment period include symptom-directed physical examination, vital signs, ECGs, ECOG performance status, and clinical laboratory assessments (CBC, coagulation [Phase 1 only], chemistry, TSH, T3 or FT3, FT4, urinalysis, CA-125 [OC patients only], and pregnancy testing). Radiographic evaluations (CT/MRI of chest [all TNBC patients and OC patients with abnormal screening scan or with clinical indication], abdomen, and pelvis) to assess extent of disease will be conducted every 9 weeks (63 days ±7 days) after Cycle 1/Day 1 while on study treatment independent of cycle delays and/or dose
interruptions and/or at any time when progression of disease is suspected. The same modality (CT or MRI) should be used throughout the study for a given patient. Brain scans will be conducted if clinically indicated; bone scans will be conducted per standard of care. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days) until disease progression. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals (ie, every 9 weeks for the first year and every 12 weeks thereafter). All radiographic images/scans will be sent to a central imaging vendor upon acquisition and archived for future evaluation if needed. Per RECIST v1.1, patients who achieved complete response (CR) or partial response (PR) should have the response confirmed; tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated. Blood sampling for PK and biomarker evaluations will be conducted for patients in both Phase 1 and Phase 2 (see Section 6.4).

In patients who consent to fresh biopsies, serial fresh biopsies will be obtained for exploratory biomarker analysis at 3 time points: during the screening period, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion and, whenever possible, at the time of disease progression (note: although the biopsy is voluntary, it is highly encouraged). The serial biopsies at different time points should be on the same lesion preferably. A core biopsy is recommended (details are provided in the Study Manual); if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted as the screening biopsy. Blood samples will also be obtained for biomarker analysis predose on Day 1 of Cycle 1 and Cycle 2, as well as at the end of treatment (EOT).

All patients will undergo an EOT visit within 7 days of the last dose of study treatment and a safety follow-up visit conducted 30 days (+7 days) post-treatment. Thereafter, all patients will enter the post-treatment period for telephone assessment of survival status and the occurrence of any new malignancies every 90 days (±14 days).

All AEs will be collected and recorded for each patient from the day of signing the ICF until 30 days after last study drug administration; serious adverse events (SAEs) and Events of Clinical Interest (ECIs) (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies are to be captured through 120 days post-treatment. All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, until abnormal laboratory values have returned to baseline or normalized, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.
4. **STUDY POPULATION**

4.1. **Inclusion Criteria**

To be considered eligible to participate in this study, all of the following requirements must be met:

1. Patient is male or female, at least 18 years of age. Male patients are only for TNBC and not OC.

2. Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below according to study phase and disease type:

   a. Phase 1 patients (breast or ovarian cancer)
      
      - Patients with advanced or metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (ie, triple-negative breast cancer, TNBC). Patients with disease recurrence or progression following neoadjuvant or adjuvant therapy are eligible. Patients with advanced or metastatic disease may have up to 4 lines of cytotoxic therapy. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.

      - Patients must have any epithelial (ie, serous, endometroid, mucinous, clear cell) ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator’s assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have received up to 5 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Treatment with small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.

   b. Phase 2 patients (breast or ovarian cancer)
      
      - Patients with advanced or metastatic breast cancer must have TNBC. Patients with disease recurrence or progression following neoadjuvant or adjuvant therapy are eligible. Patients with advanced or metastatic disease may have received up to 2 lines of cytotoxic therapy. Adjuvant and/or neoadjuvant therapies are not counted in the number of lines of therapy. Targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted. TNBC patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within 8 weeks from the day of the last platinum administration.
Patients must have with high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator’s assessment (e.g., patient is not eligible for further platinum containing treatment). Patients may have had up to 4 lines of cytotoxic therapy for advanced or metastatic disease. Neoadjuvant, adjuvant, and the combination of both will be considered as one line of therapy. Treatment with small molecules (e.g., tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (e.g., bevacizumab, aflibercept) are not counted in the number of lines of therapy.

3. Patient has archival tumor tissue available that is formalin-fixed and paraffin-embedded.
   a. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation.
   b. Serial fresh tumor tissue samples will be collected in patients with lesions amenable for a biopsy who consent to such a procedure.

4. Patient has measurable lesions by RECIST v1.1.

5. Patient has an ECOG performance status of 0 to 1.

6. Patient has adequate organ function, defined as (Note: CBC test should be obtained without transfusion or receipt of colony stimulating factors within 2 weeks before obtaining sample):
   a. Absolute neutrophil count (ANC) ≥ 1,500/µL
   b. Platelets ≥ 100,000/µL
   c. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
   d. Serum creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5x institutional ULN
   e. Total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ 1x ULN
   f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN unless liver metastases are present, in which case they must be ≤ 5x ULN
   g. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
   h. Activated partial thromboplastin time (aPTT) ≤ 1.5x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

7. Patient is able to take oral medications.

8. Female patient has a negative serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):
   a. ≥ 45 years of age and has not had menses for > 1 year
b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation

c. Post hysterectomy, bilateral oophorectomy, or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study therapy. Please see Section 5.7.2 for a list of acceptable birth control methods. Information must be captured appropriately within the site's source documents.

Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

9. Male patient agrees to use an adequate method of contraception (please see Section 5.7.2 for a list of acceptable birth control methods) starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

10. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.

4.2. Exclusion Criteria

Patients will not be eligible for study entry if any of the following criteria are met:

1. Patients with primary platinum refractory ovarian cancer (ie, progressive disease on or within 6 months of first-line platinum therapy) are not eligible in Phase 1 or Phase 2 of this study.

2. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.

3. Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

4. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific
examples include, but are not limited to, has history of (non-infectious) pneumonitis that required steroids or current pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).

5. Patient has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient’s participation for the full duration of the study treatment. Patients who received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment are not eligible.

6. Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.

7. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

8. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

9. Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected).

10. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

11. Patient has not recovered (i.e, to ≤Grade 1 or to baseline) from cytotoxic therapy-induced AEs. Note: Patient with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia is an exception to this criterion and may qualify for the study.

12. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

13. Patient has had a prior cytotoxic therapy, anticancer targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents within 5 half-lives, or monoclonal antibodies (mAb) within 5 half-lives or 4 weeks (whichever is shorter) of that treatment prior to study Day 1 or radiation therapy encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

14. Patient has not recovered adequately from AEs and/or complications from any major surgery prior to starting therapy.

15. Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or the patient has previously participated in Merck MK-3475 (pembrolizumab) clinical studies.
16. Patient has received a live vaccine within 30 days of planned start of study therapy.

17. Patient has undergone prior treatment with a known PARP inhibitor.

18. Patient has a heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening.
   Note: If a patient has a prolonged QT interval and the prolongation is deemed to be due to a pacemaker upon Investigator evaluation (i.e., the patient otherwise has no cardiac abnormalities), the patient may be eligible to participate in the study following discussion with the Medical Monitor.

19. Patient has a known hypersensitivity to niraparib or pembrolizumab components or excipients.

20. Known history or current diagnosis of MDS or AML.

4.3. Patient Withdrawal and Replacement

4.3.1. Discontinuation from Treatment

Patients may be discontinued from study treatment at any time. Specific examples of reasons for discontinuing all study treatments are given below.

- Adverse event
- Disease progression as outlined in Section 6.3 or based on clinical criteria by Investigator
- Risk to patient as judged by the Investigator and/or Sponsor
- Severe noncompliance with the protocol as judged by the Investigator and/or Sponsor
- Patient request
- Patient becomes pregnant
- Sponsor decision to terminate study

Details of required niraparib dose modifications, including interruptions, dose reductions, and permanent discontinuations, related to toxicity are provided in Section 5.4.1.

Details of required pembrolizumab dose interruptions and permanent discontinuation related to toxicity are provided in Section 5.4.2.

Note: If a patient is required to be discontinued from one of the study medications in the combination, treatment with the other study medication may be continued per decision of the Investigator in consultation with Sponsor.

Discontinuation of treatment may be considered for patients who have attained a confirmed CR, have been treated for at least 24 weeks with study treatments, and had at least 2 cycles of treatment beyond the date when the initial CR was declared.

Patients who discontinue from all study treatments will continue to receive follow-up assessments (see Table 6) as part of the study unless they are discontinued from the study (Section 4.3.2).
4.3.2. Discontinuation from the Study

Patients may be discontinued from the study for any of the following reasons:

- Withdrawal of consent by the patient, who is at any time free to discontinue their participation in the study, without prejudice to further treatment
- Death from any cause
- Loss to follow-up
- Sponsor decision to terminate study
- Investigator’s decision

If a patient is lost to follow-up or withdraws from study treatment, attempts should be made to contact the patient to determine the reason for discontinuation. For patients who are lost to follow-up, at least 3 documented attempts, including one via certified mail, should be made to contact the patient before considering the patient lost to follow-up.

4.3.3. Replacement of Patients

After consultation between the Sponsor and the Principal Investigator, enrollment may be extended to replace patient(s) that become non-evaluable for safety during Phase 1.

In Phase 2, if a patient discontinues study treatment prior to the first assessment of disease (either scheduled radiological assessment at 9 weeks post treatment initiation or clinically indicated disease assessment prior to 9 weeks), the patient should be replaced for the purposes of efficacy analysis after consultation between the Sponsor and Principal Investigator.

4.4. Patient Identification and Randomization

4.4.1. Patient Identification

All patients who enter into the screening period of the study (defined as the point at which the patient signs the ICF) will receive a unique patient identification number. This number will be used to identify the patient throughout the study and must be used on all study documentation related to that patient. A patient will be considered enrolled when the patient has been consented, screened, and all eligibility criteria have been confirmed in the electronic case report form (eCRF). The patient identification number must remain constant throughout the entire study; it must not be changed at the time of enrollment.

4.4.2. Randomization Scheme

Not applicable, as this is a single-arm study.
5. **STUDY MEDICATION**

5.1. **Identity**

5.1.1. **Niraparib**

Niraparib ([3S]-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl] piperidine [tosylate monohydrate salt]) is an orally available, potent, highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied as 100-mg capsules.

5.1.2. **Pembrolizumab**

Pembrolizumab is a potent and highly selective humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pembrolizumab Powder for Solution for Infusion is a sterile, non-pyrogenic lyophilized powder for IV infusion supplied in single-use Type I glass vial containing 50 mg of pembrolizumab. The product is preservative-free, white to off-white powder and free from visible foreign matter.

5.2. **Administration**

5.2.1. **Niraparib**

Niraparib will be supplied as 100-mg capsules and will be administered orally once daily (QD) continuously starting on Cycle 1/Day 1. The daily dose to be administered each day (ie, 300 mg as $3 \times 100$-mg capsules, 200 mg as $2 \times 100$-mg capsules, or 100 mg as $1 \times 100$-mg capsules) will depend on the phase of the study, and in Phase 1, the cohort assignment. See Section 3.1.2.1 for the RP2D of the combination. Patients will be instructed to take their dose at the same time each day, preferably in the morning. Patients must swallow and not chew all capsules. The consumption of water and food is permissible.

Niraparib capsules will be dispensed to patients on Cycle 1/Day 1 and on Day 1 of every cycle (21-day cycles) thereafter until the patient discontinues study treatment. On Day 1 of each cycle, a niraparib dose will be administered at the clinic upon completion of the pembrolizumab infusion.

Details on the administration of niraparib can be found in the Pharmacy Manual.

5.2.2. **Pembrolizumab**

Pembrolizumab will be administered at the study site on Day 1 of each 21-day treatment cycle after all procedures and assessments have been completed as detailed in Table 6. Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

Pembrolizumab will be administered at a dose of 200 mg IV using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Given the variability of infusion pumps from site to site, however, a window between -5 minutes and +10 minutes is permitted.
See Section 3.1.2.1 for the RP2D of the combination.

The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion and administration of the infusion solution.

### 5.3. Dose-Limiting Toxicity

The following are to be considered DLTs for this study (as assessed during Cycle 1, i.e., during the first 21 days of treatment, Day 1 through Day 21 during Phase 1):

- Any treatment-related Grade $\geq 3$ non-hematologic clinical (non-laboratory) AE
- Any treatment-related Grade 3 or Grade 4 non-hematologic laboratory abnormality if:
  - Medical intervention is required to treat the patient, or
  - The abnormality leads to hospitalization, or
  - The abnormality persists for $\geq 7$ days.
- Any treatment-related hematologic toxicity specifically defined as:
  - Thrombocytopenia Grade 4 for $\geq 7$ days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion;
  - Neutropenia Grade 4 for $\geq 7$ days, or Grade 3 or 4 associated with infection or febrile neutropenia;
  - Anemia Grade 4, or Grade 3 or 4 requiring blood transfusion.
- Any treatment-related AE leading to niraparib dose interruption per the following criteria:
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 3) for a non-DLT laboratory abnormality (e.g., for Grade 2 or 3 thrombocytopenia or for Grade 3 anemia or neutropenia) lasting $\geq 14$ days.
  - A dose interruption per dose modification rules (see Section 5.4.1, Table 2) for non-hematologic AE leading to $< 80\%$ of an intended dose being administered (e.g., niraparib dose interruption for $> 4$ days within Cycle 1).

Note that niraparib dosing has been safely managed with dose interruptions and/or adjustments for AEs, including laboratory abnormalities, while maintaining activity in the single-agent setting (see Section 5.4.1, Table 2 and Table 3, and niraparib Investigator’s Brochure). Therefore, niraparib dose interruption and/or reduction for an AE that does not meet a DLT definition as described above will be considered a non-DLT modification. The non-DLT dose modifications will not be considered in determining the MTD but will be considered in determining the niraparib dose intensity and RP2D.

### 5.4. Dose Modification

Study treatment dosing interruptions are permitted in the case of medical / surgical events or logistical reasons not related to study therapy (e.g., surgery, unrelated medical events, patient
vacation, and/or holidays). Patients should be placed back on study therapy within 28 days of the scheduled interruption, unless otherwise discussed with the Sponsor.

All treatment interruptions and dose reductions (including any missed doses), and the reasons for the reductions/interruptions, are to be recorded in the electronic case report form (eCRF).

5.4.1. Niraparib

Dose interruption of niraparib may be implemented per the Investigator’s judgement after Cycle 1 in patients enrolled in Phase 1 and at any time in patients enrolled in Phase 2. See the following sections for permitted duration of interruption prior to required discontinuation from treatment.

Intra-patient Dose Escalation

For patients in Phase 1, the dose of niraparib may be increased after Cycle 1 to a higher dose level that has been found to be safe during the dose escalation phase following discussion with the Sponsor.

See Section 3.1.2.1 for the RP2D.

Niraparib Dose Modifications for Non-Hematologic Toxicity

Treatment with niraparib must be interrupted for any treatment-related non-hematologic CTCAE Grade 3 or 4 event. Once resolved to Grade ≤ 1, the patient may restart treatment with niraparib with a dose level reduction (see Table 2) unless prophylaxis is considered feasible. If the event recurs at a similar or worse grade, treatment should be interrupted again and, upon resolution, a further dose reduction must be made to a lower dose level, if available, or niraparib dosing should be discontinued. If the toxicity requiring dose interruption has not resolved to CTCAE Grade ≤ 1 during a maximum 4-week (28-day) dose interruption period, and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), the patient must permanently discontinue treatment with niraparib. Once the dose of niraparib has been reduced, any re-escalation must be discussed with the Sponsor. Note that treatment with pembrolizumab may continue if discontinuation criteria as outlined in Section 5.4.2 have not been met.

Table 2 Niraparib Dose Reductions for Non-Hematologic Toxicity

<table>
<thead>
<tr>
<th>Event</th>
<th>Dosea,b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial dose</td>
<td>300 mg QD</td>
</tr>
<tr>
<td>1st dose reduction for treatment-related CTCAE Grade 3 or 4 AE or SAE where prophylaxis is not considered feasible</td>
<td>200 mg QD</td>
</tr>
<tr>
<td>2nd dose reduction for treatment-related CTCAE Grade 3 or 4 AE or SAE where prophylaxis is not considered feasible</td>
<td>100 mg QD</td>
</tr>
<tr>
<td>Continued treatment-related CTCAE Grade 3 or 4 AE or SAE ≥ 28 days</td>
<td>Discontinue niraparib</td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; CTCAE = Common Terminology for Adverse Events; QD = once daily; SAE = serious adverse event.

a Dose not to be decreased below 100 mg daily.

b If initial dose is below 300 mg, the same dose reduction principles will apply with fewer dose modification steps available.
Niraparib Dose Modifications for Hematologic Toxicity

The dose interruption/modification criteria for niraparib for hematologic toxicities will be based on blood counts and are outlined in Table 3.

For thrombocytopenia, patients with a platelet count ≥ 25,000 to < 75,000/µL must have niraparib interrupted and have blood counts monitored twice weekly until recovery to ≥ 100,000/µL; upon recovery, niraparib can be resumed at the same dose for the first occurrence with once weekly monitoring for 3 weeks to confirm no recurrence of thrombocytopenia. For a further recurrence of platelet count at this level or any occurrence of platelet count < 25,000/µL, dose interruption followed by dose reduction upon recovery to ≥ 100,000/µL with subsequent monitoring once weekly for 3 weeks to ensure the safety of the new dose level is required (see Table 2).

For Grade 3 or 4 neutropenia or anemia, treatment with niraparib must be interrupted with blood counts monitored twice weekly for neutropenia and once or twice weekly for anemia until recovery to ≤ Grade 1. Niraparib dosing should be resumed with a dose level reduction (see Table 2) at that time and the patient monitored once weekly for 3 weeks to ensure the safety of the new dose level. If clinically indicated, use of G-CSF is allowed according to current American Society of Clinical Oncology (ASCO) guidelines.\(^{(60)}\)

If the hematologic toxicity does not recover to the specified level within 4 weeks (28 days) of dose interruption and/or the patient has already undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg QD), then niraparib should be discontinued.

Any patient requiring transfusion of platelets or red blood cells (1 or more units) or hematopoietic growth factor support must undergo a niraparib dose reduction upon recovery if study treatment is resumed.

It is strongly recommended that the patient be referred to a hematologist for further evaluation (1) if transfusions are required on more than 1 occasion or (2) if the treatment-related hematologic toxicities have not recovered to CTCAE ≤ Grade 1 within 4 weeks. If a diagnosis of MDS/AML is confirmed by a hematologist, the patient must permanently discontinue niraparib. Note that treatment with pembrolizumab may continue following discussion with the Sponsor if discontinuation criteria as outlined in Section 5.4.2 have not been met.

The reason for interruption, reduction, or discontinuation of niraparib should be recorded in the eCRF.
### Table 3  Management of Hematologic Toxicities*

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet count 25,000 to &lt; 75,000/μL</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly CBC monitored until recovery. Niraparib may then be resumed at same dose. After recovery, blood counts once weekly for 3 weeks.</td>
</tr>
<tr>
<td>Further occurrence of platelet count 25,000 to &lt; 75,000/μL</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 2); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level. A further dose reduction should be made if an additional treatment interruption is needed in less than 3 weeks after resuming treatment.</td>
</tr>
<tr>
<td>Platelet count &lt; 25,000/μL&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Niraparib must be interrupted until platelet count is ≥ 100,000/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 2); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
<tr>
<td>Neutrophil &lt; 1,000/μL</td>
<td>Niraparib must be interrupted until neutrophil counts are ≥ 1,500/μL with twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 2); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
<tr>
<td>Hemoglobin ≤ 8 g/dL</td>
<td>Niraparib must be interrupted until hemoglobin is ≥ 9 g/dL with once- or twice-weekly CBCs monitored until recovery. Niraparib may then be resumed at a reduced dose (see Table 2); after recovery, blood counts once weekly for 3 weeks to ensure the safety of the new dose level.</td>
</tr>
</tbody>
</table>

Abbreviations: CBC = complete blood count.

* If blood counts do not recover within 28 days to normal values (ie, platelets ≥ 100,000/μL, hemoglobin ≥ 9 g/dL, neutrophils ≥ 1,500/μL) niraparib should be discontinued.

<sup>a</sup> Dose not to be decreased below 100 mg daily.

<sup>b</sup> For patients with platelet count ≤ 10,000/μL, prophylactic platelet transfusion per guidelines should be considered.<sup>61, 62</sup> For patients taking anticoagulation or antiplatelet drugs, consider the risk/benefit of interrupting these drugs and/or prophylactic transfusion at an alternate threshold, such as ≤ 20,000/μL.

#### 5.4.2. Pembrolizumab

Adverse events (both non-serious and serious) associated with pembrolizumab exposure may represent an immunologic etiology. These AEs may occur shortly after the first dose or several months after the last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or life-threatening AEs per Table 4. See also Section 6.1.6, Events of Clinical Interest (ECIs).

Table 4 provides detailed information for dose interruptions and discontinuations related to toxicity for pembrolizumab. No dose reductions of pembrolizumab are permitted. Note that treatment with
niraparib may continue following discussion with the Sponsor if discontinuation criteria as outlined in Section 5.4.1 have not been met.

The reason for interruption or discontinuation of pembrolizumab should be recorded in the eCRF.
<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Hold Treatment For Grade</th>
<th>Timing for Restarting Treatment</th>
<th>Treatment Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea/colitis</td>
<td>2-3</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>AST, ALT, or increased bilirubin</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose.</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>Permanently discontinue (see exception below).</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Type 1 diabetes mellitus (if new onset) or hyperglycemia</td>
<td>T1DM or 3-4</td>
<td>Hold pembrolizumab for new onset Type 1 diabetes mellitus or Grade 3-4 hyperglycemia associated with evidence of beta cell failure.</td>
<td>Resume pembrolizumab when patients are clinically and metabolically stable.</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>2-4</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapy with pembrolizumab can be continued while endocrine replacement therapy is instituted.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>3</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td></td>
<td>Therapy with pembrolizumab can be continued while thyroid replacement therapy is instituted.</td>
<td>Therapy with pembrolizumab can be continued while thyroid replacement therapy is instituted.</td>
</tr>
<tr>
<td>Infusion reaction</td>
<td>2,b</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Permanently discontinue if toxicity develops despite adequate premedication.</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
</tbody>
</table>
### Table 4  Pembrolizumab Dose Modifications for Non-hematologic Toxicities (Continued)

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Hold Treatment For Grade</th>
<th>Timing for Restarting Treatment</th>
<th>Treatment Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonitis</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td>3-4 or Recurrent 2</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>Renal failure or nephritis</td>
<td>2</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
<tr>
<td>All other drug-related toxicity</td>
<td>3 or severe</td>
<td>Toxicity resolves to Grade 0-1.</td>
<td>Toxicity does not resolve within 12 weeks of last dose or inability to reduce corticosteroid to 10 mg or less of prednisone or equivalent per day within 12 weeks.</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Permanently discontinue.</td>
<td>Permanently discontinue.</td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; T1DM=type 1 diabetes mellitus.

Note: Permanently discontinue for any severe or Grade 3 (Grade 2 for pneumonitis) drug-related AE that recurs or any life-threatening event.

*For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by greater than or equal to 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.*

If symptoms resolve within one hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (e.g. from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the subject should be premedicated for the next scheduled dose; Refer to Section 5.7.3 Infusion Treatment Guidelines for further management details.

*Patients with intolerable or persistent Grade 2 drug-related AE may hold study medication at physician discretion. Permanently discontinue study drug for persistent Grade 2 adverse reactions for which treatment with study drug has been held, that do not recover to Grade 0-1 within 12 weeks of the last dose.*
5.5. **Packaging, Labeling, and Storage**

Niraparib 100-mg capsules will be packed in high-density polyethylene bottles with child-resistant closures.

Pembrolizumab for injection is supplied as 50-mg lyophilized powder single-use vials.

The label text of the study treatments will comply with Good Manufacturing Practice and national legislation to meet the requirements of the participating countries. The study treatment will be open-label and non-patient-specific.

All study treatment supplies must be stored in accordance with the Pharmacy Manual instructions and package labeling. Until dispensed or administered to the patients, the study treatment will be stored in a securely locked area, accessible to authorized personnel only.

5.6. **Drug Accountability**

The Investigator or designee is responsible for maintaining accurate dispensing records of the study treatments throughout the clinical study.

Details of maintaining drug accountability, including information on the accountability log, will be provided in the Pharmacy Manual.

All dispensation and accountability records will be available for Sponsor review. The study monitor will assume the responsibility to reconcile the study treatment accountability log. The pharmacist will dispense study treatment for each patient according to the protocol and Pharmacy Manual, if applicable.

5.7. **Previous and Concomitant Medications**

Any medication the patient takes during the study other than the study treatments, including herbal and other nontraditional remedies, is considered a concomitant medication. All concomitant medications must be recorded in the eCRF. The following information must be recorded in the eCRF for each concomitant medication: generic name, route of administration, start date, stop date, dosage, and indication. Any changes in the dosage or regimen of a concomitant medication must be recorded in the eCRF.

At screening, patients will be asked what medications they have taken during the last 30 days. At each subsequent study visit, patients will be asked what concomitant medications they are currently taking or have taken since the previous visit.

Niraparib has potential to induce cytochrome P450 (CYP)1A2 and is a substrate for P-glycoprotein (P-gp); therefore, investigators should be advised to use caution with drugs that are sensitive substrates for CYP1A2 (see Appendix A).

The niraparib safety profile includes risk for thrombocytopenia; therefore, investigators should be advised to use caution with anticoagulation and antiplatelet drugs.
5.7.1. Prohibited Medications

Patients are prohibited from receiving the following therapies during the screening and treatment phase of this study:

- Antineoplastic systemic chemotherapy or biological therapy
- Immunotherapy not specified in this protocol
- Chemotherapy not specified in this protocol
- Investigational agents other than niraparib and pembrolizumab
- Radiation therapy is prohibited if encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1.

Note: The following may be considered exceptions on a case-by-case basis after consultation with the Sponsor: Radiation therapy to pre-existing small areas of painful metastases that cannot be managed with local or systemic analgesics (excluding palliative radiotherapy encompassing > 20% of the bone marrow) as long as no evidence of disease progression is present. The patient must have clear measurable disease outside the radiated field. Administration of palliative radiation therapy may be considered clinical progression for the purposes of determining PFS.

- Systemic glucocorticoids for any purpose other than to modulate symptoms from an ECI of suspected immunologic etiology. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.

Note: Inhaled steroids are allowed for the management of asthma.

- Live vaccines within 30 days prior to the first dose of study treatment and while participating in the study. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacille Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. Intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines, however, and are not allowed.

- Prophylactic cytokines (G-CSF) should not be administered in the first cycle of the study but may be administered in subsequent cycles according to current ASCO guidelines.\(^{60}\)

If there is a clinical indication for any medication or vaccination specifically prohibited during the study, discontinuation from study therapy may be required. The Investigator should discuss any questions regarding this with the Sponsor. The final decision on any supportive therapy or vaccination rests with the Investigator and/or the patient’s primary physician. The decision to continue the patient on study therapy, however, requires the mutual agreement of the Investigator, the Sponsor, and the patient.

5.7.2. Contraception

Pembrolizumab and niraparib are known to have properties that require the patient to use contraception. For details on niraparib, please refer to the Investigator’s Brochure.
Pembrolizumab may have adverse effects on a fetus in utero. Furthermore, it is not known if pembrolizumab has transient adverse effects on the composition of sperm. Therefore, non-pregnant, non-breastfeeding women may only be enrolled if they are willing to use 2 methods of birth control or are considered highly unlikely to conceive. Highly unlikely to conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥ 45 years of age and has not had menses for > 1 year will be considered postmenopausal), or 3) not heterosexually active for the duration of the study. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Patients should start using birth control from screening throughout the study period up to 120 days after the last dose of pembrolizumab.

The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents). Abstinence is acceptable if this is the established and preferred contraception for the patient.

Patients should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in the study they must adhere to the contraception requirement (described above) for the duration of the study and through 120 days after the last study treatment. If there is any question that a patient will not reliably comply with the requirements for contraception, that patient should not be entered into the study.

5.7.3. **Rescue Medications and Supportive Care Guidelines During Treatment with Pembrolizumab**

Patients should receive appropriate supportive care measures as deemed necessary by the treating Investigator. Suggested supportive care measures for the management of AEs with potential immunologic etiology are outlined below. Note that several courses of steroid tapering may be necessary, as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the Investigator determines the events to be related to pembrolizumab.

Note: it may be necessary to perform additional procedures such as bronchoscopy, endoscopy, or skin photography as part of evaluation of the event.

The following text details specific guidance by type of AE.

- **Pneumonitis:**
  - For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.
  - For Grade 3-4 events, immediately treat with IV steroids. Administer additional anti-inflammatory measures, as needed.
Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration.

- **Diarrhea/Colitis:**

  Patients should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus).

- All patients who experience diarrhea/colitis should be advised to drink liberal quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion. For Grade 2 or higher diarrhea, consider gastrointestinal consultation and endoscopy to confirm or rule out colitis.

- For Grade 2 diarrhea/colitis that persists greater than 3 days, administer oral corticosteroids.

- For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with IV steroids followed by high-dose oral steroids.

- When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.

- **Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis:**

  - For Type 1 diabetes mellitus or Grade 3-4 hyperglycemia
    - Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
    - Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide.

- **Hypophysitis:**

  - For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.

  - For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.
• **Hyperthyroidism or Hypothyroidism:**
  Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
  
  − Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):
    • In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are suggested as initial therapy.
    • In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyronine, is indicated per standard of care.
  
  − Grade 3-4 hyperthyroidism
    • Treat with an initial dose of IV corticosteroids followed by oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.

• **Hepatic:**
  
  − For Grade 2 events, monitor liver function tests more frequently until returned to baseline values (consider weekly).
    
    − Treat with IV or oral corticosteroids.
  
  − For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours.
  
  − When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over no less than 4 weeks.

• **Renal Failure or Nephritis:**
  
  − For Grade 2 events, treat with corticosteroids.
  
  − For Grade 3-4 events, treat with systemic corticosteroids.
  
  − When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.

• **Management of Infusion Reactions:**
  Signs and symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of infusion.

  *Table 5* shows treatment guidelines for patients who experience an infusion reaction associated with administration of pembrolizumab.
### Table 5 Pembrolizumab Infusion Reaction Treatment Guidelines

<table>
<thead>
<tr>
<th>NCI CTCAE Grade</th>
<th>Treatment</th>
<th>Premedication at Subsequent Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.</td>
<td>None</td>
</tr>
</tbody>
</table>
| Mild reaction; infusion interruption not indicated; intervention not indicated | Stop infusion and monitor symptoms. Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  

Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.  
If symptoms resolve within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate (eg, from 100 mL/hr to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and the patient should be premedicated for the next scheduled dose.  
Patients who develop Grade 2 toxicity despite adequate premedication should be permanently discontinued from further study treatment administration. | Patient may be premedicated 1.5 hour (± 30 minutes) prior to infusion of pembrolizumab with:  
Diphenhydramine 50 mg PO (or equivalent dose of antihistamine).  
Acetaminophen 500-1000 mg PO (or equivalent dose of antipyretic). |
| Grade 2         | Stop Infusion. Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epinephrine  
Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.  
Hospitalization may be indicated.  
Patient is permanently discontinued from further study treatment administration. | No subsequent dosing |
| Requires infusion interruption but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 hrs | | |
| Grades 3 or 4   | | |
| Grade 3:       | Stop Infusion. Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epinephrine  
Increase monitoring of vital signs as medically indicated until the patient is deemed medically stable in the opinion of the Investigator.  
Hospitalization may be indicated.  
Patient is permanently discontinued from further study treatment administration. | No subsequent dosing |
| Prolonged (ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae (eg, renal impairment, pulmonary infiltrates) | | |
| Grade 4:       | | |
| Life-threatening; pressor or ventilatory support indicated | | |

Abbreviations: IV=intravenous; NSAID=nonsteroidal anti-inflammatory; PO=oral.  
Note: Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of drug administration.
5.7.4. Other Study Restrictions

Patients who are blood donors should not donate blood during the study and for 90 days after the last dose of study treatment.

Patients should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea, or vomiting.
6. **ENDPOINTS AND METHODS OF ASSESSMENT**

6.1. **Safety Endpoints**

Safety parameters evaluated during the conduct of the study include treatment-emergent AEs (TEAEs), clinical laboratory values (hematology, chemistry, coagulation, thyroid function, urinalysis), vital signs, ECGs, physical examination findings, and use of concomitant medications. Additionally, the relationship between cytogenetic abnormalities and safety parameters may be explored.

6.1.1. **Definitions**

**Adverse event:** An *adverse event* is any untoward medical occurrence that occurs in a patient or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product.

Adverse events may include the onset of new illness and the exacerbation of pre-existing medical conditions. An AE can include an undesirable medical condition occurring at any time, including baseline or washout periods, even if no study treatment has been administered.

A *treatment-emergent adverse event* will be defined as any new AE that begins, or any preexisting condition that worsens in severity, after at least 1 dose of study treatment has been administered.

**Serious adverse event:** A *serious adverse event* is defined as any untoward medical occurrence that, at any dose:

- Results in death
- Is life-threatening
  - Note: This means that the patient is at immediate risk of death at the time of the event; it does not mean that the event hypothetically might have caused death if it were more severe
- Requires inpatient hospitalization or prolongation of existing hospitalization
  - Any AE that prolongs hospitalization will be considered an SAE.
  - Exception: Planned hospitalization (eg, for observation, protocol compliance, elective procedures, social reasons, etc.) will not be considered an SAE; however, the reason for the planned hospitalization should be captured in medical history.
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly or birth defect
• Is an important medical event(s)
  – An important medical event may not be immediately life-threatening or result in
death or hospitalization but may jeopardize the patient or require intervention to
prevent one of the above outcomes. Examples of such events are intensive
treatment in an emergency room or at home for allergic bronchospasm, blood
dyscrasias or convulsions that do not result in hospitalization, or development of
drug dependency or drug abuse.

6.1.2. Assessment of Adverse Events
Each AE will be assessed by the Investigator with regard to intensity and causality with regard to
study treatment as outlined in the following sections.

6.1.2.1. Intensity
Investigators should assess the severity of AEs according to CTCAE. In general, CTCAE (v4.03)
severity grades are:

Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;
intervention not indicated

Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental activities of daily living (ADL). (Instrumental ADL refer
to preparing meals, shopping for groceries or clothes, using the telephone,
managing money, etc.)

Grade 3: Severe or medically significant but not immediately life-threatening;
hospitalization or prolongation of hospitalization indicated; disabling; limiting
self-care ADL. (Self-care ADL refer to bathing, dressing and undressing, feeding
self, using the toilet, taking medications, and not bedridden.)

Grade 4: Life-threatening consequences; urgent intervention indicated

Grade 5: Death related to AE

A distinction should be made between serious and severe AEs. Severity is a measure of intensity
whereas seriousness is defined by the criteria above in Section 6.1.1. For example, a mild degree
gastrointestinal bleeding requiring an overnight hospitalization for monitoring purposes may
be considered an SAE but is not necessarily severe. Similarly, an AE that is severe in intensity is
not necessarily an SAE. For example, alopecia may be assessed as severe in intensity but may
not be considered an SAE.

6.1.2.2. Causality
The Investigator will assess the causality/relationship between the study drug and the AE. One of
the following categories should be selected based on medical judgment, considering the
definitions and all contributing factors:

• Related: A clinical event, including laboratory test abnormality, occurs in a plausible
time relationship to treatment administration, and which concurrent disease or other
drugs or chemicals cannot explain. The response to withdrawal of the treatment should be clinically plausible.

- **Possibly related**: A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the treatment, unlikely to be attributed to concurrent disease or other drugs or chemicals.

- **Unlikely related**: A clinical event, including laboratory test abnormality, with a temporal relationship to treatment administration which makes a causal relationship improbable, or in which other drugs, chemicals or underlying disease provide likely explanations.

- **Unrelated**: A clinical event, including laboratory test abnormality, with little or no temporal relationship with treatment administration. Typically explained by extraneous factors (e.g., concomitant disease, environmental factors, or other drugs or chemicals).

### 6.1.3. Collecting and Recording Adverse Events

All AEs, regardless of the source of identification (e.g., physical examination, laboratory assessment, ECG, reported by patient), must be documented in the eCRF.

All AEs will be collected and recorded in the eCRF for each patient from the day of signed informed consent until 30 days after the last dose of study treatment; SAEs will be monitored through 90 days after the last dose of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy). All AEs and SAEs experienced by a patient, irrespective of the suspected causality, will be monitored until the AE or SAE has resolved, any abnormal laboratory values have returned to baseline or normal levels, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died.

If an Investigator becomes aware of an SAE after the specified follow-up period post treatment discontinuation and considers the SAE related to investigational product, the Investigator should report the SAE to the Sponsor according to timelines for reporting SAEs described in this section.

Adverse events may be volunteered spontaneously by the study patient, or discovered by the study staff during physical examinations or by asking an open, non-leading question such as: “How have you been feeling since you were last asked?” The Investigator will document the nature of AE, date of onset of the AE (and time, if known), date of outcome of the AE (and time, if known), severity of the AE, action taken with study drug as a result of the AE, assessment of the seriousness of the AE, and assessment of the causal relationship of the AE to study drug and/or study procedure.

All AEs should be recorded individually in the patient’s own words (verbatim) unless, in the opinion of the Investigator, the AEs constitute components of a recognized condition, disease, or syndrome. In the latter case, the condition, disease, or syndrome should be named rather than each individual symptom.
Concomitant illnesses that existed before entry into the study will not be considered an AE unless the illness worsens during the treatment period. Pre-existing conditions will be recorded in the eCRF as well as on the SAE Report Form medical history section.

6.1.4. Reporting Disease Progression

The event of disease progression is an efficacy criterion and is therefore not considered an AE. Disease progression should be reported within the eCRF. If AE(s)/SAE(s) occur in relation to disease progression, the AE(s)/SAE(s) must be reported per AE/SAE reporting requirements described in Section 6.1.3 and Section 6.1.5.

6.1.5. Serious Adverse Events

6.1.5.1. Reporting of Serious Adverse Events

The Investigator must report all SAEs within 24 hours of becoming aware of the initial SAE or any follow-up information regarding the SAE using the SAE reporting contact information as printed on the SAE forms and in the SAE Completion guidelines.

For all SAEs, an SAE report form must be completed by the Investigator for all initial and follow-up SAEs. A follow-up SAE report must be completed each time an Investigator becomes aware of any additional information regarding the SAE. For the follow-up SAE Report Form, the following fields must be completed on each form: follow-up number, site number, patient/subject number, protocol number, and the SAE term(s) and date of awareness. Additionally, only the appropriate field(s) on the SAE Report Form where the Investigator received additional or updated information should be completed. Previously provided information does not have to be entered on the follow-up SAE Report Form.

Initial and follow-up SAE reports and any additional supporting documentation (eg, hospital reports, consultant reports, death certificates, autopsy reports, etc.) included with the SAE report should be sent to the Sponsor (or designee) within 24 hours of the Investigator/site awareness or receipt. If supporting documentation is provided, the Investigator should highlight all relevant and pertinent information. Also, any additional SAE documentation must be a clear photocopy with the patient’s personal identifiers removed. The Investigator must sign and date all SAE forms.

The minimum information required for an initial SAE report is:

- Name of person sending the report (ie, name, address of Investigator)
- Patient identification (screening/randomization number, initials [if permitted by local data privacy regulations], NOT patient name)
  - Protocol number
  - Description of SAE
  - Causality assessment
  - Seriousness assessment

In case the Investigator has no ability to either fax or email an SAE (eg, due to technical issues), pharmacovigilance can be contacted by phone. If an SAE is reported via phone and during usual
business hours, the Sponsor pharmacovigilance (or designee) will capture the information on a
telephone contact form or similar method. Outside usual business hours, the message will be
recorded and the required follow-up actions initiated during the next business day. Once
technical issues are resolved, the Investigator should fax or email the completed SAE form to the
Sponsor (or designee).

After receipt of the initial report, the Sponsor (or designee) will review the information and, if
necessary, contact the Investigator to obtain further information.

6.1.5.2. Submission and Distribution of Adverse Events/Serious Adverse Events
Per regulatory requirements, if an SAE is required to be submitted to a Regulatory Authority a
copy of this report (CIOMS or MedWatch 3500A) will be distributed to the Investigators/site.
The Investigator/site will submit a copy the report to their respective Institutional Review Board
(IRB) or Independent Ethics Committee (IEC).

6.1.6. Events of Clinical Interest
Selected non-serious AEs and SAEs are also known as Events of Clinical Interest (ECIs) and
must be recorded as such on the eCRF and reported within 24 hours to the Sponsor as noted for
SAEs in Section 6.1.5.1.

6.1.6.1. Pembrolizumab
Patients are to be monitored through 90 days after the last dose of study treatment for the
following ECI:

1. An overdose of pembrolizumab that is not associated with clinical symptoms or abnormal
   laboratory results. For this study, an overdose is defined as a dose \( \geq 1000 \text{ mg} \) (5 times the
dose) of pembrolizumab. No specific information is available on the treatment of
overdose of pembrolizumab. In the event of overdose, the patient should be observed
closely for signs of toxicity. Appropriate supportive treatment should be provided if
clinically indicated

2. An elevated AST or ALT value that is \( \geq 3 \times \text{ULN} \) concurrent with an elevated total
   bilirubin value that is \( \geq 2 \times \text{ULN} \) and, at the same time, an alkaline phosphatase value that
   is \( < 2 \times \text{ULN} \), as determined by protocol-specified laboratory testing or unscheduled
   laboratory testing.

   Note: These criteria are based upon available regulatory guidance documents.\(^{63}\) The
   purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require
   an additional evaluation for an underlying etiology. The study site guidance for
   assessment and follow up of these criteria can be found in the Investigator Trial File
   Binder (or equivalent).

6.1.6.2. Niraparib
Patients are to be monitored through 90 days after the last dose of study treatment for the
following ECI:

1. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ECIs must be
   reported to the Sponsor as soon as the Investigator becomes aware of them.
2. An overdose is defined as the accidental or intentional ingestion or infusing of any dose of study treatment that exceeds the dose described in the protocol. Overdoses are not considered AEs; however, all overdoses should be recorded on a Serious Adverse Event Form (Section 6.1.5.1) within 24 hours of becoming aware. An overdose should be reported even if it does not result in an AE. Overdoses do not need to be recorded on the eCRF; dosing information is recorded on the eCRF.

3. In conjunction with the survival assessment, new malignancy information will be collected for all patients via telephone every 90 (±14) days (Section 7.2.10). Additionally, the relationship between cytogenetic abnormalities and safety parameters may be explored.

6.1.7. Pregnancy Reporting and Follow-up

Pregnancies occurring in patients enrolled in a study or in a female partner of a male patient must be reported and followed to outcome. If a female patient inadvertently becomes pregnant while on study treatment, the patient will immediately be removed from the study. Any pregnancies that occur within 120 days following the last dose of study treatment must be captured in the eCRF.

The Investigator should complete the Initial Pregnancy Notification report form and forward it to the Sponsor (or designee) within 24 hours of knowledge of the pregnancy. If there is an associated serious outcome, then both the Initial Pregnancy Notification report form and SAE report form should be completed.

The site will follow-up with the patient at least monthly and document the patient’s status until the pregnancy has been completed or terminated. The Investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor. The Pregnancy Outcome report form should be completed and submitted to the Sponsor within 24 hours after the Investigator becomes aware of the pregnancy outcome.

In the event the pregnancy outcome occurs following the end of the study and database lock, the Investigator will report the pregnancy outcome to the Sponsor (or designee) within 24 hours after the outcome of the pregnancy is known to the Investigator in accordance with the procedure for reporting SAEs (see Section 6.1.5).

Pregnancy alone is not regarded as an AE unless there is a possibility that the study drug may have interfered with the effectiveness of a contraceptive medication. Elective abortions without complications should not be considered AEs unless they were therapeutic abortions. Hospitalization for normal delivery of a healthy newborn should not be considered an SAE. Pregnancy is not considered an SAE unless there is an associated serious outcome. Spontaneous abortions should always be reported as SAEs.

Any SAE that occurs during pregnancy must be recorded on the SAE Report Form (eg, maternal serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, birth defect) and reported within 24 hours in accordance with the procedure for reporting SAEs.
6.1.8. Clinical Laboratory Assessments

The following laboratory variables will be determined in accordance with the schedule of events (Table 6). These tests will be performed by the local laboratory at the clinical site.

- **Complete blood count:**
  - Hemoglobin
  - Mean corpuscular volume
  - White blood cell count
  - Platelets
  - Mean platelet volume (optional)*
  - Differential white cell count

* Note: Although mean platelet volume collection is optional, it is highly encouraged, especially for patients with high-grade thrombocytopenia.

- **Coagulation factors:**
  - International normalized ratio
  - Activated partial thromboplastin time

- **Serum chemistry:**
  - Sodium
  - Potassium
  - Calcium
  - Magnesium
  - Chloride
  - Glucose (fasting at baseline)
  - Creatinine
  - Urea or blood urea nitrogen
  - Sodium
  - Amylase
  - Total bilirubin
  - Alkaline phosphatase
  - Aspartate aminotransferase
  - Alanine aminotransferase
  - Total protein
  - Albumin
  - Lactate dehydrogenase

- **Urinalysis:**
  - Specific gravity
  - Leukocyte esterase
  - Nitrite
  - Blood
  - Protein
  - Glucose
  - Ketones
  - Urobilinogen
  - Bilirubin

- **TSH, T3, or FT3, and FT4**
- **Serum CA-125 (OC patients only)**
- **Serum pregnancy testing / urine pregnancy testing**
Any laboratory values assessed as clinically significant should be recorded as an AE. If SAE criteria are met or the laboratory abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).

Hematological testing may occur more frequently than is specified in Table 6 when additional testing is medically indicated per Investigator judgment or if the event meets the criteria for niraparib dose modification (see Section 5.4.1). Additional tests may be performed at a laboratory facility other than the study site, but test results must be reported to the study site, the study site must keep a copy of test results with the patient’s study file, and the results must be entered into the eCRF.

It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s Medical Monitor. The study site must receive a copy of the hematologist's report of aspirate/biopsy findings, which must include a classification according to World Health Organization (WHO), and other sample testing reports related to MDS/AML. Report data will be entered in the appropriate eCRF pages and the site must keep a copy of all reports with the patient’s study file.

Whole blood samples will be collected prior to the start of the study drug and at treatment discontinuation for cytogenetic analysis. Further details on sample collection and analysis can be found in the Study Manual.

### 6.1.9. Physical Examination and Vital Signs

Physical examinations, including height (screening only), weight, and vital signs (blood pressure [BP], pulse, and temperature), will be performed in accordance with the schedule of events (Table 6).

Any physical examination or vital signs assessed as clinically significant should be recorded as an AE or SAE. If SAE criteria are met or the abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).

### 6.1.10. Eastern Cooperative Oncology Group Performance Status

Performance status will be assessed using the ECOG scale (see Appendix G) in accordance with the schedule of events (Table 6). The same observer should assess performance status each time.

### 6.1.11. Additional Safety Assessments

All patients will undergo ECGs in accordance with the schedule of events (Table 6). Electrocardiograms should be performed prior to blood draws for PK. Patients will be supine and rested for approximately 2 minutes before ECGs are recorded.

Any ECG findings assessed as clinically significant should be recorded as an AE. If SAE criteria are met or the abnormality is an ECI (see Section 6.1.6), the event should be recorded and reported according to the SAE reporting process (see Section 6.1.5).
6.2. Demographics and Baseline Characteristics

Demographics and baseline characteristics consist of those variables that are assessed at screening/baseline.

6.2.1. Patient Eligibility

Compliance with inclusion and exclusion criteria will be assessed as outlined in Section 4.1 and Section 4.2.

6.2.2. Patient Demography

Patient demography consists of age at screening, race, ethnicity, and sex.

6.2.3. Disease History

For disease history the following will be documented:

- Date of first diagnosis
- Tumor type
- Stage at time of initial diagnosis
- Histology and grade of disease at diagnosis and most recent biopsy if additional biopsy performed
- Information on first anticancer treatment:
  - Intent (adjuvant, neoadjuvant, curative, palliative) (TNBC patients)
  - Date of start of first treatment
  - Agents used in first treatment
  - Date of last dose of first treatment
- Information on second and subsequent anticancer treatments:
  - Intent (adjuvant, neoadjuvant, curative, palliative) (TNBC patients)
  - Dates of start of all subsequent treatments
  - Agents in all subsequent treatments
  - Dates of last dose of all subsequent treatments
- Best response and toxicities (including hematologic events) for each prior anticancer treatment
- Date of recurrence for each prior anticancer treatment

6.2.4. Medical and Surgical History

Major medical and surgical history (including medication history), including history of thrombocytopenia, neutropenia, leukopenia, or anemia, will be collected. Details of any prior invasive malignancy will be collected. Medical and surgical history will be obtained by interviewing the patient or by reviewing the patient’s medical records.
6.2.5. Previous and Concomitant Medications

Previous and concomitant medication will be documented as described in Section 5.7. Medications will be coded using World Health Organization Anatomical Therapeutic Chemical classification.

6.3. Efficacy Endpoint(s)

6.3.1. Evaluation of Tumor Response

6.3.1.1. Overview

The efficacy of combination treatment with niraparib and pembrolizumab will be evaluated by assessment of tumor response to treatment according to RECIST v1.1 (65) and irRECIST (see Section 6.3.1.3 and Section 6.3.1.4, respectively) per investigator assessment. Tumor marker data (CA-125) will not be used for defining objective responses or disease progression; however, CA-125 can be used for clinical decisions. Clinical criteria such as the GCIG criteria (66) (see Appendix F) will also be considered for management of OC patients with clinical events (eg, bowel obstruction) without radiographic evidence of disease progression. The Study Committee will adjudicate such cases (see Section 9.12).

Response to treatment will primarily be based on Investigator evaluation of radiographic images. All radiographic images/scans at the time points specified in Table 6, as well as any unscheduled images/scans, will be sent by the study sites to the central imaging vendor upon acquisition and archived for potential future evaluation.

The process for image collection and transmission to the central imaging vendor can be found in the Site Imaging Manual.

Tumor imaging (chest, abdomen, and pelvis [plus brain if clinically indicated]) should be performed by CT (preferred). Magnetic resonance imaging should only be used when CT is contraindicated or for imaging of the brain, but the same imaging technique should be used in a patient throughout the study. CT scan is the more commonly used modality and is preferred for the majority of patients. An MRI can be utilized if clinically appropriate. Positron emission tomography/CT may be used according to RECIST guidelines.

If the chest (OC patients only) and/or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up.

Bone scans should be conducted per standard of care.

6.3.1.2. Timing of Radiographic Evaluations

All patients will undergo serial radiographic assessments to assess tumor response. Initial tumor imaging at screening must be performed within 21 days prior to the date of the first dose of study treatment. Scans performed prior to the signing of the ICF as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and performed within 21 days prior to first dose date.
The first on-study imaging assessment should be performed at 9 weeks (63 ± 7 days) from the date of first dose of study treatment; in the case of progressive disease (PD), a confirmatory image will be required 4 weeks later (eg, 13 weeks [91 ±7 days]) (see Section 6.3.1.4). Subsequent tumor imaging should be performed every 9 weeks (63 ± 7 days) or more frequently if clinically indicated and at the time of suspected disease progression. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days). Imaging should not be delayed for delays in cycle starts or extension of combination treatment cycle intervals.

Per RECIST v1.1 (see Appendix D), CR or PR should be confirmed by a repeat tumor imaging assessment. The tumor imaging for confirmation of response may be performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated.

Continue to perform imaging until whichever of the following occurs:

- The start of new anticancer treatment
- Withdrawal of consent
- Death
- End of the study (when responder or discontinuation status for all patients is known)

Patients who discontinue study treatment for reasons other than PD will continue post-treatment imaging studies for disease status follow-up at the same frequency as already followed, eg, every 9 or 12 weeks (± 7 days) depending on the length of treatment with the study combination drugs, until disease progression, start of a non–study anticancer treatment, withdrawal of consent to study participation, becoming lost to follow-up, death, or end of the study.

6.3.1.3. Assessment of Response by RECIST

RECIST v1.1 will be used by the Investigator as the primary measure for assessment of tumor response, date of disease progression, and as a basis for all protocol guidelines related to disease status. Note that irRECIST will be followed in cases of disease progression to assess continuation of treatment in clinically stable patients until progression is confirmed (see Section 6.3.1.4).

Details on RECIST v1.1, including evaluation of target and non-target lesions and definitions of response are provided in Appendix D.

6.3.1.4. Assessment of Response by Immune-Related RECIST

RECIST v1.1 will be adapted to account for the unique tumor response characteristics seen during treatment with pembrolizumab. Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by potentiating endogenous cancer-specific immune responses. The response patterns seen with such an approach may extend beyond the typical time course of responses seen with cytotoxic agents and can manifest a clinical response after an initial increase in tumor burden or even the appearance of new lesions. Standard RECIST v1.1 may, thus, not provide an accurate response assessment of immunotherapeutic agents such as pembrolizumab. irRECIST will be used by local site Investigators to assess tumor response and progression and make treatment decisions.
Therefore, RECIST v1.1 will be used with the following adaptations (ie, irRECIST) (see also Appendix E).

- If repeat imaging shows < 20% increase in tumor burden compared with nadir, stable or improved previous new lesion (if identified as cause for initial PD), and stable/improved non-target disease (if identified as cause for initial PD), treatment may be continued / resumed, and the next tumor imaging should be conducted according to the protocol schedule of every 9 weeks (63 ± 7 days) (or every 12 weeks [84 ± 7 days] if after 1 year).

- If repeat imaging confirms PD due to any of the scenarios listed below, patients will be discontinued from study therapy.

In determining whether or not the tumor burden has increased or decreased per irRECIST, the local site Investigator should consider all target and non-target lesions, as well as any incremental new lesion(s).

If ANY of the following occur by irRECIST on repeat imaging, PD is confirmed:

- Tumor burden remains ≥ 20% and at least 5-mm absolute increase compared with nadir
- Non-target disease resulting in initial PD is worse (qualitative)
- New lesion resulting in initial PD is worse (qualitative)
- Additional new lesion(s) since last evaluation
- Additional new non-target progression since last evaluation

In patients who have initial evidence of radiological PD, it is at the discretion of the treating physician whether to continue a patient on study treatment until repeat imaging is obtained. This clinical judgment decision should be based on the patient’s overall clinical condition, including performance status, clinical symptoms, and laboratory data. Patients may receive pembrolizumab treatment while waiting for confirmation of PD if they are clinically stable as defined by the following criteria:

- Absence of signs and symptoms indicating clinically significant progression of disease, including worsening of laboratory values
- No decline in ECOG performance status
- Absence of rapid progression of disease
- Absence of progressive tumor at critical anatomical sites (eg, cord compression) requiring urgent alternative medical intervention

When feasible, patients should not be discontinued until progression is confirmed. This allowance to continue treatment despite initial radiologic progression takes into account the observation that some patients can have a transient tumor flare in the first few months after the start of immunotherapy but with subsequent disease response. Patients who are deemed clinically unstable are not required to have repeat imaging for confirmation of progressive disease.
6.3.2. Efficacy Endpoints

6.3.2.1. Objective Response Rate

The primary efficacy endpoint is ORR, defined as the proportion of patients achieving CR or PR as assessed by the Investigator per RECIST (v1.1) (Appendix D). Tumor assessments after the initiation of further anticancer therapy are excluded for the assessment of best overall response. ORR by irRECIST (Section 6.3.1.4) will also be evaluated as a secondary endpoint.

6.3.2.2. Duration of Response

Duration of response will be evaluated as a secondary endpoint and is defined as the time from first documentation of CR or PR by RECIST v1.1 until: (1) the time of first documentation of disease progression per RECIST v1.1 (Appendix D); and (2) the time of first documentation of disease progression per irRECIST (Section 6.3.1.4). Note that date of progression based on either RECIST v1.1 or irRECIST may be overwritten in patients with OC if clinical criteria (Appendix F) indicate earlier progression as adjudicated by the Study Committee (Section 9.12). DOR by irRECIST (Section 6.3.1.4) will also be evaluated as a secondary endpoint.

6.3.2.3. Disease Control Rate

Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST v1.1 (Appendix D) and irRECIST (Section 6.3.1.4).

6.3.2.4. Progression-Free Survival

Progression-free survival will be assessed as a secondary endpoint and is defined as the time from enrollment to the earlier date of assessment of progression or death by any cause in the absence of progression based on: (1) the time of first documentation of disease progression per RECIST v1.1 (Appendix D); and (2) the time of first documentation of disease progression per irRECIST (Section 6.3.1.4). Note that date of progression based on either RECIST v1.1 or irRECIST may be overwritten in patients with OC if clinical criteria (Appendix F) indicate earlier progression as adjudicated by the Study Committee (Section 9.12).

6.3.2.5. Overall Survival

Overall survival will be assessed as a secondary endpoint and is defined as the time from date of first dose of study treatment to the date of death by any cause. New malignancy information will also be collected as part of this assessment (Section 7.2.10).

6.4. Pharmacokinetics

Pharmacokinetic samples will be collected from patients in both Phase 1 and Phase 2. An overview of sampling times for blood for PK analysis and concurrent ECG assessments, see Table 8 (Phase 1) and Table 9 (Phase 2).

For niraparib and major metabolite M1, the plasma samples from both Phase 1 and Phase 2 patients will be analyzed using liquid chromatography with mass spectroscopic detection (LC-MS-MS). For pembrolizumab in Phase 1, serum PK samples will be collected according to
the schedule defined in Section 6.4.1, and the samples in an individual patient may be analyzed using enzyme-linked immunosorbent assay (ELISA) if required for understanding of AEs.

The timing of each required sample collection listed in Table 7 and Table 8 for niraparib and major metabolite M1, and pembrolizumab for PK blood draws will be recorded.

Complete instructions for collection, processing, shipping, and handling of samples are detailed in the Study Manual.

6.4.1. Phase 1

For all patients in Phase 1, blood samples for measurements of plasma levels of niraparib and M1 will be obtained on Day 1 of Cycles 1 and 2 at the following time points: 0 (predose within 30 minutes) and 1 hour (±5 minutes), 2 hours (±5 minutes), 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours (±10 minutes), and 24 hours (±30 minutes) postdose.

In addition, blood samples for measurements of drug levels of niraparib and M1 will be obtained on Day 1 of Cycles 4 and 8 at the following time points: 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.

For all patients in Phase 1, blood samples for pembrolizumab will only be analyzed to understand an AE in an individual patient. The samples will be collected according to the following schedule, stored, and analyzed as needed. Predose blood samples for trough measurement of serum levels of pembrolizumab will be obtained at Cycles 1, 2, 4, and 8. All predose trough samples should be drawn within 30 minutes (±5 minutes) before infusion of pembrolizumab. Additional postdose peak PK serum samples will be drawn within 30 minutes after the end of the pembrolizumab infusion at Cycles 1 and 8. An additional single PK serum sample should be drawn at 24 hours (±30 minutes) (Day 2), 168 hours (±2 hours) (Day 8), and 336 hours (±4 hours) (Day 15) after Cycle 1 dosing.

6.4.2. Phase 2

For patients in Phase 2, blood samples for measurements of plasma levels of niraparib and M1 will be obtained on Day 1 of Cycles 1, 2, 4, and 8 at the following time points: 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.

6.4.3. Determination of Pharmacokinetic Parameters

Model predicted area under the concentration × time curves (AUCs) will be derived. Parameters of interest are AUC, minimum concentration (Cmin), maximum concentration (Cmax), clearance after oral administration (CL/F), volume of distribution after oral administration (V/F), AUC at steady state (AUCss), Cmin at steady state (Cmin,ss), and Cmax at steady state (Cmax,ss).

6.5. Biomarkers

Biomarker classifiers will be evaluated in archival OC and TNBC tumor samples obtained during screening. In addition, in the subset of patients who undergo serial biopsies, biomarkers will be evaluated in fresh tumor samples obtained at screening, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion and, whenever possible, at the time of disease progression. Core biopsies (3 to 6) are preferred; fine needle aspirate, frozen sample, plastic embedded sample, cell block, clot, or cytologic specimen will not be acceptable for analysis.
Blood samples for biomarker analysis will be obtained predose on Day 1 of Cycles 1 and Cycle 2, as well as at the EOT visit for analysis of tumor-related circulating biomarkers, such as circulating tumor cells and circulating tumor DNA. Biopsy samples will be collected and managed centrally, and tumor sections will be distributed to the designated translational research laboratories. DNA/RNA will be extracted from samples at a central location and analyzed for exploratory biomarkers including HRD mutational status of genes relevant for OC and TNBC, and RNA expression. Immunohistochemistry for PD-L1, as well as additional immune checkpoint proteins and markers for infiltrating immune cells will also be performed. Other exploratory analyses may be performed with the remaining samples.

HRD status, PD-L1 positivity and other biomarkers will be correlated with efficacy outcomes. Special attention will be devoted to subsets of OC and TNBC which may have distinct underlying DNA repair pathway deficiency (homologous recombination, nucleotide excision repair (NER), and mismatch repair (MMR) deficiency) and distinct drug responses.

Details on blood and tissue sample collection and analysis can be found in the Study Manual.

Samples from blood and tumor will be stored and may be used at a later time for biomarker testing, including potential to bridging to candidate companion diagnostic assays.
7. **STUDY CONDUCT**

7.1. **Schedule of Procedures**

A schedule of study procedures is provided in Table 6 and Table 7.
Table 6  Schedule of Events

<table>
<thead>
<tr>
<th>Procedure:</th>
<th>Cycle/Visit:</th>
<th>Screening</th>
<th>Cycle 1</th>
<th>Subsequent Cycles(^1)</th>
<th>EOT(^2)</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>2(^3)</td>
<td>8(^4)</td>
<td>15</td>
<td>Cycle n, Day 1</td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Archival tissue(^5)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional serial tumor biopsy(^6)</td>
<td>X (^6,7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for PK(^9)</td>
<td>X (^3)</td>
<td>X (^3)</td>
<td>X (^3)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor assessment (RECIST and irRECIST)</td>
<td>X (^7,10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC(^13)</td>
<td>X (^7)</td>
<td>X (^14)</td>
<td>X (^4)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum chemistry</td>
<td>X (^7)</td>
<td>X (^14)</td>
<td>X (^4)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coagulation</td>
<td>X (^7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X (^7,17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X (^7)</td>
<td>X (^14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td>X (^7)</td>
<td>X (^14)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td>X (^7,19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X (^7,20)</td>
<td>X (^20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X (^7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Subsequent Cycles for patients with tumor response to treatment.  
\(^2\) EOT (End of Treatment) Follow-up.  
\(^3\) Day 1 of Cycle n.  
\(^4\) Day 8 of Cycle n.  
\(^5\) Archival tissue includes optional serial tumor biopsy and archived tissue.  
\(^6\) Blood sample for exploratory biomarkers includes blood sample for PK.  
\(^7\) Blood sample for PK includes tumor assessment.  
\(^8\) Laboratory assessments include CBC, serum chemistry, urinalysis, Pregnancy test, and Urinalysis.  
\(^9\) ECG, Physical examination, and TSH, T3 or FT3, and FT4 are conducted on Day 30 + 7 days.  
\(^10\) Safety follow-up includes assessments conducted every 90 ± 14 days via telephone.
## Cycle/Visit: Screening

### Procedure:

<table>
<thead>
<tr>
<th>Day:</th>
<th>-21 to -1</th>
<th>1</th>
<th>2³</th>
<th>8⁴</th>
<th>15</th>
<th>Cycle n, Day 1</th>
<th>Cycle 2, Day 2⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom-directed physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vital signs, height, and weight²¹</td>
<td>X⁷</td>
<td>X</td>
<td>X²</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X³</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X</td>
<td>X</td>
<td>X³</td>
<td>X</td>
<td>X</td>
<td>X²²</td>
<td>X²²</td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered²³</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collected²⁴</td>
<td>X²⁵</td>
<td>X²⁵</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X²⁶</td>
<td>X²⁶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis</td>
<td></td>
<td></td>
<td></td>
<td>X²⁷</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECI = event of clinical interest; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; irRECIST = immune-related RECIST; IV = intravenous; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; OC = ovarian cancer; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; RP2D = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.

¹ Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.

² EOT visit should be completed within 7 days of the last dose of study drug.

³ Required for Phase 1 patients only.

⁴ Patients in Phase 1 are required to have an in-clinic visit on Day 8 with CBC done at the study center’s laboratory. For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an
adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

5 For patients who do not have archival tissue, fresh tissue sample is to be obtained at screening, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing.

6 In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. The serial biopsies at different time points should be on the same lesion preferably. A core biopsy is recommended; if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted as the screening biopsy.

7 Standard of care tests/procedures, including biopsy, radiographic scans, laboratory assessments (fasting glucose at baseline), ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first dose for these procedures with the exception of the biopsy, which may have been conducted within 12 weeks of first dose, and pregnancy test, which must be conducted within 72 hours of first dose) and any relevant guidelines (eg, diagnostic quality for scans).

8 Required on Day 1 of Cycle 2 only.

9 Blood samples are to be obtained for niraparib and major metabolite M1, pembrolizumab PK assessments; see Table 8 and Table 9 for the detailed schedule.

10 Tumor assessment per RECIST and irRECIST via CT or MRI (chest, abdomen, and pelvis [brain, only if clinically indicated]) required at screening, every 9 weeks (63 ±7 days) from Cycle 1/Day 1 for the first year, and then every 12 weeks (84 ±7 days) until progression; at the time of progression, a final follow up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.

11 May be done within 24 hours prior to the visit.

12 May be done at the study center’s local laboratory or at a laboratory local to the patient if the laboratory is included on FDA Form 1572.

13 If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly (thrombocytopenia or neutropenia) or once weekly (anemia) blood draws (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.

14 If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.

15 Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples.

16 Required for Phase 1 patients only. Required on Day 1 of Cycle 2 and Cycle 3 only.

17 Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 cycles for duration of study (ie, Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.

18 If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.
19 Blood samples for TSH, T3 or FT3, and FT4 are to be collected at screening, every 6 weeks from C1D1, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 30-day post-treatment safety follow-up only if assessment is clinically indicated.

20 Patients will undergo ECG monitoring as per Table 8 and Table 9.

21 Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only.

22 AEs are required to be captured through 30 days after cessation of study treatment, SAEs and ECIs (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

23 Administer pembrolizumab once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

24 See Table 10 for details of niraparib administration in Phase 1, and Section 3.1.2.1 for the RP2D of the combination. Niraparib dose may be escalated on or after C3D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL and neutrophils ≥ 1500/µL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

25 Niraparib dose administered upon completion of pembrolizumab infusion.

26 Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor’s medical monitor finds evaluation necessary for assessing niraparib-related risk for MDS/AML (eg, the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

27 It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s medical monitor. The study site must receive a copy of the hematologist’s report of aspirate/biopsy findings, which must include a classification according to WHO criteria,64 and other sample testing results related to MDS/AML.
### Table 7  Schedule of Events - Phase 2 Only

<table>
<thead>
<tr>
<th>Procedure:</th>
<th>Cycle/Visit:</th>
<th>Screening</th>
<th>Cycle 1</th>
<th>Subsequent Cycles&lt;sup&gt;1&lt;/sup&gt;</th>
<th>EOT&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>8&lt;sup&gt;3&lt;/sup&gt;</td>
<td>15 Cycle n, Day 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Archival tissue&lt;sup&gt;4&lt;/sup&gt;</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional serial tumor biopsy&lt;sup&gt;5&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;5,6&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;5&lt;/sup&gt;</td>
<td>X&lt;sup&gt;5&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td></td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;7&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for PK&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Tumor assessment (RECIST and irRECIST)</td>
<td></td>
<td>X&lt;sup&gt;6,9&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;10&lt;/sup&gt;</td>
<td>X&lt;sup&gt;11&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC&lt;sup&gt;12&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;3&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;14&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Serum chemistry</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Coagulation</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td></td>
<td>X&lt;sup&gt;6,15&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td></td>
<td>X&lt;sup&gt;6,17&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td></td>
<td>X&lt;sup&gt;6,18&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td></td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom-directed physical examination</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure:</td>
<td>Cycle/Visit:</td>
<td>Screening</td>
<td>Cycle 1</td>
<td>Subsequent Cycles&lt;sup&gt;1&lt;/sup&gt;</td>
<td>EOT&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Safety Follow-up</td>
<td>Follow-up Assessments (every 90 ± 14 days) via telephone</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>-----------</td>
<td>---------</td>
<td>-------------------------------</td>
<td>---------------</td>
<td>-----------------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>8&lt;sup&gt;1&lt;/sup&gt;</td>
<td>15</td>
<td>Cycle n, Day 1</td>
<td>30 + 7 days</td>
</tr>
<tr>
<td>Vital signs, height, and weight&lt;sup&gt;19&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;20&lt;/sup&gt;</td>
<td>X&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered&lt;sup&gt;21&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collection&lt;sup&gt;22&lt;/sup&gt;</td>
<td>X&lt;sup&gt;23&lt;/sup&gt;</td>
<td>X&lt;sup&gt;23&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X&lt;sup&gt;24&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;24&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;25&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AE = adverse event; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECI = event of clinical interest; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; irRECIST = immune-related RECIST; IV = intravenous; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; OC = ovarian cancer; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; RP2D = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.

<sup>1</sup> Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.

<sup>2</sup> EOT visit should be completed within 7 days of the last dose of study drug.

<sup>3</sup> For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

<sup>4</sup> For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing.

<sup>5</sup> In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. The serial biopsies at different time points should be on the same lesion preferably. A core biopsy is recommended; if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted as the screening biopsy.

<sup>6</sup> Standard of care tests/procedures, including biopsy, radiographic scans, laboratory assessments (fasting glucose at baseline), ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the...
tests/procedures meet the protocol-required timelines (ie, within 21 days of first dose for these procedures with the exception of the biopsy, which may have been conducted within 12 weeks of first dose, and pregnancy test, which must be conducted within 72 hours of first dose) and any relevant guidelines (eg, diagnostic quality for scans).

7 Required on Day 1 of Cycle 2 only.

8 Blood samples are to be obtained for niraparib and major metabolite M1, pembrolizumab PK assessments; see Table 8 and Table 9 for the detailed schedule.

9 Tumor assessment per RECIST and irRECIST via CT or MRI (chest, abdomen, and pelvis [brain, only if clinically indicated]) required at screening, every 9 weeks (63 ±7 days) from Cycle 1/Day 1 for the first year, and then every 12 weeks (84 ±7 days) until progression; at the time of progression, a final follow up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.

10 May be done within 24 hours prior to the visit.

11 May be done at the study center’s local laboratory or at a laboratory local to the patient if the laboratory is included on FDA Form 1572.

12 If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly (thrombocytopenia or neutropenia) or once weekly (anemia) blood draws (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.

13 If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.

14 Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples.

15 Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 cycles for duration of study (ie, Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.

16 If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.

17 Blood samples for TSH, T3 or FT3, and FT4 are to be collected at screening, every 6 weeks from C1D1, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 30-day post-treatment safety follow-up only if assessment is clinically indicated.

18 Patients will undergo ECG monitoring as per Table 8 and Table 9.

19 Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only.

20 AEs are required to be captured through 30 days after cessation of study treatment, SAEs and ECIs (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

21 Administer pembrolizumab once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.
22 See Table 11 for details of niraparib administration in Phase 2. See Section 3.1.2.1 for the RP2D of the combination. Niraparib dose may be escalated on or after C3D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL and neutrophils ≥ 1500/µL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

23 Niraparib dose administered upon completion of pembrolizumab infusion.

24 Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor's medical monitor finds evaluation necessary for assessing niraparib-related risk for MDS/AML (eg, the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

25 It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s medical monitor. The study site must receive a copy of the hematologist’s report of aspirate/biopsy findings, which must include a classification according to WHO criteria, (64) and other sample testing results related to MDS/AML.
### Table 8  Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 1

<table>
<thead>
<tr>
<th>Visit/Cycle:</th>
<th>Screen</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 4</th>
<th>Cycle 8</th>
<th>EOT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Day:</td>
<td>-21 to -1</td>
<td>1</td>
<td>2</td>
<td>8</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td>Anytime</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Niraparib dose</td>
<td>a</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Niraparib dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 hr (±5 min)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 hr (±5 min)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>4 hr (±5 min)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 hr (±5 min)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 hr (±10 min)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 hr (±30 min)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Pembrolizumab infusion</td>
<td>c</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Pembrolizumab infusion</td>
<td>d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 min (±5 minutes)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 hrs (±30 minutes)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>168 hrs (±2 hours)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>336 hour (±4 hours)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ECG = electrocardiogram; EOT = end of treatment; hr = hour; min = minute

a  To be obtained within 30 minutes of niraparib dose; ECG should be conducted prior to blood draws.
b  Sample to be obtained 2 hours ±15 minutes post niraparib dose.
c  To be obtained within 30 minutes (±5 minutes) before the start of infusion of pembrolizumab; samples will only be analyzed to understand any AE in an individual patient.
d  Samples will only be analyzed to understand an AE in an individual patient. Times are relative to the end of the infusion.
### Table 9  Pharmacokinetic Sampling and Electrocardiogram Schedule – Phase 2

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assessment:</td>
<td>ECG</td>
<td>ECG</td>
<td>Blood</td>
<td>ECG</td>
<td>Blood</td>
<td>ECG</td>
</tr>
<tr>
<td>Anytime</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pre Niraparib dose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Post Niraparib dose</td>
<td>2 hr (±15 min)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Abbreviations: ECG = electrocardiogram; EOT = end of treatment; hr = hour; min = minute

<sup>a</sup> To be obtained within 30 minutes of niraparib dose; ECG should be conducted prior to blood draws.

### Table 10  Niraparib Administration – Phase 1

<table>
<thead>
<tr>
<th>Cycle 1</th>
<th>Day</th>
<th>1</th>
<th>7</th>
<th>8</th>
<th>14</th>
<th>15</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niraparib 200 mg QD PO (Dose Level 1)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Niraparib 300 mg QD PO (Dose Level 2)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Niraparib 200 or 300 mg QD PO (Dose Level -1)&lt;sup&gt;a b&lt;/sup&gt;</td>
<td>X</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Niraparib 200 or 300 mg QD PO (Dose Level -2)&lt;sup&gt;a b&lt;/sup&gt;</td>
<td>X</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

Abbreviations: PO = oral; QD = once daily

<sup>a</sup> For all dose levels, niraparib will be administered during Cycle 1 in combination with pembrolizumab (200 mg IV on Day 1 of the 21-day cycle).

<sup>b</sup> Schedule of niraparib administration will be determined by agreement between Investigators and Sponsor (see Section 9.12).
Table 11  Niraparib Administration – Phase 2

<table>
<thead>
<tr>
<th>Cycle</th>
<th>N&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day</td>
<td></td>
</tr>
<tr>
<td>1 to 21</td>
<td></td>
</tr>
</tbody>
</table>

| Niraparib 200 mg QD PO Phase 2 | X                   |

Abbreviations:  PO = oral; QD = once daily

<sup>a</sup> The RP2D to be implemented in the Phase 2 portion of this study is niraparib 200 mg/day PO on days 1-21 and pembrolizumab 200 mg IV on day 1 of each 21-day cycle; niraparib dose may be escalated on or after C3D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/µL and neutrophils ≥ 1500/µL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.
7.2. Procedures by Visit

7.2.1. Screening (Day -21 to Day -1)

Standard of care tests/procedures, including laboratory assessments, ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first with the exception of the pregnancy test which must be conducted within 72 hours of first dose). Note that source documents must clearly identify the standard of care tests/procedures that are used for screening and the results of these tests/procedures must be entered in the eCRF.

At screening, the following procedures/tests will be performed:

- Obtain written informed consent
  - A single study ICF will be signed before any study procedures
- Inclusion/exclusion criteria review
- Demographics
- Medical/surgical/cancer/medication history
- Archival tumor sample for biomarker testing
  - For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing.
- Optional tumor biopsy for biomarker testing
  - For patients who consented to serial biopsies. See the Study Manual for details on sample collection and processing. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted in lieu of the screening biopsy.
- Sample collection (whole blood) for cytogenetic analysis.
- Tumor assessment (CT/MRI) for determination of measurable disease (RECIST v1.1)
  - Chest, abdomen, and pelvis (brain, if clinically indicated) CT (preferred method) or MRI (if clinically indicated). If the chest (applies to OC patients only) and/or brain (applies to OC and TNBC patients) CT/MRI is clear at screening, repeat imaging is not required in the absence of clinical indication requiring follow-up. Positron emission tomography (PET)/CT may be used according to RECIST v1.1 guidelines.
  - Scans performed prior to informed consent as part of routine clinical management are acceptable for use as initial tumor imaging if they are of diagnostic quality and are performed within 21 days prior to first dose date.
- Bone scans performed per standard of care.
- Laboratory assessments:
  - Serum pregnancy test for women of childbearing potential within 72 hours of first
dose of study treatment
  - CBC
  - Serum chemistry
  - TSH, T3 or FT3, and FT4
  - Coagulation
  - Serum CA-125 (OC patients only)
  - Urinalysis
- ECG
- Physical examination
- Vital signs (BP, pulse, and temperature) and weight
- Height
- ECOG performance status
- Concomitant medications
- AE monitoring

### 7.2.2. Cycle 1/Day 1
- Inclusion/exclusion criteria review
- Laboratory assessments (if screening assessments were performed within 72 hours of
Day 1, repeat testing is not required):
  - CBC
  - Serum chemistry
  - Serum CA-125 (OC patients only)
  - Urinalysis
- Symptom-directed physical examination
- Vital signs (BP, pulse, and temperature) and weight
- Concomitant medications
- AE monitoring
- Blood sample to be obtained predose for exploratory biomarkers
- Pembrolizumab study treatment administered after other visit procedures are
completed
• Blood samples for pembrolizumab PK assessment
  – **Phase 1 patients only**: Blood samples will be obtained predose (within 30 minutes) and within 30 minutes (±5 minutes) after the end of the pembrolizumab infusion.

• Niraparib first dose administered in clinic after completion of pembrolizumab infusion

• ECG
  – ECG monitoring to be conducted prior to the niraparib dose and 2 hours postdose. ECGs should be performed prior to PK blood draws.

• Blood samples for niraparib and M1 PK assessment
  – **Phase 1 patients only**: Patients at each dose level will undergo intensive niraparib and M1 PK evaluation with blood samples obtained at 0 (predose within 30 minutes) and at 1, 2, 4, and 6 hours (±5 minutes), and 8 hours (±10 minutes) postdose.
   
  – Phase 2 patients: Blood samples for niraparib and M1 PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.

7.2.3. **Cycle 1/Day 2 (Phase 1 Patients Only)**

• Blood samples for pembrolizumab PK assessment
  – **Phase 1 patients only**: Obtain blood sample 24 hours (±30 minutes) after the end of the pembrolizumab infusion.

• Blood sample for niraparib PK and M1 assessment
  – **Phase 1 patients only**: Obtain blood sample 24 hours (±30 minutes) postdose following the Cycle 1, Day 1 dose.

7.2.4. **Cycle 1/Day 8**

For Phase 1 patients, visit to be conducted at the study site to include:

• Vital signs (BP, pulse, and temperature) and weight

• Blood samples for pembrolizumab PK assessment obtained 168 hours (±2 hours) Day 8) after the end of the pembrolizumab infusion.

• CBC

• Concomitant medications

• AE monitoring

For Phase 2 patients:

• CBC: may be done at the study center’s local laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The
laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

7.2.5. **Cycle 1/Day 15**
- Laboratory assessments:
  - CBC
  - Serum chemistry
  - Coagulation (*Phase 1 patients only*)
- Symptom-directed physical examination
- Vital signs (BP, pulse, and temperature) and weight
- **Phase 1 patients only**: Blood samples for pembrolizumab PK will be obtained 336 hours (±4 hours) (Day 15) after the end of the pembrolizumab infusion.
- Concomitant medications
- AE monitoring

7.2.6. **Day 1, Subsequent Cycles**
- Tumor assessment (RECIST v1.1 and irRECIST)
  - Conduct radiographic evaluations of chest (all TNBC patients and OC patients with abnormal screening assessment or clinical indication), abdomen, pelvis, and brain (if abnormal at screening or clinical indication). The first on-study imaging assessment should be performed at 9 weeks (63 ±7 days) from the date of first dose of study treatment; in the case of PD, a confirmatory image will be required 4 weeks later (eg, 13 weeks [91 ±7 days]) (see Section 6.3.1.4). Subsequent tumor imaging should be performed every 9 weeks (63 ±7 days) or more frequently if clinically indicated and at the time of suspected disease progression. After 1 year of radiographic assessments, patients will have imaging performed every 12 weeks (84 ±7 days). Imaging should not be delayed for delays in cycle starts or extension of combination treatment cycle intervals. The same modality (ie, CT or MRI) should be used for a given patient throughout the study. PET/CT may be used according to RECIST v1.1 guidelines.
  - Patients with CR or PR should have the response confirmed by a repeat tumor imaging assessment performed at the earliest 4 weeks after the first indication of response, or at the next scheduled scan (ie, 9 weeks later), whichever is clinically indicated.
- Bone scans performed per standard of care.
- Laboratory assessments: may be done within 24 hours prior to the visit
  - CBC
  - Serum chemistry
Coagulation (**Phase 1 patients only; Day 1 of Cycles 2 and 3 only**)
- TSH, T3 or FT3, and FT4 (every 6 weeks)
- Serum CA-125 (OC patients only)
- Urinalysis

- Urine pregnancy test for females of childbearing potential conducted every 3 cycles for duration of study (ie, Cycle 4, Cycle 7, etc.). Symptom-directed physical examination
- Vital signs (BP, pulse, and temperature) and weight
- ECOG performance status
- Blood sample to be obtained prior to study treatment for exploratory biomarkers on Day 1 of Cycle 2 only
- Pembrolizumab study treatment administered after other visit procedures are completed
- Blood samples for pembrolizumab PK assessment
  - **Phase 1 patients (Cycles 2, 4, and 8 only):** Blood samples will be obtained predose (within 30 minutes). An additional sample will be obtained within 30 minutes after the end of the pembrolizumab infusion in Cycle 8.
- Niraparib dose administered in clinic after completion of pembrolizumab infusion
- ECG
  - Patients will undergo ECG monitoring on Cycle 2/Day 1 prior to the niraparib dose and 2 hours postdose and on Cycle 4/Day 1 and Cycle 8/Day 1 predose. ECGs should be performed prior to PK blood draws.
- Blood samples for niraparib and M1 PK assessment
  - **Phase 1 patients (Cycle 2 only):** Patients at each dose level will undergo intensive niraparib and M1 PK evaluation with blood samples obtained at 0 (predose within 30 minutes) and at 1, 2, 4, and 6 hours (±5 minutes), and 8 hours (±10 minutes) postdose.
  - **Phase 1 patients (Cycles 4 and 8 only):** Blood samples for niraparib and M1 PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.
  - Phase 2 patients (Cycles 2, 4, and 8 only): Blood samples for niraparib and M1 PK will be obtained at 0 (predose within 30 minutes) and 2 hours (±15 minutes) postdose.
- Optional tumor biopsy for biomarker testing
  - Sample to be obtained 1 to 3 days before or on Cycle 3/Day 1 prior to pembrolizumab infusion. See the Study Manual for details on sample collection and processing.
• Concomitant medications
• AE monitoring

7.2.7. Cycle 2, Day 2 (Phase 1 Patients Only)
• Blood sample for niraparib and M1 PK assessment
  – **Phase 1 patients only**: Obtain blood sample 24 hours (±30 minutes) postdose following the Cycle 2, Day 1 dose.

7.2.8. End of Treatment (within 7 days of last dose)
• Optional fresh tumor sample
  – If possible, sample to be obtained at the time of disease progression. See the Study Manual for details on sample collection and processing.
• Sample collection (whole blood) for cytogenetic analysis.
• Tumor assessment (RECIST and irRECIST)
  – A final set of radiographic images is required at the time of disease progression, if not done within the last 4 weeks.
  – If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, radiographic scans/images and CA-125 testing (OC patients only) should continue every 9 weeks (63 ±7 days) through 1 year and every 12 weeks (84 ±7 days) thereafter.
• ECG
• Laboratory assessments:
  – CBC
  – Serum chemistry
  – TSH, T3 or FT3, and FT4
  – Serum CA-125 (OC patients only)
  – Urinalysis
• Physical examination
• Vital signs (BP, pulse, and temperature) and weight
• ECOG performance status
• Concomitant medications
• AE monitoring
• Niraparib study treatment collected
7.2.9. **Safety Follow-up (30 days [+ 7 days] Post-treatment)**

- Tumor assessment (RECIST and irRECIST) and serum CA-125 (OC patients only)
  - Patients who discontinue treatment for reasons other than disease progression, death, withdrawal of consent, or loss to follow-up will be followed for disease assessments, including radiographic scans and CA-125 testing (OC patients only), per the specified schedule.
- Symptom-directed physical examination
- Laboratory assessments: may be done at the study center’s local laboratory or at a laboratory local to the patient if the laboratory is included on FDA Form 1572:
  - CBC
  - Serum chemistry
  - TSH, T3 or FT3, and FT4 (only if clinically indicated)
  - Serum CA-125 (OC patients only)
  - Urine pregnancy test
  - Urinalysis
- Vital signs (BP, pulse, and temperature) and weight
- Concomitant medications
- AE monitoring – AEs are required to be captured through 30 days after cessation of study treatment, SAEs, and ECI (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

7.2.10. **Follow-up Assessments**

- Tumor assessment (RECIST and irRECIST) and serum CA-125 (OC patients only)
  - Patients who discontinue treatment for reasons other than disease progression, death, withdrawal of consent, or loss to follow-up will be followed for disease assessments, including radiographic scans and CA-125 testing (OC patients only), per the specified schedule.
- Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples (see Section 7.2.4).
- AE monitoring – SAEs and ECI (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy)
• Subsequent anti-cancer therapy information are required to be captured through post-treatment if the patient starts alternate anticancer therapy

• Pregnancy status assessed (through Day 120 post-treatment)

• Survival/new malignancy assessment
  – Patients will be followed by telephone every 90 days for survival status and the occurrence of any new malignancies

7.2.11. Unscheduled Assessments

• For any patient diagnosed with MDS/AML while on study, a bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis. See Section 6.1.8 for details.
8. STATISTICAL METHODS

Details of the statistical analyses presented below will be provided in the study’s statistical analysis plan (SAP). A change to the data analysis methods described in the protocol will require a protocol amendment only if it alters a principal feature of the protocol. The SAP will be finalized prior to database lock. Any changes to the methods described in the plan will be described and justified in the final clinical study report.

8.1. Study Populations

Three analysis populations will be defined as follows:

- Safety Population: All patients who receive any amount of study drug. The assessment of DLTs in Phase 1 will include only those patients completing the first cycle of therapy, unless the patient discontinued study drug due to a DLT.
- Full Analysis Set (FAS): All patients who receive any amount of study drug. The primary analysis of efficacy endpoints will be performed on the FAS population.
- Per-Protocol Population: All patients who receive at least two cycles of study drug, have protocol-required post-baseline disease assessments and have no major protocol violations that would impact efficacy evaluations. Supportive analyses of efficacy endpoints will be performed on the per-protocol population.

8.2. Demographics, Medical History, Baseline Characteristics, and Concomitant Medications

Demographics, baseline characteristics, and medical history information will be summarized by dose level for Phase 1, and by indication for Phase 2, for the Safety population using descriptive statistics. No formal statistical comparisons will be performed.

Demographic, baseline characteristics, and medical history data for each patient will be provided in data listings.

8.3. Safety Analyses

The following key safety parameters will be evaluated by study phase, pooled dose schedule across phases, by disease type, and overall, unless noted otherwise:

- Dose-limiting toxicities during the first cycle (ie, during the first 21 days of treatment, ie, Cycle 1/Day 1 through Cycle 1/Day 21) for Phase 1
- Incidence of TEAEs during the first cycle compared to the second and subsequent cycles
- Incidence of TEAEs occurring while patients are on treatment or up to 30 days after the last dose of study drug
- Incidence of SAEs and ECI occurring while patients are on treatment or up to 90 days after the last dose of study drug
- Incidence of any new malignancies
Changes in clinical laboratory parameters (hematology, chemistry, thyroid function, coagulation, urinalysis), vital signs, ECOG performance status, ECG parameters, physical examinations, and usage of concomitant medications

All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system and displayed in tables and data listings using system organ class and preferred term. Analyses of AEs will be performed for those events that are considered treatment-emergent, where treatment-emergent is defined per protocol as any AE with onset beginning at the day of first administration of study drug, throughout the treatment period until 30 days after the last dose of study drug, any SAE or ECI that occurs through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), or any event that was present at baseline but worsened in intensity or was subsequently considered drug-related by the Investigator through the end of the study. DLTs will be tabulated by dose level in Phase 1.

The number and percentage of patients with any TEAE, with any TEAE assessed by the Investigator as related to treatment (definite, probable, or possible relationship), and with any SAE will be summarized by treatment group and overall. In these tabulations, each patient will contribute only once (ie, the most related occurrence or the most intense occurrence) to each of the incidence rates in the descriptive analysis, regardless of the number of episodes. No formal hypothesis-testing analysis of AE incidence rates will be performed.

The occurrence of and reasons for any requirement for dose interruption or modification will be tabulated, and distinguished as to presumptive causality from niraparib or pembrolizumab, if known.

All AEs occurring on-study will be listed in patient data listings. By-patient listings also will be provided for the following: patient deaths, SAEs, and AEs leading to withdrawal.

8.4. Pharmacokinetic Analyses

All patients who receive at least 1 dose of study drug and have measureable drug concentrations will be included in PK analyses.

Non-compartmental methods will be used to evaluate the PK characteristics of niraparib and its major metabolite M1, and pembrolizumab as appropriate. Pharmacokinetic parameters to be determined will include AUC, AUC<sub>ss</sub>, C<sub>min</sub>, C<sub>max</sub>, CL/F, V<sub>Z</sub>/F, C<sub>min,ss</sub>, and C<sub>max,ss</sub>. Plasma concentrations and PK parameter estimates will be presented using descriptive statistics by dose level.

8.5. Post-Treatment Analyses

Descriptive summary statistics will be used to summarize post-treatment data (ie, any new occurrence of MDS/AML).

8.6. Efficacy Analyses

All efficacy endpoints will be summarized on the Phase 2 population by disease type; in addition, data may be pooled for patients in Phase 1 and Phase 2, by disease type. All analyses will include summary statistics, including number and percentage for categorical variables and
number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables. Two-sided exact 90% confidence intervals (CIs) based on the Clopper-Pearson method \(^\text{(67)}\) will be provided where appropriate. Time-to-event analyses will be performed using Kaplan-Meier (KM) methods. Comparisons in the Phase 1 portion of the study will be made using descriptive statistics. As the Phase 2 portion of the study is single-arm, any statistical analysis to be performed among subgroups is for descriptive and future study purposes.

### 8.6.1. Primary Efficacy Parameter

The primary efficacy endpoint will be ORR, defined as the achievement of CR or PR using RECIST \((v1.1)\), as assessed by the Investigator. Point estimates and 1-sided 95% CI, corresponding to the specifications of the sample size calculation will be provided. The primary analysis will be performed for each patient cohort and no multiplicity adjustment will be made since separate inferences will be drawn for each cohort.

### 8.6.2. Secondary Efficacy Parameter(s)

Objective response rate as assessed by the Investigator using irRECIST will be assessed as a secondary endpoint.

Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving best overall response of CR, PR, or SD as assessed by the Investigator per RECIST \((v1.1)\) and irRECIST, with point estimates and 2-sided 95% CIs.

Duration of response, PFS and OS will be presented through use of summary statistics using KM methods, to include 25\(^{\text{th}}\), 50\(^{\text{th}}\) (median), and 75\(^{\text{th}}\) percentiles and associated 2-sided 95% CIs, number of events and number of censored observations. DOR and PFS will be defined by both RECIST \((v1.1)\) and irRECIST criteria, based on the date of PD that will be used to determine duration, and will be analyzed separately by both criteria.

### 8.7. Biomarker Analyses

For each patient in the study, blood and tumor samples will be prospectively collected, evaluated and archived to support exploratory biomarker analysis. PD-L1 expression (retrospective analysis), HRD score, immune cell infiltrates, and other exploratory biomarkers will be correlated with response.

### 8.8. Probability of Dose Escalation

Based on the dose escalation schema planned for the Phase 1 portion of the study as outlined in Section 3.1.2, the following decision rules will be used to determine if a dose is or is not increased:
Table 12   Dose Escalation Decision Rules

<table>
<thead>
<tr>
<th>First 6 Patients</th>
<th>Second 6 Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of</td>
<td>Number of</td>
</tr>
<tr>
<td>Hematologic DLTs</td>
<td>Non-hematologic DLTs</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Any</td>
</tr>
</tbody>
</table>

Abbreviations: DLT = dos-limiting toxicity; NA = not applicable; second 6 patients are not required to be enrolled.

To model the probabilities of dose escalation given various rates of true hematological and non-hematological DLTs, let \( X \) = number of hematological DLTs observed and \( Y \) = number of non-hematological DLTs observed. Then the joint distribution of \((X,Y)\) is multinomial (trinomial) with parameters: \( N \) = number of patients evaluated, \( PH \) = true probability of a hematological DLT, and \( PN \) = true probability of a non-hematological DLT. There are 2 probabilities to calculate. First, the probability of escalation based on the first 6 patients enrolled. Second is the conditional probability of escalation based on the second 6 patients enrolled, given \((X,Y) = (1,1)\) or \((0,2)\) in the first 6 patients. The probability of dose escalation is the sum of these 2 probabilities. It is assumed that a given patient cannot have more than 1 DLT, and that hematologic DLTs take precedence over non-hematologic DLTs. The following graph presents the probabilities of dose escalation for ranges of true rates of DLTs, where it is assumed the true rates will be approximately 18% (range 12-24%) for hematologic DLTs and 5% (range 3-7%) for non-hematologic DLTs.

As shown in Figure 2, the probability of dose escalation decreases as the DLT rate increases, as expected. Over the restricted range of DLT rates, the probabilities are close to a linear relationship as the true DLT rates increase.
Figure 2  Probability of Dose Escalation in a 6 + 6 Design

Figure 3 shows the probability of dose escalation for a standard 3+3 escalation design, contrasted with the 6 + 6 design, at the fixed rate of 0.05 for non-hematologic DLTs (the anticipated rate). As can be seen, the protocol-specified 6 + 6 design has a similar probability of escalation as the 3+3 design, and is, in fact, somewhat more conservative for hematologic DLT rates >0.15.
8.9. **Interim Analyses**

To minimize the risk of exposing patients to an ineffective treatment, a series of response assessments will be performed when 6, 12, and 18 of 48 Phase 2 patients from each cancer type have at least 2 post-baseline tumor assessments. A formal decision regarding futility, which could result in stopping the study early, will be conducted separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier response assessments, however, will inform the conduct of the formal interim analysis as follows: If no responder is observed in all three response assessments from 6, 12, and 18 patients, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If $\geq 1$ responder is observed in any single response assessment from 6, 12, or 18 patients, then enrollment will not be curtailed. The decision rule regarding the formal interim analysis at N=24 is as follows: If there are fewer than 3 responders out of 24, enrollment may be closed and the corresponding cohort may be stopped for futility. Otherwise, the study will continue to the planned enrollment of 48 patients.

8.10. **Determination of Sample Size**

Phase 1: In the Phase 1 portion of this study, 14 patients with advanced TNBC or OC were enrolled in Dose Level 1 or Dose Level 2. Twelve patients were eligible for DLT evaluation. In Dose Level 1, 1 of 6 DLT-eligible patients experienced multiple DLTs including Grade 3 anemia, Grade 4 neutropenia, and Grade 4 thrombocytopenia. In Dose Level 2, 1 of 6 DLT-eligible patients experienced 1 DLT, Grade 4 thrombocytopenia; an additional patient experienced an
adverse event that was deemed to be a DLT-equivalent; the patient had epistaxis on C1D17 and Grade 4 thrombocytopenia on C2D1.

Phase 2: A total of approximately 96 evaluable patients (approximately 48 patients in each tumor type) will be enrolled to ensure understanding of the activity of the combination treatment. With 48 patients treated in each cohort, observed 12 responses (CR and/or PR) at the final analysis will rule out a 15% response rate. The study has approximately 82%/94% power for each cohort to rule out a ≤15% ORR (null hypothesis) when the true ORR is 30%/35% at the 10% type I error rate (two-sided).

The following table shows the two-sided 90% CI for ORR based on 48 subjects for different observed response rates.

<table>
<thead>
<tr>
<th>Number of Observed Responses</th>
<th>ORR Estimate</th>
<th>90% CI for ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>16.7%</td>
<td>(8.6%, 28.1%)</td>
</tr>
<tr>
<td>10</td>
<td>20.8%</td>
<td>(11.8%, 32.8%)</td>
</tr>
<tr>
<td>12</td>
<td>25.0%</td>
<td>(15.1%, 37.3%)</td>
</tr>
<tr>
<td>14</td>
<td>29.2%</td>
<td>(18.6%, 41.8%)</td>
</tr>
<tr>
<td>16</td>
<td>33.3%</td>
<td>(22.2%, 46.1%)</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; ORR = objective response rate
9. **ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS**

9.1. **Data Quality Assurance**

The Sponsor (or designee) will conduct a study initiation visit to verify the qualifications of the Investigator, inspect the facilities, and inform the Investigator of responsibilities and procedures for ensuring adequate and correct documentation.

The Investigator must prepare and maintain adequate and accurate records of all observations and other data pertinent to the clinical study for each study participant. Frequent communication between the clinical site and the Sponsor is essential to ensure that the safety of the study is monitored adequately. The Investigator will make all appropriate safety assessments on an ongoing basis. The Sponsor’s Medical Monitor may review safety information as it becomes available throughout the study.

All aspects of the study will be carefully monitored with respect to GCP and standard operating procedures for compliance with applicable government regulations. The Study Monitor will be an authorized individual designated by the Sponsor. The Study Monitor will have access to all records necessary to ensure integrity of the data and will periodically review the progress of the study with the Principal Investigator.

9.2. **Access to Source Data/Documents**

An electronic data capture system to manage data collection will be utilized during this study. The electronic data capture system is a software tool designed to ensure quality assurance and facilitate data capture during clinical studies. The system is fully compliant with Code of Federal Regulations 21 Part 11.

The Investigator will ensure the accuracy, completeness, and timeliness of the data reported to the Sponsor. Data collection processes and procedures will be reviewed and validated to ensure completeness, accuracy, reliability, and consistency. A complete audit trail will be maintained of all data changes. The Investigator or designee will cooperate with the Sponsor’s representative(s) for the periodic review of study documents to ensure the accuracy and completeness of the data capture system at each scheduled monitoring visit.

Electronic consistency checks and manual review will be used to identify any errors or inconsistencies in the data. This information will be provided to the respective study sites by means of electronic or manual queries.

The Investigator or designee will prepare and maintain adequate and accurate study documents (medical records, ECGs, AE, and concomitant medication reporting, raw data collection forms, etc.) designed to record all observations and other pertinent data for each patient receiving study treatment.

The Investigator will allow Sponsor representatives, contract designees, authorized regulatory authority inspectors, and the IRB/IEC to have direct access to all documents pertaining to the study.
9.3. Archiving Study Documents

Essential clinical documents will be maintained to demonstrate the validity of the study and the integrity of the data collected. Master files should be established at the beginning of the study, maintained for the duration of the study, and retained according to the appropriate regulations. According to International Conference on Harmonisation (ICH) guidelines, essential documents should be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the study treatment.

9.4. Good Clinical Practice

This study will be conducted in accordance with the ICH for good clinical practices (GCPs) and the Declaration of Helsinki (Version 2008). The clinical study will also be carried out in accordance with national and local regulatory requirement(s).

9.5. Informed Consent

Before each patient is enrolled in the clinical study, written informed consent will be obtained from the patient according to the regulatory and legal requirements of the participating country. As part of this procedure, the Investigator must explain orally and in writing the nature, duration, and purpose of the study, and the action of the study treatment in such a manner that the patient is aware of the potential risks, inconveniences, or AEs that may occur. The patient should be informed that he or she is free to withdraw from the study at any time. The patient will receive all information that is required by regulatory authorities and ICH guidelines. The Investigator or designee will provide the Sponsor with a copy of the IRB/IEC-approved ICF prior to the start of the study.

The ICF must be signed and dated; one copy will be given to the patient and the Investigator will retain a copy as part of the clinical study records. The Investigator will not undertake any investigation specifically required for the clinical study until written consent has been obtained. The terms of the consent and when it was obtained must also be documented.

If a protocol amendment is required, then the ICF may need to be revised to reflect the changes to the protocol. If the ICF is revised, it must be reviewed and approved by the responsible IRB/IEC and signed by all patients subsequently enrolled in the clinical study as well as those currently enrolled in the clinical study.

9.6. Protocol Approval and Amendment

Before the start of the study, the study protocol and/or other relevant documents will be approved by the IEC/IRB/Competent Authorities, in accordance with local legal requirements. The Sponsor must ensure that all ethical and legal requirements have been met before the first patient is enrolled in the study.

This protocol is to be followed exactly. To alter the protocol, amendments must be written, receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority approval prior to implementation (if appropriate). In the United States, following approval, the protocol amendment(s) will be submitted to the IND under which the study is being conducted.
Administrative changes (not affecting the patient benefit/risk ratio) may be made without the need for a formal amendment. All amendments will be distributed to all protocol recipients, with appropriate instructions.

9.7. Patient Confidentiality and Data Protection

All clinical study findings and documents will be regarded as confidential. Study documents (protocols, IBs, and other material) will be stored appropriately to ensure their confidentiality. The Investigator and members of his/her research team (including the IRB/IEC) must not disclose such information without prior written approval from the Sponsor, except to the extent necessary to obtain informed consent from patients who wish to participate in the study or to comply with regulatory requirements.

The anonymity of participating patients must be maintained. Patients will be specified on study documents by their enrollment number or birth date, not by name. Documents that identify the patient (e.g., the signed informed consent document) must be maintained in confidence by the Investigator.

9.8. Study Monitoring

Monitoring and auditing procedures approved by the Sponsor will be followed in order to comply with GCP guidelines. On-site checking of the eCRFs for completeness and clarity, cross-checking with source documents, and clarification of administrative matters will be performed.

The study will be monitored by the Sponsor or its designee. Monitoring will be done by personal visits from a representative of the Sponsor (site monitor) who will review the eCRFs and source documents. The site monitor will ensure that the investigation is conducted according to protocol design and regulatory requirements by frequent site visits and by communications (letter, telephone, and fax).

All unused study treatment and other study materials will be returned to the Sponsor after the clinical phase of the study has been completed.

9.9. Audits and Inspections

Regulatory authorities, the IRB/IEC, and/or the Sponsor’s clinical quality assurance group, or its designee, may request access to all source documents, eCRFs, and other study documentation for on-site audit or inspection. Direct access to these documents must be guaranteed by the Investigator, who must provide support at all times for these activities.

9.10. Ethical Considerations

The study will be conducted in accordance with ethical principles founded in the Declaration of Helsinki. The IRB/IEC will review all appropriate study documentation in order to safeguard the rights, safety, and well-being of the patients. The study will only be conducted at sites where IRB/IEC approval has been obtained. The protocol, Investigator Brochure, informed consent, advertisements (if applicable), written information given to the patients, safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB/IEC by the Investigator.
9.11. **Publication Policy**

Information regarding publication of study results is contained in the Clinical Trial Agreement for this study.

9.12. **Study Committee**

A Study Committee comprised of Investigators and Sponsor representatives will be established to provide review and assessment of the study data on an ongoing basis and to safeguard the interest and safety of the participating patients in the study. The details on membership, key responsibilities, and corresponding procedures are provided in the Study Committee charter.
10. REFERENCE LIST


57. Data on file at Tesaro.


APPENDIX A. ASCO TNBC GUIDANCE 2010(70)


Recommendations.—The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls.
### APPENDIX B. DRUGS KNOWN TO INHIBIT OR INDUCE CYP1A2 OR ARE SUBSTRATES OF CYP1A2

<table>
<thead>
<tr>
<th>Inhibitors of CYP1A2</th>
<th>Moderate</th>
<th>Weak</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strong</strong></td>
<td>≥ 2 but &lt; 5-fold increase in AUC or 50%-80% decrease in CL</td>
<td>≥ 1.25 but &lt; 2-fold increase in AUC or 20%-50% decrease in CL</td>
</tr>
<tr>
<td>Strong</td>
<td>≥ 5-fold increase in AUC or &gt; 80% decrease in CL</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin, enoxacin, fluvoxamine</td>
<td>Methoxsalen, mexiletine, oral contraceptives, phenylpropanolamine, thiabendazole, vemurafenib, zileuton</td>
<td>Acyclovir, allopurinol, caffeine, cimetidine, Daidzein, disulfiram, Echinacea, famotidine, norfloxacin, propafenone, propranolol, terbinafine, ticlopidine, verapamil</td>
</tr>
<tr>
<td>Moderate</td>
<td>50%-80% decrease in CL</td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>20%-50% decrease in AUC</td>
<td></td>
</tr>
<tr>
<td>Inducers of CYP1A2</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td>Strong</td>
<td>80% decrease in AUC</td>
<td></td>
</tr>
<tr>
<td>Weak</td>
<td>50%-80% decrease in AUC</td>
<td></td>
</tr>
<tr>
<td>Strong</td>
<td>20%-50% decrease in AUC</td>
<td></td>
</tr>
<tr>
<td>Inducers</td>
<td>Montelukast, phenytoin, smokers versus non-smokers</td>
<td>Moricizine, omeprazole, phenobarbital</td>
</tr>
<tr>
<td>Substrates of CYP1A2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitive substrates</td>
<td>Substrates with narrow therapeutic range</td>
<td></td>
</tr>
<tr>
<td>Alosetron, caffeine, duloxetine, melatonin, ramelteon, tacrine, tizanidine</td>
<td>Theophylline, tizanidine, warfarin</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AUC = area under the curve; CL = clearance.

Source: (68)

a Sensitive CYP substrates refers to drugs whose plasma AUC values have been shown to increase 5-fold or higher when coadministered with a known CYP inhibitor or AUC ratio in poor metabolizers vs. extensive metabolizers is greater than 5-fold.

b CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety concerns (eg, Torsades de Pointes).
APPENDIX C. DRUGS THAT ARE SUBSTRATES OR INHIBITORS OF P-GLYCOPROTEIN

<table>
<thead>
<tr>
<th>Substrates</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aliskiren</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>Ambrisentan</td>
<td>Azithromycin</td>
</tr>
<tr>
<td>Colchicine</td>
<td>Captopril</td>
</tr>
<tr>
<td>Dabigatran etexilate</td>
<td>Carvedilol</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Clarithromycin</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Conivaptan</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>Cyclosporine</td>
</tr>
<tr>
<td>Imatinib</td>
<td>Diltiazem</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Dronedarone</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>Erythromycin</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>Felodipine</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Itraconazole</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>Ketoconazole</td>
</tr>
<tr>
<td>Saxagliptin</td>
<td>Lopinavir and Ritonavir</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Quercetin</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Talinolol</td>
<td>Ranolazine</td>
</tr>
<tr>
<td>Tolvaptan</td>
<td>Ticagrelor</td>
</tr>
<tr>
<td>Topotecan</td>
<td>Verapamil</td>
</tr>
</tbody>
</table>

Source: (68)
APPENDIX D.  RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST), V1.1

Response Criteria by RECIST v1.1

Evaluation of Target Lesions

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Note: If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).

Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
### Table 13  
**RECIST Response for Patients with Measurable Disease (ie, Target Disease)**

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
<th>Best Overall Response when Confirmation is Required*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/Non-PD</td>
<td>No</td>
<td>PR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>SD</td>
<td>documented at least once &gt; 4 wks. from baseline**</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or No</td>
<td>PD</td>
<td>no prior SD, PR or CR</td>
</tr>
<tr>
<td>Any</td>
<td>PD***</td>
<td>Yes or No</td>
<td>PD</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**  
CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease

* See RECIST v1.1 publication (65) for further details on what is evidence of a new lesion.
** Only for non-randomized trials with response as primary endpoint.
*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

*Note:* Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document the objective progression even after discontinuation of treatment.

### Table 14  
**RECIST Response for Patients with Non-Measurable Disease (ie, Non-Target Disease)**

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/Non-PD</td>
<td>No</td>
<td>Non-CR/Non-PD*</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>not evaluated</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

**Abbreviations:**  
CR = complete response; PD = progressive disease

*‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised
APPENDIX E. IMMUNE-RELATED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (irRECIST)

Immune-related RECIST will be used by local site Investigators to assess tumor response and progression and make treatment decisions.

Table 15 provides a high-level summary of the imaging procedures and treatment decisions to be made based on evidence of progression of disease per RECIST v1.1. See also details provided in Section 6.3.1.4.

Table 15  Imaging and Treatment after First Radiologic Evidence of Progressive Disease

<table>
<thead>
<tr>
<th>Timing of Imaging</th>
<th>Clinically Stable</th>
<th>Clinically Unstable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tumor Imaging</td>
<td>Treatment</td>
</tr>
<tr>
<td>1st radiologic evidence of PD</td>
<td>Repeat imaging at ≥ 4 weeks at site to confirm PD</td>
<td>May continue study treatment at the local site Investigator’s discretion while awaiting confirmatory tumor imaging</td>
</tr>
<tr>
<td>Repeat tumor imaging confirms PD</td>
<td>No additional imaging required</td>
<td>Discontinue treatment</td>
</tr>
<tr>
<td>Repeat tumor imaging shows SD, PR or CR</td>
<td>Continue regularly scheduled imaging assessments</td>
<td>Continue study treatment at the local site Investigator’s discretion</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; irRECIST = immune-related Response Criteria in Solid Tumors; N/A = not applicable; PD = progressive disease; PR = partial response; RECIST = Response Criteria in Solid Tumors; SD = stable disease
APPENDIX F. ASSESSMENT OF RESPONSE IN OVARIAN CANCER BY GYNECOLOGIC CANCER INTERGROUP (GCIG) CRITERIA

Because of the pelvic location of the primary tumor in patients with OC and the frequent occurrence of peritoneal disease, imaging may not always be reliable for documentation of PD in patients with OC. Criteria other than RECIST may be applicable to define PD in these patients. For this protocol, the GCIG criteria for disease progression will also be considered for patients with OC. Based on these criteria, PD may also be determined if at least 1 of the following criteria is met:

1. Additional diagnostic tests (eg, histology/cytology, ultrasound techniques, endoscopy, positron emission tomography) identify new lesions or determine existing lesions qualify for unequivocal PD AND CA-125 progression according to GCIG criteria.

2. Definitive clinical signs and symptoms of PD unrelated to nonmalignant or iatrogenic causes ([a] intractable cancer-related pain; [b] malignant bowel obstruction/worsening dysfunction; or [c] unequivocal symptomatic worsening of ascites or pleural effusion) AND CA-125 progression according to GCIG criteria.

Abnormal CA-125 levels on-study do not represent disease progression; however, they may prompt imaging if clinically indicated. Progressive disease will not be diagnosed in case of CA-125 progression in the absence of at least 1 of the criteria defined above.

The Investigator will describe how PD was diagnosed in the eCRF.

The date of PD is defined as the earliest time point when one of the PD criteria is met. If CT/MRI shows existing (baseline) lesions that only equivocally suggest PD and additional diagnostic tests are required to determine unequivocal PD, the official date of PD will be the date PD was unequivocally determined. Alternatively, with new lesions (except ascites and effusions) that are initially equivocal that are later unequivocally determined, the date of progression will be the date the lesion was initially identified.
## APPENDIX G. EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS

<table>
<thead>
<tr>
<th>Description</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully active, able to carry on all pre-disease performance without restriction.</td>
<td>0</td>
</tr>
<tr>
<td>Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, ie, light house work, office work.</td>
<td>1</td>
</tr>
<tr>
<td>Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.</td>
<td>2</td>
</tr>
<tr>
<td>Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.</td>
<td>3</td>
</tr>
<tr>
<td>Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.</td>
<td>4</td>
</tr>
</tbody>
</table>

Source: [69]
# Statistical Analysis Plan

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol No:</td>
<td>3000-PN162-01-001</td>
</tr>
<tr>
<td>Project Id:</td>
<td>TSRNIRPD-NIRPD1</td>
</tr>
<tr>
<td>Version Date:</td>
<td>1.0/11-JUL-2016</td>
</tr>
<tr>
<td>Version No.:</td>
<td>v1.0</td>
</tr>
</tbody>
</table>

**Title:** Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

<table>
<thead>
<tr>
<th>CRF Version No./Date:</th>
<th>0.100/25-JAN-2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP No.</td>
<td>1.0</td>
</tr>
</tbody>
</table>

## 1.0 Approvals

<table>
<thead>
<tr>
<th>Sponsor Name:</th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Representative/ Title:</td>
<td></td>
</tr>
<tr>
<td>Signature /Date:</td>
<td></td>
</tr>
</tbody>
</table>

| Project Manager/Title: | 
| Signature /Date: | 

| Biostatistician / Title (Owner): | 
| Signature /Date: |
Table of Contents

1.0 Approvals ................................................................. 1
Table of Contents ................................................................................................................. 2
2.0 Purpose ........................................................................... 4
3.0 Scope ............................................................................ 4
4.0 Introduction ..................................................................... 4
4.1 Changes from Protocol .................................................. 4
5.0 Study Objectives .......................................................... 4
  5.1 Phase 1 .......................................................................... 4
    5.1.1 Primary Objectives .................................................. 4
    5.1.2 Secondary Objectives .............................................. 5
  5.2 Phase 2 .......................................................................... 5
    5.2.1 Primary Objective: .................................................. 5
    5.2.2 Secondary Objective: .............................................. 5
  5.3 Exploratory Objectives ................................................. 5
6.0 Study Design ............................................................... 5
  6.1 Sample Size Considerations ......................................... 7
  6.2 Randomization ............................................................ 7
7.0 Study Variables and Covariates ...................................... 7
  7.1 Primary Variables ....................................................... 7
    Phase 1 ........................................................................... 7
    Phase 2 ........................................................................... 8
  7.2 Secondary Variables ................................................... 8
    7.2.1 Efficacy ................................................................. 8
    7.2.2 Safety ...................................................................... 8
    7.2.3 Exploratory Endpoints ........................................... 8
  7.3 Pharmacokinetic Variables .......................................... 8
    7.3.1 Presentation of Pharmacokinetic Concentrations ...... 10
8.0 Definitions ...................................................................... 10
9.0 Analysis Sets ............................................................... 14
  9.1 Screening Analysis Set ................................................. 14
  9.2 Full Analysis Set .......................................................... 14
  9.3 Safety Analysis Set ....................................................... 14
  9.4 DLT Analysis Set .......................................................... 14
  9.5 Efficacy Evaluable (EE) Analysis Set: ......................... 14
    9.5.1 EE Analysis Set- HRD-positive ................................ 14
    9.5.2 EE Analysis Set- PD-L1 Expression ......................... 14
  9.6 Pharmacokinetic (PK) Analysis Set ............................... 14
10.0 Interim Analyses ......................................................... 14
11.0 Data Review ............................................................... 15
  11.1 Data Handling and Transfer ........................................ 15
  11.2 Data Cleaning ............................................................ 15
  11.3 Handling of Dropouts or Missing Data ....................... 16
12.0 Statistical Methods ..................................................... 17
  12.1 Patient Disposition ..................................................... 17
  12.2 Important Protocol Deviations .................................... 17
  12.3 Treatments ............................................................... 18
12.3.1 Extent of Study Treatment Exposure .................................................................................. 18
12.3.2 Prior and Concomitant Medications .................................................................................. 19
12.4 Demographic and Baseline Characteristics ......................................................................... 19
  12.4.1 Primary Cancer History ..................................................................................................... 19
  12.4.2 Medical History, Surgical History .................................................................................... 19
12.5 Efficacy Analyses ...................................................................................................................... 20
  12.5.1 Primary Endpoints ............................................................................................................ 20
  12.5.2 Methods for Handling Dropouts and Missing Data .......................................................... 21
  12.5.3 Multiplicity .......................................................................................................................... 21
  12.5.4 Pooling of Sites .................................................................................................................... 21
  12.5.5 Secondary Endpoints ........................................................................................................ 21
12.6 Safety Analyses ........................................................................................................................... 21
  12.6.1 Adverse Events .................................................................................................................. 22
  12.6.2 Deaths and Serious Adverse Events ................................................................................ 23
  12.6.3 Laboratory Data ................................................................................................................ 23
  12.6.4 Vital Signs ........................................................................................................................... 25
  12.6.5 Physical Examinations and Other Observations Related to Safety .................................. 25
  12.6.6 ECG ..................................................................................................................................... 25
13.0 Validation ................................................................................................................................. 26
14.0 References ............................................................................................................................... 28
15.0 List of Abbreviations ............................................................................................................... 29
16.0 Appendix 1: Common Terminology Criteria for Adverse Events V4.03 (CTCAE) .................. 32
17.0 Appendix 2: Best Overall Response per RECIST v1.1 ......................................................... 34
18.0 Appendix 3: Schedule of events ............................................................................................. 35
19.0 Appendix 4 Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 ....................... 38
20.0 Appendix 5: Immune-Related response evaluation criteria in solid tumors ....................... 40
21.0 Appendix 6: Laboratory Standard Units ............................................................................... 41
23.0 Document History .................................................................................................................... 42
2.0 Purpose

The statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and analyses of data collected under TESARO Inc. Protocol 3000-PN162-01-001.

3.0 Scope

This plan is a living document that will be created during the trial start-up. SAP 1 will be drafted within three months of final CRF, and maintained throughout the lifecycle of the trial. The SAP 2 will be finalized prior to database lock. SAP 2 will require sign off from the Project Manager and the sponsor.

The SAP outlines the following:
- Study objectives
- Study design
- Variables analyzed and analysis sets
- Applicable study definitions
- Statistical methods regarding important protocol deviations, study treatment exposure, efficacy analysis, concomitant medications, adverse events handling and laboratory data.

4.0 Introduction

This SAP describes the statistical methods to be used during the reporting and analyses of data collected under TESARO, Inc. Protocol 3000-PN-01-001.

This SAP should be read in conjunction with the study protocol and case report form (CRF). This version of the plan has been developed using the protocol dated 19-OCT-2015 (Version 1.0) and CRF dated 25-JAN-2016. Any further changes to the protocol or CRF may necessitate updates to the SAP.

The SAP is to be developed in two stages. The purpose is to “finalize” a SAP so that we can start programming earlier in the process. Versions of the SAP up to initial sponsor approval will be known as SAP1. Changes following approval of SAP1 will be tracked in the SAP Change Log, and a final version of the SAP, known as SAP 2, will be issued for sponsor approval prior to database lock.

4.1 Changes from Protocol

The definition of progression-free survival has changed from “enrollment to the earlier date of assessment of progression etc…” to “first dose date to the earlier date of assessment of progression etc…”.

5.0 Study Objectives

5.1 Phase 1

5.1.1 Primary Objectives

- To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment.
- To establish a recommended Phase 2 dose (RP2D) and schedule.
5.1.2 Secondary Objectives

- To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- To evaluate the pharmacokinetics (PK) of niraparib during combination treatment.

5.2 Phase 2

5.2.1 Primary Objective:

- To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separately for the triple-negative breast cancer (TNBC) and ovarian cancer (OC) cohorts.

5.2.2 Secondary Objective:

- To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST v1.1 (irRECIST);
  - Duration of response (DOR) by RECIST v1.1 and irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
  - Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
  - Overall survival (OS).
- To evaluate the PK of niraparib during combination treatment.

5.3 Exploratory Objectives

- To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of tumor-infiltrating lymphocytes (TILs), and circulating biomarkers.
- To correlate homologous recombination deficiency (HRD) score with other immune-related biomarkers and with efficacy outcomes.

6.0 Study Design

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with previously treated TNBC or OC.

The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the recommended Phase 2 dose (RP2D) and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab to be used in the Phase 2 portion.

Dosing will initiate at Dose Level 1 with a cohort of 6 patients with either TNBC or OC enrolled and treated with a combination of niraparib 200 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV
on Day 1 every 21 days. Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either
TNBC or OC will be enrolled in Dose Level 2 and treated with a combination of niraparib 300 mg PO
daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. No further dose escalation
will be considered if Dose Level 2 is reached. The maximum tolerated dose (MTD) will be defined as the
highest dose with DLTs observed in less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12
patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients
experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be
opened for enrollment if not yet evaluated.

The following are 4 dose levels/schedules planned for the Phase 1 of the study; each cohort will contain 6
patients but may be expanded to 12 patients:

- Dose Level 1: niraparib 200 mg/day orally (PO) on Days 1-21 and pembrolizumab 200 mg
  intravenously (IV) on Day 1 of each 21-day cycle.
- Dose Level 2: niraparib 300 mg/day PO on Days 1-21 and pembrolizumab 200 mg IV on Day 1
  of each 21-day cycle.
- Dose Level (-1): niraparib 200 or 300 mg/day PO on Days 1-14 of each 21-day cycle and
  pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. (See Section 9.12 of the protocol)
- Dose Level (-2): niraparib 200 or 300 mg/day PO on Days 1 – 7 of each 21-day cycle and
  pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. (See Section 9.12 of the protocol).

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion.
Two cohorts of 48 patients each with advanced TNBC or OC will be evaluated.

Patients in this phase of the study will receive the RP2D of niraparib in combination with pembrolizumab
200 mg IV on Day 1 of each 21-day cycle.

In Phase 2, pembrolizumab will be administered once every 21 days (200 mg IV). Pembrolizumab may be
administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to
administrative reasons. Niraparib dose will be administered upon completion of pembrolizumab infusion.
The RP2D of the combination will be based on the results in Phase 1.

Combination pembrolizumab/niraparib treatment may continue for up to 2 years unless specific
withdrawal criteria are met (Section 4.3 of the protocol). Continued treatment with niraparib beyond 2
years may be considered following discussion between the Sponsor and Investigator. Figure 1 describes
the study schema. The schedule of events is added in the appendix of section 18.0.
6.1 Sample Size Considerations

A total sample size of approximately 18 patients is estimated for the Phase 1 portion of the study to provide initial comparison of the incidence of DLTs and safety profiles of the combination treatment between dose schedules in each patient population. More patients could be enrolled (e.g., if the Dose Level -2 is explored, or if expansion at any dose level is required to better understand safety and tolerability); up to a total of 36 patients may be enrolled.

A total of approximately 96 evaluable patients (48 patients in each tumor type) will be enrolled in Phase 2 to ensure understanding of the activity of the combination treatment and to obtain adequate representation of different molecular cancer subtypes and biomarkers.

6.2 Randomization

Not applicable, as this is a single-arm study and Phase 2 is conducted in 2 cohorts.

7.0 Study Variables and Covariates

7.1 Primary Variables

Phase 1

- DLTs of combination treatment during the first treatment cycle
- MTD(s) defined as the highest dose of niraparib with DLTs observed in less than one-third of patients (i.e., < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment.
• RP2D - defined as the greatest dose intensity and regimen of niraparib that can be safely combined with the recommended dose and regimen of pembrolizumab

Phase 2
• ORR for combination treatment with pembrolizumab and niraparib using RECIST v1.1 criteria based on the investigator assessment.

7.2 Secondary Variables

7.2.1 Efficacy
• ORR for combination treatment with pembrolizumab and niraparib using irRECIST criteria.
• Duration of Response (DOR) per RECIST v1.1
• Duration of Response (DOR) per irRECIST
• Disease Control Rate per RECIST v1.1
• Disease Control Rate (DCR) per irRECIST
• Progression Free Survival (PFS) per RECIST v1.1
• Progression Free Survival (PFS) per irRECIST
• Overall Survival (OS)

7.2.2 Safety
• Treatment emergent adverse events (TEAE) (all, serious, maximum CTCAE grades, relation to study medications)
• Events of clinical interest for pembrolizumab and niraparib
• Changes in clinical laboratory values ((hematology, chemistry, coagulation, thyroid function, urinalysis)
• Vital signs
• ECG’s
• Physical examination findings
• Concomitant medications

7.2.3 Exploratory Endpoints
The relationship between cytogenetic abnormalities and safety parameters will be evaluated.

7.3 Pharmacokinetic Variables
The pharmacokinetic analysis set will consist of all patients with sufficient data to enable estimation of at least one PK parameter listed below.
The following PK parameters will be calculated for niraparib for Phase 1 using standard non-compartmental methods in Phoenix®, WinNonlin® (WNL) (Pharsight Corporation, Version 6.3 or higher):
### Table 1: PK parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>SAS Programming Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$</td>
<td>Observed maximum concentration during the dosing interval.</td>
<td>$C_{\text{max}}$ from WNL</td>
</tr>
<tr>
<td>$C_{\text{min}}$</td>
<td>Observed minimum concentration during the dosing interval</td>
<td>$C_{\text{min}}$ from WNL</td>
</tr>
<tr>
<td>$T_{\text{max}}$</td>
<td>Time of the maximum observed concentration.</td>
<td>$T_{\text{max}}$ from WNL</td>
</tr>
<tr>
<td>$AUC_{(0-24)}$</td>
<td>Area under the plasma concentration-time curve from time 0 to 24 hours.</td>
<td>$AUC_{(0-24)}$ from WNL (partial area)</td>
</tr>
<tr>
<td>$AUC_{(0-\text{last})}$</td>
<td>Area under the concentration-time curve between time zero (predose) and time of last quantifiable concentration.</td>
<td>$AUC_{\text{last}}$ from WNL</td>
</tr>
<tr>
<td>$AUC_{(0-\text{tau})}$</td>
<td>Area under the plasma concentration-time curve during a dosing interval.</td>
<td>$AUC_{\tau}$ from WNL where $\tau$ is equal to XX hr</td>
</tr>
<tr>
<td>$AUC_{(0-\text{tau}) \text{ ss}}$</td>
<td>The accumulation ratio will be calculated as the exposure at steady state within $\tau$ divided by the first dose exposure within $\tau$.</td>
<td>$AUC_{(0-\tau) \text{ ss}} / AUC_{(0-\tau)}$</td>
</tr>
<tr>
<td>$AR$</td>
<td>The accumulation ratio will be calculated as the exposure at steady state within $\tau$ divided by the first dose exposure within $\tau$.</td>
<td></td>
</tr>
<tr>
<td>$AUC_{(0-\text{inf})}$</td>
<td>Area under the concentration-time curve between time zero (predose) extrapolated to infinity.</td>
<td>$AUC_{\text{inf, obs}}$ from WNL If $AUC_{%\text{Extrap, obs}} \leq 20%$ or $R^2 &gt; 0.70$ is required to retain $AUC_{\text{inf}}$ parameter will not be reported.</td>
</tr>
<tr>
<td>$\text{CL/F}$</td>
<td>Apparent clearance calculated as $\text{CL} = \text{Dose} / AUC_{\text{inf}}$</td>
<td>$\text{CL/F, obs}$ from WNL If $AUC_{%\text{Extrap, obs}} &gt; 20%$ then parameter is deleted</td>
</tr>
<tr>
<td>$V_z/F$</td>
<td>Apparent volume of distribution as $V_z/F = (\text{CL/F}) / \lambda_z$</td>
<td>$V_z/F, \text{obs}$ from WNL If $AUC_{%\text{Extrap, obs}} &gt; 20%$ or $R^2 \leq 0.70$ then parameter is deleted</td>
</tr>
</tbody>
</table>

Due to sparse data in Phase 2, calculation of niraparib PK parameters, such as $C_{\text{max}}$ etc., may be considered depending on the observed data.

PK parameters similar to those in niraparib Phase 1 may be calculated for pembrolizumab.

PK analysis will use actual times as recorded on the CRF. If actual times are missing, nominal times may be used with sponsor approval.

Concentrations are used as supplied by the analytical laboratory for PK analysis. The units of concentration and resulting PK parameters, with amount or concentration in the unit, will be presented as they are received from the analytical laboratory. Concentration values that are below the level of quantification (BLQ) will be set to zero, with defined exceptions as follows: any embedded BLQ value (between 2 quantifiable concentrations) and BLQ values following the last quantifiable concentration in a profile will be set to missing for the purposes of PK analysis.
If there are late quantifiable concentration values following 2 BLQ concentration values in the apparent terminal phase, these values will be evaluated. If these values are considered to be anomalous, they will be set to missing. If an entire concentration-time profile is BLQ, the profile will be excluded from the PK analysis. If concentration values at the beginning of the profile (i.e. pre-dose) are missing, these values may be set to zero with sponsor approval.

7.3.1 Presentation of Pharmacokinetic Concentrations

- The following rules will be applied if there are values that are below the lower limit of quantification (BLQ) or if there are missing values (e.g., no result [NR]) in a plasma concentration data series to be summarized.
  - For the calculation of summary statistics, BLQ values will be set to zero.
  - Where there is NR, these will be set to missing.
- If all the values are BLQ, then the arithmetic mean, arithmetic SD, median, min and max will be presented as zero and the geometric mean and geometric CV% will be denoted as not calculated (NC).
- If the value of any descriptive statistic calculation is BLQ, these will be presented as zero and the geometric mean and geometric CV% will be denoted as NC.

8.0 Definitions

Actual Dose Intensity:
The actual dose intensity (ADI) is the cumulative dose divided by the duration of exposure in cycles (number of cycles) of each study therapy. For both study treatments, the cumulative dose is the sum of dose given (including doses modified in the case of niraparib).

Age:
The age collected at time of screening, presented in whole years.

Age Group:
There will be three age groups summarized in the demographics tables: <65 years old, ≥65-75 years old and ≥75 years old.

Average Relative Dose Intensity:
Average relative dose intensity (ARDI) in percent per patient will be defined as 100% times the average ADI divided by the expected cumulative dose.

The expected cumulative dose of pembrolizumab is defined as 200 mg * number of cycles.
The expected cumulative dose of niraparib in Phase 1 is as follows:

- If patient follows dose level 1: the expected cumulative dose is \((200*21)\)(# of cycles).
- If patient follows dose level 2: the expected cumulative dose is \((300*21)\)(# of cycles).
- If patient follows dose level -1: the expected cumulative dose is \((200/300*14)\)(# of cycles). The first planned dose level given to the patient should be used in deciding between 200/300 if both levels are administered to the patient.
- If patient follows dose level -2: the expected cumulative dose is \((200/300*7)\)# of cycles. The first planned dose level given to the patient should be used in deciding between 200/300 if both levels are administered to the patient.
- In Phase 2: The expected cumulative dose is \((RP2D)\)(# of cycles). Where, RP2D is the recommended Phase 2 dose determined at the end of Phase 1.
Baseline:
Unless otherwise specified, baseline is the last measurement taken on or prior to first dose of pembrolizumab or niraparib whichever is earlier (baseline can be the same date as first dose, given the measurement is expected prior to first dose, otherwise consider both time and date of dosing (if time is available for both).

Best Overall Response (BOR) per RECIST v1.1:
The best overall response (BOR) according to RECIST v1.1 will be assessed based on reported overall timepoint responses at different evaluation time points from the first dose date until documented disease progression, according to the following rules:

- **CR** = at least two determinations of CR at least 4 weeks apart with no evidence of progression between the two determinations.
- **PR** = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR).
- **SD**= at least one SD assessment (or better) ≥ 52 days after baseline and before progression (and not qualifying for a CR or PR).
- **PD**= progression after baseline and less than or at 18 weeks after the last tumor assessment. Note that a determination of CR followed at least 4 weeks later by an SD (≥ 52 days after baseline), will result in a BOR of PD.

Only tumor assessments performed before the start of any further anti-cancer treatment will be considered in the assessment of BOR. Clinical deterioration will not be considered as documented disease progression.

Best Overall Response (irBOR) per irRECIST:
The best overall response (irBOR) according to irRECIST will be assessed based on reported overall timepoint responses at different evaluation time points from the first dose date until documented disease progression. Follow the rules described for BOR RECIST v1.1 for the categories of irCR, irPR, irSD and irPD.

Body Mass Index (BMI):
Calculated at each visit and is equal to the weight (in kg)/ [height at screening (in m)^2].

Corrected QT Interval (QTcF):
QTcF is defined as corrected QT interval with Fridericia’s correction formula: QTcF=QT/(RR)^{1/3}, where QT is the heart rate interval, measured in milliseconds and RR is the interval from the onset of one QRS complex to the onset of the next QRS complex, measured in seconds.

Disease Control Rate (DCR) per RECIST v1.1:
Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST v1.1.

Disease Control Rate (irDCR) per irRECIST:
Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving irCR, irPR, or stable disease (irSD) as assessed by the Investigator per irRECIST.

Duration of Response (DOR) per RECIST v1.1:
DOR is applicable to patients that achieve either CR/PR per RECISTv1.1 and is defined as time from the first assessment of CR/PR until the date of the first occurrence of PD, or until the date of death (if death date is less than or equal to last dose date+30 days). Follow Table 2 for censoring rules of DOR.

**Duration of Response (irDOR) per irRECIST:**
irDOR is applicable to patients that achieve either irCR/irPR per irRECIST and is defined as time from the first assessment of irCR/irPR until the date of the first occurrence of irPD, or until the date of death (if death date is less than or equal to last dose date+30 days). Follow Table 2 for censoring rules of irDOR.

**Last Known Contact Date:**
The date of last known contact date will be derived for patients not known to have died at the analysis cut-off using the latest complete date among the following:

- Patient assessment dates (blood draws [laboratory, PK], vital signs, performance status, ECG, tumor assessments, ECOG, tumor measurement, or tumor biopsy dates)
- Start and end dates of anti-cancer therapies administered after study treatment discontinuation.
- AE start and end dates
- Last date of contact collected on the ‘Survival information’ eCRF (do not use date of survival follow-up assessment unless status is ‘alive’)
- Study treatment start and end dates
- Date of discontinuation on disposition eCRF pages (do not use if reason for discontinuation is lost to follow-up).

Only dates associated with actual examinations of the patient will be used in the derivation. Dates associated with a technical operation unrelated to patient status such as the date a blood sample was processed will not be used. Assessment dates after the cut-off date will not be applied to derive the last contact date, if applicable.

**Objective Response Rate (ORR) per RECIST v1.1:**
ORR will be assessed using tumor data recorded by the Investigator, and the denominator will be all treated patients with measurable disease at baseline.

The ORR is the proportion of patients who achieved best overall response of CR (complete response) or PR (partial response). The objective responses should be confirmed by a repeat tumor imaging assessment, at least 4 weeks apart, per RECIST v1.1. Patients who do not have a post-baseline radiographic tumor assessment due to early progression, who receive post baseline anti-tumor treatments other than the study treatments prior to reaching a CR or PR, or who die, progress, or drop out for any reason prior to reaching a CR or PR will be counted as non-responders in the assessment of ORR. Each patient will have an objective response status (0: no OR; 1: OR).

**Objective Response Rate (irORR) per irRECIST:**
irORR will be assessed using tumor data recorded by the Investigator, and the denominator will be all treated patients with measurable disease at baseline.

The irORR is the proportion of patients who achieved best overall response of confirmed irCR (complete response) or irPR (partial response) per irRECIST. Patients who do not have a post-baseline radiographic tumor assessment due to early progression, who receive anti-tumor treatments other than the study treatments prior to reaching a irCR or irPR, or who die, progress, or drop out for any reason prior to reaching a irCR or irPR will be counted as non-responders in the assessment of ORR. Each patient will have an objective response status (0: no OR; 1: OR).
Overall Response:
Overall tumor response assessment at each time point is a combination of target lesions, non-target lesions and new lesions assessed by the investigator following the guidelines presented specified in RECIST v1.1 or irRECIST. The response evaluation criteria per RECIST v1.1 and irRECIST are presented in Appendix D and E of the protocol respectively.

Overall Survival (OS):
Overall survival will be assessed as a secondary endpoint and is defined as the time from date of first dose of study treatment to the date of death by any cause. Patients last known to be alive will be censored at date of last known contact.

Progression-Free Survival Time (PFS) per RECIST v1.1:
Progression-free survival will be assessed as a secondary endpoint and is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Censoring rules for PFS events follow the guidelines presented in Table 2.

Progression-Free Survival Time (irPFS) per irRECIST:
PFS based on time of first confirmed documentation of disease progression per irRECIST, i.e. Overall time point irPD per irRECIST confirmed by the site investigator, will be presented as a sensitivity analysis.
Censoring rules for irPFS events follow the guidelines presented in Table 2.

Table 2: Censoring Rules for PFS/irPFS and DOR/irDOR.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Date of event/censoring</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>No baseline assessment or no post-baseline assessment</td>
<td>First dose date</td>
<td>Censored</td>
</tr>
<tr>
<td>Progression or death ≤ 18 weeks after last tumor assessment or ≤ 18 weeks after first dose date</td>
<td>Date of progression or death</td>
<td>Event</td>
</tr>
<tr>
<td>Progression or death &gt; 18 weeks after the last tumor assessment</td>
<td>Date of last adequate assessment</td>
<td>Censored</td>
</tr>
<tr>
<td>No progression</td>
<td>Date of last adequate assessment</td>
<td>Censored</td>
</tr>
<tr>
<td>New anticancer therapy given</td>
<td>Date of last adequate assessment before anticancer therapy given</td>
<td>Censored</td>
</tr>
</tbody>
</table>

*However if the patient dies ≤18 weeks after first dose date the death is an event with date on death date

Study Treatments:
Study treatments are niraparib and pembrolizumab.

Treatment Cycle:
Cycles will be identified in the visit label in the clinical database associated with dosing records.

Treatment Emergent Adverse Event (TEAE):
TEAE’s are AE’s with the onset date beginning on or after the day of first administration of either study treatment, throughout the treatment period until 30 days after the last dose of either study treatment (note that deaths and SAE’s are reported from first administration until 90 days after the last dose date of either
study treatment as noted in section 12.6.2. An AE with completely missing onset and stop dates, or with the onset date missing and a stop date later than the first dose date of either study treatment, will be considered to be treatment emergent.

9.0 Analysis Sets

9.1 Screening Analysis Set
All patients that signed the informed consent form including screen failures.

9.2 Full Analysis Set
The full analysis set (FAS) will consist of all Phase 2 patients who receive any amount of study treatment. Patients will be classified according to the study treatment actually received. If a patient receives more than one treatment the patient will be classified according to the first treatment received. The primary analysis of efficacy endpoints will be performed on the FAS population.

9.3 Safety Analysis Set
The safety analysis set will include all patients who receive any amount of study treatment in Phase 1 or Phase 2. In Phase 1, patients will be evaluated by dose level actually received and tumor type. In Phase 2, patients can be evaluated by tumor type. If a patient receives more than one dose level, the patient will be classified according to the first dose level received. In this non-randomized study the FAS and the safety analysis set in Phase 2 are identical.

9.4 DLT Analysis Set
The DLT analysis set will consist of all Phase 1 patients who complete the first cycle of therapy i.e. patients who started cycle 2 or discontinued at least 21 days after the first dose of either study medications in cycle 1, unless the patient discontinues due to a DLT, and is able to take more than 80% of the intended dose of both agents. The DLT analysis set will be used for the evaluation of the MTD in Phase 1.

9.5 Efficacy Evaluable (EE) Analysis Set:
The EE analysis set will consist of all dosed (with either pembrolizumab or niraparib) FAS patients with at least one post-baseline tumor assessment.

9.5.1 EE Analysis Set - HRD-positive
Patients in EE analysis set who are HRD positive.

9.5.2 EE Analysis Set - PD-L1 Expression
Patients in EE analysis set with PD-L1 expression.

9.6 Pharmacokinetic (PK) Analysis Set
The pharmacokinetic analysis set will consist of all patients with sufficient data to enable estimation of at least one PK parameter.

10.0 Interim Analyses
To minimize the risk of exposing patients to an ineffective treatment, a series of futility assessments will be performed when 6, 12, 18, and 24 of 48 Phase 2 patients from each cancer type have at least 2 post-
baseline tumor assessments. Please note that futility assessments at the 6, 12 and 18 patient enrollment are non-binding to study conduct, and a formal interim analysis will only be made at the 24 patient enrollment. A formal decision regarding futility, which could result in stopping the study early, will be conducted separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier assessments, however, will inform the conduct of the formal interim analysis as follows: If all three futility assessments from 6, 12, and 18 patients cross the futility boundary, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If any single futility assessment from 6, 12, or 18 patients fails to cross the futility boundary, then enrollment will not be curtailed. The futility boundaries in terms of the numbers of responders (that is, patients with a confirmed PR or CR) are summarized in Table 3.

Table 3: Futility Boundaries in Terms of the Numbers of Responders in Phase 2.

<table>
<thead>
<tr>
<th>Interim Look #</th>
<th>Number of Patients With at Least 2 Post-baseline Tumor Assessments</th>
<th>Number of Responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>&lt;3</td>
</tr>
<tr>
<td>5a</td>
<td>48</td>
<td>&lt;12</td>
</tr>
</tbody>
</table>

*a This represents the final analysis for response rate.

Thus, the decision rule regarding the formal interim analysis at N=24 is as follows: If there are no responders at interim looks 1, 2, and 3, then enrollment will be suspended at 24 patients until after interim look #4. If, however, there is at least 1 responder at any of the first 3 looks, then enrollment will not be curtailed. Note that the number of responders is cumulative in the sense that a response at an early look will be included in the counts of responders at all subsequent looks. Note also that the decision rule implies that a response at look #1 or look #2 would eliminate the need for another look until look #4.

If, at the 4th look, there are fewer than 3 responders out of 24, enrollment may be closed and the study may be stopped for futility. Otherwise, the study will continue to the planned enrollment of 48 patients. If, at the 5th and final look, there are at least 12 responders out of 48, then the Phase 2 primary objective will have been met.

11.0 Data Review

Final data for analysis will be cleaned prior to receipt by statistical programming. Ongoing data handling will take place by the study programmer, until the time at which the study team has full access to the data.

11.1 Data Handling and Transfer

All of the data will come from the TESARO data management group and be extracted in SAS® dataset format (SAS v9.4 or later) and converted to SDTM v3.1.2 or higher. Please refer to the Data Management Plan for details.

11.2 Data Cleaning

Beyond the data cleaning built into the DMP, will be programming analysis datasets and TFLs and will provide additional data cleaning. Data issues identified during the process of programming analysis datasets and TFLs programming is ongoing, will be sent to Data Management.
All derived datasets will include patient-level variables, such as analysis set inclusion, sex, tumor cohort, and dose dates.

Any methodologies used to address any issues identified in the data will be documented in the analysis data set specifications, and finalized before database lock.

Variables generated at the patient level will be stored in a consolidated data set for the study. Variables at the patient level or below (e.g., at the visit level) will be generated in analysis data set programs, not in the programs generating the TFLs. Exceptions may include simple concatenation or formatting that will only be used once.

The content of the analysis data sets will be detailed in a separate document. For each derived data set, the label, sort order, and structure (expected number of records per patient/visit) will be specified. For each variable, the name, label, type, length, format, and source or derivation description will be specified. Detailed rules devised to handle specific data patterns found in data reviews will be included. The analysis dataset specifications will be finalized before database lock.

Review of a pre-lock TFL run on the ready-to-lock database allow for further data screening prior to lock. The pre-lock TFLs may be discussed with TESARO in a data review meeting to identify any final data issues and seek corrections prior to database lock. The statistician and TESARO must approve database lock ahead of locking the database.

11.3 Handling of Dropouts or Missing Data

Missing observations will generally be treated as missing at random and will not be imputed, unless otherwise noted.

Incomplete dates for disease history (e.g. initial diagnosis date, date of documented, locally advanced, metastatic disease diagnosis, date of response or progression in prior treatment) will be imputed as follows:

- If the day is missing, it will be imputed to the 1st day of the month.
- If both day and month are missing, the month and day will be imputed as January 1st.
- If the date is completely missing, no imputation will be performed.

Incomplete dates for adverse event and concomitant medication dates will be imputed as follows:

Start Date:
- If only ‘day’ is missing, and the month and year are not the same as the month and year of first dose, then impute day with ‘01’. Otherwise, if the month and year are the same as first dose date, use first dose date.
- If ‘day’ and ‘month’ are missing, and ‘year’ is not missing, then impute month and day with month and day of first dose date (assuming same ‘year’).
- If the year is not the same as the year of first dose, impute 01 for day and 01 for month.
- If the start date is completely missing, it will be set to the first dose date.

Stop Date:
- If only ‘day’ is missing, impute day with last day of the month.
- If ‘day’ and ‘month’ are missing, and ‘year’ is not missing, then impute month with ’12’ and day with ‘31’ (or date of study discontinuation/completion if earlier than 12-31).
- If the stop date is completely missing, it will be set to the date of study discontinuation/completion. A stop date will not be applied to ongoing AEs.
- If the imputed stop date is greater than last contact date then set to last contact date.
Note, for all listings the actual value for date (not imputed) will be presented in all data listings and imputed dates will only be used for programming flags, etc.

12.0 Statistical Methods

In general, categorical data will be summarized using number of patients (n), frequency and percentages, with the denominator for percentages being the number of patients in the analysis set for each cohort. Percentages will be rounded to 1 decimal place except for 100%, which will have no decimal place.

Continuous data will be summarized using the number of patients, mean, standard deviation, median, quartiles (Q1, Q3), minimum, and maximum. The mean, median and quartiles (Q1, Q3) will be presented to 1 decimal place greater than the original data; the standard deviation will be presented to 2 decimal places greater than the original data; and the minimum and maximum will have the same number of decimal places as the original data.

Results will be displayed for each of the TNBC and OC cohorts as well as the overall population. All statistical analyses and data listings will be performed using SAS.

Two-sided exact 90% confidence intervals (CIs) based on the Clopper-Pearson method (3) will be provided to summarize the binomial proportion of the derived best overall response for both irRECIST and RECISTv1.1 assessments where applicable:

The Clopper-Pearson CI (3) can be carried out using the FREQ procedure in SAS v9.4 or higher.

Time-to-event analyses will be performed using Kaplan-Meier (KM) methods. Comparisons in the Phase 1 portion of the study will be made using descriptive statistics. Any statistical analysis to be performed among subgroups is for descriptive and future study purposes given that the Phase 2 portion of the study is not designed to be comparative.

12.1 Patient Disposition

Disposition of patients includes the number and percentage of patients for the following categories:

- patients in each of the analysis sets,
- patients discontinued from treatment,
- primary reason for discontinuation from treatment,
- patients discontinued from the study, and
- primary reason for discontinuation from the study.

Numbers and percentages of patients will be presented by dose level in the Phase 1 portion and for all patients by tumor cohort in the Phase 2 portion.

A listing will present data for patient disposition.

12.2 Important Protocol Deviations

Important Protocol Deviations (IPD) will be identified and documented based on a review of potentially IPDs. The potential IPDs will be identified through programmatic checks of study data, as well as through review of selected data listings. Potential IPDs will be assessed as to whether or not they have a significant impact on the assessment of safety or efficacy. The IPD categories include, but are not limited to:

- Did not meet inclusion/exclusion criteria
- Did not meet continuation criteria
- Received any disallowed concomitant medication or therapy
- Late informed consent was obtained
• Study visit procedure was violated

Per processes, IPD data will be entered into Clinical Trials Management System (CTMS). The study team and the sponsor will conduct ongoing reviews of the IPD data from CTMS and the resulting set of evaluable patients throughout the study, adjusting the IPD criteria as deemed appropriate by the medical monitor in consultation with the study team. The evaluable patients set should be finalized at the post-freeze data review meeting (or earlier), prior to database lock. Reasons for exclusion from an analysis dataset will be summarized. Specific IPDs, category codes and deviation codes are outlined in the Protocol Deviation Guidance document as noted in the Clinical Management Plan.

The number of patients with each type of IPD will be tabulated by deviation category and by deviation type for all patients in the safety analysis set per dose level in in Phase 1 and per tumor cohort in Phase 2. A listing of all deviations (important and non-important) including deviation date, deviation type, significance (important vs non-important), deviation description and any relevant comments will be generated.

12.3 Treatments

12.3.1 Extent of Study Treatment Exposure

An overall summary of drug exposure will be presented for each study treatment including:

• The number of treatment cycles.
• Numbers and percentages of patients who had ≥1, ≥2, ≥3 treated cycles,
• Cumulative dose and total number of doses administered.
• The actual dose intensity.
• Relative dose intensity.
• The number and percentage of patients with niraparib dose reductions, dose re-escalations, dose delays dose interruptions, and number of patients with at least one reported missed dose will also be presented.
• Number of patients with pembrolizumab dose interruptions and dose delays.
• Number of patients with niraparib dose interruptions, reductions and delays.

A by-patient listing based on the safety population will also be produced per each study treatment, disease type and phase of the study.

The actual duration of exposure (in cycles) is defined as \[((\text{first dose date of last cycle} - \text{first dose date of first cycle})/21 + 1)\].

The actual duration of exposure for pembrolizumab (days) will be calculated as: last dose date +21 – first dose date +1.

The actual duration of exposure for niraparib (days) will be calculated as: (date of last dose of niraparib administered – first dose date +1).

The cumulative dose for each drug is the sum of all doses administered.

Actual dose intensity (ADI) and relative dose intensity (RDI) will also be presented. Refer to section 8.0 for the definitions.
12.3.2 Prior and Concomitant Medications

Medications collected at Screening and during the study will be coded using the current version of the World Health Organization (WHO) Drug dictionary. The medications will be categorized as prior or concomitant using the following definitions:

- **Prior medications**: any medications, other than study treatments and pre-medications for study treatment, which ended prior to the first dose date of study treatment.
- **Concomitant medications**: any medications, other than study treatments, being taken on or after the initial study treatment dosing date through 30 days after the last dose or until the start of subsequent antitumor therapy.

Both prior medications and concomitant medications will be summarized by Anatomical Therapeutic Chemical (ATC) classification drug class and WHO preferred name using the number and percentage of patients for each cohort. A patient reporting the same medication more than once will be counted only once when calculating the number and percentage of patients who received that medication in a given time category (prior or concomitant). The summary of concomitant medications will be ordered alphabetically by drug class and then by descending frequency of preferred name in total within the drug class. For drugs with the same frequency, sorting will be done alphabetically. Summaries will be based on the safety population.

All prior and concomitant medications (other than per-protocol study treatments) will be provided in a by-patient listing sorted by patient ID number and administration date in chronological order.

12.4 Demographic and Baseline Characteristics

Demographic and baseline characteristics will be summarized per dose level in Phase 1 and per tumor cohort in Phase 2. Descriptive statistics will be provided for age (<65, ≥65 to <75, and ≥75), sex (male versus female), race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, or other), Ethnicity (Hispanic or Non-Hispanic), baselines for weight (kg), height (m), and BMI (kg/m²).

12.4.1 Primary Cancer History

A summary of primary cancer history will be presented including: the tumor site, histology and grade of disease at diagnosis, the most recent cancer stage, and the most recent grade and histology. A by-patient listing for primary cancer history characteristics will also be provided.

12.4.2 Medical History, Surgical History

General medical history information (including past and ongoing) and prior medications and will be summarized for category and conditions ongoing or resolved at study entry based on the FAS (Phase 2) or safety set (Phase 1). Medical history conditions will be collected by CRF at time of screening. The count and percentage of patients with each medical history event will be summarized by categories and described conditions in CRF. General medical history information will be coded by System Organ Class (SOC) and Preferred Term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA), using the most recent version available at the data cutoff. The count and percentage of patients with each medical history event will be summarized by MedDRA SOC and PT for all patients only (not by dose cohort). SOCs will be presented alphabetically with PTs in descending order of frequency.

A by-patient listing of general medical history will be provided by patient ID number in ascending order. A special table and listing will be added to summarize any prior blood disorders of thrombocytopenia, leukopenia, anemia or neutropenia.
Prior anticancer treatment will be summarized per agent preferred name for all patients in the FAS. Prior surgery, and prior anti-cancer regimens, along with prior response information will be listed. The number and percentage of patients in each of the following prior anti-cancer therapy categories will be tabulated:

- Patients with at least one type of prior anti-cancer treatment
- Patients with at least one prior anti-cancer drug therapy
- Patients with at least one prior anti-cancer radiotherapy
- Patients with at least one prior anti-cancer surgery

Prior anti-cancer drug therapy will be summarized as follows based on the number and percentage of patients with the following:

- Patients with at least one prior anti-cancer drug therapy
- Number of any prior anti-cancer therapy regimens: missing, 1, 2, 3 ≥4
- Type of prior anti-cancer therapy
- Intent of Therapy: Neo-Adjuvant / Adjuvant / Other
- Best response: Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) / Progressive Disease (PD) / Not assessable / Unknown / Not applicable. Best response is derived from the last treatment regimen prior to study start date.

In addition, prior platinum therapy response (sensitive, refractory, and resistant) will be summarized for ovarian cancer patients.

### 12.5 Efficacy Analyses

All efficacy endpoints will be summarized on the Phase 2 EE analysis set by disease type (OC, TNBC). All efficacy analysis will be summarized for 3 groups of patients:

- All patients in the EE analysis set
- All patients in the HRD positive group of the EE analysis set (HRD positivity will be determined from the HRD score at a cutoff to be evaluated prior to database lock.)
- All patients with PD-L1 expression in the EE analysis set.

In addition, data for patients in Phase 1 at the RP2D dose level may be pooled with Phase 2, by tumor type for analysis at the end of the study if deemed necessary.

All analyses will include summary statistics, including number and percentage for categorical variables and number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables. Two-sided exact 90% CIs based on the Clopper-Pearson method will be presented for the primary efficacy endpoint ORR per RECIST v1.1 as well as the following secondary endpoints: ORR per irRECIST, DCR per RECIST v1.1 and DCR per irRECIST. Time-to-event data will be summarized by 25th, 50th (median), and 75th percentiles with associated 2-sided 90% CIs as well as percent of censored observations.

Any statistical analysis performed among subgroups will be for descriptive and future study purposes.

#### 12.5.1 Primary Endpoints

Objective Response Rate (ORR): Evaluated separately for TNBC and OC cohorts in Phase 2 of the study. The ORR is defined as the proportion of patients achieving a confirmed best overall response of CR or
PR as assessed by the Investigator per RECIST (v1.1). Tumor assessments after the initiation of further anticancer therapy are excluded. Point estimates and two-sided 90% exact confidence intervals will be provided for ORR.

12.5.2 Methods for Handling Dropouts and Missing Data

Missing observations will generally be treated as missing at random and will not be imputed, unless otherwise noted. Adverse event and concomitant medication dates will be imputed as mentioned in Section 12.2. Note, for all listings the actual value for date (not imputed) will be presented in all data listings and imputed dates will only be used for programming flags, etc.

12.5.3 Multiplicity

Adjustments for multiplicity will not be made since this is an estimation study and separate inferences will be drawn for each tumor cohort.

12.5.4 Pooling of Sites

All data from all sites will be pooled. Study center or treatment-by-center interaction will not be included in any statistical analysis.

12.5.5 Secondary Endpoints

The following are the secondary endpoints to be evaluated in Phase 2 of the study per disease type, please note that the derivation of time point assessment per irRECIST is provided in Appendix 4.

- irORR by irRECIST
- Duration of response: DOR by RECIST v1.1 and irDOR by irRECIST;
- Disease control rate: DCR by RECIST v1.1 and irDCR by irRECIST;
- Progression-free survival: PFS by RECIST v1.1 and irPFS by irRECIST;
- Overall survival (OS).

DOR, PFS, and OS will be presented through use of summary statistics using KM methods, to include 25th, 50th (median), and 75th percentiles and associated 2-sided 95% CI’s using the method of Brookmeyer and Crowley (5), number of events and number of censored observations.

Additionally, PFS/irPFS will be summarized at months 3, 6 and 9, and OS rates will be summarized at months 6, 9 and 12. The standard error of the KM estimates of event-free probability will be estimated using the Greenwood’s formula (6).

DOR/irDOR and PFS/irPFS defined by both RECIST v1.1 and irRECIST will be analyzed separately by both criteria. The time to event endpoints (PFS, DOR, and OS) will also be summarized graphically with KM estimates of the survivor function and the number of patients at risk for selected timepoints. Additionally, the figures will include the median of the survival distribution.

All time to event analysis (i.e. PFS, OS and DOR) may be performed if more than 10 events are observed in each cohort.

12.6 Safety Analyses

Safety Tables and Listings will be presented to summarize TEAE’s, laboratory data and vital signs and in Phase 1 as well as Phase 2. Phase 1 patients with RP2D dose levels may be pooled with Phase 2 patients in the same tables/listings by tumor type if deemed necessary at the end of the study. In general, all summaries of by-cycle and day safety parameters will only be summarized through Cycle 6 Day 1 (end of
Cycle 5) and at the treatment discontinuation visit. Additional summaries will be derived as the minimum and maximum for all on-study assessments and presented similarly to the other time points at the end of the summary table. This will allow an assessment of either the best or worst value assessed throughout the conduct of the study. The maximum and minimum calculations will use all post-baseline data, including any unscheduled assessments.

12.6.1 Adverse Events

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). Only TEAE’s (refer to Section 8.0 for definition) will be analyzed but all AEs occurring on-study will be listed in patient data listings. By-patient listings will also be provided for the following: patient deaths, SAEs, and AEs leading to withdrawal.

An overall summary AE table will include numbers and percentages of patients who had:

- at least one AE,
- AE’s related to study treatment,
- grade 3 or higher AE,
- grade 3 or higher AE’s related to study treatment,
- SAE, and SAE related to study treatment,
- AE’s resulting in discontinuation,
- AE’s resulting in dose modification (which include dose reductions, and dose interruptions of either study treatments),
- AE’s of clinical interest,
- drug-related AE leading to discontinuation of study medication,
- death occurring between first dose day and last dose date + 90 days,
- DLT’s for the Phase 1 portion only.

AEs will be tabulated by SOC and preferred term. Summary tabulations include the following subsets:

- DLT’s during the period of Cycle 1/Day 1 through Cycle 1/Day 21 for Phase 1 will be summarized by dose level to which they were originally assigned, including those who receive subsequent treatment at a different dose. The AE’s will also be classified by their CTCAE grades.
- Incidence of TEAE’s occurring while patients are on treatment or up to 30 days after the last dose of either study treatment.
- Patients with any TEAE assessed by the Investigator as related to either study treatment (‘Related’, ‘Possibly Related’, or ‘Unlikely Related”),
- Incidence of SAE’s occurring while patients are on treatment or up to 90 days after the last dose of either study treatment (or to a minimum of 30 days post treatment if the patient starts alternate anticancer therapy). In addition, a by-patient listing of SAEs will be presented (the patient listing will contain all SAEs regardless of treatment-emergent AE status).
- Incidence of deaths while patients are on treatment. A by-patient listing of deaths (including days since last dose) will be presented. All deaths occurring on-study and during follow-up will be displayed (regardless of treatment-emergent AE status).
- Incidence of AE’s resulting in discontinuation of study treatment, and a by-patient listing of AE’s resulting in discontinuation of study treatment will be presented.
Incidence of AE’s resulting in dose modifications (dose interruptions or dose reduction). A by-patient listing of AEs resulting in dose reduction of either study treatment will be presented. All AEs resulting in dose modification of study treatment occurring on study will be displayed.

CTCAE Grade 3 or greater TEAEs and treatment related TEAE’s. Patients with the same AE more than once will have the maximum intensity of that event counted within each SOC, and once within each PT.

Most commonly reported (at least 5% of all patients) treatment-emergent and treatment related AEs.

Incidence of AE’s of clinical interest as specified in the protocol:
- Overdose of pembrolizumab (defined as a dose ≥ 1000 mg [5 times the dose]).
- An elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value that is ≥ 3× upper limit of normal (ULN) concurrent with an elevated total bilirubin value that is ≥ 2× ULN and, at the same time, an alkaline phosphatase value that is < 2× ULN.
- New malignancy

Overall, patients with the same AE more than once will have that event counted only once within each SOC, and once within each PT.

Additionally, by-patient listings of AE’s of clinical interest will be presented if appropriate.

### 12.6.2 Deaths and Serious Adverse Events

The number and percentage of patients experiencing at least 1 SAE between the first dose date and 90 days after the last dose date will be summarized by MedDRA SOC and PT. Drug-related SAE’s and deaths will be summarized similarly.

In addition, a by-patient listing of SAE’s will be presented (the patient listing will contain all SAE’s regardless of timing).

A by-patient listing of deaths (including days since last dose) will be presented. All deaths after the first dose date will be listed.

### 12.6.3 Laboratory Data

All laboratory values, for which a normal range is available, will be classified into NCTC CTCAE v 4.03 grades. The categories are defined according to the criteria available on the following website:

http://evs.nci.nih.gov/ftp1/CTCAE/About.html

For the purposes of summarization in both the tables and listings, all laboratory values will be converted to standardized units and differentials of white blood cell (WBC) count should always be converted to absolute counts in SI units for summarization (e.g. % is not an SI unit). If a laboratory value is reported using a non-numeric qualifier it will not be taken into consideration in the derivation of CTCAE criteria (e.g., hypokalemia grade 1 and grade 2 are only distinguished by a non-numerical qualifier (symptomatic; intervention indicated) and therefore grade 2 will not be derived). In general, clinical assessments listed will not be considered, only numeric results will be assessed. Additional laboratory results that are not part of NCI-CTCAE will be presented according to the categories: below normal limit, within normal limits and above normal limit (according to the laboratory normal ranges). Furthermore, only the numeric part in laboratory values that contain non-numeric qualifiers, such as less than (<) a certain value, or greater than (>) a certain value, will be used in the summary statistics.

Multiple measurements taken during the visit for a patient will be represented by the most severe value for each hematology test. The most severe value will be determined first by the value closest to the upper or lower limit of the normal limits (dependent on which direction is considered severe) if the value is
within the normal limits. If the value is outside the normal limits, the value furthest from the upper or lower limit will be selected (dependent on which direction is considered severe). In the event that this algorithm does not allow for determining the most severe (i.e., a tie) the measurement closest to dosing date (either niraparib or pembrolizumab) will be selected. Patients who develop ≥ Grade 3 toxicity will be listed.

The following hematology tests will be summarized:
- WBC count, lymphocytes, monocytes, absolute neutrophil count, eosinophils, basophils, hemoglobin, platelets, mean platelet volume (MPV), erythrocyte mean corpuscular volume.

The following chemistry tests will be summarized:
- Sodium, amylase, potassium, total bilirubin, calcium, alkaline phosphatase (ALP), magnesium, AST, chloride, ALT, glucose, total protein, creatinine, albumin, urea or blood urea nitrogen, lactate dehydrogenase.

The following coagulation factors will be summarized: International normalized ratio (INR) and activated partial thromboplastin time (aPTT).

The following urinalysis parameters will be summarized:
- Specific gravity, protein, leukocyte esterase, glucose, nitrite, ketones, blood, urobilinogen, bilirubin.

Additionally, a by-patient listing will be presented for thyroid functions (thyroid-stimulating hormone, triiodothyronine (T3), or free T3 and free thyroxin), serum CA-125 (OC patients only) and serum pregnancy testing /urine pregnancy testing.

NCI CTCAE grades (given in Section 16.0) will be applied for the following lab parameters:
- Hematology: hemoglobin (anemia), WBC (leukopenia), lymphocytes (lymphopenia), neutrophils (neutropenia), and platelets (thrombocytopenia).
- Chemistry: albumin (hypoalbuminemia), alkaline phosphatase (alkaline phosphatase increased), ALT, AST, total bilirubin (blood bilirubin increased), corrected calcium (hypocalcemia, hypercalcemia), creatinine (creatinine increased), glucose (hyperglycemia, hypoglycemia), magnesium (hypermagnesemia, hypomagnesemia), phosphorus (hypophosphatemia), potassium (hyperkalemia, hypokalemia), and sodium (hyponatremia, hypernatremia).
- Coagulation: aPTT, INR.

Where corrected calcium is derived with the following formula:
Corrected calcium (mmol/L) = (0.02 * (40 (g/L) – normal albumin (g/L))) + serum calcium (mmol/L).

A summary of maximum severity observed on-study treatment for all parameters noted above will be generated for the coded hematology and chemistry parameters. Patients will only be included once, in the maximum severity, for each laboratory parameter. Additionally, a shift summary of baseline to maximum severity on-study treatment will also be produced. Patients with at least 1 on-study treatment measurement for each laboratory parameter will be included, regardless of whether or not a baseline assessment is present (baseline will be included as a missing category). Thus, percentages for each parameter will be based on the total number of patients with an on-study treatment measurement for the parameter of interest.
Laboratory measurements that are within their institutional limits of normal and are not graded as 1-4, per the CTCAE, will be summarized as “Grade 0,” which is defined as normal.

**Liver function tests:** ALT, AST, and total bilirubin are used to assess possible drug induced liver toxicity. The ratios of test result over ULN will be calculated and classified for these three parameters during the on-treatment period.

Summary of liver function tests will include the following categories. The number and percentage of patients with each of the following during the on-treatment period will be summarized by treatment group:

- ALT ≥ 3×ULN, ALT ≥ 5×ULN, ALT ≥ 10×ULN, ALT ≥ 20×ULN
- AST ≥ 3×ULN, AST ≥ 5×ULN, AST ≥ 10×ULN, AST ≥ 20×ULN
- (ALT or AST) ≥ 3×ULN, (ALT or AST) ≥ 5×ULN, (ALT or AST) ≥ 10×ULN, (ALT or AST) ≥ 20×ULN
- Total bilirubin ≥ 2×ULN
- Concurrent ALT ≥ 3×ULN and total bilirubin ≥ 2×ULN
- Concurrent AST ≥ 3×ULN and total bilirubin ≥ 2×ULN
- Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN
- Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN and ALP > 2×ULN
- Hų’s law: Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN and ALP ≤ 2×ULN or missing

Concurrent measurements are those occurring on the same date. Categories will be cumulative, i.e., a patient with an elevation of AST ≥ 10×ULN will also appear in the categories ≥ 5×ULN and ≥ 3×ULN. Liver function elevation and possible Hų’s Law cases will be summarized using frequency and percentage.

By-patient listings will be presented for hematology, coagulation factors, urinalysis and serum chemistry. Any laboratory values assessed as clinically significant should be recorded as an AE.

**12.6.4 Vital Signs**

Vital signs: diastolic and systolic blood pressure (mmHg), body temperature, pulse rate (beats/min) at each visit, change from baseline to each post-baseline visit, post-baseline maximum/minimum, and change from baseline to post-baseline maximum/minimum will be summarized for the safety analysis set using descriptive statistics (n, mean, SD, median, Q1, Q3, minimum, and maximum) by dose level or tumor cohort.

A by-patient listing of vital signs will be provided by patient ID number and visit in chronological order.

**12.6.5 Physical Examinations and Other Observations Related to Safety**

ECOG parameters will be presented by tumor cohort for each dose level and within each tumor cohort at baseline, at each post-treatment time point and at the end of treatment. The ECOG shift from baseline to highest score during the on-treatment period will be summarized by dose level or tumor cohort.

Height, Weight, Pregnancy test results will be presented in a by-patient listing. Physical examination at screening will also be listed.

**12.6.6 ECG**

The following analyses will be performed for each applicable ECG parameters (RR, PR, QRS, QT, ventricular rate -denoted as HR in what follows, and QTc) by treatment group, during the on-treatment period.
For each of the ECG parameters (HR, and QT, QTc, QRS, PR intervals), descriptive statistics at baseline, at each post-baseline time point and changes from baseline at each post-baseline time point.

Frequency (number and percentage) of patients with notable ECG values according to the following categories presented in Table 4.

**Table 4: Notable ECG Values for QTc Interval Prolongation**

<table>
<thead>
<tr>
<th>TEST</th>
<th>Notable ECG Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Rate</td>
<td>≤ 50 bpm and decrease from baseline ≥ 20 bpm</td>
</tr>
<tr>
<td></td>
<td>≥ 120 bpm and increase from baseline ≥ 20 bpm</td>
</tr>
<tr>
<td>PR Interval</td>
<td>≥ 220 ms and increase from baseline ≥ 20 ms</td>
</tr>
<tr>
<td>QRS</td>
<td>≥ 120 ms</td>
</tr>
<tr>
<td>QTcF Absolute</td>
<td>interval &gt;450 msec and interval ≤480 msec</td>
</tr>
<tr>
<td></td>
<td>interval &gt;480 msec and interval ≤ 500 msec</td>
</tr>
<tr>
<td></td>
<td>interval &gt;500 msec</td>
</tr>
<tr>
<td>QTcF change from baseline</td>
<td>Increase from baseline &gt; 30 ms and ≤ 60 ms</td>
</tr>
<tr>
<td></td>
<td>Increase from baseline &gt; 60 ms</td>
</tr>
</tbody>
</table>

Frequency (number and percentage) of patients with post-baseline qualitative ECG abnormalities (morphology) will be summarized. Patients with notable ECG interval values and qualitative ECG abnormalities will be listed for each patient and time point and the corresponding notable values and abnormality findings will be included in the listings.

Unscheduled ECG measurements will not be used in computing the descriptive statistics for change from baseline at each post-baseline time point. However, they will be used in the analysis of notable ECG changes and the shift table analysis of notable QT parameters.

A shift table of the investigators’ assessment of ECG results at each visit compared with the latest ECG collected prior to first dose will be presented by treatment group using the following categories: normal; abnormal, not clinically significant; abnormal, clinically significant; or missing. The number and percentage of patients in each cross-classification group of the shift table will be presented. Patients with a missing value at baseline or post-baseline will not be included in the denominator for percentage calculation.

### 13.0 Validation

The goal is to ensure that each table, listing and figure (TFL) delivery is submitted to the highest level of quality. Our quality control procedures will be documented separately in the study-specific quality control plan.

- Derived datasets are independently reprogrammed by a second programmer. The separate datasets produced by the 2 programmers must match 100%. Detailed specifications for the derived datasets are documented in the study Data Mapping Tool provided to the client at study conclusion.
- Tables are independently quality controlled by a second programmer for numeric results.
• Figures are checked for consistency against corresponding tables and listings, or independently reprogrammed if there are no corresponding tables or listings.
• Listings are double programmed and checked for consistency against corresponding tables, figures, and derived datasets.

The entire set of TFL is checked for completeness and consistency prior to its delivery to the client by the lead clinical programmer, the lead statistician, and a senior level or above statistician, who is not a member of the project team.

The validation process is repeated any time TFL are redelivered using different data. Execution of this validation process is documented through the study Table of Programs that is provided to the client at study conclusion.

The goal is to ensure that each TFL delivery is submitted to the highest level of quality. Our quality control procedures will be documented separately in the study specific quality control plan.
14.0 References

1. Data on file at TESARO.
### 15.0 List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukemia</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>aPTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration × time curve</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;ss&lt;/sub&gt;</td>
<td>area under the concentration × time curve at steady state</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>clearance after oral administration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max,ss&lt;/sub&gt;</td>
<td>maximum concentration at steady state</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>minimum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min,ss&lt;/sub&gt;</td>
<td>minimum concentration at steady state</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DCR</td>
<td>disease control rate</td>
</tr>
<tr>
<td>DKA</td>
<td>diabetic ketoacidosis</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECI</td>
<td>events of clinical interest</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EOT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>ER-</td>
<td>estrogen receptor</td>
</tr>
<tr>
<td>FT3</td>
<td>free triiodothyronine</td>
</tr>
<tr>
<td>FT4</td>
<td>free thyroxine</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GCIG</td>
<td>Gynecologic Cancer Intergroup</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCV RNA</td>
<td>hepatitis C virus ribonucleic acid</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>homologous recombination</td>
</tr>
<tr>
<td>HRD</td>
<td>homologous recombination deficiency</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IgG</td>
<td>immunoglobulin G</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>irRECIST</td>
<td>immune-related Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan-Meier</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplastic syndrome</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>OC</td>
<td>primary peritoneal ovarian cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>Short Form</td>
<td>Full Form</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PARP</td>
<td>poly(ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death-1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed death ligand-1</td>
</tr>
<tr>
<td>PD-L2</td>
<td>programmed death ligand-2</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PO</td>
<td>oral(ly)</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PR-</td>
<td>progesterone receptor</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>QD</td>
<td>once daily</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>RP2D</td>
<td>recommended Phase 2 dose</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>TEAE</td>
<td>Treatment-emergent adverse event</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
</tbody>
</table>
### 16.0 Appendix 1: Common Terminology Criteria for Adverse Events V4.03 (CTCAE)

<table>
<thead>
<tr>
<th>Lab Test Name</th>
<th>Lab Test Code</th>
<th>Standard Unit</th>
<th>CTCAE v4.03 SOC</th>
<th>CTCAE v4.03 Term</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>HGB</td>
<td>g/L</td>
<td>Blood and lymphatic system disorders</td>
<td>Anemia</td>
<td>&lt;LLN - 100 g/L</td>
<td>&lt;100 - 80 g/L</td>
<td>&lt;80 g/L</td>
<td></td>
</tr>
<tr>
<td>Leukocytes</td>
<td>WBC</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>White blood cell decreased</td>
<td>&lt;LLN - 3.0 x 10^9/L</td>
<td>&lt;3.0 - 2.0 x 10^9/L</td>
<td>&lt;2.0 - 1.0 x 10^9/L</td>
<td>&lt;1.0 x 10^9/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>PLAT</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Platelet count decreased</td>
<td>&lt;LLN - 75.0 x 10^9/L</td>
<td>&lt;75.0 - 50.0 x 10^9/L</td>
<td>&lt;50.0 - 25.0 x 10^9/L</td>
<td>&lt;25.0 x 10^9/L</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>NEUT</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Neutrophil count decreased</td>
<td>&lt;LLN - 1.5 x 10^9/L</td>
<td>&lt;1.5 - 1.0 x 10^9/L</td>
<td>&lt;1.0 - 0.5 x 10^9/L</td>
<td>&lt;0.5 x 10^9/L</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>LYM</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Lymphocyte count decreased</td>
<td>&lt;LLN - 0.8 x 10^9/L</td>
<td>&lt;0.8 - 0.5 x 10^9/L</td>
<td>&lt;0.5 - 0.2 x 10^9/L</td>
<td>&lt;0.2 x 10^9/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>SODIUM</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyponatremia</td>
<td>&lt;LLN - 130 mmol/L</td>
<td>&lt;130 - 120 mmol/L</td>
<td>&lt;120 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>K</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypokalemia</td>
<td>&lt;ULN - 3.0 mmol/L</td>
<td>&lt;3.0 - 2.5 mmol/L</td>
<td>&lt;2.5 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>K</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyperkalemia</td>
<td>&gt;ULN - 5.5 mmol/L</td>
<td>&gt;5.5 - 6.0 mmol/L</td>
<td>&gt;6.0 - 7.0 mmol/L</td>
<td>&gt;7.0 mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>CREAT</td>
<td>umol/L</td>
<td>Investigations</td>
<td>Creatinine increased</td>
<td>&gt;ULN - 1.5 x ULN</td>
<td>&gt;1.5 - 3.0 x ULN</td>
<td>&gt;3.0 - 6.0 x ULN</td>
<td>&gt;6.0 x ULN</td>
</tr>
<tr>
<td>Glucose</td>
<td>GLUC</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypoglycemia</td>
<td>&lt;ULN - 3.0 mmol/L</td>
<td>&lt;3.0 - 2.2 mmol/L</td>
<td>&lt;2.2 - 1.7 mmol/L</td>
<td>&lt;1.7 mmol/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>GLUC</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyperglycemia</td>
<td>&gt;ULN - 8.9 mmol/L</td>
<td>&gt;8.9 - 13.9 mmol/L</td>
<td>&gt;13.9 - 27.8 mmol/L</td>
<td>&gt;27.8 mmol/L</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>BILI</td>
<td>umol/L</td>
<td>Investigations</td>
<td>Blood bilirubin increased</td>
<td>&gt;ULN - 1.5 x ULN</td>
<td>&gt;1.5 - 3.0 x ULN</td>
<td>&gt;3.0 - 10.0 x ULN</td>
<td>&gt;10.0 x ULN</td>
</tr>
<tr>
<td>Alanine</td>
<td>ALT</td>
<td>U/L</td>
<td>Investigations</td>
<td>Alanine aminotransferase increased</td>
<td>&gt;ULN - 3.0 x ULN</td>
<td>&gt;3.0 - 5.0 x ULN</td>
<td>&gt;5.0 - 20.0 x ULN</td>
<td>&gt;20.0 x ULN</td>
</tr>
<tr>
<td>Aspartate</td>
<td>AST</td>
<td>U/L</td>
<td>Investigations</td>
<td>Aspartate aminotransferase increased</td>
<td>&gt;ULN - 3.0 x ULN</td>
<td>&gt;3.0 - 5.0 x ULN</td>
<td>&gt;5.0 - 20.0 x ULN</td>
<td>&gt;20.0 x ULN</td>
</tr>
<tr>
<td>Calcium (corrected)</td>
<td>CA</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypocalcemia</td>
<td>&lt;ULN - 2.0 mmol/L</td>
<td>&lt;2.0 - 1.75 mmol/L</td>
<td>&lt;1.75 - 1.5 mmol/L</td>
<td>&lt;1.5 mmol/L</td>
</tr>
<tr>
<td>Calcium (corrected)</td>
<td>CA</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypercalcemia</td>
<td>&gt;ULN - 2.9 mmol/L</td>
<td>&gt;2.9 - 3.1 mmol/L</td>
<td>&gt;3.1 - 3.4 mmol/L</td>
<td>&gt;3.4 mmol/L</td>
</tr>
<tr>
<td>Albumin</td>
<td>ALB</td>
<td>g/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypoalbuminemia</td>
<td>&lt;LLN - 30 g/L</td>
<td>&lt;30 - 20 g/L</td>
<td>&lt;20 g/L</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----</td>
<td>-----</td>
<td>-----------------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Prothrombin Intl. Normalized Ratio</td>
<td>INR</td>
<td>Investigations</td>
<td>INR increased</td>
<td>&gt;1 - 1.5 x ULN</td>
<td>&gt;1.5 - 2.5 x ULN</td>
<td>&gt;2.5 x ULN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4</td>
<td>CD4</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>CD4 lymphocytes decreased</td>
<td>&lt;LLN - 0.5x10^9/L</td>
<td>0.5 - 0.2x10^9/L</td>
<td>&lt;0.2 - 0.05x10^9/L</td>
<td>&lt;0.05x10^9/L</td>
</tr>
<tr>
<td>QTc</td>
<td>QTc</td>
<td>ms</td>
<td>Electrocardiogram QT corrected interval prolonged</td>
<td>450 - 480 ms</td>
<td>481 - 500 ms</td>
<td>&gt;=501 ms</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 2: Best Overall Response per RECIST v1.1

#### Table 5: RECIST Response for Patients with Measurable Disease (ie, Target Disease)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
<th>Best Overall Response when Confirmation is Required*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/Non-PD</td>
<td>No</td>
<td>PR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>Non-CR/Non-PD/Not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>Non-CR/Non-PD/Not evaluated</td>
<td>No</td>
<td>SD</td>
<td>documented at least once &gt; 4 wks. from baseline**</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or No</td>
<td>PD</td>
<td>no prior SD, PR or CR</td>
</tr>
<tr>
<td>Any</td>
<td>PD***</td>
<td>Yes or No</td>
<td>PD</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease

* See RECIST v1.1 publication (2) for further details on what is evidence of a new lesion.

** Only for non-randomized trials with response as primary endpoint.

*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document the objective progression even after discontinuation of treatment.

#### Table 6: RECIST Response For Patients with Non-Measurable Disease (ie, Non-Target Disease)

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/Non-PD</td>
<td>No</td>
<td>Non-CR/Non-PD*</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>not evaluated</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

**Abbreviations:** CR = complete response; PD = progressive disease

**‘Non-CR/Non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised**
### 18.0 Appendix 3: Schedule of events

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening</th>
<th>Cycle 1</th>
<th>Subsequent Cycles</th>
<th>EOT</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor biopsy</td>
<td>X&lt;sup&gt;4&lt;/sup&gt;</td>
<td>X&lt;sup&gt;5&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td>X</td>
<td>X&lt;sup&gt;7&lt;/sup&gt;</td>
<td>X&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for PK</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;10&lt;/sup&gt;</td>
<td>X&lt;sup&gt;11&lt;/sup&gt;</td>
<td>X&lt;sup&gt;12&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Tumor assessment (RECIST and irRECIST)</td>
<td>X&lt;sup&gt;14&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
<td>X&lt;sup&gt;16&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td>X&lt;sup&gt;19&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Serum chemistry</td>
<td>X&lt;sup&gt;20&lt;/sup&gt;</td>
<td>X&lt;sup&gt;21&lt;/sup&gt;</td>
<td>X&lt;sup&gt;22&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coagulation</td>
<td>X&lt;sup&gt;23&lt;/sup&gt;</td>
<td>X&lt;sup&gt;24&lt;/sup&gt;</td>
<td>X&lt;sup&gt;25&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X&lt;sup&gt;26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td>X&lt;sup&gt;27&lt;/sup&gt;</td>
<td>X&lt;sup&gt;28&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>X&lt;sup&gt;29&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td>X&lt;sup&gt;30&lt;/sup&gt;</td>
<td>X&lt;sup&gt;31&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X&lt;sup&gt;32&lt;/sup&gt;</td>
<td>X&lt;sup&gt;33&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X&lt;sup&gt;34&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom-directed physical examination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations:
- AE = adverse event
- CBC = complete blood count
- CT = computed tomography
- ECG = electrocardiogram
- ECOG = Eastern Cooperative Oncology Group
- EOT = end of treatment
- FISH = fluorescence in situ hybridization
- irRECIST = immune-related RECIST

---

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Screening</th>
<th>Cycle 1</th>
<th>Subsequent Cycles</th>
<th>EOT</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vital signs, height, and weight&lt;sup&gt;1&lt;/sup&gt;</td>
<td>X&lt;sup&gt;35&lt;/sup&gt;</td>
<td>X&lt;sup&gt;36&lt;/sup&gt;</td>
<td>X&lt;sup&gt;37&lt;/sup&gt;</td>
<td>X&lt;sup&gt;38&lt;/sup&gt;</td>
<td>X&lt;sup&gt;39&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X&lt;sup&gt;40&lt;/sup&gt;</td>
<td>X&lt;sup&gt;41&lt;/sup&gt;</td>
<td>X&lt;sup&gt;42&lt;/sup&gt;</td>
<td>X&lt;sup&gt;43&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X&lt;sup&gt;44&lt;/sup&gt;</td>
<td>X&lt;sup&gt;45&lt;/sup&gt;</td>
<td>X&lt;sup&gt;46&lt;/sup&gt;</td>
<td>X&lt;sup&gt;47&lt;/sup&gt;</td>
<td>X&lt;sup&gt;48&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered&lt;sup&gt;2&lt;/sup&gt;</td>
<td>X&lt;sup&gt;49&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collected&lt;sup&gt;2&lt;/sup&gt;</td>
<td>X&lt;sup&gt;50&lt;/sup&gt;</td>
<td>X&lt;sup&gt;51&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Sample collection (whole blood) for FISH/MDS</td>
<td>X&lt;sup&gt;52&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X&lt;sup&gt;53&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X&lt;sup&gt;54&lt;/sup&gt;</td>
</tr>
<tr>
<td>cytogenetic analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Abbreviations:**
- ECOG = Eastern Cooperative Oncology Group (4)
- EOT = end of treatment
- FISH = fluorescence in situ hybridization
- irRECIST = immune-related RECIST

---
Evaluation Criteria in Solid Tumors; RP2D = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.
a. Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.
b. EOT visit should be completed within 7 days of the last dose of study treatment.
c. Required for Phase 1 patients only.
d. Patients in Phase 1 are required to have an in-clinic visit on Day 8 with CBC done at the study center’s laboratory. For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.
e. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing. If a patient has had a biopsy prior to entering screening and within 12 weeks of study treatment, that biopsy may be accepted as the screening biopsy.
f. In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 8 to approximately 12 weeks after initiating study treatment, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. A core biopsy is recommended; if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion.
g. Standard of care tests/procedures, including biopsy, radiographic scans, laboratory assessments, ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first dose for these procedures with the exception of the biopsy, which may have been conducted within 12 weeks of first dose, and pregnancy test, which must be conducted within 72 hours of first dose) and any relevant guidelines (eg, diagnostic quality for scans).
h. Required on Day 1 of Cycle 2 only.
i. Blood samples are to be obtained for niraparib and pembrolizumab PK assessments; see Table 6 and Table 7 of the protocol for the detailed schedule.
j. Tumor assessment per RECIST and irRECIST via CT or MRI (chest, abdomen, and pelvis [brain, only if clinically indicated]) required at screening, every 9 weeks (63 ± 7 days) from Cycle 1/Day 1 for the first year, and then every 12 weeks (84 ± 7 days) until progression; at the time of progression, a final follow up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.
k. If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly (thrombocytopenia or neutropenia) or once weekly (anemia) blood draws (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.
l. If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.
m. Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.6 of the protocol). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples.

n. Required on Day 1 of Cycle 2 and Cycle 3 only.
o. Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 months for duration of study (ie, Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.
p. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.
q. Blood samples for TSH, T3 or FT3, and FT4 are to be collected at screening, every 6 weeks thereafter, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 30-day post-treatment safety follow-up only if assessment is clinically indicated.

r. Patients will undergo ECG monitoring as per Table 6 and Table 7 of the protocol.
s Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only.

t AEs are required to be captured through 30 days after cessation of study treatment; SAEs and ECI s (see Section 6.1.6 of the protocol) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

u Administer pembrolizumab once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

v See Table 8 of the protocol for details of niraparib administration in Phase 1. The RP2D of the combination will be based on the results of Phase 1.

w Niraparib dose administered upon completion of pembrolizumab infusion.

x FISH/MDS: test result must be negative for cytogenetic abnormalities commonly observed in myeloid malignancies. The FISH/MDS result must be received prior to first dose.

y Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor's medical monitor finds evaluation necessary for assessing niraparib-related risk for MDS/AML (e.g., the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

z It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s medical monitor. The study site must receive a copy of the hematologist’s report of aspirate/biopsy findings, which must include a classification according to WHO criteria, and other sample testing results related to MDS/AML.
19.0 Appendix 4 Response Evaluation Criteria in Solid Tumors (RECIST), v1.1

Response Criteria by RECIST v1.1

Evaluation of Target Lesions

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Note: If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).

Table 7: RECIST Response for Patients with Measurable Disease (ie, Target Disease)
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease

* See RECIST v1.1 publication for further details on what is evidence of a new lesion.
** Only for non-randomized trials with response as primary endpoint.
*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document the objective progression even after discontinuation of treatment.

Table 8: RECIST Response For Patients with Non-Measurable Disease (ie, Non-Target Disease)

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD*</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>not evaluated</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; PD = progressive disease

*’Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not Advised.
# Appendix 5: Immune-Related response evaluation criteria in solid tumors

## Table 9: Imaging and Treatment after First Radiologic Evidence of Progressive Disease

<table>
<thead>
<tr>
<th>Timing of Imaging</th>
<th>Clinically Stable</th>
<th>Clinically Unstable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tumor Imaging</td>
<td>Treatment</td>
</tr>
<tr>
<td>1st radiologic</td>
<td>Repeat imaging at</td>
<td>May continue study</td>
</tr>
<tr>
<td>evidence of PD</td>
<td>≥ 4 weeks at site</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to confirm PD</td>
<td>treatment at the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>local site</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Investigator’s</td>
</tr>
<tr>
<td></td>
<td></td>
<td>discretion while</td>
</tr>
<tr>
<td></td>
<td></td>
<td>awaiting confirmatory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tumor imaging</td>
</tr>
<tr>
<td>Repeat tumor</td>
<td>No additional</td>
<td>No additional</td>
</tr>
<tr>
<td>imaging confirms</td>
<td>imaging required</td>
<td>imaging required</td>
</tr>
<tr>
<td>PD</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Repeat tumor</td>
<td>Continue regularly</td>
<td></td>
</tr>
<tr>
<td>imaging shows</td>
<td>scheduled imaging</td>
<td>Continue regularly</td>
</tr>
<tr>
<td>SD, PR or CR</td>
<td>assessments</td>
<td>scheduled imaging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>assessments</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**
- **CR** = complete response
- **irRECIST** = immune-related Response Criteria in Solid Tumors
- **N/A** = not applicable
- **PD** = progressive disease
- **PR** = partial response
- **RECIST** = Response Criteria in Solid Tumors
- **SD** = stable disease
## Appendix 6: Laboratory Standard Units

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>SI Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>g/L</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>U/L</td>
</tr>
<tr>
<td><strong>Absolute neutrophil count</strong></td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Basophils</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Blood Urea Nitrogen</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>frac of 1</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>g/L</td>
</tr>
<tr>
<td>INR</td>
<td>1</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Mean Corpuscular Hemoglobin</td>
<td>pg</td>
</tr>
<tr>
<td>Mean Corpuscular Volume</td>
<td>fL</td>
</tr>
<tr>
<td>Monocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Total Protein</td>
<td>g/L</td>
</tr>
<tr>
<td>Prothrombin Time</td>
<td>s</td>
</tr>
<tr>
<td>Partial Thromboplastin Time</td>
<td>s</td>
</tr>
<tr>
<td>Red Blood Cells</td>
<td>$10^{12}$/L</td>
</tr>
<tr>
<td>Aspartate Transaminase</td>
<td>U/L</td>
</tr>
<tr>
<td>Alanine Transaminase</td>
<td>U/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>White Blood Cells</td>
<td>$10^9$/L</td>
</tr>
</tbody>
</table>
23.0 Document History
1.0 Statistical Analysis Plan

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>TESARO, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol No:</td>
<td>3000-PN162-01-001, Amendment 2</td>
</tr>
<tr>
<td>Project Id:</td>
<td>TSRNIRPD-NIRPD1</td>
</tr>
<tr>
<td>Version No.:</td>
<td>Protocol v3.0</td>
</tr>
<tr>
<td>Title:</td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
<tr>
<td>CRF Version No./Date:</td>
<td>2.135/31-May-2018</td>
</tr>
<tr>
<td>SAP Version Date:</td>
<td>12-October-2018</td>
</tr>
<tr>
<td>SAP No.</td>
<td>Draft v2.0</td>
</tr>
</tbody>
</table>

2.0 Approvals

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Name:</td>
</tr>
<tr>
<td>Representative/ Title:</td>
</tr>
<tr>
<td>Signature /Date:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Name:</td>
</tr>
<tr>
<td>Representative/ Title:</td>
</tr>
<tr>
<td>Signature /Date:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project Manager/Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature /Date:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistician / Title (Owner):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature /Date:</td>
</tr>
</tbody>
</table>
# Table of Contents

1.0 Statistical Analysis Plan .................................................................................................................. 1

2.0 Approvals ........................................................................................................................................... 1

Table of Contents ....................................................................................................................................... 2

3.0 Purpose ................................................................................................................................................ 4

4.0 Scope .................................................................................................................................................... 4

5.0 Introduction ......................................................................................................................................... 4

5.1 Changes from Protocol ....................................................................................................................... 4

6.0 Study Objectives ................................................................................................................................. 5

6.1 Phase 1 .................................................................................................................................................. 5

6.1.1 Primary Objectives ....................................................................................................................... 5

6.1.2 Secondary Objectives .................................................................................................................. 5

6.2 Phase 2 ................................................................................................................................................ 5

6.2.1 Primary Objective: ....................................................................................................................... 5

6.2.2 Secondary Objective: .................................................................................................................... 5

6.2.3 Exploratory Objectives .................................................................................................................. 5

7.0 Study Design ....................................................................................................................................... 6

7.1 Sample Size Considerations ............................................................................................................. 7

7.2 Randomization .................................................................................................................................... 7

8.0 Study Variables and Covariates .......................................................................................................... 7

8.1 Primary Variables ............................................................................................................................... 7

8.1.1 Primary Variables: Phase 1 ........................................................................................................ 7

8.1.2 Primary Variables: Phase 2 ........................................................................................................ 8

8.2 Secondary Variables ............................................................................................................................ 8

8.2.1 Efficacy ......................................................................................................................................... 8

8.2.2 Safety ........................................................................................................................................... 8

8.2.3 Exploratory Endpoints .................................................................................................................. 9

8.3 Pharmacokinetic Variables .................................................................................................................. 9

8.3.1 Presentation of Pharmacokinetic Concentrations ........................................................................ 10

9.0 Definitions .......................................................................................................................................... 10

10.0 Biomarker Definitions ....................................................................................................................... 14

11.0 Analysis Sets .................................................................................................................................... 15

11.1 Screening Analysis Set ...................................................................................................................... 15

11.2 Full Analysis Set ............................................................................................................................... 15

11.3 Pooled OC Full Analysis Set ......................................................................................................... 15

11.4 Safety Analysis Set ........................................................................................................................... 15

11.5 DLT Analysis Set .............................................................................................................................. 15

11.6 Efficacy Evaluable (EE) Analysis Set .............................................................................................. 16

11.7 Pooled OC EE Analysis Set ............................................................................................................ 16

11.8 Pharmacokinetic (PK) Analysis Set .................................................................................................. 16

12.0 Interim Analyses ............................................................................................................................... 16

13.0 Data Review ...................................................................................................................................... 16

13.1 Data Handling and Transfer ............................................................................................................ 16

13.2 Data Cleaning .................................................................................................................................. 17

13.3 Handling of Dropouts or Missing Data ............................................................................................ 17

14.0 Statistical Methods ............................................................................................................................. 18

14.1 Patient Disposition ........................................................................................................................... 19

....
14.2 Protocol Deviations................................................................................................................................................ 19
14.3 Treatments ................................................................................................................................................................ 19
  14.3.1 Extent of Study Treatment Exposure ........................................................................................................... 19
  14.3.2 Prior and Concomitant Medications ............................................................................................................. 21
14.4 Demographic and Baseline Characteristics ................................................................................................. 22
  14.4.1 Primary Cancer History ............................................................................................................................... 22
  14.4.2 Medical History, Surgical History ............................................................................................................ 22
14.5 Efficacy Analyses ..................................................................................................................................................... 24
  14.5.1 Primary Endpoints ......................................................................................................................................... 24
  14.5.2 Methods for Handling Dropouts and Missing Data .................................................................................. 24
  14.5.3 Multiplicity ........................................................................................................................................................ 24
  14.5.4 Pooling of Sites ................................................................................................................................................ 24
  14.5.5 Secondary Endpoints .................................................................................................................................... 24
  14.5.6 Examination of Subgroups ........................................................................................................................... 25
14.6 Safety Analyses ........................................................................................................................................................ 27
  14.6.1 Adverse Events ................................................................................................................................................ 27
  14.6.2 Laboratory Data .............................................................................................................................................. 29
  14.6.3 Vital Signs .......................................................................................................................................................... 31
  14.6.4 Physical Examinations and Other Observations Related to Safety ............................................................ 31
  14.6.5 ECG ....................................................................................................................................................................... 31
15.0 Validation .................................................................................................................................................................. 32
16.0 References ............................................................................................................................................................... 33
17.0 List of Abbreviations ................................................................................................................................................ 34
18.0 Appendix 1: Common Terminology Criteria for Adverse Events V4.03 (CTCAE) ........................................ 37
19.0 Appendix 2: Schedule of events ........................................................................................................................... 39
20.0 Appendix 3 Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 ........................................... 43
21.0 Appendix 4: Immune-Related response evaluation criteria in solid tumors .............................................. 45
22.0 Appendix 5: Laboratory Standard Units ............................................................................................................. 46
23.0 Appendix 6: Drugs Excluded from Prior Lines of Therapy ............................................................................. 47
24.0 Appendix 7: Immune-Related Adverse Events ................................................................................................. 50
25.0 Document History .................................................................................................................................................. 52
3.0 Purpose

The statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and analyses of data collected under TESARO Inc. Protocol 3000-PN162-01-001.

4.0 Scope

This plan is a living document that will be created during the trial start-up. SAP 1 will be drafted within three months of final CRF, and maintained throughout the lifecycle of the trial, an email approval of SAP 1 from the sponsor is sufficient to start programming activities. The SAP 2 will be finalized prior to database lock. SAP 2 will require sign off from the Project Manager and the sponsor. The SAP outlines the following:

- Study objectives
- Study design
- Variables analyzed and analysis sets
- Applicable study definitions
- Statistical methods regarding important protocol deviations, study treatment exposure, efficacy analysis, concomitant medications, adverse events handling and laboratory data.

5.0 Introduction

This SAP describes the statistical methods to be used during the reporting and analyses of data collected under TESARO, Inc. Protocol 3000-PN-01-001.

This SAP should be read in conjunction with the study protocol and case report form (CRF). This version of the plan has been developed using the protocol dated 01-MAR-2017 (Amendment 2) and CRF dated 31-MAY-2018. Any further changes to the protocol or CRF may necessitate updates to the SAP.

The SAP is to be developed in two stages. The purpose is to “finalize” an SAP so that we can start programming earlier in the process. A final version of the SAP, known as SAP 2, will be issued for sponsor approval prior to database lock. Changes made to the SAP after database lock will be documented in the Clinical Study Report.

5.1 Changes from Protocol

The protocol describes a per-protocol population for use in evaluation of supportive analyses of efficacy. This population will not be used in this SAP.

The protocol defined evaluation of irRECIST endpoints (objective response rate, duration of response, disease control rate and progression free survival). These endpoints were not consistently collected across all patients and therefore cannot formally be evaluated. All collected data will be listed. In addition, for patients who received study treatment for ≥28 days beyond radiological progression per RECIST v1.1 and who have post-progression tumor assessments, the irRECIST evaluations will be listed along-side the RECIST v1.1 evaluations, as available.

The relationship between cytogenetic abnormalities and safety parameters was to be evaluated per protocol, however this was not done since there is no cytogenetic abnormality assessment.
6.0 Study Objectives

6.1 Phase 1

6.1.1 Primary Objectives
- To evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment.
- To establish a recommended Phase 2 dose (RP2D) and schedule.

6.1.2 Secondary Objectives
- To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- To evaluate the pharmacokinetics (PK) of niraparib and associated major metabolite M1 during combination treatment.

6.2 Phase 2

6.2.1 Primary Objective:
- To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separately for the triple-negative breast cancer (TNBC) and ovarian cancer (OC) cohorts.

6.2.2 Secondary Objective:
- To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v.4.03)
- Phase 2: To evaluate additional measures of clinical benefit as assessed by the Investigators, including:
  - ORR by immune-related RECIST v1.1 (irRECIST);
  - Duration of response (DOR) by RECIST v1.1 and irRECIST;
  - Disease control rate (DCR) by RECIST v1.1 and irRECIST;
  - Progression-free survival (PFS) by RECIST v1.1 and by irRECIST;
  - Overall survival (OS).
- To evaluate the PK of niraparib and associated major metabolite M1 during combination treatment.

6.2.3 Exploratory Objectives
- To identify the biomarker-based patient population that would derive benefit from the combination treatment based on the tumor tissue molecular profile, molecular profile of tumor-infiltrating lymphocytes (TILs) and circulating biomarkers.
- To correlate homologous recombination deficiency (HRD) score with other immune-related biomarkers and with efficacy outcomes.
7.0 **Study Design**

This is a multicenter, open-label, single-arm Phase 1/2 study evaluating the safety and efficacy of combination treatment with niraparib and pembrolizumab in patients with previously treated TNBC or OC.

The study will be conducted in 2 parts. The Phase 1 portion of the study will be a dose-escalation evaluation to determine the recommended Phase 2 dose (RP2D) and schedule of niraparib to be administered in combination with the recommended dose of pembrolizumab to be used in the Phase 2 portion.

Dosing will initiate at Dose Level 1 with a cohort of 6 patients with either TNBC or OC enrolled and treated with a combination of niraparib 200 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. Once Dose Level 1 is determined to be safe, a cohort of 6 patients with either TNBC or OC will be enrolled in Dose Level 2 and treated with a combination of niraparib 300 mg PO daily for Days 1-21 and pembrolizumab 200 mg IV on Day 1 every 21 days. No further dose escalation will be considered if Dose Level 2 is reached. The maximum tolerated dose (MTD) will be defined as the highest dose with DLTs observed in less than one-third of patients (ie, < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment. If one-third or more of the evaluable patients experiences a DLT, then this dose will be considered to exceed the MTD and a lower dose level may be opened for enrollment if not yet evaluated.

The following are 4 dose levels/schedules planned for the Phase 1 of the study; each cohort will contain 6 patients but may be expanded to 12 patients:

- **Dose Level 1**: niraparib 200 mg/day orally (PO) on Days 1-21 and pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.
- **Dose Level 2**: niraparib 300 mg/day PO on Days 1-21 and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.
- **Dose Level (-1)**: niraparib 200 or 300 mg/day PO on Days 1-14 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. (See Section 9.12 of the protocol)
- **Dose Level (-2)**: niraparib 200 or 300 mg/day PO on Days 1 – 7 of each 21-day cycle and pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. (See Section 9.12 of the protocol).

The Phase 2 portion of the study will commence after the RP2D is determined during the Phase 1 portion. Two cohorts of 48 patients each with advanced TNBC or OC will be evaluated.

Patients in this phase of the study will receive the RP2D of niraparib in combination with pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.

In Phase 2, pembrolizumab will be administered once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons. Niraparib dose will be administered upon completion of pembrolizumab infusion. The RP2D of the combination will be based on the results in Phase 1.

Combination pembrolizumab/niraparib treatment may continue for up to 2 years unless specific withdrawal criteria are met (Section 4.3 of the protocol). Continued treatment with niraparib beyond 2 years may be considered following discussion between the Sponsor and Investigator. Figure 1 describes the study schema. The schedule of events is added in the appendix of section 19.0.
7.1 Sample Size Considerations

A total sample size of approximately 18 patients is estimated for the Phase 1 portion of the study to provide initial comparison of the incidence of DLTs and safety profiles of the combination treatment between dose schedules in each patient population. More patients could be enrolled (e.g., if the Dose Level -2 is explored, or if expansion at any dose level is required to better understand safety and tolerability); up to a total of 36 patients may be enrolled.

A total of approximately 96 evaluable patients (48 patients in each tumor type) will be enrolled in Phase 2 to ensure understanding of the activity of the combination treatment and to obtain adequate representation of different molecular cancer subtypes and biomarkers. For each cohort, with 48 evaluable patients, the study has approximately 82%/94% power for each cohort to rule out a ≤15% ORR (null hypothesis) when the true ORR is 30%/35% at the 10% type I error rate (two-sided).

7.2 Randomization

Not applicable, as this is a single-arm study and Phase 2 is conducted in two cohorts.

8.0 Study Variables and Covariates

8.1 Primary Variables

Phase 1

- DLTs of combination treatment during the first treatment cycle
8. MTD defined as the highest dose of niraparib with DLTs observed in less than one-third of patients (i.e., < 2 of 6 patients or < 4 of 12 patients) during Cycle 1 of combination treatment.

8. RP2D - defined as the greatest dose intensity and regimen of niraparib that can be safely combined with the recommended dose and regimen of pembrolizumab

Phase 2

8. ORR for combination treatment with pembrolizumab and niraparib using RECIST v1.1 criteria based on the investigator assessment.

8.2 Secondary Variables

8.2.1 Efficacy

- ORR for combination treatment with pembrolizumab and niraparib using irRECIST criteria.
- Duration of Response (DOR) per RECIST v1.1
- Duration of Response (DOR) per irRECIST
- Disease Control Rate per RECIST v1.1
- Disease Control Rate (DCR) per irRECIST
- Progression Free Survival (PFS) per RECIST v1.1
- Progression Free Survival (PFS) per irRECIST
- Overall Survival (OS)

Protocol specified irRECIST endpoints were not consistently collected across all patients and therefore cannot formally be evaluated using standard summaries. irRECIST timepoint assessments will be listed, as available.

8.2.2 Safety

All treatment emergent adverse events including serious and non-serious will be collected. Severity will be assessed based on CTCAE (v 4.03) grades. The reported events will be assessed for causal relationship to study drugs. Events of clinical interest for pembrolizumab and niraparib will also be collected.

The following additional safety information will be collected.

- Changes in clinical laboratory values (hematology, chemistry, coagulation, thyroid function, urinalysis)
- Vital signs
- ECG’s
- Physical examination findings
- Concomitant medications
8.2.3 Exploratory Endpoints

The relationship between cytogenetic abnormalities and safety parameters was to be evaluated per protocol, however this was not done since there is no cytogenetic abnormality assessment.

8.3 Pharmacokinetic Variables

The pharmacokinetic analysis set will consist of all patients with sufficient data to enable estimation of at least one PK parameter listed below. The following PK parameters will be calculated for niraparib and major metabolite M1 for Phase 1 using standard non-compartmental methods in Phoenix® WinNonlin® (WNL) (Pharsight Corporation, Version 6.3 or higher):

Table 1: PK parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>SAS Programming Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$</td>
<td>Observed maximum concentration during the dosing interval.</td>
<td>$C_{\text{max}}$ from WNL</td>
</tr>
<tr>
<td>$C_{\text{min}}$</td>
<td>Observed minimum concentration during the dosing interval.</td>
<td>$C_{\text{min}}$ from WNL</td>
</tr>
<tr>
<td>$T_{\text{max}}$</td>
<td>Time of the maximum observed concentration.</td>
<td>$T_{\text{max}}$ from WNL</td>
</tr>
<tr>
<td>$AUC(0\text{-}24)$</td>
<td>Area under the plasma concentration-time curve from time 0 to 24 hours. This parameter will be calculated for Phase 1, Cycle 1 and Cycle 2.</td>
<td>$AUC(0\text{-}24)$ from WNL (partial area)</td>
</tr>
<tr>
<td>$AUC(0\text{-}\text{last})$</td>
<td>Area under the concentration-time curve between time zero (predose) and time of last quantifiable concentration.</td>
<td>$AUC_{\text{last}}$ from WNL</td>
</tr>
<tr>
<td>$AUC(0\text{-}\tau)$; $AUC(0\text{-}\tau)_{\text{ss}}$</td>
<td>Area under the plasma concentration-time curve during a dosing interval. This parameter will be calculated after a single dose and after multiple doses at steady state based on available data.</td>
<td>$AUC_{\tau}$ from WNL where $\tau$ is equal to XX hr</td>
</tr>
<tr>
<td>AR</td>
<td>The accumulation ratio will be calculated as the exposure at steady state within $\tau$ divided by the first dose exposure within $\tau$.</td>
<td>$AUC(0\text{-}\tau)_{\text{ss}} / AUC(0\text{-}\tau)$</td>
</tr>
<tr>
<td>$AUC(0\text{-}\text{inf})$</td>
<td>Area under the concentration-time curve between time zero (predose) extrapolated to infinity. $AUC_{%\text{Extrap_obs}} \leq 20%$ or $R^2 &gt; 0.70$ is required to retain $AUC_{\text{inf}}$ This parameter will be calculated for Phase 1, Cycle 1 only.</td>
<td>$AUC_{\text{INF_obs}}$ from WNL If $AUC_{%\text{Extrap_obs}} &gt; 20%$ or $R^2 \leq 0.70$ then parameter will not be reported.</td>
</tr>
<tr>
<td>CL/F</td>
<td>Apparent clearance calculated as $CL = \text{Dose} / AUC_{\text{inf}}$ Percent extrapolation less than or equal to 20% and $r^2$ greater than 0.70 is required to retain CL/F.</td>
<td>$CL_{F_obs}$ from WNL If $AUC_{%\text{Extrap_obs}} &gt; 20%$ or $R^2 \leq 0.70$ then parameter is deleted</td>
</tr>
<tr>
<td>$V_z/F$</td>
<td>Apparent volume of distribution as $V_z/F = (CL/F)/\lambda_z$ Percent extrapolation less than or equal to 20% and $r^2$ greater than 0.70 is required to retain $V_z/F$.</td>
<td>$V_{z_F_obs}$ from WNL If $AUC_{%\text{Extrap_obs}} &gt; 20%$ or $R^2 \leq 0.70$ then parameter is deleted</td>
</tr>
</tbody>
</table>
General statistics will be summarized for both Phase 1 and sparse data in Phase 2.
PK analysis will use actual times as recorded on the CRF. If actual times are missing, nominal times may be used with sponsor approval.
Concentrations are used as supplied by the analytical laboratory for PK analysis. The units of concentration and resulting PK parameters, with amount or concentration in the unit, will be presented as they are received from the analytical laboratory. Concentration values that are below the level of quantification (BLQ) will be set to zero, with defined exceptions as follows: any embedded BLQ value (between 2 quantifiable concentrations) and BLQ values following the last quantifiable concentration in a profile will be set to missing for the purposes of PK analysis.
If there are late quantifiable concentration values following 2 BLQ concentration values in the apparent terminal phase, these values will be evaluated. If these values are considered to be anomalous, they will be set to missing. If an entire concentration-time profile is BLQ, the profile will be excluded from the PK analysis. If concentration values at the beginning of the profile (i.e. pre-dose) are missing, these values may be set to zero with sponsor approval.

8.3.1 Presentation of Pharmacokinetic Concentrations

- The following rules will be applied if there are values that are below the lower limit of quantification (BLQ) or if there are missing values (e.g., no result [NR]) in a plasma concentration data series to be summarized.
  - For the calculation of summary statistics, BLQ values will be set to zero.
  - Where there is NR, these will be set to missing.
- If all the values are BLQ, then the arithmetic mean, arithmetic SD, median, min and max will be presented as zero and the geometric mean and geometric CV% will be denoted as not calculated (NC).
- If the value of any descriptive statistic calculation is BLQ, these will be presented as zero and the geometric mean and geometric CV% will be denoted as NC.

9.0 Definitions

Age:
The age collected at time of screening, presented in whole years.

Age Group:
There will be three age groups summarized in the demographics tables: <65 years old, ≥65-<75 years old and ≥ 75 years old.

Baseline:
Unless otherwise specified, baseline is the last measurement taken on or prior to first dose of pembrolizumab or niraparib, whichever is earlier (baseline can be the same date as first dose, given the measurement is expected prior to first dose, otherwise consider both time and date of dosing (if time is available for both).

Best Overall Response (BOR) per RECIST v1.1 - Confirmed:
The best overall response (BOR) according to RECIST v1.1 will be assessed based on reported overall timepoint responses at different evaluation time points from the first dose date until documented disease progression, according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart with no evidence of progression between the two determinations.

PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR).

SD= at least one SD assessment (or better) ≥ 28 days after the baseline scan and before progression (and not qualifying for a CR or PR).

PD= progression after baseline.

Only tumor assessments performed before the start of any further anti-cancer treatment will be considered in the assessment of BOR. Clinical deterioration will not be considered as documented disease progression.

**Best Overall Response (BOR) per RECIST v1.1 Without Confirmation Requirements:**
The best overall response (BOR) according to RECIST v1.1 without confirmation requirements will be assessed based on reported overall timepoint responses at different evaluation time points from the first dose date until documented disease progression, according to the following rules:

- Confirmed CR = at least two determinations of CR at least 4 weeks apart with no evidence of progression between the two determinations.

- Unconfirmed CR = at least one determinations of CR and not followed by another CR meeting the requirement for confirmation.

- Confirmed PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR).

- Unconfirmed PR = at least one determinations of PR or better before progression (and not qualifying for a CR), and not followed by another PR meeting the requirement for confirmation.

- SD= at least one SD assessment after baseline and before progression [and not qualifying for any type of CR or PR above (confirmed or unconfirmed)].

- PD= progression after baseline.

Only tumor assessments performed before the start of any further anti-cancer treatment will be considered in the assessment of BOR. Clinical deterioration will not be considered as documented disease progression.

**Body Mass Index (BMI):**
Calculated at each visit and is equal to the weight (in kg)/ [height at screening (in m)]².

**Clinical Benefit Rate at 18 weeks (CBR18):**
The clinical benefit rate at 18 weeks is the proportion of patients in the analysis population who achieved confirmed CR or PR, or achieved SD ≥18 weeks without evidence of radiologic progression prior to this point. A seven day window will be used to accommodate scan timing, thereby considering any SD, PR or CR beyond 17 weeks (ie, ≥119 days). Patients who are ongoing treatment who have not reached the timepoint of interest will not be included in the denominator.

**Corrected QT Interval (QTcF):**
QTcF is defined as corrected QT interval with Fridericia’s correction formula: QTcF = QT/(RR)^{1/3}, where QT is the heart rate interval, measured in milliseconds and RR is the interval from the onset of one QRS complex to the onset of the next QRS complex, measured in seconds.

**Disease Control Rate (DCR) per RECIST v1.1:**
Disease control rate will be assessed as a secondary endpoint and is defined as the proportion of patients achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST v1.1. DCR will be assessed requiring confirmation and without confirmation requirements.

**Duration of Response (DOR) per RECIST v1.1:**
DOR is applicable to patients that achieve either CR/PR per RECISTv1.1 and is defined as time from the first assessment of CR/PR until the date of the first occurrence of PD, or until the date of death. Follow Table 2 for censoring rules of DOR. DOR will be assessed for both confirmed responses only and for responses without confirmation requirements.

\[
DOR (\text{months}) = \frac{\text{Date of PD/Death/Censoring} - \text{Date of First recorded CR or PR} + 1}{30.4375}
\]

**Last Known Contact Date:**
The date of last known contact date will be derived for patients not known to have died at the analysis cut-off using the latest complete date among the following:

- Patient assessment dates (blood draws [laboratory, PK], vital signs, performance status, ECG, tumor assessments, ECOG, tumor measurement, or tumor biopsy dates)
- Start and end dates of anti-cancer therapies administered after study treatment discontinuation.
- AE start and end dates
- Last date of contact collected on the ‘Survival information’ eCRF (do not use date of survival follow-up assessment unless status is ‘alive’)
- Study treatment start and end dates
- Date of discontinuation on disposition eCRF pages (do not use if reason for discontinuation is lost to follow-up).

Only dates associated with actual examinations of the patient will be used in the derivation. Dates associated with a technical operation unrelated to patient status such as the date a blood sample was processed will not be used. Assessment dates after the cut-off date will not be applied to derive the last contact date, if applicable.

**Objective Response Rate (ORR) per RECIST v1.1:**
ORR will be assessed using tumor data recorded by the Investigator, and the denominator will be based on all patients in the defined analysis population. The ORR is the proportion of patients who achieved best overall response of CR (complete response) or PR (partial response). ORR will be assessed requiring confirmation and without confirmation requirements. When confirmation is required, the objective responses should be confirmed by a repeat tumor imaging assessment, at least 4 weeks apart, per RECIST v1.1. Each patient will have an objective response status (0: OR=no; 1: OR=yes).
Overall Response:
Overall tumor response assessment at each time point is a combination of target lesions, non-target lesions and new lesions assessed by the investigator following the guidelines presented specified in RECIST v1.1. The response evaluation criteria per RECIST v1.1 are presented in Appendix D of the protocol.

Overall Survival (OS):
Overall survival will be assessed as a secondary endpoint and is defined as the time from date of first dose of study treatment to the date of death by any cause. Patients last known to be alive will be censored at date of last known contact.

\[
OS(\text{months}) = \frac{\text{Date of Death/Censoring} - \text{Date of First Dose} + 1}{30.4375}
\]

Progression-Free Survival Time (PFS) per RECIST v1.1:
Progression-free survival will be assessed as a secondary endpoint and is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Censoring rules for PFS events follow the guidelines presented in Table 2.

\[
PFS(\text{months}) = \frac{\text{Date of PD/Death/Censoring} - \text{Date of First Dose} + 1}{30.4375}
\]

Table 2: Censoring Rules for PFS and DOR.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Date of event/censoring</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>No baseline assessment or no post-baseline assessment</td>
<td>First dose date</td>
<td>Censored a</td>
</tr>
<tr>
<td>Progression or death ≤ 18 weeks after last tumor assessment or ≤ 18 weeks after first dose date</td>
<td>Date of progression or death</td>
<td>Event</td>
</tr>
<tr>
<td>Progression or death &gt; 18 weeks after the last tumor assessment</td>
<td>Date of last adequate assessment</td>
<td>Censored</td>
</tr>
<tr>
<td>No progression</td>
<td>Date of last adequate assessment</td>
<td>Censored</td>
</tr>
<tr>
<td>New anticancer therapy given (excluding radiation therapy)</td>
<td>Date of last adequate assessment before anticancer therapy given</td>
<td>Censored</td>
</tr>
</tbody>
</table>

a However if the patient dies ≤18 weeks after first dose date the death is an event with date on death date

Study Treatments:
Study treatments are niraparib and pembrolizumab.

Treatment Cycle:
Cycles will be identified in the visit label in the clinical database associated with dosing records.

Treatment Emergent Adverse Event (TEAE):
All AEs were collected and recorded in the eCRF for each patient from the day of signed informed consent until 30 days after the last dose of study treatment; SAEs were monitored through 90 days after the last dose of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy). All AEs and SAEs experienced by a patient,
irrespective of the suspected causality, were to be monitored until the AE or SAE has resolved, any abnormal laboratory values have returned to baseline or normal levels, until there is a satisfactory explanation for the changes observed, until the patient is lost to follow-up, or until the patient has died. Per protocol (Section 6.1.1), a treatment emergent adverse event was defined as any new AE that began, or any preexisting condition that worsens in severity after at least 1 dose of study treatment has been administered. For analysis, TEAE’s are AE’s with the onset date beginning on or after the day of first administration of either study treatment. It is expected that data cleaning activities will ensure collection of all reportable events in the clinical database. An AE with completely missing onset and stop dates, or with the onset date missing and a stop date later than the first dose date of either study treatment, will be considered to be treatment emergent.

10.0 Biomarker Definitions

HRR status: Mutational status of Homologous Recombination Repair (HRR) pathway genes: . In this document, HRR status is primarily determined using the Myriad Research HRD test on tumor sample collected prior to enrollment. This test only reports HRR mutational status in the tumor and cannot distinguish germline mutation from somatic mutation. In addition, local germline testing results for BRCA1, BRCA2 are collected for all patients. Local testing results for other HRR genes, when available, are also included.

- BRCA mutant (BRCA-mut): gBRCA mutant OR tBRCA mutant
  - gBRCA mutant (gBRCA-mut): At least one deleterious or suspected deleterious mutation found in BRCA1 or BRCA2 in local germline testing.
  - tBRCA mutant (tBRCA-mut): At least one deleterious or suspected deleterious mutation found in BRCA1 or BRCA2 in the tumor.
- BRCA wild type (BRCA-wt): tBRCA-wt AND not gBRCA-mut
  - tBRCA wild type (tBRCA-wt): No deleterious or suspected deleterious mutation found in BRCA1 or BRCA2.
- Unknown BRCA status: Not BRCA-mut AND not BRCA-wt
- Other HRR mutant (oHRR-mut): At least one deleterious or suspected deleterious mutation found in one or more of the HRR pathway genes, excluding BRCA1 and BRCA2.
- Other HRR wild type (oHRR-wt): No deleterious or suspected deleterious mutation found in any of the HRR pathway genes, excluding BRCA1 and BRCA2.
- HRR mutant (HRR-mut): BRCA-mut or oHRR-mut.
- HRR wild type (HRR-wt): BRCA-wt AND oHRR-wt.
- Unknown HRR status: No sample tested or failed sample AND not gBRCA mutant

HRD status: Homologous recombination deficiency (HRD) – Dysregulation in the homologous recombination pathway (due to genetic mutations or alterations) leading to cellular genomic instability and an inability to efficiently repair damaged DNA. In this document, HRD status is determined using the Myriad Research HRD test on tumor sample collected prior to enrollment.
• HRD positive (HRD-pos): Any tumor with an HRD score ≥42, OR BRCA mutant, is considered HRD positive.

• HRD negative (HRD-neg): Any tumor with an HRD score <42, AND not BRCA mutant, is considered HRD negative.

• HRD unknown (HRD-unk): No sample tested or failed sample AND not gBRCA mutant.

PD-L1 status: PD-L1 is one of the ligands that bind to PD-1 on tumor infiltrating T cells and renders the T cells inactive. PD-L1 expression has been used as a biomarker for identifying patients who may benefit from anti-PD1/L1 therapies. In this document, PD-L1 status is determined using the Agilent/DAKO 22C3 immunohistochemistry (IHC) clinical trial assay (CTA) on tumor sample collected prior to enrollment.

• PD-L1 positive (PD-L1-pos): Any tumor with a combined proportion score (CPS) score ≥1. CPS is defined as: (the number of PD-L1 positive tumor and immune cells/the number total tumor cells)*100.

• PD-L1 negative (PD-L1-neg): Any tumor with a combined proportion score (CPS) score <1.

• PD-L1 unknown: No sample tested or failed sample.

11.0 Analysis Sets

11.1 Screening Analysis Set
All patients that signed the informed consent form including screen failures.

11.2 Full Analysis Set
The full analysis set (FAS) will consist of all Phase 2 patients who receive any amount of study treatment. If a patient receives more than one dose level of study treatment, the patient will be classified according to the original dose level received. The primary analysis of efficacy endpoints will be performed on the FAS population.

11.3 Pooled OC Full Analysis Set:
Given the similarities of the Phase 1 and Phase 2 patient population for the ovarian cancer cohort, corresponding efficacy analyses will be provided using the pooled Phase 1 and Phase 2 data. This analysis set will include all OC patients that are treated with any amount of study treatment.

11.4 Safety Analysis Set
The safety analysis set will include all patients who receive any amount of study treatment in Phase 1 or Phase 2. In Phase 1, patients will be evaluated by dose level actually received and tumor type. In Phase 2, patients can be evaluated by tumor type. If a patient receives more than one dose level, the patient will be classified according to the first dose level received. In this non-randomized study, the FAS and the safety analysis set in Phase 2 are identical. The safety analysis set will be used to summarize patient disposition.

11.5 DLT Analysis Set
The DLT analysis set will consist of all Phase 1 patients who complete the first cycle of therapy i.e. patients who started cycle 2 or discontinued at least 21 days after the first dose of either study medications in cycle
1, unless the patient discontinues due to a DLT, and is able to take more than 80% of the intended dose of both agents. The DLT analysis set will be used for the evaluation of the MTD in Phase 1.

11.6 Efficacy Evaluable (EE) Analysis Set

The EE analysis set will consist of all dosed (with either pembrolizumab or niraparib) FAS patients with at least one evaluable post-baseline tumor assessment. Tumor response endpoints including ORR, DOR and DCR will be analyzed using the EE analysis set.

11.7 Pooled OC EE Analysis Set

Given the similarities of the Phase 1 and Phase 2 patient population for the ovarian cancer cohort, corresponding efficacy analyses will be provided using the pooled Phase 1 and Phase 2 data. This analysis set will include all OC patients that are treated with any amount of study treatment and least one evaluable post-baseline tumor assessment.

11.8 Pharmacokinetic (PK) Analysis Set

The pharmacokinetic analysis set will consist of all patients with sufficient data to enable estimation of at least one PK parameter. Patients who are enrolled without meeting inclusion/exclusion criteria may be excluded upon Sponsor’s review.

12.0 Interim Analyses

To minimize the risk of exposing patients to an ineffective treatment, a series of response assessments will be performed when 6, 12, 18, 48 Phase 2 patients from each cancer type have at least 2 post-baseline tumor assessments. A formal decision regarding futility, which could result in stopping the study early, will be conducted separately for the TNBC and OC cohorts and will only be made from the analysis of 24 patients within each cohort. The earlier assessments, however, will inform the conduct of the formal interim analysis as follows: If no responder is observed in all three response assessments from 6, 12 and 18 patients, then enrollment will be suspended after 24 patients have been enrolled, and no further patients will be enrolled until the result of the formal interim analysis of 24 patients is known. If ≥ 1 responder are observed in any single response assessment from 6, 12 or 18 patients, then enrollment will not be curtailed. The decision rule regarding the formal interim analysis at N=24 is as follows: If there are fewer than 3 responders of 24, enrollment may be closed, and the corresponding cohort may be stopped for futility. Otherwise, the study will continue to the planned enrollment of 48 patients.

13.0 Data Review

Final data for analysis will be cleaned prior to receipt by statistical programming. Ongoing data handling will take place by the study programmer, until the time at which the study team has full access to the data.

13.1 Data Handling and Transfer

All the data will come from the TESARO data management group and be extracted in SAS® dataset format (SAS v9.4 or later) and converted to SDTM v3.2. Please refer to the Data Management Plan for details.
13.2 Data Cleaning

Beyond the data cleaning built into the DMP, [redacted] will be programming analysis datasets and TFLs and will provide additional data cleaning. Data issues identified during the process of programming analysis datasets and TFLs programming, will be sent to Data Management.

All derived datasets will include patient-level variables, such as analysis set inclusion, sex, tumor cohort, and dose dates.

Any methodologies used to address any issues identified in the data will be documented in the analysis data set specifications and finalized before database lock.

Variables generated at the patient level will be stored in a consolidated data set for the study. Variables at the patient level or below (e.g., at the visit level) will be generated in analysis data set programs, not in the programs generating the TFLs. Exceptions may include simple concatenation or formatting that will only be used once.

The content of the analysis data sets will be detailed in a separate document. For each derived data set, the label, sort order, and structure (expected number of records per patient/visit) will be specified. For each variable, the name, label, type, length, format, and source or derivation description will be specified. Detailed rules devised to handle specific data patterns found in data reviews will be included. The analysis dataset specifications will be finalized before database lock.

Review of a pre-lock TFL run on the ready-to-lock database allow for further data screening prior to lock. The pre-lock TFLs may be discussed with TESARO in a data review meeting to identify any final data issues and seek corrections prior to database lock. The [redacted] and TESARO statistician must approve database lock ahead of locking the database. The TESARO statistician will sign off per TESARO process.

13.3 Handling of Dropouts or Missing Data

Missing observations will generally be treated as missing at random and will not be imputed, unless otherwise noted.

Incomplete dates for disease history (e.g. initial diagnosis date, date of documented, locally advanced, metastatic disease diagnosis, date of response or progression in prior treatment) will be imputed as follows:

1. If the day is missing, it will be imputed to the 1st day of the month.
2. If both day and month are missing, the month and day will be imputed as January 1st.
3. If the date is completely missing, no imputation will be performed.

Incomplete days for the calculation of platinum-free interval (PFI) will be imputed as follows:

- Platinum start/end dates:
  - If the day is missing, it will be imputed to the 1st day of the month.
  - If both day and month are missing, the month and day will be imputed as January 1st.
  - If the date is completely missing, no imputation will be performed.

- Date of progression:
  - If the day is missing, it will be imputed to the 1st day of the month.
  - If day and month are missing or the date is completely missing, the start of the next chemotherapy regimen will be used.
Incomplete dates for adverse event and concomitant medication dates will be imputed as follows:

Start Date:
- If only ‘day’ is missing, and the month and year are not the same as the month and year of first dose, then impute day with ‘01’. Otherwise, if the month and year are the same as first dose date, use first dose date.
- If ‘day’ and ‘month’ are missing, and ‘year’ is not missing, then impute month and day with month and day of first dose date (assuming same ‘year’).
- If the year is not the same as the year of first dose, impute 01 for day and 01 for month.
- If the start date is completely missing, it will be set to the first dose date.

Stop Date:
- If only ‘day’ is missing, impute day with last day of the month.
- If ‘day’ and ‘month’ are missing, and ‘year’ is not missing, then impute month with '12' and day with '31' (or date of study discontinuation/completion if earlier than 12-31).
- If the stop date is completely missing, it will be set to the date of study discontinuation/completion. A stop date will not be applied to ongoing AEs.
- If the imputed stop date is greater than last contact date, then set to last contact date.

Note, for all listings the actual value for date (not imputed) will be presented in all data listings and imputed dates will only be used for programming flags, etc.

### 14.0 Statistical Methods

In general, categorical data will be summarized using number of patients (n), frequency and percentages, with the denominator for percentages being the number of patients in the analysis set for each cohort. Percentages will be rounded to 1 decimal place except for 100%, which will have no decimal place.

Continuous data will be summarized using the number of patients, mean, standard deviation, median, quartiles (Q1, Q3), minimum, and maximum. The mean, median and quartiles (Q1, Q3) will be presented to 1 decimal place greater than the original data; the standard deviation will be presented to 2 decimal places greater than the original data; and the minimum and maximum will have the same number of decimal places as the original data.

Results will be displayed for each of the TNBC and OC cohorts as well as the overall population. All statistical analyses and data listings will be performed using SAS.

Two-sided exact 90% confidence intervals (CIs) based on the Clopper-Pearson method (3) will be provided to summarize the binomial proportion of the derived best overall response for RECISTv1.1 assessments where applicable:

The Clopper-Pearson CI (3) can be carried out using the FREQ procedure in SAS v9.4 or higher.

Time-to-event analyses will be performed using Kaplan-Meier (KM) methods. Comparisons in the Phase 1 portion of the study will be made using descriptive statistics. Subgroup analyses will be performed using descriptive statistics and are considered exploratory.

In addition:
- Weeks will be calculated as Number of days divided by 7
- Months will be calculated as Number of days divided by 30.4375
- Study Day 1 will be considered the first day of study treatment
14.1 Patient Disposition

Disposition of patients includes the number and percentage of patients for the following categories:

- patients in each of the analysis sets,
- patients discontinued from treatment,
- primary reason for discontinuation from treatment,
- patients discontinued from the study, and
- primary reason for discontinuation from the study.

Numbers and percentages of patients will be presented by dose level in the Phase 1 portion and for all patients by tumor cohort in the Phase 2 portion.

A listing will present data for patient disposition.

14.2 Protocol Deviations

A protocol deviation (PD) is any failure to comply with the study protocol as approved by the relevant regulatory authority, ethics committee and/or institutional review board, whether planned or unplanned.

PD will be assessed and classified as important or significant. A protocol deviation is classified as an important PD if there is the potential to:

- Impact the completeness, accuracy, and/or reliability of the study data, or
- Affect a subject’s rights, safety, or well-being.

A protocol deviation is classified as a significant PD if it has been confirmed to:

- Adversely impact the completeness, accuracy, and/or reliability of the study data
- Affect a subject’s rights, safety, or well-being.

All PDs will be identified and finalized prior to database lock.

The number of patients with each type of important protocol deviations and the number of deviations will be tabulated by deviation category and by deviation type for all patients in the safety analysis set per dose level in Phase 1 and per tumor cohort in Phase 2. A listing of all deviations (including deviation date, deviation type, important or significant categorization, and deviation description) will be generated.

14.3 Treatments

14.3.1 Extent of Study Treatment Exposure

The following study drug exposure parameters will be summarized:

Any study drug

- Duration of study drug exposure in months defined as:

\[
\text{max(End of treatment date per CFR)} - \text{min(End of treatment date per CFR)} + 1
\]

30.4375
The number of study treatment cycles initiated as a categorical and continuous variable

A listing of patients who discontinued one treatment but continued with the other will be provided along with number of cycles and last dosing date for each treatment.

**Niraparib**

- Duration of niraparib treatment in months
  
  \[
  \frac{\text{Date of last dose of niraparib} - \text{Date of first dose of niraparib} + 1}{30.4375}
  \]

- The number of niraparib treatment cycles initiated as a categorical and continuous variable

- Cumulative niraparib dose (mg) defined as the sum of all niraparib doses received. This will be derived using pill count data (dispensed - returned), when available. If the returned pill count data is not available for a particular cycle, the dosing data along with dosing modifications will be used to compute cumulative dose for that cycle.

- Actual dose intensity (mg/day) for niraparib defined as:

  \[
  \frac{\text{Cumulative niraparib dosage (mg) received}}{(# \text{ of study treatment cycles initiated}) \times # \text{ planned dosing days per cycle}}
  \]

- Intended dose intensity (mg/day) for niraparib defined as:

  \[
  \frac{\text{Planned dose at first cycle (mg) \times # of planned niraparib dosing days per cycle}}{# \text{ planned dosing days per cycle}}
  \]

The intended dose intensities (IDI) for the different dose levels are provided below:

- Dose level 1: \(\text{IDI} = 200\text{mg/day} \times 21\text{days/cycle} = 4200\text{mg/cycle}\)
- Dose level 2: \(\text{IDI} = 300\text{mg/day} \times 21\text{days/cycle} = 6300\text{mg/cycle}\)
- Recommended phase 2 dose: \(\text{IDI} = 200\text{mg/day} \times 21\text{ days} = 4200\text{mg/cycle}\)

- Relative dose intensity (%) for niraparib defined as:

  \[
  \frac{\text{Actual dose intensity}}{\text{Intended dose intensity}} \times 100\%
  \]

- The number and percentage of patients with niraparib dose reductions, dose re-escalations, dose-escalations above starting dose, dose interruptions, and number of patients with at least one reported missed dose will also be presented.

In addition, the starting dose of niraparib by cycle will be summarized.
Pembrolizumab

- Duration of pembrolizumab treatment in months
  \[
  \frac{\text{Date of last dose of pembrolizumab} - \text{Date of first dose of pembrolizumab}}{30.4375} + 21
  \]

- The number of pembrolizumab cycles initiated as a categorical and continuous variable.
- Cumulative pembrolizumab dose (mg) defined as the sum of all pembrolizumab doses received.
- Actual dose intensity (mg/cycle) for pembrolizumab defined as
  \[
  \frac{\text{Cumulative pembrolizumab dosage (mg) received}}{\text{(# of study treatment cycles initiated)}}
  \]

- Intended dose intensity (mg/cycle) for pembrolizumab defined as
  \[
  \frac{200 \text{ (mg)}}{1 \text{ (cycle)}} = 200 \text{ (mg/cycle)}
  \]

- Relative dose intensity (%) for pembrolizumab defined as
  \[
  \frac{\text{Actual dose intensity}}{\text{Intended dose intensity}} \times 100%
  \]

- Number of patients with pembrolizumab infusion interruptions.

A by-patient listing based on the safety population will also be produced per each study treatment, disease type and phase of the study.

14.3.2 Prior and Concomitant Medications

Medications collected at Screening and during the study will be coded using the current version of the World Health Organization (WHO) Drug dictionary. The medications will be categorized as prior or concomitant using the following definitions:

- Prior medications: any medications, other than study treatments and pre-medications for study treatment, which started prior to the first dose date of study treatment.
- Concomitant medications: any medications, other than study treatments, being taken on or after the initial study treatment dosing date through 30 days after the last dose or until the start of subsequent antitumor therapy

Using the definition above, medications can be classified as both prior and concomitant. Both prior medications and concomitant medications will be summarized by Anatomical Therapeutic Chemical (ATC) classification drug class level 3 and WHO preferred name using the number and percentage of patients for each cohort (WHO Drug Dictionary, September 2017). A patient reporting the same medication more than once will be counted only once when calculating the number and percentage of
patients who received that medication in a given time category (prior or concomitant). The summary of concomitant medications will be ordered by descending frequency with respect to drug class and by descending frequency of preferred name in total within the drug class. For drugs with the same frequency, sorting will be done alphabetically. Summaries will be based on the safety population.

All prior and concomitant medications (other than per-protocol study treatments) will be provided in a by-patient listing sorted by patient ID number and administration date in chronological order.

14.4 Demographic and Baseline Characteristics

Demographic and baseline characteristics will be summarized per dose level in Phase 1, per tumor cohort in Phase 2, and for all OC patients combined in Phase 1 and Phase 2. Descriptive statistics will be provided for age (<65, ≥65 to <75, and ≥75), sex (male versus female), race (American Indian or Alaska Native, Asian, Black, Native Hawaiian or other Pacific Islander, White, or other), Ethnicity (Hispanic or Latino Not Hispanic or Latino), baselines for weight (kg), height (m), and BMI (kg/m²). Additionally, PD-L1, BRCA, HRD, and HRR status will be summarized as below:

- PD-L1 Status (Positive, Negative, Unknown)
- BRCA Status (BRCA-mut [gBRCA-mut, s-BRCA (gBRCAwt/tBRCA-mut), gBRCAunk/tBRCA-mut], BRCA-wt, Unknown)
- HRD Status (HRD-positive [BRCA-mut, BRCA-wt/HRD-positive], HRD-negative, Unknown)
- HRR Status (HRR-mut [BRCA-mut, BRCAwt/oHRR-mut, BRCAunk/oHRR-mut], HRR-wt, Unknown)

The concordance between gBRCA status and tBRCA status will also be evaluated.

14.4.1 Primary Cancer History

A summary of primary cancer history will be presented including: the tumor site, histology and grade of disease at diagnosis, the most recent cancer stage, and the most recent grade and histology. A by-patient listing for primary cancer history characteristics will also be provided.

14.4.2 Medical History, Surgical History

General medical history information (including past and ongoing) and prior medications and will be summarized for category and conditions ongoing or resolved at study entry based on the FAS (Phase 2) or safety set (Phase 1). Medical history conditions will be collected by CRF at time of screening. General medical history information will be coded by System Organ Class (SOC) and Preferred Term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA), using version 20.0. The count and percentage of patients with each medical history event will be summarized by MedDRA SOC and PT for all patients and by dose cohort. SOCs will be presented by descending frequency with PTs in descending order of frequency for adverse events within the SOC (and further sorted alphabetically, for PTs with the same number of AEs reported within a SOC).

A by-patient listing of general medical history will be provided by patient ID number in ascending order. A special table and listing will be added to summarize any prior blood disorders of thrombocytopenia, leukopenia, anemia or neutropenia.

Prior anticancer treatment will be summarized per agent preferred name and grouping for all patients in the FAS. Groupings are defined as platinum therapies (cisplatin and carboplatin); anthracycline therapies (doxorubicin, pegylated liposomal doxorubicin, doxorubicin hydrochloride, pegylated liposomal
doxorubicin hydrochloride), taxanes (docetaxel, paclitaxel or nab-paclitaxel) and other. The following two summaries will be produced:

- All therapies (regardless of what setting therapy was given in)
- Therapies in metastatic/recurrent setting (excluding the treatments given in adjuvant or neoadjuvant setting)

Prior surgery, and prior anti-cancer regimens, along with prior response information will be listed. The number and percentage of patients in each of the following prior anti-cancer therapy categories will be tabulated:

- Patients with at least one type of any prior anti-cancer treatment (drug, radiotherapy or surgery)
- Patients with at least one prior anti-cancer drug therapy
- Patients with at least one prior anti-cancer radiotherapy
- Patients with at least one prior anti-cancer surgery

Prior anti-cancer drug therapy will be summarized as follows based on the number and percentage of patients with the following:

- Patients with at least one prior anti-cancer drug therapy
  - Number of any prior anti-cancer therapy regimens: 0, 1, 2, 3, 4, ≥5. Hormonal agents, monoclonal antibodies that inhibit angiogenesis, tyrosine kinase inhibitors and all investigational drugs are not considered for either cohort. Agents will be categorized as noted in Appendix 6.
  - Phase 1: Adjuvant and neo-adjuvant are not considered when counting lines.
  - Phase 2:
    - OC cohort, neo-adjuvant, adjuvant, and the combination of both will be considered as one line of therapy.
    - TNBC cohort, adjuvant and neo-adjuvant are not considered when counting lines.
  - Pooled OC: Phase 1 and Phase 2 rules will be followed for each Phase as noted above.
- Intent of Therapy: Neo-Adjuvant / Adjuvant / Chemotherapy / Other.
- Prior Bevacizumab Therapy (Yes [first-line, recurrent setting, both], No)

In addition, the platinum-free interval (PFI) will be used to classify the response to last platinum therapy. Platinum-based therapeutics will consist of cisplatin and carboplatin regimens. PFI will be defined as the time between the end date of last platinum therapy to progression. If PD date is not available, the onset of the next therapy will be used. Using the PFI, the response to last platinum therapy will be determined using the following definitions for ovarian patients:

- Platinum-refractory: PFI ≤ 28 days
- Platinum-resistant: 28 days < PFI < 180 days
- Platinum-sensitive: PFI ≥ 180 days

For TNBC patients, the following categories will be used:

- PFI ≤ 56 days (8 weeks)
- PFI > 56 days (8 weeks)
14.5 Efficacy Analyses

All efficacy endpoints will be summarized on the Phase 2 FAS analysis set by disease type (OC, TNBC). In addition, response and duration of response endpoints will be evaluated using the EE analysis set. In addition, given the similarities of the Phase 1 and Phase 2 patient population for the ovarian cancer cohort, corresponding efficacy analyses will be provided using the pooled Phase 1 and Phase 2 data.

All analyses will include summary statistics, including number and percentage for categorical variables and number of patients, mean, standard deviation, median, minimum, and maximum for continuous variables. Two-sided exact 90% CIs based on the Clopper-Pearson method will be presented for the primary efficacy endpoint ORR per RECIST v1.1 as well as the following secondary endpoints: DCR per RECIST v1.1. Time-to-event data will be summarized by 25th, 50th (median), and 75th percentiles with associated 2-sided 90% CIs as well as percent of censored observations.

Tumor size (sum of longest (non-nodal) dimension and shortest (nodal) axes of all target lesions) will be presented graphically using waterfall plots, to present each subject’s best percentage change in tumor size as a separate bar, with the bars ordered from the largest increase to the largest decrease. A reference line at the −30% change in tumor size levels will be added to the plots, which correspond with the definitions of progression and ‘partial’ response, respectively.

Swimmer plots will be produced. This depicts each patient’s nature and duration of response as a separate bar (horizontally) over time.

14.5.1 Primary Endpoints

Objective Response Rate (ORR): Evaluated separately for TNBC and OC cohorts in Phase 2 of the study. The ORR is defined as the proportion of patients achieving a confirmed best overall response of CR or PR as assessed by the Investigator per RECIST (v1.1). Tumor assessments after the initiation of further anticancer therapy are excluded. Point estimates and two-sided 90% exact confidence intervals will be provided for ORR.

14.5.2 Methods for Handling Dropouts and Missing Data

Missing observations will generally be treated as missing at random and will not be imputed, unless otherwise noted. Adverse event and concomitant medication dates will be imputed as mentioned in Section 13.3. Note, for all listings the actual value for date (not imputed) will be presented in all data listings and imputed dates will only be used for programming flags, etc.

14.5.3 Multiplicity

Adjustments for multiplicity will not be made since this is an estimation study and separate inferences will be drawn for each tumor cohort.

14.5.4 Pooling of Sites

All data from all sites will be pooled. Study center or treatment-by-center interaction will not be included in any statistical analysis.

14.5.5 Secondary Endpoints

The following are the secondary endpoints to be evaluated in Phase 2 of the study per disease type:

– Duration of response: DOR by RECIST v1.1;
− Disease control rate: DCR by RECIST v1.1;
− Progression-free survival: PFS by RECIST v1.1;
− Overall survival (OS).

DOR, PFS, and OS will be presented through use of summary statistics using KM methods, to include 25th, 50th (median), and 75th percentiles and associated 2-sided 95% CI’s using the method of Brookmeyer and Crowley (5), number of events and number of censored observations.

Additionally, PFS will be summarized at months 3, 6, 9, and 12 and OS rates will be summarized at months 6, 9 and 12. The standard error of the KM estimates of event-free probability will be estimated using the Greenwood’s formula (6).

DOR and PFS defined by RECIST v1.1 will be analyzed separately by both criteria. The time to event endpoints (PFS, DOR, and OS) will also be summarized graphically with KM estimates of the survivor function and the number of patients at risk for selected timepoints. Additionally, the figures will include the median of the survival distribution.

All time to event analysis (i.e. PFS, OS and DOR) may be performed if more than 10 events are observed in each cohort. Additionally, duration of follow-up, defined as the time from first dose until date where patients were censored for overall survival, will be summarized, and the KM estimate of potential follow-up (reverse KM) will be presented.

Tumor response endpoints (ORR, DOR, DCR) will also be analyzed without the confirmation requirements for CR and PR and without duration requirement for SD using the same methodology as described above.

Protocol specified irRECIST secondary endpoints were not consistently collected across all patients and therefore cannot formally be evaluated using standard summaries. These endpoints will be listed. For patients who received treatment beyond radiological progression per RECIST v1.1 by ≥ 28 days and who have post-progression tumor assessments, the irRECIST evaluations will be listed alongside the RECIST v1.1 evaluations, as available. Date of study treatment discontinuation will also be included.

Exploratory analyses of clinical benefit rate (CBR) at 18 weeks, per definition in Section 8, will be performed for the FAS and EE populations.

14.5.6 Examination of Subgroups

Descriptive exploratory subgroup analyses of ORR, DCR (with and without confirmation requirements), PFS and OS will be performed. The EE population will be used for ORR and DCR whereas the FAS will be used to analyze PFS and OS. For the TNBC cohort, the respective Phase 2 populations will be of focus, whereas for the OC cohort, the respective pooled populations will be used.

− Prior Lines of Therapy: OC cohort (1-2; 3+); TNBC cohort (0-1; 2+)
− Response to Last Platinum-Based Therapy in OC cohort (refractory, resistant, sensitive and refractory/resistant pooled)
Prior Bevacizumab Use in OC cohort (yes [first line setting, recurrent setting, both first line/recurrent], no prior bevacizumab)

BRCA status (BRCA-mut, BRCA-wt, unknown) for OC and TNBC.

HRD status (HRD-pos, HRD-neg, unknown); further breakdown of HRD-pos as BRCA-mut and BRCA-wt+HRD-pos will be performed for OC and TNBC.

HRR status for TNBC cohort only (HRR-mut, HRR-wt, unknown); further breakdown of HRR-mut as BRCA-mut and non-BRCA-mut/oHRR-mut will be performed. Non-BRCA-mut includes BRCAwt and BRCAunk.

PD-L1 status (PDL1-pos, PDL1-neg, unknown) for OC and TNBC.

A detailed listing for responders and patients with SD will be produced including the above-mentioned variables. A summary of all analyses to be conducted by population and subgroups is included in Table 4.

### Table 4: Efficacy analyses to be conducted by population and subgroup

<table>
<thead>
<tr>
<th>Analysis</th>
<th>TNBC Phase 2</th>
<th>OC Phase 2</th>
<th>OC Pooled (Phase 1+Phase 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FAS</td>
<td>EE</td>
<td>FAS</td>
</tr>
<tr>
<td>ORR/DCR</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>DOR</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>PFS</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>OS</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ORR/DCR Subgroups</td>
<td></td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>PFS Subgroups</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>OS Subgroups</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

a) Analyses will be performed using RECIST v1.1 and repeated for Best Observed Overall Response.

Note:

TNBC Subgroups:
1. Prior Lines of Therapy
2. BRCA Status
3. HRR Status
4. HRD Status
5. PD-L1 Status

OC Subgroups:
1. Prior Lines of Therapy
2. Prior Bevacizumab Use
3. Response to Last Platinum Therapy
4. BRCA Status
5. HRD Status
6. PD-L1 Status
14.6 Safety Analyses

Safety Tables and Listings will be presented to summarize TEAE’s, laboratory data and vital signs and in Phase 1 as well as Phase 2. Phase 1 patients with RP2D dose levels may be pooled with Phase 2 patients in the same tables/listings by tumor type if deemed necessary at the end of the study. In general, all summaries of by-cycle and day safety parameters will be summarized through Cycle 6 Day 1 (end of Cycle 5) and all cycles beyond when information is available, as well as at the treatment discontinuation visit. This includes laboratory values, vital signs and ECG parameters. Additional summaries will be derived as the minimum and maximum for all on-study assessments and presented similarly to the other time points at the end of the summary table. This will allow an assessment of either the best or worst value assessed throughout the conduct of the study. The maximum and minimum calculations will use all post-baseline data, including any unscheduled assessments.

14.6.1 Adverse Events

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.0. Only TEAE’s (refer to Section 8 for definition) will be analyzed but all AEs occurring on-study will be listed in patient data listings. By-patient listings will also be provided for the following: patient deaths, SAEs, and AEs leading to withdrawal.

A high-level overview of AEs will be presented in a summary table. This table will include the numbers and percentages of patients who had:

- at least one TEAE,
- any TEAE’s related to study treatment,
- any grade 3 or higher TEAE,
- any grade 3 or higher TEAE’s related to study treatment,
- any SAE
- any SAE related to study treatment,
- any grade 3 or higher SAE related to study treatment,
- any TEAE’s resulting in withdrawal of study medication,
- any TEAE’s resulting in dose reduction of Niraparib,
- any TEAE’s resulting in dose interruption of either study treatments,
- any TEAE’s of clinical interest,
- any drug-related TEAE leading to withdrawal of study medication,
- any TEAE with outcome of death.
- any drug-related TEAE with outcome of death
- DLT’s for the Phase 1 portion only.

AEs will be tabulated by SOC and preferred term. Summary tabulations include the following subsets:

- DLT’s during the period of Cycle 1/Day 1 through Cycle 1/Day 21 for Phase 1 will be summarized by dose level to which they were originally assigned, including those who receive subsequent treatment at a different dose. The AE’s will also be classified by their CTCAE 4.03 grades.
- Incidence of TEAEs.
• Incidence of related TEAEs defined as treatment-emergent AEs assessed by the Investigator as related to either study treatment (‘Related’, ‘Possibly Related’, or missing).
• Incidence of treatment-emergent SAEs. In addition, a by-patient listing of SAEs will be presented (the patient listing will contain all SAEs regardless of treatment-emergent AE status).
• Incidence of related treatment-emergent SAEs.
• Incidence of TEAEs with outcome of death. A by-patient listing of deaths (including days since last dose) will be presented. All AEs with outcome of deaths occurring on-study and during follow-up will be displayed in the listing (regardless of treatment-emergent AE status).
• Incidence of related TEAEs with outcome of death.
• Incidence of TEAEs resulting in withdrawal of study treatment, and a by-patient listing of TEAEs resulting in withdrawal of study treatment will be presented.
• Incidence of related TEAEs resulting in withdrawal of study treatment.
• Incidence of TEAEs resulting in dose reduction of Niraparib.
• Incidence of TEAEs resulting in dose interruption of either study drugs.
• Incidence of TEAEs by maximum CTCAE grade
• Incidence of related TEAEs by maximum CTCAE grade
• Incidence of CTCAE Grade 3 or greater TEAEs.
• Incidence of CTCAE Grade 3 or greater treatment related TEAE’s.
• Incidence of TEAE’s of clinical interest as specified in the protocol:
  o Overdose of pembrolizumab (defined as a dose ≥ 1000 mg [5 times the dose]).
  o An elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value that is ≥ 3× upper limit of normal (ULN) concurrent with an elevated total bilirubin value that is ≥ 2× ULN and, at the same time, an alkaline phosphatase value that is < 2× ULN.
  o New malignancy
  o Overdose of niraparib
  o MDS/AML
    ▪ Myelodysplastic syndrome
    ▪ Myelodysplastic syndrome transformation
    ▪ Myelodysplastic syndrome unclassifiable
    ▪ Acute myeloid leukaemia
    ▪ Acute myeloid leukaemia recurrent
    ▪ Blast crisis in myelogenous leukaemia
    ▪ Myeloid leukaemia
• A summary of hematologic events including thrombocytopenic (preferred terms='thrombocytopenia' or 'platelet count decreased'), anemic (preferred terms='anaemia' and 'haemoglobin decreased') and neutropenic events (preferred terms = 'neutropenia', 'febrile neutropenia', 'neutrophil count decreased' and 'neutropenic sepsis').
• A summary of immune related adverse events as defined in Appendix 7.
Overall, patients with the same AE more than once will have that event counted only once within each SOC, and once within each PT. When summarized by severity, patients with the same AE more than once will have the maximum severity of that event counted within each SOC, and once within each PT.

Adverse event summaries will be ordered by decreasing frequency for SOC and decreasing frequency for PT within SOC (and further sorted alphabetically, for PTs with the same number of AEs reported within a SOC).

Additionally, by-patient listings of AE’s of clinical interest will be presented if appropriate.

### 14.6.2 Laboratory Data

All laboratory values, for which a normal range is available, will be classified into NCI CTCAE v 4.03 grades. The categories are defined according to the criteria available on the following website: [http://evs.nci.nih.gov/ftp1/CTCAE/About.html](http://evs.nci.nih.gov/ftp1/CTCAE/About.html).

For the purposes of summarization in both the tables and listings, all laboratory values will be converted to standardized units and differentials of white blood cell (WBC) count should always be converted to absolute counts in SI units for summarization (e.g., % is not an SI unit). If a laboratory value is reported using a non-numeric qualifier it will not be taken into consideration in the derivation of CTCAE criteria (e.g., hypokalemia grade 1 and grade 2 are only distinguished by a non-numerical qualifier (symptomatic; intervention indicated) and therefore grade 2 will not be derived). In general, clinical assessments listed will not be considered, only numeric results will be assessed. Additional laboratory results that are not part of NCI-CTCAE will be presented according to the categories: below normal limit, within normal limits and above normal limit (according to the laboratory normal ranges). Furthermore, only the numeric part in laboratory values that contain non-numeric qualifiers, such as less than (<) a certain value, or greater than (> ) a certain value, will be used in the summary statistics.

Multiple measurements taken during the visit for a patient will be represented by the most severe value for each hematology test. The most severe value will be determined first by the value closest to the upper or lower limit of the normal limits (dependent on which direction is considered severe) if the value is within the normal limits. If the value is outside the normal limits, the value furthest from the upper or lower limit will be selected (dependent on which direction is considered severe). If this algorithm does not allow for determining the most severe (i.e., a tie) the measurement closest to dosing date (either niraparib or pembrolizumab) will be selected. Patients who develop ≥ Grade 3 toxicity will be listed.

The following hematology tests will be summarized:
- WBC count, lymphocytes, monocytes, absolute neutrophil count, eosinophils, basophils, hemoglobin, platelets, erythrocyte mean corpuscular volume.

The following chemistry tests will be summarized:
- Sodium, amylase, potassium, total bilirubin, calcium, alkaline phosphatase (ALP), magnesium, AST, chloride, ALT, glucose, total protein, creatinine, albumin, urea or blood urea nitrogen, lactate dehydrogenase. Only non-fasting glucose will be included in summary tables as fasting glucose was only collected per-protocol at screening.

The following coagulation factors will be listed: International normalized ratio (INR) and activated partial thromboplastin time (aPTT).

The following urinalysis parameters will be summarized:
Specific gravity, protein, leukocyte esterase, glucose, nitrite, ketones, blood, urobilinogen, bilirubin.

Additionally, a by-patient listing will be presented for thyroid functions (thyroid-stimulating hormone, triiodothyronine (T3), or free T3 and free thyroxin), serum CA-125 (OC patients only) and serum pregnancy testing /urine pregnancy testing

NCI CTCAE grades (given in Appendix 1) will be applied for the following lab parameters:

- Hematology: hemoglobin (anemia), WBC (leukopenia), lymphocytes (lymphopenia), neutrophils (neutropenia), and platelets (thrombocytopenia).
- Chemistry: albumin (hypoalbuminemia), alkaline phosphatase (alkaline phosphatase increased), ALT, AST, total bilirubin (blood bilirubin increased), corrected calcium (hypocalcemia, hypercalcemia), creatinine (creatinine increased), glucose (hyperglycemia, hypoglycemia), magnesium (hypermagnesemia, hypomagnesemia), potassium (hyperkalemia, hypokalemia), and sodium (hyponatremia, hypernatremia).
- Coagulation: aPTT, INR.

Where corrected calcium is derived with the following formula:
Corrected calcium (mmol/L) = (0.02 * (40 (g/L) – normal albumin (g/L))) + serum calcium (mmol/L).

For Hyperglycemia, CTCAE grades 1 and 2 will not be considered as they require fasting glucose, but fasting glucose will not be summarized in any outputs in the SAP. These will be displayed in Table as NA (not applicable).

A summary of maximum severity observed on-study treatment for all parameters noted above will be generated for the coded hematology and chemistry parameters. Patients will only be included once, in the maximum severity, for each laboratory parameter. Additionally, a shift summary of baseline to maximum severity on-study treatment will also be produced. Patients with at least 1 on-study treatment measurement for each laboratory parameter will be included, regardless of whether a baseline assessment is present (baseline will be included as a missing category). Thus, percentages for each parameter will be based on the total number of patients with an on-study treatment measurement for the parameter of interest.

Liver function tests: ALT, AST, and total bilirubin are used to assess possible drug induced liver toxicity. The ratios of test result over ULN will be calculated and classified for these three parameters during the on-treatment period.

Summary of liver function tests will include the following categories. The number and percentage of patients with each of the following during the on-treatment period will be summarized by treatment group:

- ALT ≥ 3×ULN, ALT ≥ 5×ULN, ALT ≥ 10×ULN, ALT ≥ 20×ULN
- AST ≥ 3×ULN, AST ≥ 5xULN, AST ≥ 10×ULN, AST ≥ 20×ULN
- (ALT or AST) ≥ 3×ULN, (ALT or AST) ≥ 5×ULN, (ALT or AST) ≥ 10×ULN, (ALT or AST) ≥ 20xULN
- Total bilirubin ≥ 2×ULN
• Concurrent ALT ≥ 3×ULN and total bilirubin ≥ 2×ULN
• Concurrent AST ≥ 3×ULN and total bilirubin ≥ 2×ULN
• Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN
• Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN and ALP > 2×ULN
• Hy’s law: Concurrent (ALT or AST) ≥ 3×ULN and total bilirubin ≥ 2×ULN and ALP < 2×ULN or missing

Concurrent measurements are those occurring on the same date. Categories will be cumulative, i.e., a patient with an elevation of AST ≥ 10×ULN will also appear in the categories ≥ 5×ULN and ≥ 3×ULN. Liver function elevation and possible Hy’s Law cases will be summarized using frequency and percentage.

By-patient listings will be presented for hematology, coagulation factors, urinalysis and serum chemistry. Any laboratory values assessed as clinically significant should be recorded as an AE.

14.6.3 Vital Signs
Vital signs: diastolic and systolic blood pressure (mm Hg), body temperature, pulse rate (beats/min) at each visit, change from baseline to each post-baseline visit, post-baseline maximum/minimum, and change from baseline to post-baseline maximum/minimum will be summarized for the safety analysis set using descriptive statistics (n, mean, SD, median, Q1, Q3, minimum, and maximum) by dose level or tumor cohort.
A by-patient listing of vital signs will be provided by patient ID number and visit in chronological order.

14.6.4 Physical Examinations and Other Observations Related to Safety
ECOG parameters will be presented by tumor cohort for each dose level and within each tumor cohort at baseline, at each post-treatment time point and at the end of treatment. The ECOG shift from baseline to highest score during the on-treatment period will be summarized by dose level or tumor cohort.
Height, Weight, Pregnancy test results will be presented in a by-patient listing. Physical examination at screening will also be listed.

14.6.5 ECG
The following analyses will be performed for each applicable ECG parameters (RR, PR, QRS, QT, ventricular rate -denoted as HR in what follows, QTcB and QTcF) by treatment group, during the on-treatment period.

• For each of the ECG parameters (HR, and QT, QTcF, QTcB, QRS, PR intervals), descriptive statistics at baseline, at each post-baseline time point and changes from baseline at each post-baseline time point
• Frequency (number and percentage) of patients with notable ECG values according to the following categories presented in Table 5.

<table>
<thead>
<tr>
<th>TEST</th>
<th>Notable ECG Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Rate</td>
<td>≤ 50 bpm and decrease from baseline ≥ 20 bpm</td>
</tr>
<tr>
<td></td>
<td>≥ 120 bpm and increase from baseline ≥ 20 bpm</td>
</tr>
<tr>
<td>PR Interval</td>
<td>≥ 220 ms and increase from baseline ≥ 20 ms</td>
</tr>
<tr>
<td>QRS</td>
<td>≥ 120 ms</td>
</tr>
</tbody>
</table>
QTcF and QTcB Absolute

<table>
<thead>
<tr>
<th>Interval</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;450 msec and ≤480 msec</td>
<td>Increase from baseline &gt; 30 ms and ≤ 60 ms</td>
</tr>
<tr>
<td>&gt;480 msec and ≤500 msec</td>
<td>Increase from baseline &gt; 60 ms</td>
</tr>
<tr>
<td>&gt;500 msec</td>
<td>Increase from baseline &gt; 60 ms</td>
</tr>
</tbody>
</table>

Frequency (number and percentage) of patients with post-baseline qualitative ECG abnormalities (morphology) will be summarized.

Patients with notable ECG interval values and qualitative ECG abnormalities will be listed for each patient and time point and the corresponding notable values and abnormality findings will be included in the listings.

Unscheduled ECG measurements will not be used in computing the descriptive statistics for change from baseline at each post-baseline time point. However, they will be used in the analysis of notable ECG changes and the shift table analysis of notable QT parameters.

A shift table of the investigators’ assessment of ECG results at each visit compared with the latest ECG collected prior to first dose will be presented by treatment group using the following categories: normal; abnormal, not clinically significant; abnormal, clinically significant; or missing. The number and percentage of patients in each cross-classification group of the shift table will be presented. Patients with a missing value at baseline or post-baseline will not be included in the denominator for percentage calculation.

15.0 Validation

The goal is to ensure that each table, listing and figure (TFL) delivery is submitted to the highest level of quality. Our quality control procedures will be documented separately in the study-specific quality control plan.

- Derived datasets are independently reprogrammed by a second programmer. The separate datasets produced by the 2 programmers must match 100%. Detailed specifications for the derived datasets are documented in the study Data Mapping Tool provided to the client at study conclusion.

- Tables are independently quality controlled by a second programmer for numeric results.

- Figures are checked for consistency against corresponding tables and listings, or independently reprogrammed if there are no corresponding tables or listings.

- Listings are double programmed and checked for consistency against corresponding tables, figures, and derived datasets.

The complete set of TFLs are checked for completeness and consistency prior to its delivery to the client by the lead clinical programmer, the lead statistician, and a senior level or above statistician, who is not a member of the project team.

The validation process is repeated any time TFL are redelivered using different data. Execution of this validation process is documented through the study Table of Programs that is provided to the client at study conclusion.

The goal is to ensure that each TFL delivery is submitted to the highest level of quality. Our quality control procedures will be documented separately in the study specific quality control plan.
16.0 References

1. Data on file at TESARO.


# 17.0 List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>AML</td>
<td>acute myeloid leukemia</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
</tr>
<tr>
<td>aPTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the concentration × time curve</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;ss&lt;/sub&gt;</td>
<td>area under the concentration × time curve at steady state</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CL/F</td>
<td>clearance after oral administration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;max,ss&lt;/sub&gt;</td>
<td>maximum concentration at steady state</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>minimum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min,ss&lt;/sub&gt;</td>
<td>minimum concentration at steady state</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DCR</td>
<td>disease control rate</td>
</tr>
<tr>
<td>DKA</td>
<td>diabetic ketoacidosis</td>
</tr>
<tr>
<td>DLT</td>
<td>dose-limiting toxicity</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECI</td>
<td>events of clinical interest</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>EE</td>
<td>efficacy-evaluable</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EOT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>ER-</td>
<td>estrogen receptor</td>
</tr>
<tr>
<td>FT3</td>
<td>free triiodothyronine</td>
</tr>
<tr>
<td>FT4</td>
<td>free thyroxine</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>granulocyte macrophage colony-stimulating factor</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HCV RNA</td>
<td>hepatitis C virus ribonucleic acid</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>homologous recombination</td>
</tr>
<tr>
<td>HRD</td>
<td>homologous recombination deficiency</td>
</tr>
<tr>
<td>ICF</td>
<td>informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IgG</td>
<td>immunoglobulin G</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>irRECIST</td>
<td>immune-related Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan-Meier</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplastic syndrome</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MTD</td>
<td>maximum tolerated dose</td>
</tr>
<tr>
<td>OC</td>
<td>primary peritoneal ovarian cancer</td>
</tr>
<tr>
<td>ORR</td>
<td>objective response rate</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PARP</td>
<td>poly(ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PD-1</td>
<td>programmed death-1</td>
</tr>
<tr>
<td>PD-L1</td>
<td>programmed death ligand-1</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFI</td>
<td>Platinum-free interval</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PO</td>
<td>oral(ly)</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PR-</td>
<td>progesterone receptor</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>QD</td>
<td>once daily</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>RP2D</td>
<td>recommended Phase 2 dose</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>TEAE</td>
<td>Treatment-emergent adverse event</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
</tbody>
</table>
### 18.0 Appendix 1: Common Terminology Criteria for Adverse Events V4.03 (CTCAE)

<table>
<thead>
<tr>
<th>Lab Test Name</th>
<th>Lab Test Code</th>
<th>Standard Unit</th>
<th>CTCAE v4.03 SOC</th>
<th>CTCAE v4.03 Term</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activated partial thromboplastin</td>
<td>APTT</td>
<td>sec</td>
<td>Investigations</td>
<td>Activated partial thromboplastin time prolonged</td>
<td>&gt;ULN - 1.5 x ULN</td>
<td>1.5 - 2.5 x ULN</td>
<td>&gt;2.5 x ULN</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>ALB</td>
<td>g/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypoalbuminemia</td>
<td>&lt;ULN - 3 g/dL; &lt;ULN - 30 g/L</td>
<td>&lt;3 - 2 g/dL; &lt;30 - 20 g/L</td>
<td>&lt;2 g/dL; &lt;20 g/L</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>HGB</td>
<td>g/L</td>
<td>Blood and lymphatic system disorders</td>
<td>Anemia</td>
<td>&lt;ULN - 100 g/L</td>
<td>100 - 80 g/L</td>
<td>&lt;80 g/L</td>
<td></td>
</tr>
<tr>
<td>Leukocytes</td>
<td>WBC</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>White blood cell decreased</td>
<td>&lt;ULN - 3 x 10^9/L</td>
<td>&lt;3.0 - 2.0 x 10^9/L</td>
<td>&lt;2.0 - 1.0 x 10^9/L</td>
<td>&lt;1.0 x 10^9/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>PLAT</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Platelet count decreased</td>
<td>&lt;ULN - 75.0 x 10^9/L</td>
<td>&lt;75.0 - 50.0 x 10^9/L</td>
<td>&lt;50.0 - 25.0 x 10^9/L</td>
<td>&lt;25.0 x 10^9/L</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>NEUT</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Neutrophil count decreased</td>
<td>&lt;ULN - 1.5 x 10^9/L</td>
<td>&lt;1.5 - 1.0 x 10^9/L</td>
<td>&lt;1.0 - 0.5 x 10^9/L</td>
<td>&lt;0.5 x 10^9/L</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>LYM</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Lymphocyte count decreased</td>
<td>&lt;ULN - 0.8 x 10^9/L</td>
<td>&lt;0.8 - 0.5 x 10^9/L</td>
<td>&lt;0.5 - 0.2 x 10^9/L</td>
<td>&lt;0.2 x 10^9/L</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>LYM</td>
<td>10^9/L</td>
<td>Investigations</td>
<td>Lymphocyte count increased</td>
<td>&gt;4 x 10^9/L - 20 x 10^9/L</td>
<td>&gt;20 x 10^9/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>SODIUM</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyponatremia</td>
<td>&lt;ULN - 130 mmol/L</td>
<td>&lt;130 - 120 mmol/L</td>
<td>&lt;120 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>SODIUM</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyponatremia</td>
<td>&gt;ULN - 150 mmol/L</td>
<td>&gt;150 - 155 mmol/L</td>
<td>&gt;160 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>K</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypokalemia</td>
<td>&lt;ULN - 3.0 mmol/L</td>
<td>&lt;3.0 - 2.5 mmol/L</td>
<td>&lt;2.5 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>K</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyperkalemia</td>
<td>&gt;ULN - 5.5 mmol/L</td>
<td>&gt;5.5 - 6.0 mmol/L</td>
<td>&gt;6.0 - 7.0 mmol/L</td>
<td>&gt;7.0 mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>CREAT</td>
<td>umol/L</td>
<td>Investigations</td>
<td>Creatinine increased</td>
<td>&gt;ULN - 1.5 x ULN</td>
<td>&gt;1.5 - 3.0 x ULN</td>
<td>&gt;3.0 - 6.0 x ULN</td>
<td>&gt;6.0 x ULN</td>
</tr>
<tr>
<td>Glucose</td>
<td>GLUC</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypoglycemia</td>
<td>&lt;ULN - 3.0 mmol/L</td>
<td>&lt;3.0 - 2.2 mmol/L</td>
<td>&lt;2.2 - 1.7 mmol/L</td>
<td>&lt;1.7 mmol/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>GLUC</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hyperglycemia</td>
<td>NA</td>
<td>NA</td>
<td>&gt;13.9 - 27.8 mmol/L</td>
<td>&gt;27.8 mmol/L</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>BILI</td>
<td>umol/L</td>
<td>Investigations</td>
<td>Blood bilirubin increased</td>
<td>&gt;ULN - 1.5 x ULN</td>
<td>&gt;1.5 - 3.0 x ULN</td>
<td>&gt;3.0 - 10.0 x ULN</td>
<td>&gt;10.0 x ULN</td>
</tr>
<tr>
<td>Alanine aminotransferase</td>
<td>ALT</td>
<td>U/L</td>
<td>Investigations</td>
<td>Alanine aminotransferase increased</td>
<td>&gt;ULN - 3.0 x ULN</td>
<td>&gt;3.0 - 5.0 x ULN</td>
<td>&gt;5.0 - 20.0 x ULN</td>
<td>&gt;20.0 x ULN</td>
</tr>
<tr>
<td>Aspartate aminotransferase</td>
<td>AST</td>
<td>U/L</td>
<td>Investigations</td>
<td>Aspartate aminotransferase increased</td>
<td>&gt;ULN - 3.0 x ULN</td>
<td>&gt;3.0 - 5.0 x ULN</td>
<td>&gt;5.0 - 20.0 x ULN</td>
<td>&gt;20.0 x ULN</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>ALP</td>
<td>U/L</td>
<td>Investigations</td>
<td>Alkaline phosphatase increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>------</td>
<td>-----</td>
<td>---------------------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium MG</td>
<td>mg/mol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypomagnesemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium MG</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypermagnesemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium (corrected)</td>
<td>CA</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypocalcemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium (corrected)</td>
<td>CA</td>
<td>mmol/L</td>
<td>Metabolism and nutrition disorders</td>
<td>Hypercalcemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothrombin Intl. Normalized Ratio</td>
<td>INR</td>
<td>Investigations</td>
<td>INR increased</td>
<td>&gt;1.5 x ULN</td>
<td>&gt;1.5 - 2.5 x ULN</td>
<td>&gt;2.5 x ULN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Alkaline phosphatase increased**: The table lists the range of increased values for each condition.

- **Investigations**: The table specifies the conditions investigated for each parameter.

- **Alkaline phosphatase increased**:
  - <LLN - 1.0 mg/dL; <LLN - 0.5 mmol/L
  - 1.0 - 1.9 mg/dL; <LLN - 0.5 mmol/L
  - 1.9 - 2.0 mg/dL; <LLN - 0.5 mmol/L
  - >2.0 mg/dL; >2.0 mmol/L
  - >2.0 - 3.0 mg/dL; >2.0 - 3.0 mmol/L
  - >3.0 - 5.0 mg/dL; >3.0 - 5.0 mmol/L
  - >5.0 - 20.0 mg/dL; >5.0 - 20.0 mmol/L
  - >20.0 mg/dL; >20.0 mmol/L

- **Mg**: The table lists the range of values for magnesium.

- **Mg**: The table lists the range of values for magnesium.

- **Calcium (corrected)**: The table lists the range of values for calcium.

- **Calcium (corrected)**: The table lists the range of values for calcium.

- **Prothrombin Intl. Normalized Ratio**: The table lists the range of values for prothrombin.

- **Prothrombin Intl. Normalized Ratio**: The table lists the range of values for prothrombin.
## 19.0 Appendix 2: Schedule of events

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Day</th>
<th>Cycle 1</th>
<th>Subsequent Cycles</th>
<th>EOT</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments (every 90 ± 14 days) via telephonic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-21 to -1</td>
<td>1</td>
<td>2</td>
<td>8</td>
<td>15</td>
<td>Cycle n, Day 1</td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Archival tissue</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Optional serial tumor biopsy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood sample for PK</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Tumor assessment (RECIST and nRECIST)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Laboratory assessments</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CBC</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Serum chemistry</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Coagulation</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECG</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Symptom-directed physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vital signs, height, and weight</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collected</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

**Abbreviations:** AE = adverse event; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECI = event of clinical interest; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; nRECIST = immune-related RECIST; IV = intravenous; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; OC = ovarian cancer; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; RPD = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.

1 Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.
2 EOT visit should be completed within 7 days of the last dose of study drug.
3 Required for Phase 1 patients only.
4 Patients in Phase 1 are required to have an on-clinic visit on Day 8 with CBC done at the study center’s laboratory. For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an
adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.

In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 1 to 3 days before or on C3D1 prior to pembrolizumab infusion, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. The serial biopsies at different time points should be on the same lesion preferably. A core biopsy is recommended: if an excisional or incisional biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted as the screening biopsy.

Tumor assessment per RECIST and mRECIST via CT or MRI (chest, abdomen, and pelvis; brain, only if clinically indicated) is required at screening, every 9 weeks (65 ± 7 days) from Cycle 1-Day 1 for the first year, and then every 12 weeks (84 ± 7 days) until progression, at the time of progression, a final follow-up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.

May be done within 24 hours prior to the visit.

May be done at the study center’s local laboratory or at a laboratory local to the patient if the laboratory is not on FDA Form 1572.

If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly (fleischmennopsia or neutropenia) or once weekly (anemia) blood draws (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.

If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.

Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.9). The assessment may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1-Day 8 CBC samples.

Required for Phase 1 patients only. Required on Day 1 of Cycle 2 and Cycle 3 only.

Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 cycles for duration of study (i.e., Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.

If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.

Blood samples for TSH, T3 or FT3, and FT4 are to be collected at screening, every 6 weeks from C3D1, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 90-day post-treatment follow-up only if asymptically indicated.

Patients will undergo ECG monitoring as per Table 8 and Table 9. Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only.

AEs are required to be captured through 30 days after cessation of study treatment, SAEs and ECIs (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

Administer pembrolizumab once every 21 days (200 mg IV). Pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle after Cycle 2 due to administrative reasons.

See Table 10 for details of niraparib administration in Phase 1, and Section 3.1.2.1 for the RP/2D of the combination. Niraparib dose may be escalated on or after C3D1 from 200 mg daily to 500 mg daily of hemoglobin ≥ 9 g/dL, platelets ≥ 100,000 μL, and neutrophils ≥ 1500 μL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

Niraparib dose administered upon completion of pembrolizumab infusion.

Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor’s medical monitor finds evaluation necessary for assessing niraparib-related risk for MDS/AML (e.g., the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (mutations of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor’s medical monitor. The study site must receive a copy of the hematologist’s report of aspirate biopsy findings, which must include a classification according to WHO criteria, and other sample testing results related to MDS/AML.
### Phase 2 Only

<table>
<thead>
<tr>
<th>Cycle/Visit</th>
<th>Screening</th>
<th>Cycle 1</th>
<th>Subsequent Cycles</th>
<th>EOT</th>
<th>Safety Follow-up</th>
<th>Follow-up Assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-21 to -1</td>
<td>1</td>
<td>8</td>
<td>15</td>
<td>Cycle n, Day 1</td>
<td>30 + 7 days</td>
</tr>
<tr>
<td>Procedure:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>via telephone</td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria review</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical, surgical, cancer, and medication history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Archival tissue</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optional serial tumor biopsy</td>
<td>X&lt;sup&gt;2,6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for exploratory biomarkers</td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for PK</td>
<td>X</td>
<td></td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor assessment (RECIST and irRECIST)</td>
<td>X&lt;sup&gt;4,9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td>X&lt;sup&gt;4&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
<tr>
<td>Laboratory assessments:</td>
<td>X&lt;sup&gt;10&lt;/sup&gt;</td>
<td>X&lt;sup&gt;11&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC&lt;sup&gt;12&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serum chemistry</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td>Coagulation</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
<td>X&lt;sup&gt;15&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serum CA-125 (OC patients only)</td>
<td>X&lt;sup&gt;7&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X</td>
<td>X&lt;sup&gt;16&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Urianalysis</td>
<td>X&lt;sup&gt;9&lt;/sup&gt;</td>
<td>X&lt;sup&gt;13&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;16&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>TSH, T3 or FT3, and FT4</td>
<td>X&lt;sup&gt;4,17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td>X&lt;sup&gt;17&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X&lt;sup&gt;4,13&lt;/sup&gt;</td>
<td>X&lt;sup&gt;14&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td>X&lt;sup&gt;18&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>X&lt;sup&gt;7&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom-directed physical examination</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vital signs, height, and weight&lt;sup&gt;19&lt;/sup&gt;</td>
<td>X&lt;sup&gt;6&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse event monitoring</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X&lt;sup&gt;20&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pembrolizumab study treatment administered&lt;sup&gt;21&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niraparib study treatment dispensed/collected&lt;sup&gt;22&lt;/sup&gt;</td>
<td>X&lt;sup&gt;21&lt;/sup&gt;</td>
<td>X&lt;sup&gt;21&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival assessment, including new malignancy information</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sample collection (whole blood) for cytogenetic analysis</td>
<td>X&lt;sup&gt;24&lt;/sup&gt;</td>
<td>X&lt;sup&gt;24&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy and sample collection (whole blood) for cytogenetic analysis</td>
<td>X&lt;sup&gt;25&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AE = adverse event; CBC = complete blood count; CT = computed tomography; ECG = electrocardiogram; ECI = event of clinical interest; ECOG = Eastern Cooperative Oncology Group; EOT = end of treatment; irRECIST = immune-related RECIST; IV = intravenous; MDS = myelodysplastic syndrome; MRI = magnetic resonance imaging; OC = ovarian cancer; PK = pharmacokinetics; RECIST = Response Evaluation Criteria in Solid Tumors; RP2D = recommended Phase 2 dose; SAE = serious adverse event; TNBC = triple-negative breast cancer.

1. Treatment cycles are 21 days long, with visits on Day 1 of each cycle beyond Cycle 1 unless otherwise specified. Visits for subsequent cycles continue every 21 days (± 3 days) until study treatment discontinuation.
2. EOT visit should be completed within 7 days of the last dose of study drug.
3. For patients in Phase 2, collection of blood for the Cycle 1/Day 8 CBC may be done at the study center’s laboratory or at a laboratory local to the patient, if approved by the Principal Investigator as an adequate laboratory. The laboratory must have the capability to provide results to the Principal Investigator electronically or by fax within 24 hours of blood collection.
4. For patients who do not have archivial tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation. See the Study Manual for details on sample collection and processing.
1. In patients who consent to serial biopsies, fresh tumor sample is to be obtained at screening, 1 to 3 days before or on C1D1 prior to pembrolizumab infusion, and when possible, at the time of disease progression. See the Study Manual for details on sample collection and processing. The serial biopsies at different time points should be on the same lesion preferably. A core biopsy is recommended, if an excisional or incisonal biopsy is to be performed, it must be conducted on a non-target lesion. If a patient has had a biopsy within 12 weeks prior to entering screening, that biopsy may be accepted as the screening biopsy.

2. Standard of care tests/procedures, including biopsy, radiographic scans, laboratory assessments (fasting glucose at baseline), ECG, physical examination, vital signs, height, and weight, performed prior to the patient signing the informed consent form can be used as part of the screening assessments as long as the tests/procedures meet the protocol-required timelines (ie, within 21 days of first dose for these procedures with the exception of the biopsy, which may have been conducted within 12 weeks of first dose, and pregnancy test, which must be conducted within 72 hours of first dose) and any relevant guidelines (eg, diagnostic quality for scans).

3. Required on Day 1 of Cycle 2 only.

4. Blood samples are to be obtained for miraniparib and its major metabolite M1, pembrolizumab PK assessments; see Table 8 and Table 9 for the detailed schedule.

5. Tumor assessment per RECIST and aRECIST via CT or MRI (chest, abdomen, and pelvis [brain, only if clinically indicated]) required at screening, every 9 weeks (63±7 days) from Cycle 1 Day 1 for the first year, and then every 12 weeks (84±7 days) until progression; at the time of progression, a final follow up set of images is required if not done within the last 4 weeks. The same modality (CT or MRI) should be used throughout the study for a given patient. If the chest (OC patients only) or brain (OC and TNBC patients) CT/MRI is clear at screening, repeat imaging of these areas is not required in the absence of clinical indication requiring follow-up. Positron emission tomography/CT may be used according to RECIST v1.1 guidelines. Bone scans should be conducted per standard of care. Timing of images will not be delayed for treatment interruptions, and tumor assessment should occur according to this schedule regardless of whether study treatment is interrupted. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, scans and CA-125 testing (OC patients only) should continue at the specified intervals.

6. May be done within 24 hours prior to the visit.

7. May be done at the study center's local laboratory or at a laboratory local to the patient if the laboratory is included on FDA Form 1572.

8. If dose interruption or modification is required at any point on study because of hematologic toxicity, twice-weekly thrombocytopenia or neutropenia, or once weekly (mona) blood draw (CBC) will be monitored until the AE resolves, and to ensure safety of the new dose, weekly blood draws for CBC will also be required for a subsequent 3 week cycle after the AE has been resolved to the specified levels, after which monitoring every 3 weeks may resume.

9. If screening laboratory testing (CBC, serum chemistry, CA-125, urinalysis) is performed within 72 hours of first dose of study treatment on Day 1, repeat testing is not required.

10. Serum chemistry to be conducted on Day 90 post-treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy) to assess for possible ECI (see Section 6.1.8). The assessment may be done at the study center's laboratory or at a local laboratory to the patient, if approved by the Principal Investigator as an adequate laboratory. This should be the same laboratory as conducted any Cycle 1/Day 8 CBC samples.

11. Negative serum pregnancy test required within 72 hours prior to first dose of study treatment on Day 1 for females of childbearing potential; urine pregnancy test conducted every 3 cycles for duration of study (ie, Cycle 4, Cycle 7, etc.) and at the 30-day safety follow-up visit. Pregnancy status must be determined 120 days post treatment.

12. If a patient discontinues treatment for a reason other than progression or death, withdrawal of consent, or loss to follow-up, CA-125 testing (OC patients only) should continue at the intervals specified for tumor assessments.

13. Blood samples for TSH, T3, or FT3, and FT4 to be collected at screening, every 6 weeks from C1D1, and at EOT. Blood samples for TSH, T3 or FT3, and FT4 to be collected at 30-day post-treatment safety follow-up only if assessment is clinically indicated.

14. Patients will undergo ECG monitoring as per Table 8 and Table 9.

15. Vital signs include blood pressure, pulse, and temperature. Height obtained at screening only.

16. AEs are to be captured through 30 days after cessation of study treatment. SAFEs and ECIs (see Section 6.1.6) are required to be captured through 90 days after cessation of study treatment (or to a minimum of 30 days post-treatment if the patient starts alternate anticancer therapy), and any pregnancies that occur within 120 days post-treatment are to be captured.

17. Adverse events noted on Cycle 2 due to administrative reasons.

18. See Table 11 for details of miraniparib administration in Phase 2. See Section 3.1.2.1 for the RP2D of the combination. Miraniparib dose may be escalated on or after C1D1 from 200 mg daily to 300 mg daily if hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/mL, and neutrophils ≥ 1500/mL for all labs performed during the first two cycles after discussion with Medical Monitor or Designee.

19. Miraniparib dose administered upon completion of pembrolizumab infusion.

20. Blood samples collected at screening and EOT will be stored for evaluation if the Sponsor's medical monitor finds evaluation necessary for assessing miraniparib-related risk for MDS/AML (eg, the patient develops MDS/AML). Mutation profile before and after study treatment will be compared to determine whether any mutations were present prior to study treatment. Additional details on sample collection and analysis are in the Study Manual.

21. It is strongly recommended that any suspected MDS/AML case reported while a patient is receiving treatment or being followed for post-treatment assessments be referred to a local hematologist, who must perform bone marrow aspirate and biopsy testing. A whole blood sample will also be collected for cytogenetic analysis (cytogenetics of select myeloid-associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the Sponsor's medical monitor. The study site must receive a copy of the hematologist's report of aspirate biopsy findings, which must include a classification according to WHO criteria, and other sample testing results related to MDS/AML.
20.0 Appendix 3 Response Evaluation Criteria in Solid Tumors (RECIST), v1.1

Response Criteria by RECIST v1.1

Evaluation of Target Lesions

**Complete Response (CR):** Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

**Partial Response (PR):** At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

**Progressive Disease (PD):** At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of one or more new lesions is also considered progressions).

**Stable Disease (SD):** Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Evaluation of Non-Target Lesions

**Complete Response (CR):** Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).

Note: If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.

**Non-CR/Non-PD:** Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.

**Progressive Disease (PD):** Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).

Table 8: RECIST Response for Patients with Measurable Disease (ie, Target Disease)

<table>
<thead>
<tr>
<th>Target Lesions</th>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
<th>Best Overall Response when Confirmation is Required*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>CR</td>
<td>No</td>
<td>CR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Non-CR/Non-PD</td>
<td>No</td>
<td>PR</td>
<td>&gt; 4 wks. Confirmation**</td>
</tr>
<tr>
<td>CR</td>
<td>Not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>Non-CR/Non-PD/not evaluated</td>
<td>No</td>
<td>SD</td>
<td>documented at least once &gt; 4 wks. from baseline**</td>
</tr>
<tr>
<td>PD</td>
<td>Any</td>
<td>Yes or No</td>
<td>PD</td>
<td>no prior SD, PR, or CR</td>
</tr>
<tr>
<td>Any</td>
<td>PD**</td>
<td>Yes or No</td>
<td>PD</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
<td></td>
</tr>
</tbody>
</table>
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease

* See RECIST v1.1 publication for further details on what is evidence of a new lesion.

** Only for non-randomized trials with response as primary endpoint.

*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration.” Every effort should be made to document the objective progression even after discontinuation of treatment.

Table 9: RECIST Response For Patients with Non-Measurable Disease (ie, Non-Target Disease)

<table>
<thead>
<tr>
<th>Non-Target Lesions</th>
<th>New Lesions</th>
<th>Overall Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>No</td>
<td>CR</td>
</tr>
<tr>
<td>Non-CR/non-PD</td>
<td>No</td>
<td>Non-CR/non-PD*</td>
</tr>
<tr>
<td>Not all evaluated</td>
<td>No</td>
<td>not evaluated</td>
</tr>
<tr>
<td>Unequivocal PD</td>
<td>Yes or No</td>
<td>PD</td>
</tr>
<tr>
<td>Any</td>
<td>Yes</td>
<td>PD</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; PD = progressive disease

* ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not Advised.
21.0 **Appendix 4: Immune-Related response evaluation criteria in solid tumors**

Table 10: Imaging and Treatment after First Radiologic Evidence of Progressive

<table>
<thead>
<tr>
<th>Timing of Imaging</th>
<th>Clinically Stable</th>
<th>Clinically Unstable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tumor Imaging</td>
<td>Treatment</td>
</tr>
<tr>
<td>1st radiologic evidence of PD</td>
<td>Repeat imaging at ≥ 4 weeks to confirm PD</td>
<td>May continue study treatment at the local site Investigator's discretion while awaiting confirmatory tumor imaging</td>
</tr>
<tr>
<td>Repeat tumor imaging confirms PD</td>
<td>No additional imaging required</td>
<td>Discontinue treatment</td>
</tr>
<tr>
<td>Repeat tumor imaging shows SD, PR, or CR</td>
<td>Continue regularly scheduled imaging assessments</td>
<td>Continue study treatment at the local site Investigator's discretion</td>
</tr>
</tbody>
</table>

Abbreviations: CR = complete response; irRECIST = immune-related Response Criteria in Solid Tumors; N/A = not applicable; PD = progressive disease; PR = partial response; RECIST = Response Criteria in Solid Tumors; SD = stable disease
## Appendix 5: Laboratory Standard Units

<table>
<thead>
<tr>
<th>Laboratory Test</th>
<th>SI Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>g/L</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>U/L</td>
</tr>
<tr>
<td>Absolute neutrophil count</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Basophils</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Blood Urea Nitrogen</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>frac of 1</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>g/L</td>
</tr>
<tr>
<td>INR</td>
<td>1</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Mean Corpuscular Hemoglobin</td>
<td>pg</td>
</tr>
<tr>
<td>Mean Corpuscular Volume</td>
<td>fl</td>
</tr>
<tr>
<td>Monocytes</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>$10^9$/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Total Protein</td>
<td>g/L</td>
</tr>
<tr>
<td>Prothrombin Time</td>
<td>s</td>
</tr>
<tr>
<td>Partial Thromboplastin Time</td>
<td>s</td>
</tr>
<tr>
<td>Red Blood Cells</td>
<td>$10^{12}$/L</td>
</tr>
<tr>
<td>Aspartate Transaminase</td>
<td>U/L</td>
</tr>
<tr>
<td>Alanine Transaminase</td>
<td>U/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/L</td>
</tr>
<tr>
<td>White Blood Cells</td>
<td>$10^9$/L</td>
</tr>
</tbody>
</table>
## 23.0 Appendix 6: Drugs Excluded from Prior Lines of Therapy

The following table lists the drugs that are not included when counting the number of prior lines of therapy.

<table>
<thead>
<tr>
<th>Agent Name</th>
<th>Agent If Other, specify</th>
<th>Agent If Other, specify PT</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab</td>
<td></td>
<td></td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>ABEMACICLIB</td>
<td>ABEMACICLIB</td>
<td>CDK inhibitor</td>
</tr>
<tr>
<td>Other</td>
<td>ABT 888</td>
<td>VELIPARIB</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>ADENOSINE A2A RECEPTOR ANTAGONIST CPI-444</td>
<td>ANTINEOPLASTIC AGENTS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>ANASTRASOLE</td>
<td>ANASTRASOLE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>ANASTRASOLE</td>
<td>ANASTRASOLE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>ANTI-PTK7 ANTIBODY-DRUG CONJUGATE</td>
<td>PROTEIN KINASE INHIBITORS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>ARIMIDEX</td>
<td>ANASTRASOLE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>ARQ 092</td>
<td>PROTEIN KINASE INHIBITORS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>AVASTATIN (BEVACIZUMAB)</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>AVASTATIN (BEVACIZUMAB)</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>AVASTIN (BEVACIZUMAB)</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>AVASTIN(BEACIZUMAB)</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>AVASTIN(NFI)</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>AZD1775</td>
<td>PROTEIN KINASE INHIBITORS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>BEVACIZUMAB</td>
<td>BEVACIZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>CRLX101</td>
<td>OTHER ANTINEOPLASTIC AGENTS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>ENZALUTAMIDE</td>
<td>ENZALUTAMIDE</td>
<td>nonsteroidal antiandrogen</td>
</tr>
<tr>
<td>Other</td>
<td>EVEROLIMUS</td>
<td>EVEROLIMUS</td>
<td>motor inhibitor investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>FEMARA</td>
<td>LETROZOLE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>FULVESTRANT</td>
<td>FULVESTRANT</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>GLUTAMINASE INHIBITOR CB-839</td>
<td>ANTINEOPLASTIC AGENTS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Other</td>
<td>GOG 212 (PACLITAXEL)</td>
<td>PACLITAXEL</td>
<td>Chemo maintenance therapy</td>
</tr>
<tr>
<td>Other</td>
<td>GSK 2141795</td>
<td>UPROSERTIB</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>HERCEPTIN</td>
<td>TRASTUZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>INTRAPERITONEAL THERAPY-DRUG UNKNOWN</td>
<td>ALL OTHER THERAPEUTIC PRODUCTS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>INVESTIGATIONAL PRODUCT</td>
<td>INVESTIGATIONAL DRUG</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>IPAFRICEPT</td>
<td>IPAFRICEPT</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>KADYCLA</td>
<td>TRASTUZUMAB EMΤΑΝΣΙΝΕ</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>LDE225 600 MG DAILY</td>
<td>ΣΟΝΙΔΕΓΙΒ</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>LETROZOLE</td>
<td>LETROZOLE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>LUPRON</td>
<td>LEUPRORELIN ACETATE</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>MIFAPRISTONE</td>
<td>MIFEПRΙСΤΟΝΕ</td>
<td>RU 486, for the abortion</td>
</tr>
<tr>
<td>Other</td>
<td>PALBOCICLIB</td>
<td>PALBOCICLIB</td>
<td>CDK inhibitor</td>
</tr>
<tr>
<td>Other</td>
<td>PERJECTA</td>
<td>PERTUZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>PERJETA</td>
<td>PERTUZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>PERTUZUMAB</td>
<td>PERTUZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>PEXIΔΑRTIΝΙΒ (PLX3397)</td>
<td>PEXIΔΑRTIΝΙΒ</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>PFIZER B - B7661001 - PF-6657020 - CLINICAL TIRAL</td>
<td>INVESTIGATIONAL DRUG</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>PLACEBO</td>
<td>PLACEBO</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>TAMOXIFEN</td>
<td>TAMOXIFEN</td>
<td>Hormonal therapy</td>
</tr>
<tr>
<td>Other</td>
<td>TARGETED T-CELL THERAPY ON A CLINICAL TRIAL</td>
<td>INVESTIGATIONAL ANTINEOPLASTIC DRUGS</td>
<td>investigational drug</td>
</tr>
<tr>
<td>Other</td>
<td>TRAMETINIB</td>
<td>TRAMETINIB</td>
<td>inhibitor tyrosine kinase</td>
</tr>
<tr>
<td>Other</td>
<td>TRASTUZUMAB</td>
<td>TRASTUZUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Other</td>
<td>VANTICTUMAB</td>
<td>VANTICTUMAB</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>Other</td>
<td>VX-970</td>
<td>PROTEIN KINASE INHIBITORS</td>
<td>investigational drug</td>
</tr>
</tbody>
</table>
Appendix 7: Immune-Related Adverse Events

Below is a list of MedDRA preferred terms that will be used to identify immune-related adverse events.

- Pneumonitis
- Autoimmune colitis
- Autoimmune hepatitis
- Hypophysitis
- Hyperthyroidism
- Hypothyroidism
- Thyroiditis
- Diabetic ketoacidosis
- Hyperglycaemia
- Adrenal insufficiency
- Autoimmune dermatitis
- Autoimmune nephritis
- Dermatitis exfoliative
- Pemphigoid
- Toxic epidermal necrolysis
- Steven Johnson syndrome
- Encephalitis autoimmune
- Arthritis
- Uveitis
- Myositis
- Guillain-Barre syndrome
- Myasthenia gravis
- Vasculitis
- Pancreatitis
- Haemolytic anaemia
- Seizure
- Myelitis
- Myocarditis
- Infusion related reaction
- Rhabdomyolysis
- Iritis
- Facial paresis
- Demyelination
- Polymyalgia rheumatica
- Autoimmune neuropathy
- Hypopituitarism
Systemic inflammatory response syndrome
Gastritis
Duodenitis
Sarcoidosis
Histiocytic necrotising lymphadenitis
Motor dysfunction
Aplastic anaemia
Pericarditis
Myasthenic syndrome
Vogt-Koyanagi-Harada syndrome
25.0 Document History

Version 1.1 incorporated addition of the OC Pooled analyses as well as other changes based on Amendment 2 of the protocol and the updated clinical study database at the time of approval.